modelID;licenseID;project_title;project_domain;project_target;model_title;model_language;species;species_loc;dis_area;dis_loc;model_class;class_loc;choice_loc;choice_section;model_choice;species_choice;spcchc_loc;outcome_choice;outcome_loc;replace_choice;replace_sub_choice;replace_loc;reduce_choice;reduce_sub_choice;reduce_loc;refine_choice;refine_sub_choice;refine_loc;intervention_name;intervention_type;intervention_loc
20171825_01;20171825;Het karakteriseren van nieuwe vloeibare pleisters;Translational or applied research;human;Full thickness wounds in mice;ENG;mouse;NTS_3.3;Sensory organ disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;similar disease pathology or symptoms;simple accomodation and care;APX_2B;not reported;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;substantiated statistics;consult (bio)statistician;APX_2D;methods used in procedures;use of lower species;APX_2D;wound cover;medical device;NTS_3.1
20171825_01;20171825;Het karakteriseren van nieuwe vloeibare pleisters;Translational or applied research;human;Full thickness wounds in mice;ENG;mouse;NTS_3.3;Sensory organ disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;similar disease pathology or symptoms;simple accomodation and care;APX_2B;not reported;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;substantiated statistics;consult (bio)statistician;APX_2D;methods used in procedures;experimental design;APX_2D;wound cover;medical device;NTS_3.1
20171825_01;20171825;Het karakteriseren van nieuwe vloeibare pleisters;Translational or applied research;human;Full thickness wounds in mice;ENG;mouse;NTS_3.3;Sensory organ disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;similar disease pathology or symptoms;simple accomodation and care;APX_2B;not reported;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;substantiated statistics;consult (bio)statistician;APX_2D;methods used in procedures;expertise;APX_2D;wound cover;medical device;NTS_3.1
20171825_01;20171825;Het karakteriseren van nieuwe vloeibare pleisters;Translational or applied research;human;Full thickness wounds in mice;ENG;mouse;NTS_3.3;Sensory organ disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;similar disease pathology or symptoms;availability of research tools;APX_2B;not reported;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;substantiated statistics;consult (bio)statistician;APX_2D;methods used in procedures;use of lower species;APX_2D;wound cover;medical device;NTS_3.1
20171825_01;20171825;Het karakteriseren van nieuwe vloeibare pleisters;Translational or applied research;human;Full thickness wounds in mice;ENG;mouse;NTS_3.3;Sensory organ disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;similar disease pathology or symptoms;availability of research tools;APX_2B;not reported;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;substantiated statistics;consult (bio)statistician;APX_2D;methods used in procedures;experimental design;APX_2D;wound cover;medical device;NTS_3.1
20171825_01;20171825;Het karakteriseren van nieuwe vloeibare pleisters;Translational or applied research;human;Full thickness wounds in mice;ENG;mouse;NTS_3.3;Sensory organ disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;similar disease pathology or symptoms;availability of research tools;APX_2B;not reported;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;substantiated statistics;consult (bio)statistician;APX_2D;methods used in procedures;expertise;APX_2D;wound cover;medical device;NTS_3.1
20171825_01;20171825;Het karakteriseren van nieuwe vloeibare pleisters;Translational or applied research;human;Full thickness wounds in mice;ENG;mouse;NTS_3.3;Sensory organ disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;similar disease pathology or symptoms;prior studies;APX_2B;not reported;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;substantiated statistics;consult (bio)statistician;APX_2D;methods used in procedures;use of lower species;APX_2D;wound cover;medical device;NTS_3.1
20171825_01;20171825;Het karakteriseren van nieuwe vloeibare pleisters;Translational or applied research;human;Full thickness wounds in mice;ENG;mouse;NTS_3.3;Sensory organ disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;similar disease pathology or symptoms;prior studies;APX_2B;not reported;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;substantiated statistics;consult (bio)statistician;APX_2D;methods used in procedures;experimental design;APX_2D;wound cover;medical device;NTS_3.1
20171825_01;20171825;Het karakteriseren van nieuwe vloeibare pleisters;Translational or applied research;human;Full thickness wounds in mice;ENG;mouse;NTS_3.3;Sensory organ disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;similar disease pathology or symptoms;prior studies;APX_2B;not reported;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;substantiated statistics;consult (bio)statistician;APX_2D;methods used in procedures;expertise;APX_2D;wound cover;medical device;NTS_3.1
20171825_01;20171825;Het karakteriseren van nieuwe vloeibare pleisters;Translational or applied research;human;Full thickness wounds in mice;ENG;mouse;NTS_3.3;Sensory organ disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;similar disease pathology or symptoms;cost effectiveness;APX_2B;not reported;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;substantiated statistics;consult (bio)statistician;APX_2D;methods used in procedures;use of lower species;APX_2D;wound cover;medical device;NTS_3.1
20171825_01;20171825;Het karakteriseren van nieuwe vloeibare pleisters;Translational or applied research;human;Full thickness wounds in mice;ENG;mouse;NTS_3.3;Sensory organ disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;similar disease pathology or symptoms;cost effectiveness;APX_2B;not reported;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;substantiated statistics;consult (bio)statistician;APX_2D;methods used in procedures;experimental design;APX_2D;wound cover;medical device;NTS_3.1
20171825_01;20171825;Het karakteriseren van nieuwe vloeibare pleisters;Translational or applied research;human;Full thickness wounds in mice;ENG;mouse;NTS_3.3;Sensory organ disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;similar disease pathology or symptoms;cost effectiveness;APX_2B;not reported;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;substantiated statistics;consult (bio)statistician;APX_2D;methods used in procedures;expertise;APX_2D;wound cover;medical device;NTS_3.1
20171825_01;20171825;Het karakteriseren van nieuwe vloeibare pleisters;Translational or applied research;human;Full thickness wounds in mice;ENG;mouse;NTS_3.3;Sensory organ disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;similar disease pathology or symptoms;simple accomodation and care;APX_2B;not reported;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;substantiated statistics;consult (bio)statistician;APX_2D;methods used in procedures;use of lower species;APX_2D;wound cover;medical device;NTS_3.1
20171825_01;20171825;Het karakteriseren van nieuwe vloeibare pleisters;Translational or applied research;human;Full thickness wounds in mice;ENG;mouse;NTS_3.3;Sensory organ disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;similar disease pathology or symptoms;simple accomodation and care;APX_2B;not reported;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;substantiated statistics;consult (bio)statistician;APX_2D;methods used in procedures;experimental design;APX_2D;wound cover;medical device;NTS_3.1
20171825_01;20171825;Het karakteriseren van nieuwe vloeibare pleisters;Translational or applied research;human;Full thickness wounds in mice;ENG;mouse;NTS_3.3;Sensory organ disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;similar disease pathology or symptoms;simple accomodation and care;APX_2B;not reported;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;substantiated statistics;consult (bio)statistician;APX_2D;methods used in procedures;expertise;APX_2D;wound cover;medical device;NTS_3.1
20171825_01;20171825;Het karakteriseren van nieuwe vloeibare pleisters;Translational or applied research;human;Full thickness wounds in mice;ENG;mouse;NTS_3.3;Sensory organ disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;similar disease pathology or symptoms;availability of research tools;APX_2B;not reported;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;substantiated statistics;consult (bio)statistician;APX_2D;methods used in procedures;use of lower species;APX_2D;wound cover;medical device;NTS_3.1
20171825_01;20171825;Het karakteriseren van nieuwe vloeibare pleisters;Translational or applied research;human;Full thickness wounds in mice;ENG;mouse;NTS_3.3;Sensory organ disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;similar disease pathology or symptoms;availability of research tools;APX_2B;not reported;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;substantiated statistics;consult (bio)statistician;APX_2D;methods used in procedures;experimental design;APX_2D;wound cover;medical device;NTS_3.1
20171825_01;20171825;Het karakteriseren van nieuwe vloeibare pleisters;Translational or applied research;human;Full thickness wounds in mice;ENG;mouse;NTS_3.3;Sensory organ disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;similar disease pathology or symptoms;availability of research tools;APX_2B;not reported;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;substantiated statistics;consult (bio)statistician;APX_2D;methods used in procedures;expertise;APX_2D;wound cover;medical device;NTS_3.1
20171825_01;20171825;Het karakteriseren van nieuwe vloeibare pleisters;Translational or applied research;human;Full thickness wounds in mice;ENG;mouse;NTS_3.3;Sensory organ disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;similar disease pathology or symptoms;prior studies;APX_2B;not reported;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;substantiated statistics;consult (bio)statistician;APX_2D;methods used in procedures;use of lower species;APX_2D;wound cover;medical device;NTS_3.1
20171825_01;20171825;Het karakteriseren van nieuwe vloeibare pleisters;Translational or applied research;human;Full thickness wounds in mice;ENG;mouse;NTS_3.3;Sensory organ disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;similar disease pathology or symptoms;prior studies;APX_2B;not reported;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;substantiated statistics;consult (bio)statistician;APX_2D;methods used in procedures;experimental design;APX_2D;wound cover;medical device;NTS_3.1
20171825_01;20171825;Het karakteriseren van nieuwe vloeibare pleisters;Translational or applied research;human;Full thickness wounds in mice;ENG;mouse;NTS_3.3;Sensory organ disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;similar disease pathology or symptoms;prior studies;APX_2B;not reported;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;substantiated statistics;consult (bio)statistician;APX_2D;methods used in procedures;expertise;APX_2D;wound cover;medical device;NTS_3.1
20171825_01;20171825;Het karakteriseren van nieuwe vloeibare pleisters;Translational or applied research;human;Full thickness wounds in mice;ENG;mouse;NTS_3.3;Sensory organ disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;similar disease pathology or symptoms;cost effectiveness;APX_2B;not reported;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;substantiated statistics;consult (bio)statistician;APX_2D;methods used in procedures;use of lower species;APX_2D;wound cover;medical device;NTS_3.1
20171825_01;20171825;Het karakteriseren van nieuwe vloeibare pleisters;Translational or applied research;human;Full thickness wounds in mice;ENG;mouse;NTS_3.3;Sensory organ disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;similar disease pathology or symptoms;cost effectiveness;APX_2B;not reported;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;substantiated statistics;consult (bio)statistician;APX_2D;methods used in procedures;experimental design;APX_2D;wound cover;medical device;NTS_3.1
20171825_01;20171825;Het karakteriseren van nieuwe vloeibare pleisters;Translational or applied research;human;Full thickness wounds in mice;ENG;mouse;NTS_3.3;Sensory organ disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;similar disease pathology or symptoms;cost effectiveness;APX_2B;not reported;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;substantiated statistics;consult (bio)statistician;APX_2D;methods used in procedures;expertise;APX_2D;wound cover;medical device;NTS_3.1
20173164_01;20173164;Het remmen van reuma met albumine-fusie-eiwitten;Translational or applied research;human;Collagen-induced arthritis (CIA);ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;sensitivity;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;albumin coupled to drug;biologics;NTS_3.1
20173164_01;20173164;Het remmen van reuma met albumine-fusie-eiwitten;Translational or applied research;human;Collagen-induced arthritis (CIA);ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;sensitivity;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;albumin coupled to drug;biologics;NTS_3.1
20173164_01;20173164;Het remmen van reuma met albumine-fusie-eiwitten;Translational or applied research;human;Collagen-induced arthritis (CIA);ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;sensitivity;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;sample size calculation;APX_2D;accomodation and care;expertise;APX_2D;albumin coupled to drug;biologics;NTS_3.1
20173164_01;20173164;Het remmen van reuma met albumine-fusie-eiwitten;Translational or applied research;human;Collagen-induced arthritis (CIA);ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;sensitivity;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;accomodation and care;expertise;APX_2D;albumin coupled to drug;biologics;NTS_3.1
20173164_01;20173164;Het remmen van reuma met albumine-fusie-eiwitten;Translational or applied research;human;Collagen-induced arthritis (CIA);ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;sensitivity;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;albumin coupled to drug;biologics;NTS_3.1
20173164_01;20173164;Het remmen van reuma met albumine-fusie-eiwitten;Translational or applied research;human;Collagen-induced arthritis (CIA);ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;sensitivity;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;albumin coupled to drug;biologics;NTS_3.1
20173164_01;20173164;Het remmen van reuma met albumine-fusie-eiwitten;Translational or applied research;human;Collagen-induced arthritis (CIA);ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;sensitivity;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;sample size calculation;APX_2D;accomodation and care;expertise;APX_2D;albumin coupled to drug;biologics;NTS_3.1
20173164_01;20173164;Het remmen van reuma met albumine-fusie-eiwitten;Translational or applied research;human;Collagen-induced arthritis (CIA);ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;sensitivity;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;accomodation and care;expertise;APX_2D;albumin coupled to drug;biologics;NTS_3.1
20173164_01;20173164;Het remmen van reuma met albumine-fusie-eiwitten;Translational or applied research;human;Collagen-induced arthritis (CIA);ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;sensitivity;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;albumin coupled to drug;biologics;NTS_3.1
20173164_01;20173164;Het remmen van reuma met albumine-fusie-eiwitten;Translational or applied research;human;Collagen-induced arthritis (CIA);ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;sensitivity;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;albumin coupled to drug;biologics;NTS_3.1
20173164_01;20173164;Het remmen van reuma met albumine-fusie-eiwitten;Translational or applied research;human;Collagen-induced arthritis (CIA);ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;sensitivity;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;sample size calculation;APX_2D;accomodation and care;expertise;APX_2D;albumin coupled to drug;biologics;NTS_3.1
20173164_01;20173164;Het remmen van reuma met albumine-fusie-eiwitten;Translational or applied research;human;Collagen-induced arthritis (CIA);ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;sensitivity;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;accomodation and care;expertise;APX_2D;albumin coupled to drug;biologics;NTS_3.1
20173164_01;20173164;Het remmen van reuma met albumine-fusie-eiwitten;Translational or applied research;human;Collagen-induced arthritis (CIA);ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;sensitivity;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;albumin coupled to drug;biologics;NTS_3.1
20173164_01;20173164;Het remmen van reuma met albumine-fusie-eiwitten;Translational or applied research;human;Collagen-induced arthritis (CIA);ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;sensitivity;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;albumin coupled to drug;biologics;NTS_3.1
20173164_01;20173164;Het remmen van reuma met albumine-fusie-eiwitten;Translational or applied research;human;Collagen-induced arthritis (CIA);ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;sensitivity;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;sample size calculation;APX_2D;accomodation and care;expertise;APX_2D;albumin coupled to drug;biologics;NTS_3.1
20173164_01;20173164;Het remmen van reuma met albumine-fusie-eiwitten;Translational or applied research;human;Collagen-induced arthritis (CIA);ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;sensitivity;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;accomodation and care;expertise;APX_2D;albumin coupled to drug;biologics;NTS_3.1
20173164_02;20173164;Het remmen van reuma met albumine-fusie-eiwitten;Translational or applied research;human;Antigen-induced arthritis (AIA);ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;sensitivity;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;sample size calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;albumin coupled to drug;biologics;NTS_3.1
20173164_02;20173164;Het remmen van reuma met albumine-fusie-eiwitten;Translational or applied research;human;Antigen-induced arthritis (AIA);ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;sensitivity;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;albumin coupled to drug;biologics;NTS_3.1
20173164_02;20173164;Het remmen van reuma met albumine-fusie-eiwitten;Translational or applied research;human;Antigen-induced arthritis (AIA);ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;sensitivity;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;sample size calculation;APX_2D;accomodation and care;expertise;APX_2D;albumin coupled to drug;biologics;NTS_3.1
20173164_02;20173164;Het remmen van reuma met albumine-fusie-eiwitten;Translational or applied research;human;Antigen-induced arthritis (AIA);ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;sensitivity;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;accomodation and care;expertise;APX_2D;albumin coupled to drug;biologics;NTS_3.1
20173164_02;20173164;Het remmen van reuma met albumine-fusie-eiwitten;Translational or applied research;human;Antigen-induced arthritis (AIA);ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;sensitivity;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;sample size calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;albumin coupled to drug;biologics;NTS_3.1
20173164_02;20173164;Het remmen van reuma met albumine-fusie-eiwitten;Translational or applied research;human;Antigen-induced arthritis (AIA);ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;sensitivity;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;albumin coupled to drug;biologics;NTS_3.1
20173164_02;20173164;Het remmen van reuma met albumine-fusie-eiwitten;Translational or applied research;human;Antigen-induced arthritis (AIA);ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;sensitivity;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;sample size calculation;APX_2D;accomodation and care;expertise;APX_2D;albumin coupled to drug;biologics;NTS_3.1
20173164_02;20173164;Het remmen van reuma met albumine-fusie-eiwitten;Translational or applied research;human;Antigen-induced arthritis (AIA);ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;sensitivity;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;accomodation and care;expertise;APX_2D;albumin coupled to drug;biologics;NTS_3.1
20173164_02;20173164;Het remmen van reuma met albumine-fusie-eiwitten;Translational or applied research;human;Antigen-induced arthritis (AIA);ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;sensitivity;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;sample size calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;albumin coupled to drug;biologics;NTS_3.1
20173164_02;20173164;Het remmen van reuma met albumine-fusie-eiwitten;Translational or applied research;human;Antigen-induced arthritis (AIA);ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;sensitivity;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;albumin coupled to drug;biologics;NTS_3.1
20173164_02;20173164;Het remmen van reuma met albumine-fusie-eiwitten;Translational or applied research;human;Antigen-induced arthritis (AIA);ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;sensitivity;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;sample size calculation;APX_2D;accomodation and care;expertise;APX_2D;albumin coupled to drug;biologics;NTS_3.1
20173164_02;20173164;Het remmen van reuma met albumine-fusie-eiwitten;Translational or applied research;human;Antigen-induced arthritis (AIA);ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of expertise;sensitivity;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;accomodation and care;expertise;APX_2D;albumin coupled to drug;biologics;NTS_3.1
20173164_02;20173164;Het remmen van reuma met albumine-fusie-eiwitten;Translational or applied research;human;Antigen-induced arthritis (AIA);ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;sensitivity;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;sample size calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;albumin coupled to drug;biologics;NTS_3.1
20173164_02;20173164;Het remmen van reuma met albumine-fusie-eiwitten;Translational or applied research;human;Antigen-induced arthritis (AIA);ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;sensitivity;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;albumin coupled to drug;biologics;NTS_3.1
20173164_02;20173164;Het remmen van reuma met albumine-fusie-eiwitten;Translational or applied research;human;Antigen-induced arthritis (AIA);ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;sensitivity;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;sample size calculation;APX_2D;accomodation and care;expertise;APX_2D;albumin coupled to drug;biologics;NTS_3.1
20173164_02;20173164;Het remmen van reuma met albumine-fusie-eiwitten;Translational or applied research;human;Antigen-induced arthritis (AIA);ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;sensitivity;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;accomodation and care;expertise;APX_2D;albumin coupled to drug;biologics;NTS_3.1
20173164_03;20173164;Het remmen van reuma met albumine-fusie-eiwitten;Translational or applied research;human;IL-1Ra-/- mouse model;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.2;Main Text;availability of expertise;sensitivity;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;sample size calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;albumin coupled to drug;biologics;NTS_3.1
20173164_03;20173164;Het remmen van reuma met albumine-fusie-eiwitten;Translational or applied research;human;IL-1Ra-/- mouse model;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.2;Main Text;availability of expertise;sensitivity;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;albumin coupled to drug;biologics;NTS_3.1
20173164_03;20173164;Het remmen van reuma met albumine-fusie-eiwitten;Translational or applied research;human;IL-1Ra-/- mouse model;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.2;Main Text;availability of expertise;sensitivity;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;sample size calculation;APX_2D;accomodation and care;expertise;APX_2D;albumin coupled to drug;biologics;NTS_3.1
20173164_03;20173164;Het remmen van reuma met albumine-fusie-eiwitten;Translational or applied research;human;IL-1Ra-/- mouse model;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.2;Main Text;availability of expertise;sensitivity;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;accomodation and care;expertise;APX_2D;albumin coupled to drug;biologics;NTS_3.1
20173164_03;20173164;Het remmen van reuma met albumine-fusie-eiwitten;Translational or applied research;human;IL-1Ra-/- mouse model;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;sensitivity;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;sample size calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;albumin coupled to drug;biologics;NTS_3.1
20173164_03;20173164;Het remmen van reuma met albumine-fusie-eiwitten;Translational or applied research;human;IL-1Ra-/- mouse model;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;sensitivity;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;albumin coupled to drug;biologics;NTS_3.1
20173164_03;20173164;Het remmen van reuma met albumine-fusie-eiwitten;Translational or applied research;human;IL-1Ra-/- mouse model;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;sensitivity;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;sample size calculation;APX_2D;accomodation and care;expertise;APX_2D;albumin coupled to drug;biologics;NTS_3.1
20173164_03;20173164;Het remmen van reuma met albumine-fusie-eiwitten;Translational or applied research;human;IL-1Ra-/- mouse model;ENG;mouse;NTS_3.3;Immune disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;sensitivity;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;accomodation and care;expertise;APX_2D;albumin coupled to drug;biologics;NTS_3.1
20173164_03;20173164;Het remmen van reuma met albumine-fusie-eiwitten;Translational or applied research;human;IL-1Ra-/- mouse model;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.2;Main Text;availability of expertise;sensitivity;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;sample size calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;albumin coupled to drug;biologics;NTS_3.1
20173164_03;20173164;Het remmen van reuma met albumine-fusie-eiwitten;Translational or applied research;human;IL-1Ra-/- mouse model;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.2;Main Text;availability of expertise;sensitivity;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;albumin coupled to drug;biologics;NTS_3.1
20173164_03;20173164;Het remmen van reuma met albumine-fusie-eiwitten;Translational or applied research;human;IL-1Ra-/- mouse model;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.2;Main Text;availability of expertise;sensitivity;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;sample size calculation;APX_2D;accomodation and care;expertise;APX_2D;albumin coupled to drug;biologics;NTS_3.1
20173164_03;20173164;Het remmen van reuma met albumine-fusie-eiwitten;Translational or applied research;human;IL-1Ra-/- mouse model;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.2;Main Text;availability of expertise;sensitivity;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;accomodation and care;expertise;APX_2D;albumin coupled to drug;biologics;NTS_3.1
20173164_03;20173164;Het remmen van reuma met albumine-fusie-eiwitten;Translational or applied research;human;IL-1Ra-/- mouse model;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;sensitivity;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;sample size calculation;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;albumin coupled to drug;biologics;NTS_3.1
20173164_03;20173164;Het remmen van reuma met albumine-fusie-eiwitten;Translational or applied research;human;IL-1Ra-/- mouse model;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;sensitivity;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;albumin coupled to drug;biologics;NTS_3.1
20173164_03;20173164;Het remmen van reuma met albumine-fusie-eiwitten;Translational or applied research;human;IL-1Ra-/- mouse model;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;sensitivity;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;sample size calculation;APX_2D;accomodation and care;expertise;APX_2D;albumin coupled to drug;biologics;NTS_3.1
20173164_03;20173164;Het remmen van reuma met albumine-fusie-eiwitten;Translational or applied research;human;IL-1Ra-/- mouse model;ENG;mouse;NTS_3.3;Immune disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;sensitivity;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;accomodation and care;expertise;APX_2D;albumin coupled to drug;biologics;NTS_3.1
20173344_01;20173344;Cre<eb>ren van nieuwe bloedvaten voor pati<eb>nten met nierfalen, doormiddel van lokale weefsel constructie;Translational or applied research;human;In vivo testing of an electro spun vascular access graft under clinical conditions in a large animal model;ENG;goat;APX_2B;Urogenital or reproductive disorders;NTS_1.3;Naive or healthy;APX_2A;APX_2B;Appendix;similar anatomy;similar anatomy or organ system;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;accomodation and care;cage enrichment;APX_2D;tissue construction;gene and cell-based;NTS_3.1
20173344_01;20173344;Cre<eb>ren van nieuwe bloedvaten voor pati<eb>nten met nierfalen, doormiddel van lokale weefsel constructie;Translational or applied research;human;In vivo testing of an electro spun vascular access graft under clinical conditions in a large animal model;ENG;goat;APX_2B;Urogenital or reproductive disorders;NTS_1.3;Naive or healthy;APX_2A;APX_2B;Appendix;similar anatomy;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;experimental design;optimal combination of readouts;APX_2D;accomodation and care;cage enrichment;APX_2D;tissue construction;gene and cell-based;NTS_3.1
20173344_01;20173344;Cre<eb>ren van nieuwe bloedvaten voor pati<eb>nten met nierfalen, doormiddel van lokale weefsel constructie;Translational or applied research;human;In vivo testing of an electro spun vascular access graft under clinical conditions in a large animal model;ENG;goat;APX_2B;Urogenital or reproductive disorders;NTS_1.3;Naive or healthy;APX_2A;APX_2B;Appendix;similar anatomy;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;optimal combination of readouts;APX_2D;accomodation and care;cage enrichment;APX_2D;tissue construction;gene and cell-based;NTS_3.1
20173344_01;20173344;Cre<eb>ren van nieuwe bloedvaten voor pati<eb>nten met nierfalen, doormiddel van lokale weefsel constructie;Translational or applied research;human;In vivo testing of an electro spun vascular access graft under clinical conditions in a large animal model;ENG;goat;APX_2B;Urogenital or reproductive disorders;NTS_1.3;Naive or healthy;APX_2A;APX_2B;Appendix;similar anatomy;similar anatomy or organ system;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;tissue construction;gene and cell-based;NTS_3.1
20173344_01;20173344;Cre<eb>ren van nieuwe bloedvaten voor pati<eb>nten met nierfalen, doormiddel van lokale weefsel constructie;Translational or applied research;human;In vivo testing of an electro spun vascular access graft under clinical conditions in a large animal model;ENG;goat;APX_2B;Urogenital or reproductive disorders;NTS_1.3;Naive or healthy;APX_2A;APX_2B;Appendix;similar anatomy;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;tissue construction;gene and cell-based;NTS_3.1
20173344_01;20173344;Cre<eb>ren van nieuwe bloedvaten voor pati<eb>nten met nierfalen, doormiddel van lokale weefsel constructie;Translational or applied research;human;In vivo testing of an electro spun vascular access graft under clinical conditions in a large animal model;ENG;goat;APX_2B;Urogenital or reproductive disorders;NTS_1.3;Naive or healthy;APX_2A;APX_2B;Appendix;similar anatomy;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;tissue construction;gene and cell-based;NTS_3.1
20173344_01;20173344;Cre<eb>ren van nieuwe bloedvaten voor pati<eb>nten met nierfalen, doormiddel van lokale weefsel constructie;Translational or applied research;human;In vivo testing of an electro spun vascular access graft under clinical conditions in a large animal model;ENG;goat;APX_2B;Urogenital or reproductive disorders;NTS_1.3;Naive or healthy;APX_2A;APX_2B;Appendix;similar anatomy;similar anatomy or organ system;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;expertise;APX_2D;tissue construction;gene and cell-based;NTS_3.1
20173344_01;20173344;Cre<eb>ren van nieuwe bloedvaten voor pati<eb>nten met nierfalen, doormiddel van lokale weefsel constructie;Translational or applied research;human;In vivo testing of an electro spun vascular access graft under clinical conditions in a large animal model;ENG;goat;APX_2B;Urogenital or reproductive disorders;NTS_1.3;Naive or healthy;APX_2A;APX_2B;Appendix;similar anatomy;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;expertise;APX_2D;tissue construction;gene and cell-based;NTS_3.1
20173344_01;20173344;Cre<eb>ren van nieuwe bloedvaten voor pati<eb>nten met nierfalen, doormiddel van lokale weefsel constructie;Translational or applied research;human;In vivo testing of an electro spun vascular access graft under clinical conditions in a large animal model;ENG;goat;APX_2B;Urogenital or reproductive disorders;NTS_1.3;Naive or healthy;APX_2A;APX_2B;Appendix;similar anatomy;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;expertise;APX_2D;tissue construction;gene and cell-based;NTS_3.1
20173344_01;20173344;Cre<eb>ren van nieuwe bloedvaten voor pati<eb>nten met nierfalen, doormiddel van lokale weefsel constructie;Translational or applied research;human;In vivo testing of an electro spun vascular access graft under clinical conditions in a large animal model;ENG;goat;APX_2B;Urogenital or reproductive disorders;NTS_1.3;Naive or healthy;APX_2A;APX_2B;Appendix;similar anatomy;similar anatomy or organ system;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;accomodation and care;cage enrichment;APX_2D;tissue construction;gene and cell-based;NTS_3.1
20173344_01;20173344;Cre<eb>ren van nieuwe bloedvaten voor pati<eb>nten met nierfalen, doormiddel van lokale weefsel constructie;Translational or applied research;human;In vivo testing of an electro spun vascular access graft under clinical conditions in a large animal model;ENG;goat;APX_2B;Urogenital or reproductive disorders;NTS_1.3;Naive or healthy;APX_2A;APX_2B;Appendix;similar anatomy;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;accomodation and care;cage enrichment;APX_2D;tissue construction;gene and cell-based;NTS_3.1
20173344_01;20173344;Cre<eb>ren van nieuwe bloedvaten voor pati<eb>nten met nierfalen, doormiddel van lokale weefsel constructie;Translational or applied research;human;In vivo testing of an electro spun vascular access graft under clinical conditions in a large animal model;ENG;goat;APX_2B;Urogenital or reproductive disorders;NTS_1.3;Naive or healthy;APX_2A;APX_2B;Appendix;similar anatomy;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;accomodation and care;cage enrichment;APX_2D;tissue construction;gene and cell-based;NTS_3.1
20173344_01;20173344;Cre<eb>ren van nieuwe bloedvaten voor pati<eb>nten met nierfalen, doormiddel van lokale weefsel constructie;Translational or applied research;human;In vivo testing of an electro spun vascular access graft under clinical conditions in a large animal model;ENG;goat;APX_2B;Urogenital or reproductive disorders;NTS_1.3;Naive or healthy;APX_2A;APX_2B;Appendix;similar anatomy;similar anatomy or organ system;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;tissue construction;gene and cell-based;NTS_3.1
20173344_01;20173344;Cre<eb>ren van nieuwe bloedvaten voor pati<eb>nten met nierfalen, doormiddel van lokale weefsel constructie;Translational or applied research;human;In vivo testing of an electro spun vascular access graft under clinical conditions in a large animal model;ENG;goat;APX_2B;Urogenital or reproductive disorders;NTS_1.3;Naive or healthy;APX_2A;APX_2B;Appendix;similar anatomy;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;tissue construction;gene and cell-based;NTS_3.1
20173344_01;20173344;Cre<eb>ren van nieuwe bloedvaten voor pati<eb>nten met nierfalen, doormiddel van lokale weefsel constructie;Translational or applied research;human;In vivo testing of an electro spun vascular access graft under clinical conditions in a large animal model;ENG;goat;APX_2B;Urogenital or reproductive disorders;NTS_1.3;Naive or healthy;APX_2A;APX_2B;Appendix;similar anatomy;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;tissue construction;gene and cell-based;NTS_3.1
20173344_01;20173344;Cre<eb>ren van nieuwe bloedvaten voor pati<eb>nten met nierfalen, doormiddel van lokale weefsel constructie;Translational or applied research;human;In vivo testing of an electro spun vascular access graft under clinical conditions in a large animal model;ENG;goat;APX_2B;Urogenital or reproductive disorders;NTS_1.3;Naive or healthy;APX_2A;APX_2B;Appendix;similar anatomy;similar anatomy or organ system;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;expertise;APX_2D;tissue construction;gene and cell-based;NTS_3.1
20173344_01;20173344;Cre<eb>ren van nieuwe bloedvaten voor pati<eb>nten met nierfalen, doormiddel van lokale weefsel constructie;Translational or applied research;human;In vivo testing of an electro spun vascular access graft under clinical conditions in a large animal model;ENG;goat;APX_2B;Urogenital or reproductive disorders;NTS_1.3;Naive or healthy;APX_2A;APX_2B;Appendix;similar anatomy;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;expertise;APX_2D;tissue construction;gene and cell-based;NTS_3.1
20173344_01;20173344;Cre<eb>ren van nieuwe bloedvaten voor pati<eb>nten met nierfalen, doormiddel van lokale weefsel constructie;Translational or applied research;human;In vivo testing of an electro spun vascular access graft under clinical conditions in a large animal model;ENG;goat;APX_2B;Urogenital or reproductive disorders;NTS_1.3;Naive or healthy;APX_2A;APX_2B;Appendix;similar anatomy;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;expertise;APX_2D;tissue construction;gene and cell-based;NTS_3.1
20173344_01;20173344;Cre<eb>ren van nieuwe bloedvaten voor pati<eb>nten met nierfalen, doormiddel van lokale weefsel constructie;Translational or applied research;human;In vivo testing of an electro spun vascular access graft under clinical conditions in a large animal model;ENG;goat;APX_2B;Urogenital or reproductive disorders;NTS_1.3;Naive or healthy;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;similar anatomy or organ system;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;accomodation and care;cage enrichment;APX_2D;tissue construction;gene and cell-based;NTS_3.1
20173344_01;20173344;Cre<eb>ren van nieuwe bloedvaten voor pati<eb>nten met nierfalen, doormiddel van lokale weefsel constructie;Translational or applied research;human;In vivo testing of an electro spun vascular access graft under clinical conditions in a large animal model;ENG;goat;APX_2B;Urogenital or reproductive disorders;NTS_1.3;Naive or healthy;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;experimental design;optimal combination of readouts;APX_2D;accomodation and care;cage enrichment;APX_2D;tissue construction;gene and cell-based;NTS_3.1
20173344_01;20173344;Cre<eb>ren van nieuwe bloedvaten voor pati<eb>nten met nierfalen, doormiddel van lokale weefsel constructie;Translational or applied research;human;In vivo testing of an electro spun vascular access graft under clinical conditions in a large animal model;ENG;goat;APX_2B;Urogenital or reproductive disorders;NTS_1.3;Naive or healthy;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;optimal combination of readouts;APX_2D;accomodation and care;cage enrichment;APX_2D;tissue construction;gene and cell-based;NTS_3.1
20173344_01;20173344;Cre<eb>ren van nieuwe bloedvaten voor pati<eb>nten met nierfalen, doormiddel van lokale weefsel constructie;Translational or applied research;human;In vivo testing of an electro spun vascular access graft under clinical conditions in a large animal model;ENG;goat;APX_2B;Urogenital or reproductive disorders;NTS_1.3;Naive or healthy;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;similar anatomy or organ system;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;tissue construction;gene and cell-based;NTS_3.1
20173344_01;20173344;Cre<eb>ren van nieuwe bloedvaten voor pati<eb>nten met nierfalen, doormiddel van lokale weefsel constructie;Translational or applied research;human;In vivo testing of an electro spun vascular access graft under clinical conditions in a large animal model;ENG;goat;APX_2B;Urogenital or reproductive disorders;NTS_1.3;Naive or healthy;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;tissue construction;gene and cell-based;NTS_3.1
20173344_01;20173344;Cre<eb>ren van nieuwe bloedvaten voor pati<eb>nten met nierfalen, doormiddel van lokale weefsel constructie;Translational or applied research;human;In vivo testing of an electro spun vascular access graft under clinical conditions in a large animal model;ENG;goat;APX_2B;Urogenital or reproductive disorders;NTS_1.3;Naive or healthy;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;tissue construction;gene and cell-based;NTS_3.1
20173344_01;20173344;Cre<eb>ren van nieuwe bloedvaten voor pati<eb>nten met nierfalen, doormiddel van lokale weefsel constructie;Translational or applied research;human;In vivo testing of an electro spun vascular access graft under clinical conditions in a large animal model;ENG;goat;APX_2B;Urogenital or reproductive disorders;NTS_1.3;Naive or healthy;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;similar anatomy or organ system;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;expertise;APX_2D;tissue construction;gene and cell-based;NTS_3.1
20173344_01;20173344;Cre<eb>ren van nieuwe bloedvaten voor pati<eb>nten met nierfalen, doormiddel van lokale weefsel constructie;Translational or applied research;human;In vivo testing of an electro spun vascular access graft under clinical conditions in a large animal model;ENG;goat;APX_2B;Urogenital or reproductive disorders;NTS_1.3;Naive or healthy;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;expertise;APX_2D;tissue construction;gene and cell-based;NTS_3.1
20173344_01;20173344;Cre<eb>ren van nieuwe bloedvaten voor pati<eb>nten met nierfalen, doormiddel van lokale weefsel constructie;Translational or applied research;human;In vivo testing of an electro spun vascular access graft under clinical conditions in a large animal model;ENG;goat;APX_2B;Urogenital or reproductive disorders;NTS_1.3;Naive or healthy;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;expertise;APX_2D;tissue construction;gene and cell-based;NTS_3.1
20173344_01;20173344;Cre<eb>ren van nieuwe bloedvaten voor pati<eb>nten met nierfalen, doormiddel van lokale weefsel constructie;Translational or applied research;human;In vivo testing of an electro spun vascular access graft under clinical conditions in a large animal model;ENG;goat;APX_2B;Urogenital or reproductive disorders;NTS_1.3;Naive or healthy;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;similar anatomy or organ system;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;accomodation and care;cage enrichment;APX_2D;tissue construction;gene and cell-based;NTS_3.1
20173344_01;20173344;Cre<eb>ren van nieuwe bloedvaten voor pati<eb>nten met nierfalen, doormiddel van lokale weefsel constructie;Translational or applied research;human;In vivo testing of an electro spun vascular access graft under clinical conditions in a large animal model;ENG;goat;APX_2B;Urogenital or reproductive disorders;NTS_1.3;Naive or healthy;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;accomodation and care;cage enrichment;APX_2D;tissue construction;gene and cell-based;NTS_3.1
20173344_01;20173344;Cre<eb>ren van nieuwe bloedvaten voor pati<eb>nten met nierfalen, doormiddel van lokale weefsel constructie;Translational or applied research;human;In vivo testing of an electro spun vascular access graft under clinical conditions in a large animal model;ENG;goat;APX_2B;Urogenital or reproductive disorders;NTS_1.3;Naive or healthy;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;accomodation and care;cage enrichment;APX_2D;tissue construction;gene and cell-based;NTS_3.1
20173344_01;20173344;Cre<eb>ren van nieuwe bloedvaten voor pati<eb>nten met nierfalen, doormiddel van lokale weefsel constructie;Translational or applied research;human;In vivo testing of an electro spun vascular access graft under clinical conditions in a large animal model;ENG;goat;APX_2B;Urogenital or reproductive disorders;NTS_1.3;Naive or healthy;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;similar anatomy or organ system;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;tissue construction;gene and cell-based;NTS_3.1
20173344_01;20173344;Cre<eb>ren van nieuwe bloedvaten voor pati<eb>nten met nierfalen, doormiddel van lokale weefsel constructie;Translational or applied research;human;In vivo testing of an electro spun vascular access graft under clinical conditions in a large animal model;ENG;goat;APX_2B;Urogenital or reproductive disorders;NTS_1.3;Naive or healthy;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;tissue construction;gene and cell-based;NTS_3.1
20173344_01;20173344;Cre<eb>ren van nieuwe bloedvaten voor pati<eb>nten met nierfalen, doormiddel van lokale weefsel constructie;Translational or applied research;human;In vivo testing of an electro spun vascular access graft under clinical conditions in a large animal model;ENG;goat;APX_2B;Urogenital or reproductive disorders;NTS_1.3;Naive or healthy;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;tissue construction;gene and cell-based;NTS_3.1
20173344_01;20173344;Cre<eb>ren van nieuwe bloedvaten voor pati<eb>nten met nierfalen, doormiddel van lokale weefsel constructie;Translational or applied research;human;In vivo testing of an electro spun vascular access graft under clinical conditions in a large animal model;ENG;goat;APX_2B;Urogenital or reproductive disorders;NTS_1.3;Naive or healthy;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;similar anatomy or organ system;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;expertise;APX_2D;tissue construction;gene and cell-based;NTS_3.1
20173344_01;20173344;Cre<eb>ren van nieuwe bloedvaten voor pati<eb>nten met nierfalen, doormiddel van lokale weefsel constructie;Translational or applied research;human;In vivo testing of an electro spun vascular access graft under clinical conditions in a large animal model;ENG;goat;APX_2B;Urogenital or reproductive disorders;NTS_1.3;Naive or healthy;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;expertise;APX_2D;tissue construction;gene and cell-based;NTS_3.1
20173344_01;20173344;Cre<eb>ren van nieuwe bloedvaten voor pati<eb>nten met nierfalen, doormiddel van lokale weefsel constructie;Translational or applied research;human;In vivo testing of an electro spun vascular access graft under clinical conditions in a large animal model;ENG;goat;APX_2B;Urogenital or reproductive disorders;NTS_1.3;Naive or healthy;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;expertise;APX_2D;tissue construction;gene and cell-based;NTS_3.1
20173344_01;20173344;Cre<eb>ren van nieuwe bloedvaten voor pati<eb>nten met nierfalen, doormiddel van lokale weefsel constructie;Translational or applied research;human;In vivo testing of an electro spun vascular access graft under clinical conditions in a large animal model;ENG;goat;APX_2B;Urogenital or reproductive disorders;NTS_1.3;Naive or healthy;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;accomodation and care;cage enrichment;APX_2D;tissue construction;gene and cell-based;NTS_3.1
20173344_01;20173344;Cre<eb>ren van nieuwe bloedvaten voor pati<eb>nten met nierfalen, doormiddel van lokale weefsel constructie;Translational or applied research;human;In vivo testing of an electro spun vascular access graft under clinical conditions in a large animal model;ENG;goat;APX_2B;Urogenital or reproductive disorders;NTS_1.3;Naive or healthy;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;experimental design;optimal combination of readouts;APX_2D;accomodation and care;cage enrichment;APX_2D;tissue construction;gene and cell-based;NTS_3.1
20173344_01;20173344;Cre<eb>ren van nieuwe bloedvaten voor pati<eb>nten met nierfalen, doormiddel van lokale weefsel constructie;Translational or applied research;human;In vivo testing of an electro spun vascular access graft under clinical conditions in a large animal model;ENG;goat;APX_2B;Urogenital or reproductive disorders;NTS_1.3;Naive or healthy;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;optimal combination of readouts;APX_2D;accomodation and care;cage enrichment;APX_2D;tissue construction;gene and cell-based;NTS_3.1
20173344_01;20173344;Cre<eb>ren van nieuwe bloedvaten voor pati<eb>nten met nierfalen, doormiddel van lokale weefsel constructie;Translational or applied research;human;In vivo testing of an electro spun vascular access graft under clinical conditions in a large animal model;ENG;goat;APX_2B;Urogenital or reproductive disorders;NTS_1.3;Naive or healthy;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;tissue construction;gene and cell-based;NTS_3.1
20173344_01;20173344;Cre<eb>ren van nieuwe bloedvaten voor pati<eb>nten met nierfalen, doormiddel van lokale weefsel constructie;Translational or applied research;human;In vivo testing of an electro spun vascular access graft under clinical conditions in a large animal model;ENG;goat;APX_2B;Urogenital or reproductive disorders;NTS_1.3;Naive or healthy;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;tissue construction;gene and cell-based;NTS_3.1
20173344_01;20173344;Cre<eb>ren van nieuwe bloedvaten voor pati<eb>nten met nierfalen, doormiddel van lokale weefsel constructie;Translational or applied research;human;In vivo testing of an electro spun vascular access graft under clinical conditions in a large animal model;ENG;goat;APX_2B;Urogenital or reproductive disorders;NTS_1.3;Naive or healthy;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;tissue construction;gene and cell-based;NTS_3.1
20173344_01;20173344;Cre<eb>ren van nieuwe bloedvaten voor pati<eb>nten met nierfalen, doormiddel van lokale weefsel constructie;Translational or applied research;human;In vivo testing of an electro spun vascular access graft under clinical conditions in a large animal model;ENG;goat;APX_2B;Urogenital or reproductive disorders;NTS_1.3;Naive or healthy;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;expertise;APX_2D;tissue construction;gene and cell-based;NTS_3.1
20173344_01;20173344;Cre<eb>ren van nieuwe bloedvaten voor pati<eb>nten met nierfalen, doormiddel van lokale weefsel constructie;Translational or applied research;human;In vivo testing of an electro spun vascular access graft under clinical conditions in a large animal model;ENG;goat;APX_2B;Urogenital or reproductive disorders;NTS_1.3;Naive or healthy;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;expertise;APX_2D;tissue construction;gene and cell-based;NTS_3.1
20173344_01;20173344;Cre<eb>ren van nieuwe bloedvaten voor pati<eb>nten met nierfalen, doormiddel van lokale weefsel constructie;Translational or applied research;human;In vivo testing of an electro spun vascular access graft under clinical conditions in a large animal model;ENG;goat;APX_2B;Urogenital or reproductive disorders;NTS_1.3;Naive or healthy;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;expertise;APX_2D;tissue construction;gene and cell-based;NTS_3.1
20173344_01;20173344;Cre<eb>ren van nieuwe bloedvaten voor pati<eb>nten met nierfalen, doormiddel van lokale weefsel constructie;Translational or applied research;human;In vivo testing of an electro spun vascular access graft under clinical conditions in a large animal model;ENG;goat;APX_2B;Urogenital or reproductive disorders;NTS_1.3;Naive or healthy;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;accomodation and care;cage enrichment;APX_2D;tissue construction;gene and cell-based;NTS_3.1
20173344_01;20173344;Cre<eb>ren van nieuwe bloedvaten voor pati<eb>nten met nierfalen, doormiddel van lokale weefsel constructie;Translational or applied research;human;In vivo testing of an electro spun vascular access graft under clinical conditions in a large animal model;ENG;goat;APX_2B;Urogenital or reproductive disorders;NTS_1.3;Naive or healthy;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;accomodation and care;cage enrichment;APX_2D;tissue construction;gene and cell-based;NTS_3.1
20173344_01;20173344;Cre<eb>ren van nieuwe bloedvaten voor pati<eb>nten met nierfalen, doormiddel van lokale weefsel constructie;Translational or applied research;human;In vivo testing of an electro spun vascular access graft under clinical conditions in a large animal model;ENG;goat;APX_2B;Urogenital or reproductive disorders;NTS_1.3;Naive or healthy;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;accomodation and care;cage enrichment;APX_2D;tissue construction;gene and cell-based;NTS_3.1
20173344_01;20173344;Cre<eb>ren van nieuwe bloedvaten voor pati<eb>nten met nierfalen, doormiddel van lokale weefsel constructie;Translational or applied research;human;In vivo testing of an electro spun vascular access graft under clinical conditions in a large animal model;ENG;goat;APX_2B;Urogenital or reproductive disorders;NTS_1.3;Naive or healthy;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;tissue construction;gene and cell-based;NTS_3.1
20173344_01;20173344;Cre<eb>ren van nieuwe bloedvaten voor pati<eb>nten met nierfalen, doormiddel van lokale weefsel constructie;Translational or applied research;human;In vivo testing of an electro spun vascular access graft under clinical conditions in a large animal model;ENG;goat;APX_2B;Urogenital or reproductive disorders;NTS_1.3;Naive or healthy;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;tissue construction;gene and cell-based;NTS_3.1
20173344_01;20173344;Cre<eb>ren van nieuwe bloedvaten voor pati<eb>nten met nierfalen, doormiddel van lokale weefsel constructie;Translational or applied research;human;In vivo testing of an electro spun vascular access graft under clinical conditions in a large animal model;ENG;goat;APX_2B;Urogenital or reproductive disorders;NTS_1.3;Naive or healthy;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;tissue construction;gene and cell-based;NTS_3.1
20173344_01;20173344;Cre<eb>ren van nieuwe bloedvaten voor pati<eb>nten met nierfalen, doormiddel van lokale weefsel constructie;Translational or applied research;human;In vivo testing of an electro spun vascular access graft under clinical conditions in a large animal model;ENG;goat;APX_2B;Urogenital or reproductive disorders;NTS_1.3;Naive or healthy;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;expertise;APX_2D;tissue construction;gene and cell-based;NTS_3.1
20173344_01;20173344;Cre<eb>ren van nieuwe bloedvaten voor pati<eb>nten met nierfalen, doormiddel van lokale weefsel constructie;Translational or applied research;human;In vivo testing of an electro spun vascular access graft under clinical conditions in a large animal model;ENG;goat;APX_2B;Urogenital or reproductive disorders;NTS_1.3;Naive or healthy;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;expertise;APX_2D;tissue construction;gene and cell-based;NTS_3.1
20173344_01;20173344;Cre<eb>ren van nieuwe bloedvaten voor pati<eb>nten met nierfalen, doormiddel van lokale weefsel constructie;Translational or applied research;human;In vivo testing of an electro spun vascular access graft under clinical conditions in a large animal model;ENG;goat;APX_2B;Urogenital or reproductive disorders;NTS_1.3;Naive or healthy;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;expertise;APX_2D;tissue construction;gene and cell-based;NTS_3.1
20173344_01;20173344;Cre<eb>ren van nieuwe bloedvaten voor pati<eb>nten met nierfalen, doormiddel van lokale weefsel constructie;Translational or applied research;human;In vivo testing of an electro spun vascular access graft under clinical conditions in a large animal model;ENG;goat;APX_2B;Urogenital or reproductive disorders;NTS_3.1;Naive or healthy;APX_2A;APX_2B;Appendix;similar anatomy;similar anatomy or organ system;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;accomodation and care;cage enrichment;APX_2D;tissue construction;gene and cell-based;NTS_3.1
20173344_01;20173344;Cre<eb>ren van nieuwe bloedvaten voor pati<eb>nten met nierfalen, doormiddel van lokale weefsel constructie;Translational or applied research;human;In vivo testing of an electro spun vascular access graft under clinical conditions in a large animal model;ENG;goat;APX_2B;Urogenital or reproductive disorders;NTS_3.1;Naive or healthy;APX_2A;APX_2B;Appendix;similar anatomy;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;experimental design;optimal combination of readouts;APX_2D;accomodation and care;cage enrichment;APX_2D;tissue construction;gene and cell-based;NTS_3.1
20173344_01;20173344;Cre<eb>ren van nieuwe bloedvaten voor pati<eb>nten met nierfalen, doormiddel van lokale weefsel constructie;Translational or applied research;human;In vivo testing of an electro spun vascular access graft under clinical conditions in a large animal model;ENG;goat;APX_2B;Urogenital or reproductive disorders;NTS_3.1;Naive or healthy;APX_2A;APX_2B;Appendix;similar anatomy;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;optimal combination of readouts;APX_2D;accomodation and care;cage enrichment;APX_2D;tissue construction;gene and cell-based;NTS_3.1
20173344_01;20173344;Cre<eb>ren van nieuwe bloedvaten voor pati<eb>nten met nierfalen, doormiddel van lokale weefsel constructie;Translational or applied research;human;In vivo testing of an electro spun vascular access graft under clinical conditions in a large animal model;ENG;goat;APX_2B;Urogenital or reproductive disorders;NTS_3.1;Naive or healthy;APX_2A;APX_2B;Appendix;similar anatomy;similar anatomy or organ system;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;tissue construction;gene and cell-based;NTS_3.1
20173344_01;20173344;Cre<eb>ren van nieuwe bloedvaten voor pati<eb>nten met nierfalen, doormiddel van lokale weefsel constructie;Translational or applied research;human;In vivo testing of an electro spun vascular access graft under clinical conditions in a large animal model;ENG;goat;APX_2B;Urogenital or reproductive disorders;NTS_3.1;Naive or healthy;APX_2A;APX_2B;Appendix;similar anatomy;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;tissue construction;gene and cell-based;NTS_3.1
20173344_01;20173344;Cre<eb>ren van nieuwe bloedvaten voor pati<eb>nten met nierfalen, doormiddel van lokale weefsel constructie;Translational or applied research;human;In vivo testing of an electro spun vascular access graft under clinical conditions in a large animal model;ENG;goat;APX_2B;Urogenital or reproductive disorders;NTS_3.1;Naive or healthy;APX_2A;APX_2B;Appendix;similar anatomy;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;tissue construction;gene and cell-based;NTS_3.1
20173344_01;20173344;Cre<eb>ren van nieuwe bloedvaten voor pati<eb>nten met nierfalen, doormiddel van lokale weefsel constructie;Translational or applied research;human;In vivo testing of an electro spun vascular access graft under clinical conditions in a large animal model;ENG;goat;APX_2B;Urogenital or reproductive disorders;NTS_3.1;Naive or healthy;APX_2A;APX_2B;Appendix;similar anatomy;similar anatomy or organ system;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;expertise;APX_2D;tissue construction;gene and cell-based;NTS_3.1
20173344_01;20173344;Cre<eb>ren van nieuwe bloedvaten voor pati<eb>nten met nierfalen, doormiddel van lokale weefsel constructie;Translational or applied research;human;In vivo testing of an electro spun vascular access graft under clinical conditions in a large animal model;ENG;goat;APX_2B;Urogenital or reproductive disorders;NTS_3.1;Naive or healthy;APX_2A;APX_2B;Appendix;similar anatomy;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;expertise;APX_2D;tissue construction;gene and cell-based;NTS_3.1
20173344_01;20173344;Cre<eb>ren van nieuwe bloedvaten voor pati<eb>nten met nierfalen, doormiddel van lokale weefsel constructie;Translational or applied research;human;In vivo testing of an electro spun vascular access graft under clinical conditions in a large animal model;ENG;goat;APX_2B;Urogenital or reproductive disorders;NTS_3.1;Naive or healthy;APX_2A;APX_2B;Appendix;similar anatomy;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;expertise;APX_2D;tissue construction;gene and cell-based;NTS_3.1
20173344_01;20173344;Cre<eb>ren van nieuwe bloedvaten voor pati<eb>nten met nierfalen, doormiddel van lokale weefsel constructie;Translational or applied research;human;In vivo testing of an electro spun vascular access graft under clinical conditions in a large animal model;ENG;goat;APX_2B;Urogenital or reproductive disorders;NTS_3.1;Naive or healthy;APX_2A;APX_2B;Appendix;similar anatomy;similar anatomy or organ system;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;accomodation and care;cage enrichment;APX_2D;tissue construction;gene and cell-based;NTS_3.1
20173344_01;20173344;Cre<eb>ren van nieuwe bloedvaten voor pati<eb>nten met nierfalen, doormiddel van lokale weefsel constructie;Translational or applied research;human;In vivo testing of an electro spun vascular access graft under clinical conditions in a large animal model;ENG;goat;APX_2B;Urogenital or reproductive disorders;NTS_3.1;Naive or healthy;APX_2A;APX_2B;Appendix;similar anatomy;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;accomodation and care;cage enrichment;APX_2D;tissue construction;gene and cell-based;NTS_3.1
20173344_01;20173344;Cre<eb>ren van nieuwe bloedvaten voor pati<eb>nten met nierfalen, doormiddel van lokale weefsel constructie;Translational or applied research;human;In vivo testing of an electro spun vascular access graft under clinical conditions in a large animal model;ENG;goat;APX_2B;Urogenital or reproductive disorders;NTS_3.1;Naive or healthy;APX_2A;APX_2B;Appendix;similar anatomy;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;accomodation and care;cage enrichment;APX_2D;tissue construction;gene and cell-based;NTS_3.1
20173344_01;20173344;Cre<eb>ren van nieuwe bloedvaten voor pati<eb>nten met nierfalen, doormiddel van lokale weefsel constructie;Translational or applied research;human;In vivo testing of an electro spun vascular access graft under clinical conditions in a large animal model;ENG;goat;APX_2B;Urogenital or reproductive disorders;NTS_3.1;Naive or healthy;APX_2A;APX_2B;Appendix;similar anatomy;similar anatomy or organ system;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;tissue construction;gene and cell-based;NTS_3.1
20173344_01;20173344;Cre<eb>ren van nieuwe bloedvaten voor pati<eb>nten met nierfalen, doormiddel van lokale weefsel constructie;Translational or applied research;human;In vivo testing of an electro spun vascular access graft under clinical conditions in a large animal model;ENG;goat;APX_2B;Urogenital or reproductive disorders;NTS_3.1;Naive or healthy;APX_2A;APX_2B;Appendix;similar anatomy;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;tissue construction;gene and cell-based;NTS_3.1
20173344_01;20173344;Cre<eb>ren van nieuwe bloedvaten voor pati<eb>nten met nierfalen, doormiddel van lokale weefsel constructie;Translational or applied research;human;In vivo testing of an electro spun vascular access graft under clinical conditions in a large animal model;ENG;goat;APX_2B;Urogenital or reproductive disorders;NTS_3.1;Naive or healthy;APX_2A;APX_2B;Appendix;similar anatomy;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;tissue construction;gene and cell-based;NTS_3.1
20173344_01;20173344;Cre<eb>ren van nieuwe bloedvaten voor pati<eb>nten met nierfalen, doormiddel van lokale weefsel constructie;Translational or applied research;human;In vivo testing of an electro spun vascular access graft under clinical conditions in a large animal model;ENG;goat;APX_2B;Urogenital or reproductive disorders;NTS_3.1;Naive or healthy;APX_2A;APX_2B;Appendix;similar anatomy;similar anatomy or organ system;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;expertise;APX_2D;tissue construction;gene and cell-based;NTS_3.1
20173344_01;20173344;Cre<eb>ren van nieuwe bloedvaten voor pati<eb>nten met nierfalen, doormiddel van lokale weefsel constructie;Translational or applied research;human;In vivo testing of an electro spun vascular access graft under clinical conditions in a large animal model;ENG;goat;APX_2B;Urogenital or reproductive disorders;NTS_3.1;Naive or healthy;APX_2A;APX_2B;Appendix;similar anatomy;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;expertise;APX_2D;tissue construction;gene and cell-based;NTS_3.1
20173344_01;20173344;Cre<eb>ren van nieuwe bloedvaten voor pati<eb>nten met nierfalen, doormiddel van lokale weefsel constructie;Translational or applied research;human;In vivo testing of an electro spun vascular access graft under clinical conditions in a large animal model;ENG;goat;APX_2B;Urogenital or reproductive disorders;NTS_3.1;Naive or healthy;APX_2A;APX_2B;Appendix;similar anatomy;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;expertise;APX_2D;tissue construction;gene and cell-based;NTS_3.1
20173344_01;20173344;Cre<eb>ren van nieuwe bloedvaten voor pati<eb>nten met nierfalen, doormiddel van lokale weefsel constructie;Translational or applied research;human;In vivo testing of an electro spun vascular access graft under clinical conditions in a large animal model;ENG;goat;APX_2B;Urogenital or reproductive disorders;NTS_3.1;Naive or healthy;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;similar anatomy or organ system;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;accomodation and care;cage enrichment;APX_2D;tissue construction;gene and cell-based;NTS_3.1
20173344_01;20173344;Cre<eb>ren van nieuwe bloedvaten voor pati<eb>nten met nierfalen, doormiddel van lokale weefsel constructie;Translational or applied research;human;In vivo testing of an electro spun vascular access graft under clinical conditions in a large animal model;ENG;goat;APX_2B;Urogenital or reproductive disorders;NTS_3.1;Naive or healthy;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;experimental design;optimal combination of readouts;APX_2D;accomodation and care;cage enrichment;APX_2D;tissue construction;gene and cell-based;NTS_3.1
20173344_01;20173344;Cre<eb>ren van nieuwe bloedvaten voor pati<eb>nten met nierfalen, doormiddel van lokale weefsel constructie;Translational or applied research;human;In vivo testing of an electro spun vascular access graft under clinical conditions in a large animal model;ENG;goat;APX_2B;Urogenital or reproductive disorders;NTS_3.1;Naive or healthy;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;optimal combination of readouts;APX_2D;accomodation and care;cage enrichment;APX_2D;tissue construction;gene and cell-based;NTS_3.1
20173344_01;20173344;Cre<eb>ren van nieuwe bloedvaten voor pati<eb>nten met nierfalen, doormiddel van lokale weefsel constructie;Translational or applied research;human;In vivo testing of an electro spun vascular access graft under clinical conditions in a large animal model;ENG;goat;APX_2B;Urogenital or reproductive disorders;NTS_3.1;Naive or healthy;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;similar anatomy or organ system;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;tissue construction;gene and cell-based;NTS_3.1
20173344_01;20173344;Cre<eb>ren van nieuwe bloedvaten voor pati<eb>nten met nierfalen, doormiddel van lokale weefsel constructie;Translational or applied research;human;In vivo testing of an electro spun vascular access graft under clinical conditions in a large animal model;ENG;goat;APX_2B;Urogenital or reproductive disorders;NTS_3.1;Naive or healthy;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;tissue construction;gene and cell-based;NTS_3.1
20173344_01;20173344;Cre<eb>ren van nieuwe bloedvaten voor pati<eb>nten met nierfalen, doormiddel van lokale weefsel constructie;Translational or applied research;human;In vivo testing of an electro spun vascular access graft under clinical conditions in a large animal model;ENG;goat;APX_2B;Urogenital or reproductive disorders;NTS_3.1;Naive or healthy;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;tissue construction;gene and cell-based;NTS_3.1
20173344_01;20173344;Cre<eb>ren van nieuwe bloedvaten voor pati<eb>nten met nierfalen, doormiddel van lokale weefsel constructie;Translational or applied research;human;In vivo testing of an electro spun vascular access graft under clinical conditions in a large animal model;ENG;goat;APX_2B;Urogenital or reproductive disorders;NTS_3.1;Naive or healthy;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;similar anatomy or organ system;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;expertise;APX_2D;tissue construction;gene and cell-based;NTS_3.1
20173344_01;20173344;Cre<eb>ren van nieuwe bloedvaten voor pati<eb>nten met nierfalen, doormiddel van lokale weefsel constructie;Translational or applied research;human;In vivo testing of an electro spun vascular access graft under clinical conditions in a large animal model;ENG;goat;APX_2B;Urogenital or reproductive disorders;NTS_3.1;Naive or healthy;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;expertise;APX_2D;tissue construction;gene and cell-based;NTS_3.1
20173344_01;20173344;Cre<eb>ren van nieuwe bloedvaten voor pati<eb>nten met nierfalen, doormiddel van lokale weefsel constructie;Translational or applied research;human;In vivo testing of an electro spun vascular access graft under clinical conditions in a large animal model;ENG;goat;APX_2B;Urogenital or reproductive disorders;NTS_3.1;Naive or healthy;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;expertise;APX_2D;tissue construction;gene and cell-based;NTS_3.1
20173344_01;20173344;Cre<eb>ren van nieuwe bloedvaten voor pati<eb>nten met nierfalen, doormiddel van lokale weefsel constructie;Translational or applied research;human;In vivo testing of an electro spun vascular access graft under clinical conditions in a large animal model;ENG;goat;APX_2B;Urogenital or reproductive disorders;NTS_3.1;Naive or healthy;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;similar anatomy or organ system;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;accomodation and care;cage enrichment;APX_2D;tissue construction;gene and cell-based;NTS_3.1
20173344_01;20173344;Cre<eb>ren van nieuwe bloedvaten voor pati<eb>nten met nierfalen, doormiddel van lokale weefsel constructie;Translational or applied research;human;In vivo testing of an electro spun vascular access graft under clinical conditions in a large animal model;ENG;goat;APX_2B;Urogenital or reproductive disorders;NTS_3.1;Naive or healthy;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;accomodation and care;cage enrichment;APX_2D;tissue construction;gene and cell-based;NTS_3.1
20173344_01;20173344;Cre<eb>ren van nieuwe bloedvaten voor pati<eb>nten met nierfalen, doormiddel van lokale weefsel constructie;Translational or applied research;human;In vivo testing of an electro spun vascular access graft under clinical conditions in a large animal model;ENG;goat;APX_2B;Urogenital or reproductive disorders;NTS_3.1;Naive or healthy;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;accomodation and care;cage enrichment;APX_2D;tissue construction;gene and cell-based;NTS_3.1
20173344_01;20173344;Cre<eb>ren van nieuwe bloedvaten voor pati<eb>nten met nierfalen, doormiddel van lokale weefsel constructie;Translational or applied research;human;In vivo testing of an electro spun vascular access graft under clinical conditions in a large animal model;ENG;goat;APX_2B;Urogenital or reproductive disorders;NTS_3.1;Naive or healthy;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;similar anatomy or organ system;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;tissue construction;gene and cell-based;NTS_3.1
20173344_01;20173344;Cre<eb>ren van nieuwe bloedvaten voor pati<eb>nten met nierfalen, doormiddel van lokale weefsel constructie;Translational or applied research;human;In vivo testing of an electro spun vascular access graft under clinical conditions in a large animal model;ENG;goat;APX_2B;Urogenital or reproductive disorders;NTS_3.1;Naive or healthy;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;tissue construction;gene and cell-based;NTS_3.1
20173344_01;20173344;Cre<eb>ren van nieuwe bloedvaten voor pati<eb>nten met nierfalen, doormiddel van lokale weefsel constructie;Translational or applied research;human;In vivo testing of an electro spun vascular access graft under clinical conditions in a large animal model;ENG;goat;APX_2B;Urogenital or reproductive disorders;NTS_3.1;Naive or healthy;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;tissue construction;gene and cell-based;NTS_3.1
20173344_01;20173344;Cre<eb>ren van nieuwe bloedvaten voor pati<eb>nten met nierfalen, doormiddel van lokale weefsel constructie;Translational or applied research;human;In vivo testing of an electro spun vascular access graft under clinical conditions in a large animal model;ENG;goat;APX_2B;Urogenital or reproductive disorders;NTS_3.1;Naive or healthy;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;similar anatomy or organ system;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;expertise;APX_2D;tissue construction;gene and cell-based;NTS_3.1
20173344_01;20173344;Cre<eb>ren van nieuwe bloedvaten voor pati<eb>nten met nierfalen, doormiddel van lokale weefsel constructie;Translational or applied research;human;In vivo testing of an electro spun vascular access graft under clinical conditions in a large animal model;ENG;goat;APX_2B;Urogenital or reproductive disorders;NTS_3.1;Naive or healthy;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;expertise;APX_2D;tissue construction;gene and cell-based;NTS_3.1
20173344_01;20173344;Cre<eb>ren van nieuwe bloedvaten voor pati<eb>nten met nierfalen, doormiddel van lokale weefsel constructie;Translational or applied research;human;In vivo testing of an electro spun vascular access graft under clinical conditions in a large animal model;ENG;goat;APX_2B;Urogenital or reproductive disorders;NTS_3.1;Naive or healthy;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;expertise;APX_2D;tissue construction;gene and cell-based;NTS_3.1
20173344_01;20173344;Cre<eb>ren van nieuwe bloedvaten voor pati<eb>nten met nierfalen, doormiddel van lokale weefsel constructie;Translational or applied research;human;In vivo testing of an electro spun vascular access graft under clinical conditions in a large animal model;ENG;goat;APX_2B;Urogenital or reproductive disorders;NTS_3.1;Naive or healthy;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;accomodation and care;cage enrichment;APX_2D;tissue construction;gene and cell-based;NTS_3.1
20173344_01;20173344;Cre<eb>ren van nieuwe bloedvaten voor pati<eb>nten met nierfalen, doormiddel van lokale weefsel constructie;Translational or applied research;human;In vivo testing of an electro spun vascular access graft under clinical conditions in a large animal model;ENG;goat;APX_2B;Urogenital or reproductive disorders;NTS_3.1;Naive or healthy;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;experimental design;optimal combination of readouts;APX_2D;accomodation and care;cage enrichment;APX_2D;tissue construction;gene and cell-based;NTS_3.1
20173344_01;20173344;Cre<eb>ren van nieuwe bloedvaten voor pati<eb>nten met nierfalen, doormiddel van lokale weefsel constructie;Translational or applied research;human;In vivo testing of an electro spun vascular access graft under clinical conditions in a large animal model;ENG;goat;APX_2B;Urogenital or reproductive disorders;NTS_3.1;Naive or healthy;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;optimal combination of readouts;APX_2D;accomodation and care;cage enrichment;APX_2D;tissue construction;gene and cell-based;NTS_3.1
20173344_01;20173344;Cre<eb>ren van nieuwe bloedvaten voor pati<eb>nten met nierfalen, doormiddel van lokale weefsel constructie;Translational or applied research;human;In vivo testing of an electro spun vascular access graft under clinical conditions in a large animal model;ENG;goat;APX_2B;Urogenital or reproductive disorders;NTS_3.1;Naive or healthy;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;tissue construction;gene and cell-based;NTS_3.1
20173344_01;20173344;Cre<eb>ren van nieuwe bloedvaten voor pati<eb>nten met nierfalen, doormiddel van lokale weefsel constructie;Translational or applied research;human;In vivo testing of an electro spun vascular access graft under clinical conditions in a large animal model;ENG;goat;APX_2B;Urogenital or reproductive disorders;NTS_3.1;Naive or healthy;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;tissue construction;gene and cell-based;NTS_3.1
20173344_01;20173344;Cre<eb>ren van nieuwe bloedvaten voor pati<eb>nten met nierfalen, doormiddel van lokale weefsel constructie;Translational or applied research;human;In vivo testing of an electro spun vascular access graft under clinical conditions in a large animal model;ENG;goat;APX_2B;Urogenital or reproductive disorders;NTS_3.1;Naive or healthy;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;tissue construction;gene and cell-based;NTS_3.1
20173344_01;20173344;Cre<eb>ren van nieuwe bloedvaten voor pati<eb>nten met nierfalen, doormiddel van lokale weefsel constructie;Translational or applied research;human;In vivo testing of an electro spun vascular access graft under clinical conditions in a large animal model;ENG;goat;APX_2B;Urogenital or reproductive disorders;NTS_3.1;Naive or healthy;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;expertise;APX_2D;tissue construction;gene and cell-based;NTS_3.1
20173344_01;20173344;Cre<eb>ren van nieuwe bloedvaten voor pati<eb>nten met nierfalen, doormiddel van lokale weefsel constructie;Translational or applied research;human;In vivo testing of an electro spun vascular access graft under clinical conditions in a large animal model;ENG;goat;APX_2B;Urogenital or reproductive disorders;NTS_3.1;Naive or healthy;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;expertise;APX_2D;tissue construction;gene and cell-based;NTS_3.1
20173344_01;20173344;Cre<eb>ren van nieuwe bloedvaten voor pati<eb>nten met nierfalen, doormiddel van lokale weefsel constructie;Translational or applied research;human;In vivo testing of an electro spun vascular access graft under clinical conditions in a large animal model;ENG;goat;APX_2B;Urogenital or reproductive disorders;NTS_3.1;Naive or healthy;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;expertise;APX_2D;tissue construction;gene and cell-based;NTS_3.1
20173344_01;20173344;Cre<eb>ren van nieuwe bloedvaten voor pati<eb>nten met nierfalen, doormiddel van lokale weefsel constructie;Translational or applied research;human;In vivo testing of an electro spun vascular access graft under clinical conditions in a large animal model;ENG;goat;APX_2B;Urogenital or reproductive disorders;NTS_3.1;Naive or healthy;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;accomodation and care;cage enrichment;APX_2D;tissue construction;gene and cell-based;NTS_3.1
20173344_01;20173344;Cre<eb>ren van nieuwe bloedvaten voor pati<eb>nten met nierfalen, doormiddel van lokale weefsel constructie;Translational or applied research;human;In vivo testing of an electro spun vascular access graft under clinical conditions in a large animal model;ENG;goat;APX_2B;Urogenital or reproductive disorders;NTS_3.1;Naive or healthy;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;accomodation and care;cage enrichment;APX_2D;tissue construction;gene and cell-based;NTS_3.1
20173344_01;20173344;Cre<eb>ren van nieuwe bloedvaten voor pati<eb>nten met nierfalen, doormiddel van lokale weefsel constructie;Translational or applied research;human;In vivo testing of an electro spun vascular access graft under clinical conditions in a large animal model;ENG;goat;APX_2B;Urogenital or reproductive disorders;NTS_3.1;Naive or healthy;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;accomodation and care;cage enrichment;APX_2D;tissue construction;gene and cell-based;NTS_3.1
20173344_01;20173344;Cre<eb>ren van nieuwe bloedvaten voor pati<eb>nten met nierfalen, doormiddel van lokale weefsel constructie;Translational or applied research;human;In vivo testing of an electro spun vascular access graft under clinical conditions in a large animal model;ENG;goat;APX_2B;Urogenital or reproductive disorders;NTS_3.1;Naive or healthy;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;tissue construction;gene and cell-based;NTS_3.1
20173344_01;20173344;Cre<eb>ren van nieuwe bloedvaten voor pati<eb>nten met nierfalen, doormiddel van lokale weefsel constructie;Translational or applied research;human;In vivo testing of an electro spun vascular access graft under clinical conditions in a large animal model;ENG;goat;APX_2B;Urogenital or reproductive disorders;NTS_3.1;Naive or healthy;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;tissue construction;gene and cell-based;NTS_3.1
20173344_01;20173344;Cre<eb>ren van nieuwe bloedvaten voor pati<eb>nten met nierfalen, doormiddel van lokale weefsel constructie;Translational or applied research;human;In vivo testing of an electro spun vascular access graft under clinical conditions in a large animal model;ENG;goat;APX_2B;Urogenital or reproductive disorders;NTS_3.1;Naive or healthy;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;tissue construction;gene and cell-based;NTS_3.1
20173344_01;20173344;Cre<eb>ren van nieuwe bloedvaten voor pati<eb>nten met nierfalen, doormiddel van lokale weefsel constructie;Translational or applied research;human;In vivo testing of an electro spun vascular access graft under clinical conditions in a large animal model;ENG;goat;APX_2B;Urogenital or reproductive disorders;NTS_3.1;Naive or healthy;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;expertise;APX_2D;tissue construction;gene and cell-based;NTS_3.1
20173344_01;20173344;Cre<eb>ren van nieuwe bloedvaten voor pati<eb>nten met nierfalen, doormiddel van lokale weefsel constructie;Translational or applied research;human;In vivo testing of an electro spun vascular access graft under clinical conditions in a large animal model;ENG;goat;APX_2B;Urogenital or reproductive disorders;NTS_3.1;Naive or healthy;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;expertise;APX_2D;tissue construction;gene and cell-based;NTS_3.1
20173344_01;20173344;Cre<eb>ren van nieuwe bloedvaten voor pati<eb>nten met nierfalen, doormiddel van lokale weefsel constructie;Translational or applied research;human;In vivo testing of an electro spun vascular access graft under clinical conditions in a large animal model;ENG;goat;APX_2B;Urogenital or reproductive disorders;NTS_3.1;Naive or healthy;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;expertise;APX_2D;tissue construction;gene and cell-based;NTS_3.1
20173344_02;20173344;Cre<eb>ren van nieuwe bloedvaten voor pati<eb>nten met nierfalen, doormiddel van lokale weefsel constructie;Translational or applied research;human;Desitining an optimal in situ tissue enineered vascular grafts in the rat;ENG;rat;APX_2B;Urogenital or reproductive disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;prefered to other model;cost effectiveness;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;optimal combination of readouts;APX_2D;accomodation and care;cage enrichment;APX_2D;tissue construction;gene and cell-based;NTS_3.1
20173344_02;20173344;Cre<eb>ren van nieuwe bloedvaten voor pati<eb>nten met nierfalen, doormiddel van lokale weefsel constructie;Translational or applied research;human;Desitining an optimal in situ tissue enineered vascular grafts in the rat;ENG;rat;APX_2B;Urogenital or reproductive disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;prefered to other model;cost effectiveness;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;accomodation and care;cage enrichment;APX_2D;tissue construction;gene and cell-based;NTS_3.1
20173344_02;20173344;Cre<eb>ren van nieuwe bloedvaten voor pati<eb>nten met nierfalen, doormiddel van lokale weefsel constructie;Translational or applied research;human;Desitining an optimal in situ tissue enineered vascular grafts in the rat;ENG;rat;APX_2B;Urogenital or reproductive disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;prefered to other model;cost effectiveness;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;tissue construction;gene and cell-based;NTS_3.1
20173344_02;20173344;Cre<eb>ren van nieuwe bloedvaten voor pati<eb>nten met nierfalen, doormiddel van lokale weefsel constructie;Translational or applied research;human;Desitining an optimal in situ tissue enineered vascular grafts in the rat;ENG;rat;APX_2B;Urogenital or reproductive disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;prefered to other model;cost effectiveness;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;tissue construction;gene and cell-based;NTS_3.1
20173344_02;20173344;Cre<eb>ren van nieuwe bloedvaten voor pati<eb>nten met nierfalen, doormiddel van lokale weefsel constructie;Translational or applied research;human;Desitining an optimal in situ tissue enineered vascular grafts in the rat;ENG;rat;APX_2B;Urogenital or reproductive disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;prefered to other model;cost effectiveness;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;tissue construction;gene and cell-based;NTS_3.1
20173344_02;20173344;Cre<eb>ren van nieuwe bloedvaten voor pati<eb>nten met nierfalen, doormiddel van lokale weefsel constructie;Translational or applied research;human;Desitining an optimal in situ tissue enineered vascular grafts in the rat;ENG;rat;APX_2B;Urogenital or reproductive disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;prefered to other model;cost effectiveness;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;tissue construction;gene and cell-based;NTS_3.1
20173344_02;20173344;Cre<eb>ren van nieuwe bloedvaten voor pati<eb>nten met nierfalen, doormiddel van lokale weefsel constructie;Translational or applied research;human;Desitining an optimal in situ tissue enineered vascular grafts in the rat;ENG;rat;APX_2B;Urogenital or reproductive disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;prefered to other model;cost effectiveness;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;expertise;APX_2D;tissue construction;gene and cell-based;NTS_3.1
20173344_02;20173344;Cre<eb>ren van nieuwe bloedvaten voor pati<eb>nten met nierfalen, doormiddel van lokale weefsel constructie;Translational or applied research;human;Desitining an optimal in situ tissue enineered vascular grafts in the rat;ENG;rat;APX_2B;Urogenital or reproductive disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;prefered to other model;cost effectiveness;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;expertise;APX_2D;tissue construction;gene and cell-based;NTS_3.1
20173344_02;20173344;Cre<eb>ren van nieuwe bloedvaten voor pati<eb>nten met nierfalen, doormiddel van lokale weefsel constructie;Translational or applied research;human;Desitining an optimal in situ tissue enineered vascular grafts in the rat;ENG;rat;APX_2B;Urogenital or reproductive disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;prefered to other model;cost effectiveness;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;optimal combination of readouts;APX_2D;accomodation and care;cage enrichment;APX_2D;tissue construction;gene and cell-based;NTS_3.1
20173344_02;20173344;Cre<eb>ren van nieuwe bloedvaten voor pati<eb>nten met nierfalen, doormiddel van lokale weefsel constructie;Translational or applied research;human;Desitining an optimal in situ tissue enineered vascular grafts in the rat;ENG;rat;APX_2B;Urogenital or reproductive disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;prefered to other model;cost effectiveness;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;accomodation and care;cage enrichment;APX_2D;tissue construction;gene and cell-based;NTS_3.1
20173344_02;20173344;Cre<eb>ren van nieuwe bloedvaten voor pati<eb>nten met nierfalen, doormiddel van lokale weefsel constructie;Translational or applied research;human;Desitining an optimal in situ tissue enineered vascular grafts in the rat;ENG;rat;APX_2B;Urogenital or reproductive disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;prefered to other model;cost effectiveness;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;tissue construction;gene and cell-based;NTS_3.1
20173344_02;20173344;Cre<eb>ren van nieuwe bloedvaten voor pati<eb>nten met nierfalen, doormiddel van lokale weefsel constructie;Translational or applied research;human;Desitining an optimal in situ tissue enineered vascular grafts in the rat;ENG;rat;APX_2B;Urogenital or reproductive disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;prefered to other model;cost effectiveness;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;tissue construction;gene and cell-based;NTS_3.1
20173344_02;20173344;Cre<eb>ren van nieuwe bloedvaten voor pati<eb>nten met nierfalen, doormiddel van lokale weefsel constructie;Translational or applied research;human;Desitining an optimal in situ tissue enineered vascular grafts in the rat;ENG;rat;APX_2B;Urogenital or reproductive disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;prefered to other model;cost effectiveness;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;tissue construction;gene and cell-based;NTS_3.1
20173344_02;20173344;Cre<eb>ren van nieuwe bloedvaten voor pati<eb>nten met nierfalen, doormiddel van lokale weefsel constructie;Translational or applied research;human;Desitining an optimal in situ tissue enineered vascular grafts in the rat;ENG;rat;APX_2B;Urogenital or reproductive disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;prefered to other model;cost effectiveness;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;tissue construction;gene and cell-based;NTS_3.1
20173344_02;20173344;Cre<eb>ren van nieuwe bloedvaten voor pati<eb>nten met nierfalen, doormiddel van lokale weefsel constructie;Translational or applied research;human;Desitining an optimal in situ tissue enineered vascular grafts in the rat;ENG;rat;APX_2B;Urogenital or reproductive disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;prefered to other model;cost effectiveness;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;expertise;APX_2D;tissue construction;gene and cell-based;NTS_3.1
20173344_02;20173344;Cre<eb>ren van nieuwe bloedvaten voor pati<eb>nten met nierfalen, doormiddel van lokale weefsel constructie;Translational or applied research;human;Desitining an optimal in situ tissue enineered vascular grafts in the rat;ENG;rat;APX_2B;Urogenital or reproductive disorders;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;prefered to other model;cost effectiveness;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;expertise;APX_2D;tissue construction;gene and cell-based;NTS_3.1
20173344_02;20173344;Cre<eb>ren van nieuwe bloedvaten voor pati<eb>nten met nierfalen, doormiddel van lokale weefsel constructie;Translational or applied research;human;Desitining an optimal in situ tissue enineered vascular grafts in the rat;ENG;rat;APX_2B;Urogenital or reproductive disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;cost effectiveness;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;optimal combination of readouts;APX_2D;accomodation and care;cage enrichment;APX_2D;tissue construction;gene and cell-based;NTS_3.1
20173344_02;20173344;Cre<eb>ren van nieuwe bloedvaten voor pati<eb>nten met nierfalen, doormiddel van lokale weefsel constructie;Translational or applied research;human;Desitining an optimal in situ tissue enineered vascular grafts in the rat;ENG;rat;APX_2B;Urogenital or reproductive disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;cost effectiveness;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;accomodation and care;cage enrichment;APX_2D;tissue construction;gene and cell-based;NTS_3.1
20173344_02;20173344;Cre<eb>ren van nieuwe bloedvaten voor pati<eb>nten met nierfalen, doormiddel van lokale weefsel constructie;Translational or applied research;human;Desitining an optimal in situ tissue enineered vascular grafts in the rat;ENG;rat;APX_2B;Urogenital or reproductive disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;cost effectiveness;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;tissue construction;gene and cell-based;NTS_3.1
20173344_02;20173344;Cre<eb>ren van nieuwe bloedvaten voor pati<eb>nten met nierfalen, doormiddel van lokale weefsel constructie;Translational or applied research;human;Desitining an optimal in situ tissue enineered vascular grafts in the rat;ENG;rat;APX_2B;Urogenital or reproductive disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;cost effectiveness;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;tissue construction;gene and cell-based;NTS_3.1
20173344_02;20173344;Cre<eb>ren van nieuwe bloedvaten voor pati<eb>nten met nierfalen, doormiddel van lokale weefsel constructie;Translational or applied research;human;Desitining an optimal in situ tissue enineered vascular grafts in the rat;ENG;rat;APX_2B;Urogenital or reproductive disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;cost effectiveness;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;tissue construction;gene and cell-based;NTS_3.1
20173344_02;20173344;Cre<eb>ren van nieuwe bloedvaten voor pati<eb>nten met nierfalen, doormiddel van lokale weefsel constructie;Translational or applied research;human;Desitining an optimal in situ tissue enineered vascular grafts in the rat;ENG;rat;APX_2B;Urogenital or reproductive disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;cost effectiveness;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;tissue construction;gene and cell-based;NTS_3.1
20173344_02;20173344;Cre<eb>ren van nieuwe bloedvaten voor pati<eb>nten met nierfalen, doormiddel van lokale weefsel constructie;Translational or applied research;human;Desitining an optimal in situ tissue enineered vascular grafts in the rat;ENG;rat;APX_2B;Urogenital or reproductive disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;cost effectiveness;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;expertise;APX_2D;tissue construction;gene and cell-based;NTS_3.1
20173344_02;20173344;Cre<eb>ren van nieuwe bloedvaten voor pati<eb>nten met nierfalen, doormiddel van lokale weefsel constructie;Translational or applied research;human;Desitining an optimal in situ tissue enineered vascular grafts in the rat;ENG;rat;APX_2B;Urogenital or reproductive disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;cost effectiveness;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;expertise;APX_2D;tissue construction;gene and cell-based;NTS_3.1
20173344_02;20173344;Cre<eb>ren van nieuwe bloedvaten voor pati<eb>nten met nierfalen, doormiddel van lokale weefsel constructie;Translational or applied research;human;Desitining an optimal in situ tissue enineered vascular grafts in the rat;ENG;rat;APX_2B;Urogenital or reproductive disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;cost effectiveness;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;optimal combination of readouts;APX_2D;accomodation and care;cage enrichment;APX_2D;tissue construction;gene and cell-based;NTS_3.1
20173344_02;20173344;Cre<eb>ren van nieuwe bloedvaten voor pati<eb>nten met nierfalen, doormiddel van lokale weefsel constructie;Translational or applied research;human;Desitining an optimal in situ tissue enineered vascular grafts in the rat;ENG;rat;APX_2B;Urogenital or reproductive disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;cost effectiveness;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;accomodation and care;cage enrichment;APX_2D;tissue construction;gene and cell-based;NTS_3.1
20173344_02;20173344;Cre<eb>ren van nieuwe bloedvaten voor pati<eb>nten met nierfalen, doormiddel van lokale weefsel constructie;Translational or applied research;human;Desitining an optimal in situ tissue enineered vascular grafts in the rat;ENG;rat;APX_2B;Urogenital or reproductive disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;cost effectiveness;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;tissue construction;gene and cell-based;NTS_3.1
20173344_02;20173344;Cre<eb>ren van nieuwe bloedvaten voor pati<eb>nten met nierfalen, doormiddel van lokale weefsel constructie;Translational or applied research;human;Desitining an optimal in situ tissue enineered vascular grafts in the rat;ENG;rat;APX_2B;Urogenital or reproductive disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;cost effectiveness;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;tissue construction;gene and cell-based;NTS_3.1
20173344_02;20173344;Cre<eb>ren van nieuwe bloedvaten voor pati<eb>nten met nierfalen, doormiddel van lokale weefsel constructie;Translational or applied research;human;Desitining an optimal in situ tissue enineered vascular grafts in the rat;ENG;rat;APX_2B;Urogenital or reproductive disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;cost effectiveness;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;tissue construction;gene and cell-based;NTS_3.1
20173344_02;20173344;Cre<eb>ren van nieuwe bloedvaten voor pati<eb>nten met nierfalen, doormiddel van lokale weefsel constructie;Translational or applied research;human;Desitining an optimal in situ tissue enineered vascular grafts in the rat;ENG;rat;APX_2B;Urogenital or reproductive disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;cost effectiveness;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;tissue construction;gene and cell-based;NTS_3.1
20173344_02;20173344;Cre<eb>ren van nieuwe bloedvaten voor pati<eb>nten met nierfalen, doormiddel van lokale weefsel constructie;Translational or applied research;human;Desitining an optimal in situ tissue enineered vascular grafts in the rat;ENG;rat;APX_2B;Urogenital or reproductive disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;cost effectiveness;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;expertise;APX_2D;tissue construction;gene and cell-based;NTS_3.1
20173344_02;20173344;Cre<eb>ren van nieuwe bloedvaten voor pati<eb>nten met nierfalen, doormiddel van lokale weefsel constructie;Translational or applied research;human;Desitining an optimal in situ tissue enineered vascular grafts in the rat;ENG;rat;APX_2B;Urogenital or reproductive disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;cost effectiveness;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;expertise;APX_2D;tissue construction;gene and cell-based;NTS_3.1
20173344_02;20173344;Cre<eb>ren van nieuwe bloedvaten voor pati<eb>nten met nierfalen, doormiddel van lokale weefsel constructie;Translational or applied research;human;Desitining an optimal in situ tissue enineered vascular grafts in the rat;ENG;rat;APX_2B;Urogenital or reproductive disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;prefered to other model;cost effectiveness;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;optimal combination of readouts;APX_2D;accomodation and care;cage enrichment;APX_2D;tissue construction;gene and cell-based;NTS_3.1
20173344_02;20173344;Cre<eb>ren van nieuwe bloedvaten voor pati<eb>nten met nierfalen, doormiddel van lokale weefsel constructie;Translational or applied research;human;Desitining an optimal in situ tissue enineered vascular grafts in the rat;ENG;rat;APX_2B;Urogenital or reproductive disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;prefered to other model;cost effectiveness;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;accomodation and care;cage enrichment;APX_2D;tissue construction;gene and cell-based;NTS_3.1
20173344_02;20173344;Cre<eb>ren van nieuwe bloedvaten voor pati<eb>nten met nierfalen, doormiddel van lokale weefsel constructie;Translational or applied research;human;Desitining an optimal in situ tissue enineered vascular grafts in the rat;ENG;rat;APX_2B;Urogenital or reproductive disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;prefered to other model;cost effectiveness;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;tissue construction;gene and cell-based;NTS_3.1
20173344_02;20173344;Cre<eb>ren van nieuwe bloedvaten voor pati<eb>nten met nierfalen, doormiddel van lokale weefsel constructie;Translational or applied research;human;Desitining an optimal in situ tissue enineered vascular grafts in the rat;ENG;rat;APX_2B;Urogenital or reproductive disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;prefered to other model;cost effectiveness;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;tissue construction;gene and cell-based;NTS_3.1
20173344_02;20173344;Cre<eb>ren van nieuwe bloedvaten voor pati<eb>nten met nierfalen, doormiddel van lokale weefsel constructie;Translational or applied research;human;Desitining an optimal in situ tissue enineered vascular grafts in the rat;ENG;rat;APX_2B;Urogenital or reproductive disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;prefered to other model;cost effectiveness;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;tissue construction;gene and cell-based;NTS_3.1
20173344_02;20173344;Cre<eb>ren van nieuwe bloedvaten voor pati<eb>nten met nierfalen, doormiddel van lokale weefsel constructie;Translational or applied research;human;Desitining an optimal in situ tissue enineered vascular grafts in the rat;ENG;rat;APX_2B;Urogenital or reproductive disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;prefered to other model;cost effectiveness;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;tissue construction;gene and cell-based;NTS_3.1
20173344_02;20173344;Cre<eb>ren van nieuwe bloedvaten voor pati<eb>nten met nierfalen, doormiddel van lokale weefsel constructie;Translational or applied research;human;Desitining an optimal in situ tissue enineered vascular grafts in the rat;ENG;rat;APX_2B;Urogenital or reproductive disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;prefered to other model;cost effectiveness;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;expertise;APX_2D;tissue construction;gene and cell-based;NTS_3.1
20173344_02;20173344;Cre<eb>ren van nieuwe bloedvaten voor pati<eb>nten met nierfalen, doormiddel van lokale weefsel constructie;Translational or applied research;human;Desitining an optimal in situ tissue enineered vascular grafts in the rat;ENG;rat;APX_2B;Urogenital or reproductive disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;prefered to other model;cost effectiveness;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;expertise;APX_2D;tissue construction;gene and cell-based;NTS_3.1
20173344_02;20173344;Cre<eb>ren van nieuwe bloedvaten voor pati<eb>nten met nierfalen, doormiddel van lokale weefsel constructie;Translational or applied research;human;Desitining an optimal in situ tissue enineered vascular grafts in the rat;ENG;rat;APX_2B;Urogenital or reproductive disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;prefered to other model;cost effectiveness;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;optimal combination of readouts;APX_2D;accomodation and care;cage enrichment;APX_2D;tissue construction;gene and cell-based;NTS_3.1
20173344_02;20173344;Cre<eb>ren van nieuwe bloedvaten voor pati<eb>nten met nierfalen, doormiddel van lokale weefsel constructie;Translational or applied research;human;Desitining an optimal in situ tissue enineered vascular grafts in the rat;ENG;rat;APX_2B;Urogenital or reproductive disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;prefered to other model;cost effectiveness;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;accomodation and care;cage enrichment;APX_2D;tissue construction;gene and cell-based;NTS_3.1
20173344_02;20173344;Cre<eb>ren van nieuwe bloedvaten voor pati<eb>nten met nierfalen, doormiddel van lokale weefsel constructie;Translational or applied research;human;Desitining an optimal in situ tissue enineered vascular grafts in the rat;ENG;rat;APX_2B;Urogenital or reproductive disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;prefered to other model;cost effectiveness;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;tissue construction;gene and cell-based;NTS_3.1
20173344_02;20173344;Cre<eb>ren van nieuwe bloedvaten voor pati<eb>nten met nierfalen, doormiddel van lokale weefsel constructie;Translational or applied research;human;Desitining an optimal in situ tissue enineered vascular grafts in the rat;ENG;rat;APX_2B;Urogenital or reproductive disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;prefered to other model;cost effectiveness;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;tissue construction;gene and cell-based;NTS_3.1
20173344_02;20173344;Cre<eb>ren van nieuwe bloedvaten voor pati<eb>nten met nierfalen, doormiddel van lokale weefsel constructie;Translational or applied research;human;Desitining an optimal in situ tissue enineered vascular grafts in the rat;ENG;rat;APX_2B;Urogenital or reproductive disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;prefered to other model;cost effectiveness;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;tissue construction;gene and cell-based;NTS_3.1
20173344_02;20173344;Cre<eb>ren van nieuwe bloedvaten voor pati<eb>nten met nierfalen, doormiddel van lokale weefsel constructie;Translational or applied research;human;Desitining an optimal in situ tissue enineered vascular grafts in the rat;ENG;rat;APX_2B;Urogenital or reproductive disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;prefered to other model;cost effectiveness;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;tissue construction;gene and cell-based;NTS_3.1
20173344_02;20173344;Cre<eb>ren van nieuwe bloedvaten voor pati<eb>nten met nierfalen, doormiddel van lokale weefsel constructie;Translational or applied research;human;Desitining an optimal in situ tissue enineered vascular grafts in the rat;ENG;rat;APX_2B;Urogenital or reproductive disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;prefered to other model;cost effectiveness;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;expertise;APX_2D;tissue construction;gene and cell-based;NTS_3.1
20173344_02;20173344;Cre<eb>ren van nieuwe bloedvaten voor pati<eb>nten met nierfalen, doormiddel van lokale weefsel constructie;Translational or applied research;human;Desitining an optimal in situ tissue enineered vascular grafts in the rat;ENG;rat;APX_2B;Urogenital or reproductive disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;prefered to other model;cost effectiveness;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;expertise;APX_2D;tissue construction;gene and cell-based;NTS_3.1
20173344_02;20173344;Cre<eb>ren van nieuwe bloedvaten voor pati<eb>nten met nierfalen, doormiddel van lokale weefsel constructie;Translational or applied research;human;Desitining an optimal in situ tissue enineered vascular grafts in the rat;ENG;rat;APX_2B;Urogenital or reproductive disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;prefered to other model;cost effectiveness;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;optimal combination of readouts;APX_2D;accomodation and care;cage enrichment;APX_2D;tissue construction;gene and cell-based;NTS_3.1
20173344_02;20173344;Cre<eb>ren van nieuwe bloedvaten voor pati<eb>nten met nierfalen, doormiddel van lokale weefsel constructie;Translational or applied research;human;Desitining an optimal in situ tissue enineered vascular grafts in the rat;ENG;rat;APX_2B;Urogenital or reproductive disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;prefered to other model;cost effectiveness;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;accomodation and care;cage enrichment;APX_2D;tissue construction;gene and cell-based;NTS_3.1
20173344_02;20173344;Cre<eb>ren van nieuwe bloedvaten voor pati<eb>nten met nierfalen, doormiddel van lokale weefsel constructie;Translational or applied research;human;Desitining an optimal in situ tissue enineered vascular grafts in the rat;ENG;rat;APX_2B;Urogenital or reproductive disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;prefered to other model;cost effectiveness;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;tissue construction;gene and cell-based;NTS_3.1
20173344_02;20173344;Cre<eb>ren van nieuwe bloedvaten voor pati<eb>nten met nierfalen, doormiddel van lokale weefsel constructie;Translational or applied research;human;Desitining an optimal in situ tissue enineered vascular grafts in the rat;ENG;rat;APX_2B;Urogenital or reproductive disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;prefered to other model;cost effectiveness;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;tissue construction;gene and cell-based;NTS_3.1
20173344_02;20173344;Cre<eb>ren van nieuwe bloedvaten voor pati<eb>nten met nierfalen, doormiddel van lokale weefsel constructie;Translational or applied research;human;Desitining an optimal in situ tissue enineered vascular grafts in the rat;ENG;rat;APX_2B;Urogenital or reproductive disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;prefered to other model;cost effectiveness;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;tissue construction;gene and cell-based;NTS_3.1
20173344_02;20173344;Cre<eb>ren van nieuwe bloedvaten voor pati<eb>nten met nierfalen, doormiddel van lokale weefsel constructie;Translational or applied research;human;Desitining an optimal in situ tissue enineered vascular grafts in the rat;ENG;rat;APX_2B;Urogenital or reproductive disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;prefered to other model;cost effectiveness;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;tissue construction;gene and cell-based;NTS_3.1
20173344_02;20173344;Cre<eb>ren van nieuwe bloedvaten voor pati<eb>nten met nierfalen, doormiddel van lokale weefsel constructie;Translational or applied research;human;Desitining an optimal in situ tissue enineered vascular grafts in the rat;ENG;rat;APX_2B;Urogenital or reproductive disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;prefered to other model;cost effectiveness;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;expertise;APX_2D;tissue construction;gene and cell-based;NTS_3.1
20173344_02;20173344;Cre<eb>ren van nieuwe bloedvaten voor pati<eb>nten met nierfalen, doormiddel van lokale weefsel constructie;Translational or applied research;human;Desitining an optimal in situ tissue enineered vascular grafts in the rat;ENG;rat;APX_2B;Urogenital or reproductive disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;prefered to other model;cost effectiveness;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;expertise;APX_2D;tissue construction;gene and cell-based;NTS_3.1
20173344_02;20173344;Cre<eb>ren van nieuwe bloedvaten voor pati<eb>nten met nierfalen, doormiddel van lokale weefsel constructie;Translational or applied research;human;Desitining an optimal in situ tissue enineered vascular grafts in the rat;ENG;rat;APX_2B;Urogenital or reproductive disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;prefered to other model;cost effectiveness;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;optimal combination of readouts;APX_2D;accomodation and care;cage enrichment;APX_2D;tissue construction;gene and cell-based;NTS_3.1
20173344_02;20173344;Cre<eb>ren van nieuwe bloedvaten voor pati<eb>nten met nierfalen, doormiddel van lokale weefsel constructie;Translational or applied research;human;Desitining an optimal in situ tissue enineered vascular grafts in the rat;ENG;rat;APX_2B;Urogenital or reproductive disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;prefered to other model;cost effectiveness;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;accomodation and care;cage enrichment;APX_2D;tissue construction;gene and cell-based;NTS_3.1
20173344_02;20173344;Cre<eb>ren van nieuwe bloedvaten voor pati<eb>nten met nierfalen, doormiddel van lokale weefsel constructie;Translational or applied research;human;Desitining an optimal in situ tissue enineered vascular grafts in the rat;ENG;rat;APX_2B;Urogenital or reproductive disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;prefered to other model;cost effectiveness;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;tissue construction;gene and cell-based;NTS_3.1
20173344_02;20173344;Cre<eb>ren van nieuwe bloedvaten voor pati<eb>nten met nierfalen, doormiddel van lokale weefsel constructie;Translational or applied research;human;Desitining an optimal in situ tissue enineered vascular grafts in the rat;ENG;rat;APX_2B;Urogenital or reproductive disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;prefered to other model;cost effectiveness;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;tissue construction;gene and cell-based;NTS_3.1
20173344_02;20173344;Cre<eb>ren van nieuwe bloedvaten voor pati<eb>nten met nierfalen, doormiddel van lokale weefsel constructie;Translational or applied research;human;Desitining an optimal in situ tissue enineered vascular grafts in the rat;ENG;rat;APX_2B;Urogenital or reproductive disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;prefered to other model;cost effectiveness;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;tissue construction;gene and cell-based;NTS_3.1
20173344_02;20173344;Cre<eb>ren van nieuwe bloedvaten voor pati<eb>nten met nierfalen, doormiddel van lokale weefsel constructie;Translational or applied research;human;Desitining an optimal in situ tissue enineered vascular grafts in the rat;ENG;rat;APX_2B;Urogenital or reproductive disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;prefered to other model;cost effectiveness;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;tissue construction;gene and cell-based;NTS_3.1
20173344_02;20173344;Cre<eb>ren van nieuwe bloedvaten voor pati<eb>nten met nierfalen, doormiddel van lokale weefsel constructie;Translational or applied research;human;Desitining an optimal in situ tissue enineered vascular grafts in the rat;ENG;rat;APX_2B;Urogenital or reproductive disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;prefered to other model;cost effectiveness;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;expertise;APX_2D;tissue construction;gene and cell-based;NTS_3.1
20173344_02;20173344;Cre<eb>ren van nieuwe bloedvaten voor pati<eb>nten met nierfalen, doormiddel van lokale weefsel constructie;Translational or applied research;human;Desitining an optimal in situ tissue enineered vascular grafts in the rat;ENG;rat;APX_2B;Urogenital or reproductive disorders;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;prefered to other model;cost effectiveness;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;expertise;APX_2D;tissue construction;gene and cell-based;NTS_3.1
20173344_02;20173344;Cre<eb>ren van nieuwe bloedvaten voor pati<eb>nten met nierfalen, doormiddel van lokale weefsel constructie;Translational or applied research;human;Desitining an optimal in situ tissue enineered vascular grafts in the rat;ENG;rat;APX_2B;Urogenital or reproductive disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;cost effectiveness;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;optimal combination of readouts;APX_2D;accomodation and care;cage enrichment;APX_2D;tissue construction;gene and cell-based;NTS_3.1
20173344_02;20173344;Cre<eb>ren van nieuwe bloedvaten voor pati<eb>nten met nierfalen, doormiddel van lokale weefsel constructie;Translational or applied research;human;Desitining an optimal in situ tissue enineered vascular grafts in the rat;ENG;rat;APX_2B;Urogenital or reproductive disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;cost effectiveness;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;accomodation and care;cage enrichment;APX_2D;tissue construction;gene and cell-based;NTS_3.1
20173344_02;20173344;Cre<eb>ren van nieuwe bloedvaten voor pati<eb>nten met nierfalen, doormiddel van lokale weefsel constructie;Translational or applied research;human;Desitining an optimal in situ tissue enineered vascular grafts in the rat;ENG;rat;APX_2B;Urogenital or reproductive disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;cost effectiveness;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;tissue construction;gene and cell-based;NTS_3.1
20173344_02;20173344;Cre<eb>ren van nieuwe bloedvaten voor pati<eb>nten met nierfalen, doormiddel van lokale weefsel constructie;Translational or applied research;human;Desitining an optimal in situ tissue enineered vascular grafts in the rat;ENG;rat;APX_2B;Urogenital or reproductive disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;cost effectiveness;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;tissue construction;gene and cell-based;NTS_3.1
20173344_02;20173344;Cre<eb>ren van nieuwe bloedvaten voor pati<eb>nten met nierfalen, doormiddel van lokale weefsel constructie;Translational or applied research;human;Desitining an optimal in situ tissue enineered vascular grafts in the rat;ENG;rat;APX_2B;Urogenital or reproductive disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;cost effectiveness;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;tissue construction;gene and cell-based;NTS_3.1
20173344_02;20173344;Cre<eb>ren van nieuwe bloedvaten voor pati<eb>nten met nierfalen, doormiddel van lokale weefsel constructie;Translational or applied research;human;Desitining an optimal in situ tissue enineered vascular grafts in the rat;ENG;rat;APX_2B;Urogenital or reproductive disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;cost effectiveness;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;tissue construction;gene and cell-based;NTS_3.1
20173344_02;20173344;Cre<eb>ren van nieuwe bloedvaten voor pati<eb>nten met nierfalen, doormiddel van lokale weefsel constructie;Translational or applied research;human;Desitining an optimal in situ tissue enineered vascular grafts in the rat;ENG;rat;APX_2B;Urogenital or reproductive disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;cost effectiveness;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;expertise;APX_2D;tissue construction;gene and cell-based;NTS_3.1
20173344_02;20173344;Cre<eb>ren van nieuwe bloedvaten voor pati<eb>nten met nierfalen, doormiddel van lokale weefsel constructie;Translational or applied research;human;Desitining an optimal in situ tissue enineered vascular grafts in the rat;ENG;rat;APX_2B;Urogenital or reproductive disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;cost effectiveness;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;expertise;APX_2D;tissue construction;gene and cell-based;NTS_3.1
20173344_02;20173344;Cre<eb>ren van nieuwe bloedvaten voor pati<eb>nten met nierfalen, doormiddel van lokale weefsel constructie;Translational or applied research;human;Desitining an optimal in situ tissue enineered vascular grafts in the rat;ENG;rat;APX_2B;Urogenital or reproductive disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;cost effectiveness;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;optimal combination of readouts;APX_2D;accomodation and care;cage enrichment;APX_2D;tissue construction;gene and cell-based;NTS_3.1
20173344_02;20173344;Cre<eb>ren van nieuwe bloedvaten voor pati<eb>nten met nierfalen, doormiddel van lokale weefsel constructie;Translational or applied research;human;Desitining an optimal in situ tissue enineered vascular grafts in the rat;ENG;rat;APX_2B;Urogenital or reproductive disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;cost effectiveness;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;accomodation and care;cage enrichment;APX_2D;tissue construction;gene and cell-based;NTS_3.1
20173344_02;20173344;Cre<eb>ren van nieuwe bloedvaten voor pati<eb>nten met nierfalen, doormiddel van lokale weefsel constructie;Translational or applied research;human;Desitining an optimal in situ tissue enineered vascular grafts in the rat;ENG;rat;APX_2B;Urogenital or reproductive disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;cost effectiveness;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;tissue construction;gene and cell-based;NTS_3.1
20173344_02;20173344;Cre<eb>ren van nieuwe bloedvaten voor pati<eb>nten met nierfalen, doormiddel van lokale weefsel constructie;Translational or applied research;human;Desitining an optimal in situ tissue enineered vascular grafts in the rat;ENG;rat;APX_2B;Urogenital or reproductive disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;cost effectiveness;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;tissue construction;gene and cell-based;NTS_3.1
20173344_02;20173344;Cre<eb>ren van nieuwe bloedvaten voor pati<eb>nten met nierfalen, doormiddel van lokale weefsel constructie;Translational or applied research;human;Desitining an optimal in situ tissue enineered vascular grafts in the rat;ENG;rat;APX_2B;Urogenital or reproductive disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;cost effectiveness;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;tissue construction;gene and cell-based;NTS_3.1
20173344_02;20173344;Cre<eb>ren van nieuwe bloedvaten voor pati<eb>nten met nierfalen, doormiddel van lokale weefsel constructie;Translational or applied research;human;Desitining an optimal in situ tissue enineered vascular grafts in the rat;ENG;rat;APX_2B;Urogenital or reproductive disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;cost effectiveness;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;tissue construction;gene and cell-based;NTS_3.1
20173344_02;20173344;Cre<eb>ren van nieuwe bloedvaten voor pati<eb>nten met nierfalen, doormiddel van lokale weefsel constructie;Translational or applied research;human;Desitining an optimal in situ tissue enineered vascular grafts in the rat;ENG;rat;APX_2B;Urogenital or reproductive disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;cost effectiveness;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;expertise;APX_2D;tissue construction;gene and cell-based;NTS_3.1
20173344_02;20173344;Cre<eb>ren van nieuwe bloedvaten voor pati<eb>nten met nierfalen, doormiddel van lokale weefsel constructie;Translational or applied research;human;Desitining an optimal in situ tissue enineered vascular grafts in the rat;ENG;rat;APX_2B;Urogenital or reproductive disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;cost effectiveness;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;expertise;APX_2D;tissue construction;gene and cell-based;NTS_3.1
20173344_02;20173344;Cre<eb>ren van nieuwe bloedvaten voor pati<eb>nten met nierfalen, doormiddel van lokale weefsel constructie;Translational or applied research;human;Desitining an optimal in situ tissue enineered vascular grafts in the rat;ENG;rat;APX_2B;Urogenital or reproductive disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;prefered to other model;cost effectiveness;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;optimal combination of readouts;APX_2D;accomodation and care;cage enrichment;APX_2D;tissue construction;gene and cell-based;NTS_3.1
20173344_02;20173344;Cre<eb>ren van nieuwe bloedvaten voor pati<eb>nten met nierfalen, doormiddel van lokale weefsel constructie;Translational or applied research;human;Desitining an optimal in situ tissue enineered vascular grafts in the rat;ENG;rat;APX_2B;Urogenital or reproductive disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;prefered to other model;cost effectiveness;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;accomodation and care;cage enrichment;APX_2D;tissue construction;gene and cell-based;NTS_3.1
20173344_02;20173344;Cre<eb>ren van nieuwe bloedvaten voor pati<eb>nten met nierfalen, doormiddel van lokale weefsel constructie;Translational or applied research;human;Desitining an optimal in situ tissue enineered vascular grafts in the rat;ENG;rat;APX_2B;Urogenital or reproductive disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;prefered to other model;cost effectiveness;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;tissue construction;gene and cell-based;NTS_3.1
20173344_02;20173344;Cre<eb>ren van nieuwe bloedvaten voor pati<eb>nten met nierfalen, doormiddel van lokale weefsel constructie;Translational or applied research;human;Desitining an optimal in situ tissue enineered vascular grafts in the rat;ENG;rat;APX_2B;Urogenital or reproductive disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;prefered to other model;cost effectiveness;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;tissue construction;gene and cell-based;NTS_3.1
20173344_02;20173344;Cre<eb>ren van nieuwe bloedvaten voor pati<eb>nten met nierfalen, doormiddel van lokale weefsel constructie;Translational or applied research;human;Desitining an optimal in situ tissue enineered vascular grafts in the rat;ENG;rat;APX_2B;Urogenital or reproductive disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;prefered to other model;cost effectiveness;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;tissue construction;gene and cell-based;NTS_3.1
20173344_02;20173344;Cre<eb>ren van nieuwe bloedvaten voor pati<eb>nten met nierfalen, doormiddel van lokale weefsel constructie;Translational or applied research;human;Desitining an optimal in situ tissue enineered vascular grafts in the rat;ENG;rat;APX_2B;Urogenital or reproductive disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;prefered to other model;cost effectiveness;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;tissue construction;gene and cell-based;NTS_3.1
20173344_02;20173344;Cre<eb>ren van nieuwe bloedvaten voor pati<eb>nten met nierfalen, doormiddel van lokale weefsel constructie;Translational or applied research;human;Desitining an optimal in situ tissue enineered vascular grafts in the rat;ENG;rat;APX_2B;Urogenital or reproductive disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;prefered to other model;cost effectiveness;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;expertise;APX_2D;tissue construction;gene and cell-based;NTS_3.1
20173344_02;20173344;Cre<eb>ren van nieuwe bloedvaten voor pati<eb>nten met nierfalen, doormiddel van lokale weefsel constructie;Translational or applied research;human;Desitining an optimal in situ tissue enineered vascular grafts in the rat;ENG;rat;APX_2B;Urogenital or reproductive disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;prefered to other model;cost effectiveness;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;expertise;APX_2D;tissue construction;gene and cell-based;NTS_3.1
20173344_02;20173344;Cre<eb>ren van nieuwe bloedvaten voor pati<eb>nten met nierfalen, doormiddel van lokale weefsel constructie;Translational or applied research;human;Desitining an optimal in situ tissue enineered vascular grafts in the rat;ENG;rat;APX_2B;Urogenital or reproductive disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;prefered to other model;cost effectiveness;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;optimal combination of readouts;APX_2D;accomodation and care;cage enrichment;APX_2D;tissue construction;gene and cell-based;NTS_3.1
20173344_02;20173344;Cre<eb>ren van nieuwe bloedvaten voor pati<eb>nten met nierfalen, doormiddel van lokale weefsel constructie;Translational or applied research;human;Desitining an optimal in situ tissue enineered vascular grafts in the rat;ENG;rat;APX_2B;Urogenital or reproductive disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;prefered to other model;cost effectiveness;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;accomodation and care;cage enrichment;APX_2D;tissue construction;gene and cell-based;NTS_3.1
20173344_02;20173344;Cre<eb>ren van nieuwe bloedvaten voor pati<eb>nten met nierfalen, doormiddel van lokale weefsel constructie;Translational or applied research;human;Desitining an optimal in situ tissue enineered vascular grafts in the rat;ENG;rat;APX_2B;Urogenital or reproductive disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;prefered to other model;cost effectiveness;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;tissue construction;gene and cell-based;NTS_3.1
20173344_02;20173344;Cre<eb>ren van nieuwe bloedvaten voor pati<eb>nten met nierfalen, doormiddel van lokale weefsel constructie;Translational or applied research;human;Desitining an optimal in situ tissue enineered vascular grafts in the rat;ENG;rat;APX_2B;Urogenital or reproductive disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;prefered to other model;cost effectiveness;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;tissue construction;gene and cell-based;NTS_3.1
20173344_02;20173344;Cre<eb>ren van nieuwe bloedvaten voor pati<eb>nten met nierfalen, doormiddel van lokale weefsel constructie;Translational or applied research;human;Desitining an optimal in situ tissue enineered vascular grafts in the rat;ENG;rat;APX_2B;Urogenital or reproductive disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;prefered to other model;cost effectiveness;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;tissue construction;gene and cell-based;NTS_3.1
20173344_02;20173344;Cre<eb>ren van nieuwe bloedvaten voor pati<eb>nten met nierfalen, doormiddel van lokale weefsel constructie;Translational or applied research;human;Desitining an optimal in situ tissue enineered vascular grafts in the rat;ENG;rat;APX_2B;Urogenital or reproductive disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;prefered to other model;cost effectiveness;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;tissue construction;gene and cell-based;NTS_3.1
20173344_02;20173344;Cre<eb>ren van nieuwe bloedvaten voor pati<eb>nten met nierfalen, doormiddel van lokale weefsel constructie;Translational or applied research;human;Desitining an optimal in situ tissue enineered vascular grafts in the rat;ENG;rat;APX_2B;Urogenital or reproductive disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;prefered to other model;cost effectiveness;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;expertise;APX_2D;tissue construction;gene and cell-based;NTS_3.1
20173344_02;20173344;Cre<eb>ren van nieuwe bloedvaten voor pati<eb>nten met nierfalen, doormiddel van lokale weefsel constructie;Translational or applied research;human;Desitining an optimal in situ tissue enineered vascular grafts in the rat;ENG;rat;APX_2B;Urogenital or reproductive disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;prefered to other model;cost effectiveness;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;expertise;APX_2D;tissue construction;gene and cell-based;NTS_3.1
20173344_03;20173344;Cre<eb>ren van nieuwe bloedvaten voor pati<eb>nten met nierfalen, doormiddel van lokale weefsel constructie;Translational or applied research;human;In vivo testing of an electro spun vascular access graft under clinical conditions in an uremic large animal model;ENG;goat;APX_2B;Urogenital or reproductive disorders;NTS_1.3;Induced;APX_2A;APX_2B;Appendix;similar anatomy;similar anatomy or organ system;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;accomodation and care;cage enrichment;APX_2D;tissue construction;gene and cell-based;NTS_3.1
20173344_03;20173344;Cre<eb>ren van nieuwe bloedvaten voor pati<eb>nten met nierfalen, doormiddel van lokale weefsel constructie;Translational or applied research;human;In vivo testing of an electro spun vascular access graft under clinical conditions in an uremic large animal model;ENG;goat;APX_2B;Urogenital or reproductive disorders;NTS_1.3;Induced;APX_2A;APX_2B;Appendix;similar anatomy;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;experimental design;optimal combination of readouts;APX_2D;accomodation and care;cage enrichment;APX_2D;tissue construction;gene and cell-based;NTS_3.1
20173344_03;20173344;Cre<eb>ren van nieuwe bloedvaten voor pati<eb>nten met nierfalen, doormiddel van lokale weefsel constructie;Translational or applied research;human;In vivo testing of an electro spun vascular access graft under clinical conditions in an uremic large animal model;ENG;goat;APX_2B;Urogenital or reproductive disorders;NTS_1.3;Induced;APX_2A;APX_2B;Appendix;similar anatomy;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;optimal combination of readouts;APX_2D;accomodation and care;cage enrichment;APX_2D;tissue construction;gene and cell-based;NTS_3.1
20173344_03;20173344;Cre<eb>ren van nieuwe bloedvaten voor pati<eb>nten met nierfalen, doormiddel van lokale weefsel constructie;Translational or applied research;human;In vivo testing of an electro spun vascular access graft under clinical conditions in an uremic large animal model;ENG;goat;APX_2B;Urogenital or reproductive disorders;NTS_1.3;Induced;APX_2A;APX_2B;Appendix;similar anatomy;similar anatomy or organ system;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;tissue construction;gene and cell-based;NTS_3.1
20173344_03;20173344;Cre<eb>ren van nieuwe bloedvaten voor pati<eb>nten met nierfalen, doormiddel van lokale weefsel constructie;Translational or applied research;human;In vivo testing of an electro spun vascular access graft under clinical conditions in an uremic large animal model;ENG;goat;APX_2B;Urogenital or reproductive disorders;NTS_1.3;Induced;APX_2A;APX_2B;Appendix;similar anatomy;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;tissue construction;gene and cell-based;NTS_3.1
20173344_03;20173344;Cre<eb>ren van nieuwe bloedvaten voor pati<eb>nten met nierfalen, doormiddel van lokale weefsel constructie;Translational or applied research;human;In vivo testing of an electro spun vascular access graft under clinical conditions in an uremic large animal model;ENG;goat;APX_2B;Urogenital or reproductive disorders;NTS_1.3;Induced;APX_2A;APX_2B;Appendix;similar anatomy;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;tissue construction;gene and cell-based;NTS_3.1
20173344_03;20173344;Cre<eb>ren van nieuwe bloedvaten voor pati<eb>nten met nierfalen, doormiddel van lokale weefsel constructie;Translational or applied research;human;In vivo testing of an electro spun vascular access graft under clinical conditions in an uremic large animal model;ENG;goat;APX_2B;Urogenital or reproductive disorders;NTS_1.3;Induced;APX_2A;APX_2B;Appendix;similar anatomy;similar anatomy or organ system;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;expertise;APX_2D;tissue construction;gene and cell-based;NTS_3.1
20173344_03;20173344;Cre<eb>ren van nieuwe bloedvaten voor pati<eb>nten met nierfalen, doormiddel van lokale weefsel constructie;Translational or applied research;human;In vivo testing of an electro spun vascular access graft under clinical conditions in an uremic large animal model;ENG;goat;APX_2B;Urogenital or reproductive disorders;NTS_1.3;Induced;APX_2A;APX_2B;Appendix;similar anatomy;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;expertise;APX_2D;tissue construction;gene and cell-based;NTS_3.1
20173344_03;20173344;Cre<eb>ren van nieuwe bloedvaten voor pati<eb>nten met nierfalen, doormiddel van lokale weefsel constructie;Translational or applied research;human;In vivo testing of an electro spun vascular access graft under clinical conditions in an uremic large animal model;ENG;goat;APX_2B;Urogenital or reproductive disorders;NTS_1.3;Induced;APX_2A;APX_2B;Appendix;similar anatomy;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;expertise;APX_2D;tissue construction;gene and cell-based;NTS_3.1
20173344_03;20173344;Cre<eb>ren van nieuwe bloedvaten voor pati<eb>nten met nierfalen, doormiddel van lokale weefsel constructie;Translational or applied research;human;In vivo testing of an electro spun vascular access graft under clinical conditions in an uremic large animal model;ENG;goat;APX_2B;Urogenital or reproductive disorders;NTS_1.3;Induced;APX_2A;APX_2B;Appendix;similar anatomy;similar anatomy or organ system;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;accomodation and care;cage enrichment;APX_2D;tissue construction;gene and cell-based;NTS_3.1
20173344_03;20173344;Cre<eb>ren van nieuwe bloedvaten voor pati<eb>nten met nierfalen, doormiddel van lokale weefsel constructie;Translational or applied research;human;In vivo testing of an electro spun vascular access graft under clinical conditions in an uremic large animal model;ENG;goat;APX_2B;Urogenital or reproductive disorders;NTS_1.3;Induced;APX_2A;APX_2B;Appendix;similar anatomy;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;accomodation and care;cage enrichment;APX_2D;tissue construction;gene and cell-based;NTS_3.1
20173344_03;20173344;Cre<eb>ren van nieuwe bloedvaten voor pati<eb>nten met nierfalen, doormiddel van lokale weefsel constructie;Translational or applied research;human;In vivo testing of an electro spun vascular access graft under clinical conditions in an uremic large animal model;ENG;goat;APX_2B;Urogenital or reproductive disorders;NTS_1.3;Induced;APX_2A;APX_2B;Appendix;similar anatomy;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;accomodation and care;cage enrichment;APX_2D;tissue construction;gene and cell-based;NTS_3.1
20173344_03;20173344;Cre<eb>ren van nieuwe bloedvaten voor pati<eb>nten met nierfalen, doormiddel van lokale weefsel constructie;Translational or applied research;human;In vivo testing of an electro spun vascular access graft under clinical conditions in an uremic large animal model;ENG;goat;APX_2B;Urogenital or reproductive disorders;NTS_1.3;Induced;APX_2A;APX_2B;Appendix;similar anatomy;similar anatomy or organ system;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;tissue construction;gene and cell-based;NTS_3.1
20173344_03;20173344;Cre<eb>ren van nieuwe bloedvaten voor pati<eb>nten met nierfalen, doormiddel van lokale weefsel constructie;Translational or applied research;human;In vivo testing of an electro spun vascular access graft under clinical conditions in an uremic large animal model;ENG;goat;APX_2B;Urogenital or reproductive disorders;NTS_1.3;Induced;APX_2A;APX_2B;Appendix;similar anatomy;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;tissue construction;gene and cell-based;NTS_3.1
20173344_03;20173344;Cre<eb>ren van nieuwe bloedvaten voor pati<eb>nten met nierfalen, doormiddel van lokale weefsel constructie;Translational or applied research;human;In vivo testing of an electro spun vascular access graft under clinical conditions in an uremic large animal model;ENG;goat;APX_2B;Urogenital or reproductive disorders;NTS_1.3;Induced;APX_2A;APX_2B;Appendix;similar anatomy;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;tissue construction;gene and cell-based;NTS_3.1
20173344_03;20173344;Cre<eb>ren van nieuwe bloedvaten voor pati<eb>nten met nierfalen, doormiddel van lokale weefsel constructie;Translational or applied research;human;In vivo testing of an electro spun vascular access graft under clinical conditions in an uremic large animal model;ENG;goat;APX_2B;Urogenital or reproductive disorders;NTS_1.3;Induced;APX_2A;APX_2B;Appendix;similar anatomy;similar anatomy or organ system;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;expertise;APX_2D;tissue construction;gene and cell-based;NTS_3.1
20173344_03;20173344;Cre<eb>ren van nieuwe bloedvaten voor pati<eb>nten met nierfalen, doormiddel van lokale weefsel constructie;Translational or applied research;human;In vivo testing of an electro spun vascular access graft under clinical conditions in an uremic large animal model;ENG;goat;APX_2B;Urogenital or reproductive disorders;NTS_1.3;Induced;APX_2A;APX_2B;Appendix;similar anatomy;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;expertise;APX_2D;tissue construction;gene and cell-based;NTS_3.1
20173344_03;20173344;Cre<eb>ren van nieuwe bloedvaten voor pati<eb>nten met nierfalen, doormiddel van lokale weefsel constructie;Translational or applied research;human;In vivo testing of an electro spun vascular access graft under clinical conditions in an uremic large animal model;ENG;goat;APX_2B;Urogenital or reproductive disorders;NTS_1.3;Induced;APX_2A;APX_2B;Appendix;similar anatomy;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;expertise;APX_2D;tissue construction;gene and cell-based;NTS_3.1
20173344_03;20173344;Cre<eb>ren van nieuwe bloedvaten voor pati<eb>nten met nierfalen, doormiddel van lokale weefsel constructie;Translational or applied research;human;In vivo testing of an electro spun vascular access graft under clinical conditions in an uremic large animal model;ENG;goat;APX_2B;Urogenital or reproductive disorders;NTS_1.3;Induced;APX_2A;APX_2B;Appendix;similar anatomy;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;accomodation and care;cage enrichment;APX_2D;tissue construction;gene and cell-based;NTS_3.1
20173344_03;20173344;Cre<eb>ren van nieuwe bloedvaten voor pati<eb>nten met nierfalen, doormiddel van lokale weefsel constructie;Translational or applied research;human;In vivo testing of an electro spun vascular access graft under clinical conditions in an uremic large animal model;ENG;goat;APX_2B;Urogenital or reproductive disorders;NTS_1.3;Induced;APX_2A;APX_2B;Appendix;similar anatomy;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;experimental design;optimal combination of readouts;APX_2D;accomodation and care;cage enrichment;APX_2D;tissue construction;gene and cell-based;NTS_3.1
20173344_03;20173344;Cre<eb>ren van nieuwe bloedvaten voor pati<eb>nten met nierfalen, doormiddel van lokale weefsel constructie;Translational or applied research;human;In vivo testing of an electro spun vascular access graft under clinical conditions in an uremic large animal model;ENG;goat;APX_2B;Urogenital or reproductive disorders;NTS_1.3;Induced;APX_2A;APX_2B;Appendix;similar anatomy;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;optimal combination of readouts;APX_2D;accomodation and care;cage enrichment;APX_2D;tissue construction;gene and cell-based;NTS_3.1
20173344_03;20173344;Cre<eb>ren van nieuwe bloedvaten voor pati<eb>nten met nierfalen, doormiddel van lokale weefsel constructie;Translational or applied research;human;In vivo testing of an electro spun vascular access graft under clinical conditions in an uremic large animal model;ENG;goat;APX_2B;Urogenital or reproductive disorders;NTS_1.3;Induced;APX_2A;APX_2B;Appendix;similar anatomy;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;tissue construction;gene and cell-based;NTS_3.1
20173344_03;20173344;Cre<eb>ren van nieuwe bloedvaten voor pati<eb>nten met nierfalen, doormiddel van lokale weefsel constructie;Translational or applied research;human;In vivo testing of an electro spun vascular access graft under clinical conditions in an uremic large animal model;ENG;goat;APX_2B;Urogenital or reproductive disorders;NTS_1.3;Induced;APX_2A;APX_2B;Appendix;similar anatomy;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;tissue construction;gene and cell-based;NTS_3.1
20173344_03;20173344;Cre<eb>ren van nieuwe bloedvaten voor pati<eb>nten met nierfalen, doormiddel van lokale weefsel constructie;Translational or applied research;human;In vivo testing of an electro spun vascular access graft under clinical conditions in an uremic large animal model;ENG;goat;APX_2B;Urogenital or reproductive disorders;NTS_1.3;Induced;APX_2A;APX_2B;Appendix;similar anatomy;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;tissue construction;gene and cell-based;NTS_3.1
20173344_03;20173344;Cre<eb>ren van nieuwe bloedvaten voor pati<eb>nten met nierfalen, doormiddel van lokale weefsel constructie;Translational or applied research;human;In vivo testing of an electro spun vascular access graft under clinical conditions in an uremic large animal model;ENG;goat;APX_2B;Urogenital or reproductive disorders;NTS_1.3;Induced;APX_2A;APX_2B;Appendix;similar anatomy;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;expertise;APX_2D;tissue construction;gene and cell-based;NTS_3.1
20173344_03;20173344;Cre<eb>ren van nieuwe bloedvaten voor pati<eb>nten met nierfalen, doormiddel van lokale weefsel constructie;Translational or applied research;human;In vivo testing of an electro spun vascular access graft under clinical conditions in an uremic large animal model;ENG;goat;APX_2B;Urogenital or reproductive disorders;NTS_1.3;Induced;APX_2A;APX_2B;Appendix;similar anatomy;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;expertise;APX_2D;tissue construction;gene and cell-based;NTS_3.1
20173344_03;20173344;Cre<eb>ren van nieuwe bloedvaten voor pati<eb>nten met nierfalen, doormiddel van lokale weefsel constructie;Translational or applied research;human;In vivo testing of an electro spun vascular access graft under clinical conditions in an uremic large animal model;ENG;goat;APX_2B;Urogenital or reproductive disorders;NTS_1.3;Induced;APX_2A;APX_2B;Appendix;similar anatomy;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;expertise;APX_2D;tissue construction;gene and cell-based;NTS_3.1
20173344_03;20173344;Cre<eb>ren van nieuwe bloedvaten voor pati<eb>nten met nierfalen, doormiddel van lokale weefsel constructie;Translational or applied research;human;In vivo testing of an electro spun vascular access graft under clinical conditions in an uremic large animal model;ENG;goat;APX_2B;Urogenital or reproductive disorders;NTS_1.3;Induced;APX_2A;APX_2B;Appendix;similar anatomy;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;accomodation and care;cage enrichment;APX_2D;tissue construction;gene and cell-based;NTS_3.1
20173344_03;20173344;Cre<eb>ren van nieuwe bloedvaten voor pati<eb>nten met nierfalen, doormiddel van lokale weefsel constructie;Translational or applied research;human;In vivo testing of an electro spun vascular access graft under clinical conditions in an uremic large animal model;ENG;goat;APX_2B;Urogenital or reproductive disorders;NTS_1.3;Induced;APX_2A;APX_2B;Appendix;similar anatomy;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;accomodation and care;cage enrichment;APX_2D;tissue construction;gene and cell-based;NTS_3.1
20173344_03;20173344;Cre<eb>ren van nieuwe bloedvaten voor pati<eb>nten met nierfalen, doormiddel van lokale weefsel constructie;Translational or applied research;human;In vivo testing of an electro spun vascular access graft under clinical conditions in an uremic large animal model;ENG;goat;APX_2B;Urogenital or reproductive disorders;NTS_1.3;Induced;APX_2A;APX_2B;Appendix;similar anatomy;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;accomodation and care;cage enrichment;APX_2D;tissue construction;gene and cell-based;NTS_3.1
20173344_03;20173344;Cre<eb>ren van nieuwe bloedvaten voor pati<eb>nten met nierfalen, doormiddel van lokale weefsel constructie;Translational or applied research;human;In vivo testing of an electro spun vascular access graft under clinical conditions in an uremic large animal model;ENG;goat;APX_2B;Urogenital or reproductive disorders;NTS_1.3;Induced;APX_2A;APX_2B;Appendix;similar anatomy;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;tissue construction;gene and cell-based;NTS_3.1
20173344_03;20173344;Cre<eb>ren van nieuwe bloedvaten voor pati<eb>nten met nierfalen, doormiddel van lokale weefsel constructie;Translational or applied research;human;In vivo testing of an electro spun vascular access graft under clinical conditions in an uremic large animal model;ENG;goat;APX_2B;Urogenital or reproductive disorders;NTS_1.3;Induced;APX_2A;APX_2B;Appendix;similar anatomy;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;tissue construction;gene and cell-based;NTS_3.1
20173344_03;20173344;Cre<eb>ren van nieuwe bloedvaten voor pati<eb>nten met nierfalen, doormiddel van lokale weefsel constructie;Translational or applied research;human;In vivo testing of an electro spun vascular access graft under clinical conditions in an uremic large animal model;ENG;goat;APX_2B;Urogenital or reproductive disorders;NTS_1.3;Induced;APX_2A;APX_2B;Appendix;similar anatomy;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;tissue construction;gene and cell-based;NTS_3.1
20173344_03;20173344;Cre<eb>ren van nieuwe bloedvaten voor pati<eb>nten met nierfalen, doormiddel van lokale weefsel constructie;Translational or applied research;human;In vivo testing of an electro spun vascular access graft under clinical conditions in an uremic large animal model;ENG;goat;APX_2B;Urogenital or reproductive disorders;NTS_1.3;Induced;APX_2A;APX_2B;Appendix;similar anatomy;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;expertise;APX_2D;tissue construction;gene and cell-based;NTS_3.1
20173344_03;20173344;Cre<eb>ren van nieuwe bloedvaten voor pati<eb>nten met nierfalen, doormiddel van lokale weefsel constructie;Translational or applied research;human;In vivo testing of an electro spun vascular access graft under clinical conditions in an uremic large animal model;ENG;goat;APX_2B;Urogenital or reproductive disorders;NTS_1.3;Induced;APX_2A;APX_2B;Appendix;similar anatomy;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;expertise;APX_2D;tissue construction;gene and cell-based;NTS_3.1
20173344_03;20173344;Cre<eb>ren van nieuwe bloedvaten voor pati<eb>nten met nierfalen, doormiddel van lokale weefsel constructie;Translational or applied research;human;In vivo testing of an electro spun vascular access graft under clinical conditions in an uremic large animal model;ENG;goat;APX_2B;Urogenital or reproductive disorders;NTS_1.3;Induced;APX_2A;APX_2B;Appendix;similar anatomy;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;expertise;APX_2D;tissue construction;gene and cell-based;NTS_3.1
20173344_03;20173344;Cre<eb>ren van nieuwe bloedvaten voor pati<eb>nten met nierfalen, doormiddel van lokale weefsel constructie;Translational or applied research;human;In vivo testing of an electro spun vascular access graft under clinical conditions in an uremic large animal model;ENG;goat;APX_2B;Urogenital or reproductive disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;similar anatomy or organ system;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;accomodation and care;cage enrichment;APX_2D;tissue construction;gene and cell-based;NTS_3.1
20173344_03;20173344;Cre<eb>ren van nieuwe bloedvaten voor pati<eb>nten met nierfalen, doormiddel van lokale weefsel constructie;Translational or applied research;human;In vivo testing of an electro spun vascular access graft under clinical conditions in an uremic large animal model;ENG;goat;APX_2B;Urogenital or reproductive disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;experimental design;optimal combination of readouts;APX_2D;accomodation and care;cage enrichment;APX_2D;tissue construction;gene and cell-based;NTS_3.1
20173344_03;20173344;Cre<eb>ren van nieuwe bloedvaten voor pati<eb>nten met nierfalen, doormiddel van lokale weefsel constructie;Translational or applied research;human;In vivo testing of an electro spun vascular access graft under clinical conditions in an uremic large animal model;ENG;goat;APX_2B;Urogenital or reproductive disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;optimal combination of readouts;APX_2D;accomodation and care;cage enrichment;APX_2D;tissue construction;gene and cell-based;NTS_3.1
20173344_03;20173344;Cre<eb>ren van nieuwe bloedvaten voor pati<eb>nten met nierfalen, doormiddel van lokale weefsel constructie;Translational or applied research;human;In vivo testing of an electro spun vascular access graft under clinical conditions in an uremic large animal model;ENG;goat;APX_2B;Urogenital or reproductive disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;similar anatomy or organ system;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;tissue construction;gene and cell-based;NTS_3.1
20173344_03;20173344;Cre<eb>ren van nieuwe bloedvaten voor pati<eb>nten met nierfalen, doormiddel van lokale weefsel constructie;Translational or applied research;human;In vivo testing of an electro spun vascular access graft under clinical conditions in an uremic large animal model;ENG;goat;APX_2B;Urogenital or reproductive disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;tissue construction;gene and cell-based;NTS_3.1
20173344_03;20173344;Cre<eb>ren van nieuwe bloedvaten voor pati<eb>nten met nierfalen, doormiddel van lokale weefsel constructie;Translational or applied research;human;In vivo testing of an electro spun vascular access graft under clinical conditions in an uremic large animal model;ENG;goat;APX_2B;Urogenital or reproductive disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;tissue construction;gene and cell-based;NTS_3.1
20173344_03;20173344;Cre<eb>ren van nieuwe bloedvaten voor pati<eb>nten met nierfalen, doormiddel van lokale weefsel constructie;Translational or applied research;human;In vivo testing of an electro spun vascular access graft under clinical conditions in an uremic large animal model;ENG;goat;APX_2B;Urogenital or reproductive disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;similar anatomy or organ system;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;expertise;APX_2D;tissue construction;gene and cell-based;NTS_3.1
20173344_03;20173344;Cre<eb>ren van nieuwe bloedvaten voor pati<eb>nten met nierfalen, doormiddel van lokale weefsel constructie;Translational or applied research;human;In vivo testing of an electro spun vascular access graft under clinical conditions in an uremic large animal model;ENG;goat;APX_2B;Urogenital or reproductive disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;expertise;APX_2D;tissue construction;gene and cell-based;NTS_3.1
20173344_03;20173344;Cre<eb>ren van nieuwe bloedvaten voor pati<eb>nten met nierfalen, doormiddel van lokale weefsel constructie;Translational or applied research;human;In vivo testing of an electro spun vascular access graft under clinical conditions in an uremic large animal model;ENG;goat;APX_2B;Urogenital or reproductive disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;expertise;APX_2D;tissue construction;gene and cell-based;NTS_3.1
20173344_03;20173344;Cre<eb>ren van nieuwe bloedvaten voor pati<eb>nten met nierfalen, doormiddel van lokale weefsel constructie;Translational or applied research;human;In vivo testing of an electro spun vascular access graft under clinical conditions in an uremic large animal model;ENG;goat;APX_2B;Urogenital or reproductive disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;similar anatomy or organ system;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;accomodation and care;cage enrichment;APX_2D;tissue construction;gene and cell-based;NTS_3.1
20173344_03;20173344;Cre<eb>ren van nieuwe bloedvaten voor pati<eb>nten met nierfalen, doormiddel van lokale weefsel constructie;Translational or applied research;human;In vivo testing of an electro spun vascular access graft under clinical conditions in an uremic large animal model;ENG;goat;APX_2B;Urogenital or reproductive disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;accomodation and care;cage enrichment;APX_2D;tissue construction;gene and cell-based;NTS_3.1
20173344_03;20173344;Cre<eb>ren van nieuwe bloedvaten voor pati<eb>nten met nierfalen, doormiddel van lokale weefsel constructie;Translational or applied research;human;In vivo testing of an electro spun vascular access graft under clinical conditions in an uremic large animal model;ENG;goat;APX_2B;Urogenital or reproductive disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;accomodation and care;cage enrichment;APX_2D;tissue construction;gene and cell-based;NTS_3.1
20173344_03;20173344;Cre<eb>ren van nieuwe bloedvaten voor pati<eb>nten met nierfalen, doormiddel van lokale weefsel constructie;Translational or applied research;human;In vivo testing of an electro spun vascular access graft under clinical conditions in an uremic large animal model;ENG;goat;APX_2B;Urogenital or reproductive disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;similar anatomy or organ system;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;tissue construction;gene and cell-based;NTS_3.1
20173344_03;20173344;Cre<eb>ren van nieuwe bloedvaten voor pati<eb>nten met nierfalen, doormiddel van lokale weefsel constructie;Translational or applied research;human;In vivo testing of an electro spun vascular access graft under clinical conditions in an uremic large animal model;ENG;goat;APX_2B;Urogenital or reproductive disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;tissue construction;gene and cell-based;NTS_3.1
20173344_03;20173344;Cre<eb>ren van nieuwe bloedvaten voor pati<eb>nten met nierfalen, doormiddel van lokale weefsel constructie;Translational or applied research;human;In vivo testing of an electro spun vascular access graft under clinical conditions in an uremic large animal model;ENG;goat;APX_2B;Urogenital or reproductive disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;tissue construction;gene and cell-based;NTS_3.1
20173344_03;20173344;Cre<eb>ren van nieuwe bloedvaten voor pati<eb>nten met nierfalen, doormiddel van lokale weefsel constructie;Translational or applied research;human;In vivo testing of an electro spun vascular access graft under clinical conditions in an uremic large animal model;ENG;goat;APX_2B;Urogenital or reproductive disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;similar anatomy or organ system;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;expertise;APX_2D;tissue construction;gene and cell-based;NTS_3.1
20173344_03;20173344;Cre<eb>ren van nieuwe bloedvaten voor pati<eb>nten met nierfalen, doormiddel van lokale weefsel constructie;Translational or applied research;human;In vivo testing of an electro spun vascular access graft under clinical conditions in an uremic large animal model;ENG;goat;APX_2B;Urogenital or reproductive disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;expertise;APX_2D;tissue construction;gene and cell-based;NTS_3.1
20173344_03;20173344;Cre<eb>ren van nieuwe bloedvaten voor pati<eb>nten met nierfalen, doormiddel van lokale weefsel constructie;Translational or applied research;human;In vivo testing of an electro spun vascular access graft under clinical conditions in an uremic large animal model;ENG;goat;APX_2B;Urogenital or reproductive disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;expertise;APX_2D;tissue construction;gene and cell-based;NTS_3.1
20173344_03;20173344;Cre<eb>ren van nieuwe bloedvaten voor pati<eb>nten met nierfalen, doormiddel van lokale weefsel constructie;Translational or applied research;human;In vivo testing of an electro spun vascular access graft under clinical conditions in an uremic large animal model;ENG;goat;APX_2B;Urogenital or reproductive disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;accomodation and care;cage enrichment;APX_2D;tissue construction;gene and cell-based;NTS_3.1
20173344_03;20173344;Cre<eb>ren van nieuwe bloedvaten voor pati<eb>nten met nierfalen, doormiddel van lokale weefsel constructie;Translational or applied research;human;In vivo testing of an electro spun vascular access graft under clinical conditions in an uremic large animal model;ENG;goat;APX_2B;Urogenital or reproductive disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;experimental design;optimal combination of readouts;APX_2D;accomodation and care;cage enrichment;APX_2D;tissue construction;gene and cell-based;NTS_3.1
20173344_03;20173344;Cre<eb>ren van nieuwe bloedvaten voor pati<eb>nten met nierfalen, doormiddel van lokale weefsel constructie;Translational or applied research;human;In vivo testing of an electro spun vascular access graft under clinical conditions in an uremic large animal model;ENG;goat;APX_2B;Urogenital or reproductive disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;optimal combination of readouts;APX_2D;accomodation and care;cage enrichment;APX_2D;tissue construction;gene and cell-based;NTS_3.1
20173344_03;20173344;Cre<eb>ren van nieuwe bloedvaten voor pati<eb>nten met nierfalen, doormiddel van lokale weefsel constructie;Translational or applied research;human;In vivo testing of an electro spun vascular access graft under clinical conditions in an uremic large animal model;ENG;goat;APX_2B;Urogenital or reproductive disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;tissue construction;gene and cell-based;NTS_3.1
20173344_03;20173344;Cre<eb>ren van nieuwe bloedvaten voor pati<eb>nten met nierfalen, doormiddel van lokale weefsel constructie;Translational or applied research;human;In vivo testing of an electro spun vascular access graft under clinical conditions in an uremic large animal model;ENG;goat;APX_2B;Urogenital or reproductive disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;tissue construction;gene and cell-based;NTS_3.1
20173344_03;20173344;Cre<eb>ren van nieuwe bloedvaten voor pati<eb>nten met nierfalen, doormiddel van lokale weefsel constructie;Translational or applied research;human;In vivo testing of an electro spun vascular access graft under clinical conditions in an uremic large animal model;ENG;goat;APX_2B;Urogenital or reproductive disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;tissue construction;gene and cell-based;NTS_3.1
20173344_03;20173344;Cre<eb>ren van nieuwe bloedvaten voor pati<eb>nten met nierfalen, doormiddel van lokale weefsel constructie;Translational or applied research;human;In vivo testing of an electro spun vascular access graft under clinical conditions in an uremic large animal model;ENG;goat;APX_2B;Urogenital or reproductive disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;expertise;APX_2D;tissue construction;gene and cell-based;NTS_3.1
20173344_03;20173344;Cre<eb>ren van nieuwe bloedvaten voor pati<eb>nten met nierfalen, doormiddel van lokale weefsel constructie;Translational or applied research;human;In vivo testing of an electro spun vascular access graft under clinical conditions in an uremic large animal model;ENG;goat;APX_2B;Urogenital or reproductive disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;expertise;APX_2D;tissue construction;gene and cell-based;NTS_3.1
20173344_03;20173344;Cre<eb>ren van nieuwe bloedvaten voor pati<eb>nten met nierfalen, doormiddel van lokale weefsel constructie;Translational or applied research;human;In vivo testing of an electro spun vascular access graft under clinical conditions in an uremic large animal model;ENG;goat;APX_2B;Urogenital or reproductive disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;expertise;APX_2D;tissue construction;gene and cell-based;NTS_3.1
20173344_03;20173344;Cre<eb>ren van nieuwe bloedvaten voor pati<eb>nten met nierfalen, doormiddel van lokale weefsel constructie;Translational or applied research;human;In vivo testing of an electro spun vascular access graft under clinical conditions in an uremic large animal model;ENG;goat;APX_2B;Urogenital or reproductive disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;accomodation and care;cage enrichment;APX_2D;tissue construction;gene and cell-based;NTS_3.1
20173344_03;20173344;Cre<eb>ren van nieuwe bloedvaten voor pati<eb>nten met nierfalen, doormiddel van lokale weefsel constructie;Translational or applied research;human;In vivo testing of an electro spun vascular access graft under clinical conditions in an uremic large animal model;ENG;goat;APX_2B;Urogenital or reproductive disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;accomodation and care;cage enrichment;APX_2D;tissue construction;gene and cell-based;NTS_3.1
20173344_03;20173344;Cre<eb>ren van nieuwe bloedvaten voor pati<eb>nten met nierfalen, doormiddel van lokale weefsel constructie;Translational or applied research;human;In vivo testing of an electro spun vascular access graft under clinical conditions in an uremic large animal model;ENG;goat;APX_2B;Urogenital or reproductive disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;accomodation and care;cage enrichment;APX_2D;tissue construction;gene and cell-based;NTS_3.1
20173344_03;20173344;Cre<eb>ren van nieuwe bloedvaten voor pati<eb>nten met nierfalen, doormiddel van lokale weefsel constructie;Translational or applied research;human;In vivo testing of an electro spun vascular access graft under clinical conditions in an uremic large animal model;ENG;goat;APX_2B;Urogenital or reproductive disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;tissue construction;gene and cell-based;NTS_3.1
20173344_03;20173344;Cre<eb>ren van nieuwe bloedvaten voor pati<eb>nten met nierfalen, doormiddel van lokale weefsel constructie;Translational or applied research;human;In vivo testing of an electro spun vascular access graft under clinical conditions in an uremic large animal model;ENG;goat;APX_2B;Urogenital or reproductive disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;tissue construction;gene and cell-based;NTS_3.1
20173344_03;20173344;Cre<eb>ren van nieuwe bloedvaten voor pati<eb>nten met nierfalen, doormiddel van lokale weefsel constructie;Translational or applied research;human;In vivo testing of an electro spun vascular access graft under clinical conditions in an uremic large animal model;ENG;goat;APX_2B;Urogenital or reproductive disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;tissue construction;gene and cell-based;NTS_3.1
20173344_03;20173344;Cre<eb>ren van nieuwe bloedvaten voor pati<eb>nten met nierfalen, doormiddel van lokale weefsel constructie;Translational or applied research;human;In vivo testing of an electro spun vascular access graft under clinical conditions in an uremic large animal model;ENG;goat;APX_2B;Urogenital or reproductive disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;expertise;APX_2D;tissue construction;gene and cell-based;NTS_3.1
20173344_03;20173344;Cre<eb>ren van nieuwe bloedvaten voor pati<eb>nten met nierfalen, doormiddel van lokale weefsel constructie;Translational or applied research;human;In vivo testing of an electro spun vascular access graft under clinical conditions in an uremic large animal model;ENG;goat;APX_2B;Urogenital or reproductive disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;expertise;APX_2D;tissue construction;gene and cell-based;NTS_3.1
20173344_03;20173344;Cre<eb>ren van nieuwe bloedvaten voor pati<eb>nten met nierfalen, doormiddel van lokale weefsel constructie;Translational or applied research;human;In vivo testing of an electro spun vascular access graft under clinical conditions in an uremic large animal model;ENG;goat;APX_2B;Urogenital or reproductive disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;expertise;APX_2D;tissue construction;gene and cell-based;NTS_3.1
20173344_03;20173344;Cre<eb>ren van nieuwe bloedvaten voor pati<eb>nten met nierfalen, doormiddel van lokale weefsel constructie;Translational or applied research;human;In vivo testing of an electro spun vascular access graft under clinical conditions in an uremic large animal model;ENG;goat;APX_2B;Urogenital or reproductive disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;accomodation and care;cage enrichment;APX_2D;tissue construction;gene and cell-based;NTS_3.1
20173344_03;20173344;Cre<eb>ren van nieuwe bloedvaten voor pati<eb>nten met nierfalen, doormiddel van lokale weefsel constructie;Translational or applied research;human;In vivo testing of an electro spun vascular access graft under clinical conditions in an uremic large animal model;ENG;goat;APX_2B;Urogenital or reproductive disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;experimental design;optimal combination of readouts;APX_2D;accomodation and care;cage enrichment;APX_2D;tissue construction;gene and cell-based;NTS_3.1
20173344_03;20173344;Cre<eb>ren van nieuwe bloedvaten voor pati<eb>nten met nierfalen, doormiddel van lokale weefsel constructie;Translational or applied research;human;In vivo testing of an electro spun vascular access graft under clinical conditions in an uremic large animal model;ENG;goat;APX_2B;Urogenital or reproductive disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;optimal combination of readouts;APX_2D;accomodation and care;cage enrichment;APX_2D;tissue construction;gene and cell-based;NTS_3.1
20173344_03;20173344;Cre<eb>ren van nieuwe bloedvaten voor pati<eb>nten met nierfalen, doormiddel van lokale weefsel constructie;Translational or applied research;human;In vivo testing of an electro spun vascular access graft under clinical conditions in an uremic large animal model;ENG;goat;APX_2B;Urogenital or reproductive disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;tissue construction;gene and cell-based;NTS_3.1
20173344_03;20173344;Cre<eb>ren van nieuwe bloedvaten voor pati<eb>nten met nierfalen, doormiddel van lokale weefsel constructie;Translational or applied research;human;In vivo testing of an electro spun vascular access graft under clinical conditions in an uremic large animal model;ENG;goat;APX_2B;Urogenital or reproductive disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;tissue construction;gene and cell-based;NTS_3.1
20173344_03;20173344;Cre<eb>ren van nieuwe bloedvaten voor pati<eb>nten met nierfalen, doormiddel van lokale weefsel constructie;Translational or applied research;human;In vivo testing of an electro spun vascular access graft under clinical conditions in an uremic large animal model;ENG;goat;APX_2B;Urogenital or reproductive disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;tissue construction;gene and cell-based;NTS_3.1
20173344_03;20173344;Cre<eb>ren van nieuwe bloedvaten voor pati<eb>nten met nierfalen, doormiddel van lokale weefsel constructie;Translational or applied research;human;In vivo testing of an electro spun vascular access graft under clinical conditions in an uremic large animal model;ENG;goat;APX_2B;Urogenital or reproductive disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;expertise;APX_2D;tissue construction;gene and cell-based;NTS_3.1
20173344_03;20173344;Cre<eb>ren van nieuwe bloedvaten voor pati<eb>nten met nierfalen, doormiddel van lokale weefsel constructie;Translational or applied research;human;In vivo testing of an electro spun vascular access graft under clinical conditions in an uremic large animal model;ENG;goat;APX_2B;Urogenital or reproductive disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;expertise;APX_2D;tissue construction;gene and cell-based;NTS_3.1
20173344_03;20173344;Cre<eb>ren van nieuwe bloedvaten voor pati<eb>nten met nierfalen, doormiddel van lokale weefsel constructie;Translational or applied research;human;In vivo testing of an electro spun vascular access graft under clinical conditions in an uremic large animal model;ENG;goat;APX_2B;Urogenital or reproductive disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;expertise;APX_2D;tissue construction;gene and cell-based;NTS_3.1
20173344_03;20173344;Cre<eb>ren van nieuwe bloedvaten voor pati<eb>nten met nierfalen, doormiddel van lokale weefsel constructie;Translational or applied research;human;In vivo testing of an electro spun vascular access graft under clinical conditions in an uremic large animal model;ENG;goat;APX_2B;Urogenital or reproductive disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;accomodation and care;cage enrichment;APX_2D;tissue construction;gene and cell-based;NTS_3.1
20173344_03;20173344;Cre<eb>ren van nieuwe bloedvaten voor pati<eb>nten met nierfalen, doormiddel van lokale weefsel constructie;Translational or applied research;human;In vivo testing of an electro spun vascular access graft under clinical conditions in an uremic large animal model;ENG;goat;APX_2B;Urogenital or reproductive disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;accomodation and care;cage enrichment;APX_2D;tissue construction;gene and cell-based;NTS_3.1
20173344_03;20173344;Cre<eb>ren van nieuwe bloedvaten voor pati<eb>nten met nierfalen, doormiddel van lokale weefsel constructie;Translational or applied research;human;In vivo testing of an electro spun vascular access graft under clinical conditions in an uremic large animal model;ENG;goat;APX_2B;Urogenital or reproductive disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;accomodation and care;cage enrichment;APX_2D;tissue construction;gene and cell-based;NTS_3.1
20173344_03;20173344;Cre<eb>ren van nieuwe bloedvaten voor pati<eb>nten met nierfalen, doormiddel van lokale weefsel constructie;Translational or applied research;human;In vivo testing of an electro spun vascular access graft under clinical conditions in an uremic large animal model;ENG;goat;APX_2B;Urogenital or reproductive disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;tissue construction;gene and cell-based;NTS_3.1
20173344_03;20173344;Cre<eb>ren van nieuwe bloedvaten voor pati<eb>nten met nierfalen, doormiddel van lokale weefsel constructie;Translational or applied research;human;In vivo testing of an electro spun vascular access graft under clinical conditions in an uremic large animal model;ENG;goat;APX_2B;Urogenital or reproductive disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;tissue construction;gene and cell-based;NTS_3.1
20173344_03;20173344;Cre<eb>ren van nieuwe bloedvaten voor pati<eb>nten met nierfalen, doormiddel van lokale weefsel constructie;Translational or applied research;human;In vivo testing of an electro spun vascular access graft under clinical conditions in an uremic large animal model;ENG;goat;APX_2B;Urogenital or reproductive disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;tissue construction;gene and cell-based;NTS_3.1
20173344_03;20173344;Cre<eb>ren van nieuwe bloedvaten voor pati<eb>nten met nierfalen, doormiddel van lokale weefsel constructie;Translational or applied research;human;In vivo testing of an electro spun vascular access graft under clinical conditions in an uremic large animal model;ENG;goat;APX_2B;Urogenital or reproductive disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;expertise;APX_2D;tissue construction;gene and cell-based;NTS_3.1
20173344_03;20173344;Cre<eb>ren van nieuwe bloedvaten voor pati<eb>nten met nierfalen, doormiddel van lokale weefsel constructie;Translational or applied research;human;In vivo testing of an electro spun vascular access graft under clinical conditions in an uremic large animal model;ENG;goat;APX_2B;Urogenital or reproductive disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;expertise;APX_2D;tissue construction;gene and cell-based;NTS_3.1
20173344_03;20173344;Cre<eb>ren van nieuwe bloedvaten voor pati<eb>nten met nierfalen, doormiddel van lokale weefsel constructie;Translational or applied research;human;In vivo testing of an electro spun vascular access graft under clinical conditions in an uremic large animal model;ENG;goat;APX_2B;Urogenital or reproductive disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;expertise;APX_2D;tissue construction;gene and cell-based;NTS_3.1
20173344_03;20173344;Cre<eb>ren van nieuwe bloedvaten voor pati<eb>nten met nierfalen, doormiddel van lokale weefsel constructie;Translational or applied research;human;In vivo testing of an electro spun vascular access graft under clinical conditions in an uremic large animal model;ENG;goat;APX_2B;Urogenital or reproductive disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;accomodation and care;cage enrichment;APX_2D;tissue construction;gene and cell-based;NTS_3.1
20173344_03;20173344;Cre<eb>ren van nieuwe bloedvaten voor pati<eb>nten met nierfalen, doormiddel van lokale weefsel constructie;Translational or applied research;human;In vivo testing of an electro spun vascular access graft under clinical conditions in an uremic large animal model;ENG;goat;APX_2B;Urogenital or reproductive disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;experimental design;optimal combination of readouts;APX_2D;accomodation and care;cage enrichment;APX_2D;tissue construction;gene and cell-based;NTS_3.1
20173344_03;20173344;Cre<eb>ren van nieuwe bloedvaten voor pati<eb>nten met nierfalen, doormiddel van lokale weefsel constructie;Translational or applied research;human;In vivo testing of an electro spun vascular access graft under clinical conditions in an uremic large animal model;ENG;goat;APX_2B;Urogenital or reproductive disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;optimal combination of readouts;APX_2D;accomodation and care;cage enrichment;APX_2D;tissue construction;gene and cell-based;NTS_3.1
20173344_03;20173344;Cre<eb>ren van nieuwe bloedvaten voor pati<eb>nten met nierfalen, doormiddel van lokale weefsel constructie;Translational or applied research;human;In vivo testing of an electro spun vascular access graft under clinical conditions in an uremic large animal model;ENG;goat;APX_2B;Urogenital or reproductive disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;tissue construction;gene and cell-based;NTS_3.1
20173344_03;20173344;Cre<eb>ren van nieuwe bloedvaten voor pati<eb>nten met nierfalen, doormiddel van lokale weefsel constructie;Translational or applied research;human;In vivo testing of an electro spun vascular access graft under clinical conditions in an uremic large animal model;ENG;goat;APX_2B;Urogenital or reproductive disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;tissue construction;gene and cell-based;NTS_3.1
20173344_03;20173344;Cre<eb>ren van nieuwe bloedvaten voor pati<eb>nten met nierfalen, doormiddel van lokale weefsel constructie;Translational or applied research;human;In vivo testing of an electro spun vascular access graft under clinical conditions in an uremic large animal model;ENG;goat;APX_2B;Urogenital or reproductive disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;tissue construction;gene and cell-based;NTS_3.1
20173344_03;20173344;Cre<eb>ren van nieuwe bloedvaten voor pati<eb>nten met nierfalen, doormiddel van lokale weefsel constructie;Translational or applied research;human;In vivo testing of an electro spun vascular access graft under clinical conditions in an uremic large animal model;ENG;goat;APX_2B;Urogenital or reproductive disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;expertise;APX_2D;tissue construction;gene and cell-based;NTS_3.1
20173344_03;20173344;Cre<eb>ren van nieuwe bloedvaten voor pati<eb>nten met nierfalen, doormiddel van lokale weefsel constructie;Translational or applied research;human;In vivo testing of an electro spun vascular access graft under clinical conditions in an uremic large animal model;ENG;goat;APX_2B;Urogenital or reproductive disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;expertise;APX_2D;tissue construction;gene and cell-based;NTS_3.1
20173344_03;20173344;Cre<eb>ren van nieuwe bloedvaten voor pati<eb>nten met nierfalen, doormiddel van lokale weefsel constructie;Translational or applied research;human;In vivo testing of an electro spun vascular access graft under clinical conditions in an uremic large animal model;ENG;goat;APX_2B;Urogenital or reproductive disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;expertise;APX_2D;tissue construction;gene and cell-based;NTS_3.1
20173344_03;20173344;Cre<eb>ren van nieuwe bloedvaten voor pati<eb>nten met nierfalen, doormiddel van lokale weefsel constructie;Translational or applied research;human;In vivo testing of an electro spun vascular access graft under clinical conditions in an uremic large animal model;ENG;goat;APX_2B;Urogenital or reproductive disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;accomodation and care;cage enrichment;APX_2D;tissue construction;gene and cell-based;NTS_3.1
20173344_03;20173344;Cre<eb>ren van nieuwe bloedvaten voor pati<eb>nten met nierfalen, doormiddel van lokale weefsel constructie;Translational or applied research;human;In vivo testing of an electro spun vascular access graft under clinical conditions in an uremic large animal model;ENG;goat;APX_2B;Urogenital or reproductive disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;accomodation and care;cage enrichment;APX_2D;tissue construction;gene and cell-based;NTS_3.1
20173344_03;20173344;Cre<eb>ren van nieuwe bloedvaten voor pati<eb>nten met nierfalen, doormiddel van lokale weefsel constructie;Translational or applied research;human;In vivo testing of an electro spun vascular access graft under clinical conditions in an uremic large animal model;ENG;goat;APX_2B;Urogenital or reproductive disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;accomodation and care;cage enrichment;APX_2D;tissue construction;gene and cell-based;NTS_3.1
20173344_03;20173344;Cre<eb>ren van nieuwe bloedvaten voor pati<eb>nten met nierfalen, doormiddel van lokale weefsel constructie;Translational or applied research;human;In vivo testing of an electro spun vascular access graft under clinical conditions in an uremic large animal model;ENG;goat;APX_2B;Urogenital or reproductive disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;tissue construction;gene and cell-based;NTS_3.1
20173344_03;20173344;Cre<eb>ren van nieuwe bloedvaten voor pati<eb>nten met nierfalen, doormiddel van lokale weefsel constructie;Translational or applied research;human;In vivo testing of an electro spun vascular access graft under clinical conditions in an uremic large animal model;ENG;goat;APX_2B;Urogenital or reproductive disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;tissue construction;gene and cell-based;NTS_3.1
20173344_03;20173344;Cre<eb>ren van nieuwe bloedvaten voor pati<eb>nten met nierfalen, doormiddel van lokale weefsel constructie;Translational or applied research;human;In vivo testing of an electro spun vascular access graft under clinical conditions in an uremic large animal model;ENG;goat;APX_2B;Urogenital or reproductive disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;tissue construction;gene and cell-based;NTS_3.1
20173344_03;20173344;Cre<eb>ren van nieuwe bloedvaten voor pati<eb>nten met nierfalen, doormiddel van lokale weefsel constructie;Translational or applied research;human;In vivo testing of an electro spun vascular access graft under clinical conditions in an uremic large animal model;ENG;goat;APX_2B;Urogenital or reproductive disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;expertise;APX_2D;tissue construction;gene and cell-based;NTS_3.1
20173344_03;20173344;Cre<eb>ren van nieuwe bloedvaten voor pati<eb>nten met nierfalen, doormiddel van lokale weefsel constructie;Translational or applied research;human;In vivo testing of an electro spun vascular access graft under clinical conditions in an uremic large animal model;ENG;goat;APX_2B;Urogenital or reproductive disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;expertise;APX_2D;tissue construction;gene and cell-based;NTS_3.1
20173344_03;20173344;Cre<eb>ren van nieuwe bloedvaten voor pati<eb>nten met nierfalen, doormiddel van lokale weefsel constructie;Translational or applied research;human;In vivo testing of an electro spun vascular access graft under clinical conditions in an uremic large animal model;ENG;goat;APX_2B;Urogenital or reproductive disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;expertise;APX_2D;tissue construction;gene and cell-based;NTS_3.1
20173344_03;20173344;Cre<eb>ren van nieuwe bloedvaten voor pati<eb>nten met nierfalen, doormiddel van lokale weefsel constructie;Translational or applied research;human;In vivo testing of an electro spun vascular access graft under clinical conditions in an uremic large animal model;ENG;goat;APX_2B;Urogenital or reproductive disorders;NTS_3.1;Induced;APX_2A;APX_2B;Appendix;similar anatomy;similar anatomy or organ system;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;accomodation and care;cage enrichment;APX_2D;tissue construction;gene and cell-based;NTS_3.1
20173344_03;20173344;Cre<eb>ren van nieuwe bloedvaten voor pati<eb>nten met nierfalen, doormiddel van lokale weefsel constructie;Translational or applied research;human;In vivo testing of an electro spun vascular access graft under clinical conditions in an uremic large animal model;ENG;goat;APX_2B;Urogenital or reproductive disorders;NTS_3.1;Induced;APX_2A;APX_2B;Appendix;similar anatomy;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;experimental design;optimal combination of readouts;APX_2D;accomodation and care;cage enrichment;APX_2D;tissue construction;gene and cell-based;NTS_3.1
20173344_03;20173344;Cre<eb>ren van nieuwe bloedvaten voor pati<eb>nten met nierfalen, doormiddel van lokale weefsel constructie;Translational or applied research;human;In vivo testing of an electro spun vascular access graft under clinical conditions in an uremic large animal model;ENG;goat;APX_2B;Urogenital or reproductive disorders;NTS_3.1;Induced;APX_2A;APX_2B;Appendix;similar anatomy;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;optimal combination of readouts;APX_2D;accomodation and care;cage enrichment;APX_2D;tissue construction;gene and cell-based;NTS_3.1
20173344_03;20173344;Cre<eb>ren van nieuwe bloedvaten voor pati<eb>nten met nierfalen, doormiddel van lokale weefsel constructie;Translational or applied research;human;In vivo testing of an electro spun vascular access graft under clinical conditions in an uremic large animal model;ENG;goat;APX_2B;Urogenital or reproductive disorders;NTS_3.1;Induced;APX_2A;APX_2B;Appendix;similar anatomy;similar anatomy or organ system;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;tissue construction;gene and cell-based;NTS_3.1
20173344_03;20173344;Cre<eb>ren van nieuwe bloedvaten voor pati<eb>nten met nierfalen, doormiddel van lokale weefsel constructie;Translational or applied research;human;In vivo testing of an electro spun vascular access graft under clinical conditions in an uremic large animal model;ENG;goat;APX_2B;Urogenital or reproductive disorders;NTS_3.1;Induced;APX_2A;APX_2B;Appendix;similar anatomy;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;tissue construction;gene and cell-based;NTS_3.1
20173344_03;20173344;Cre<eb>ren van nieuwe bloedvaten voor pati<eb>nten met nierfalen, doormiddel van lokale weefsel constructie;Translational or applied research;human;In vivo testing of an electro spun vascular access graft under clinical conditions in an uremic large animal model;ENG;goat;APX_2B;Urogenital or reproductive disorders;NTS_3.1;Induced;APX_2A;APX_2B;Appendix;similar anatomy;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;tissue construction;gene and cell-based;NTS_3.1
20173344_03;20173344;Cre<eb>ren van nieuwe bloedvaten voor pati<eb>nten met nierfalen, doormiddel van lokale weefsel constructie;Translational or applied research;human;In vivo testing of an electro spun vascular access graft under clinical conditions in an uremic large animal model;ENG;goat;APX_2B;Urogenital or reproductive disorders;NTS_3.1;Induced;APX_2A;APX_2B;Appendix;similar anatomy;similar anatomy or organ system;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;expertise;APX_2D;tissue construction;gene and cell-based;NTS_3.1
20173344_03;20173344;Cre<eb>ren van nieuwe bloedvaten voor pati<eb>nten met nierfalen, doormiddel van lokale weefsel constructie;Translational or applied research;human;In vivo testing of an electro spun vascular access graft under clinical conditions in an uremic large animal model;ENG;goat;APX_2B;Urogenital or reproductive disorders;NTS_3.1;Induced;APX_2A;APX_2B;Appendix;similar anatomy;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;expertise;APX_2D;tissue construction;gene and cell-based;NTS_3.1
20173344_03;20173344;Cre<eb>ren van nieuwe bloedvaten voor pati<eb>nten met nierfalen, doormiddel van lokale weefsel constructie;Translational or applied research;human;In vivo testing of an electro spun vascular access graft under clinical conditions in an uremic large animal model;ENG;goat;APX_2B;Urogenital or reproductive disorders;NTS_3.1;Induced;APX_2A;APX_2B;Appendix;similar anatomy;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;expertise;APX_2D;tissue construction;gene and cell-based;NTS_3.1
20173344_03;20173344;Cre<eb>ren van nieuwe bloedvaten voor pati<eb>nten met nierfalen, doormiddel van lokale weefsel constructie;Translational or applied research;human;In vivo testing of an electro spun vascular access graft under clinical conditions in an uremic large animal model;ENG;goat;APX_2B;Urogenital or reproductive disorders;NTS_3.1;Induced;APX_2A;APX_2B;Appendix;similar anatomy;similar anatomy or organ system;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;accomodation and care;cage enrichment;APX_2D;tissue construction;gene and cell-based;NTS_3.1
20173344_03;20173344;Cre<eb>ren van nieuwe bloedvaten voor pati<eb>nten met nierfalen, doormiddel van lokale weefsel constructie;Translational or applied research;human;In vivo testing of an electro spun vascular access graft under clinical conditions in an uremic large animal model;ENG;goat;APX_2B;Urogenital or reproductive disorders;NTS_3.1;Induced;APX_2A;APX_2B;Appendix;similar anatomy;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;accomodation and care;cage enrichment;APX_2D;tissue construction;gene and cell-based;NTS_3.1
20173344_03;20173344;Cre<eb>ren van nieuwe bloedvaten voor pati<eb>nten met nierfalen, doormiddel van lokale weefsel constructie;Translational or applied research;human;In vivo testing of an electro spun vascular access graft under clinical conditions in an uremic large animal model;ENG;goat;APX_2B;Urogenital or reproductive disorders;NTS_3.1;Induced;APX_2A;APX_2B;Appendix;similar anatomy;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;accomodation and care;cage enrichment;APX_2D;tissue construction;gene and cell-based;NTS_3.1
20173344_03;20173344;Cre<eb>ren van nieuwe bloedvaten voor pati<eb>nten met nierfalen, doormiddel van lokale weefsel constructie;Translational or applied research;human;In vivo testing of an electro spun vascular access graft under clinical conditions in an uremic large animal model;ENG;goat;APX_2B;Urogenital or reproductive disorders;NTS_3.1;Induced;APX_2A;APX_2B;Appendix;similar anatomy;similar anatomy or organ system;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;tissue construction;gene and cell-based;NTS_3.1
20173344_03;20173344;Cre<eb>ren van nieuwe bloedvaten voor pati<eb>nten met nierfalen, doormiddel van lokale weefsel constructie;Translational or applied research;human;In vivo testing of an electro spun vascular access graft under clinical conditions in an uremic large animal model;ENG;goat;APX_2B;Urogenital or reproductive disorders;NTS_3.1;Induced;APX_2A;APX_2B;Appendix;similar anatomy;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;tissue construction;gene and cell-based;NTS_3.1
20173344_03;20173344;Cre<eb>ren van nieuwe bloedvaten voor pati<eb>nten met nierfalen, doormiddel van lokale weefsel constructie;Translational or applied research;human;In vivo testing of an electro spun vascular access graft under clinical conditions in an uremic large animal model;ENG;goat;APX_2B;Urogenital or reproductive disorders;NTS_3.1;Induced;APX_2A;APX_2B;Appendix;similar anatomy;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;tissue construction;gene and cell-based;NTS_3.1
20173344_03;20173344;Cre<eb>ren van nieuwe bloedvaten voor pati<eb>nten met nierfalen, doormiddel van lokale weefsel constructie;Translational or applied research;human;In vivo testing of an electro spun vascular access graft under clinical conditions in an uremic large animal model;ENG;goat;APX_2B;Urogenital or reproductive disorders;NTS_3.1;Induced;APX_2A;APX_2B;Appendix;similar anatomy;similar anatomy or organ system;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;expertise;APX_2D;tissue construction;gene and cell-based;NTS_3.1
20173344_03;20173344;Cre<eb>ren van nieuwe bloedvaten voor pati<eb>nten met nierfalen, doormiddel van lokale weefsel constructie;Translational or applied research;human;In vivo testing of an electro spun vascular access graft under clinical conditions in an uremic large animal model;ENG;goat;APX_2B;Urogenital or reproductive disorders;NTS_3.1;Induced;APX_2A;APX_2B;Appendix;similar anatomy;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;expertise;APX_2D;tissue construction;gene and cell-based;NTS_3.1
20173344_03;20173344;Cre<eb>ren van nieuwe bloedvaten voor pati<eb>nten met nierfalen, doormiddel van lokale weefsel constructie;Translational or applied research;human;In vivo testing of an electro spun vascular access graft under clinical conditions in an uremic large animal model;ENG;goat;APX_2B;Urogenital or reproductive disorders;NTS_3.1;Induced;APX_2A;APX_2B;Appendix;similar anatomy;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;expertise;APX_2D;tissue construction;gene and cell-based;NTS_3.1
20173344_03;20173344;Cre<eb>ren van nieuwe bloedvaten voor pati<eb>nten met nierfalen, doormiddel van lokale weefsel constructie;Translational or applied research;human;In vivo testing of an electro spun vascular access graft under clinical conditions in an uremic large animal model;ENG;goat;APX_2B;Urogenital or reproductive disorders;NTS_3.1;Induced;APX_2A;APX_2B;Appendix;similar anatomy;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;accomodation and care;cage enrichment;APX_2D;tissue construction;gene and cell-based;NTS_3.1
20173344_03;20173344;Cre<eb>ren van nieuwe bloedvaten voor pati<eb>nten met nierfalen, doormiddel van lokale weefsel constructie;Translational or applied research;human;In vivo testing of an electro spun vascular access graft under clinical conditions in an uremic large animal model;ENG;goat;APX_2B;Urogenital or reproductive disorders;NTS_3.1;Induced;APX_2A;APX_2B;Appendix;similar anatomy;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;experimental design;optimal combination of readouts;APX_2D;accomodation and care;cage enrichment;APX_2D;tissue construction;gene and cell-based;NTS_3.1
20173344_03;20173344;Cre<eb>ren van nieuwe bloedvaten voor pati<eb>nten met nierfalen, doormiddel van lokale weefsel constructie;Translational or applied research;human;In vivo testing of an electro spun vascular access graft under clinical conditions in an uremic large animal model;ENG;goat;APX_2B;Urogenital or reproductive disorders;NTS_3.1;Induced;APX_2A;APX_2B;Appendix;similar anatomy;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;optimal combination of readouts;APX_2D;accomodation and care;cage enrichment;APX_2D;tissue construction;gene and cell-based;NTS_3.1
20173344_03;20173344;Cre<eb>ren van nieuwe bloedvaten voor pati<eb>nten met nierfalen, doormiddel van lokale weefsel constructie;Translational or applied research;human;In vivo testing of an electro spun vascular access graft under clinical conditions in an uremic large animal model;ENG;goat;APX_2B;Urogenital or reproductive disorders;NTS_3.1;Induced;APX_2A;APX_2B;Appendix;similar anatomy;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;tissue construction;gene and cell-based;NTS_3.1
20173344_03;20173344;Cre<eb>ren van nieuwe bloedvaten voor pati<eb>nten met nierfalen, doormiddel van lokale weefsel constructie;Translational or applied research;human;In vivo testing of an electro spun vascular access graft under clinical conditions in an uremic large animal model;ENG;goat;APX_2B;Urogenital or reproductive disorders;NTS_3.1;Induced;APX_2A;APX_2B;Appendix;similar anatomy;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;tissue construction;gene and cell-based;NTS_3.1
20173344_03;20173344;Cre<eb>ren van nieuwe bloedvaten voor pati<eb>nten met nierfalen, doormiddel van lokale weefsel constructie;Translational or applied research;human;In vivo testing of an electro spun vascular access graft under clinical conditions in an uremic large animal model;ENG;goat;APX_2B;Urogenital or reproductive disorders;NTS_3.1;Induced;APX_2A;APX_2B;Appendix;similar anatomy;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;tissue construction;gene and cell-based;NTS_3.1
20173344_03;20173344;Cre<eb>ren van nieuwe bloedvaten voor pati<eb>nten met nierfalen, doormiddel van lokale weefsel constructie;Translational or applied research;human;In vivo testing of an electro spun vascular access graft under clinical conditions in an uremic large animal model;ENG;goat;APX_2B;Urogenital or reproductive disorders;NTS_3.1;Induced;APX_2A;APX_2B;Appendix;similar anatomy;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;expertise;APX_2D;tissue construction;gene and cell-based;NTS_3.1
20173344_03;20173344;Cre<eb>ren van nieuwe bloedvaten voor pati<eb>nten met nierfalen, doormiddel van lokale weefsel constructie;Translational or applied research;human;In vivo testing of an electro spun vascular access graft under clinical conditions in an uremic large animal model;ENG;goat;APX_2B;Urogenital or reproductive disorders;NTS_3.1;Induced;APX_2A;APX_2B;Appendix;similar anatomy;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;expertise;APX_2D;tissue construction;gene and cell-based;NTS_3.1
20173344_03;20173344;Cre<eb>ren van nieuwe bloedvaten voor pati<eb>nten met nierfalen, doormiddel van lokale weefsel constructie;Translational or applied research;human;In vivo testing of an electro spun vascular access graft under clinical conditions in an uremic large animal model;ENG;goat;APX_2B;Urogenital or reproductive disorders;NTS_3.1;Induced;APX_2A;APX_2B;Appendix;similar anatomy;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;expertise;APX_2D;tissue construction;gene and cell-based;NTS_3.1
20173344_03;20173344;Cre<eb>ren van nieuwe bloedvaten voor pati<eb>nten met nierfalen, doormiddel van lokale weefsel constructie;Translational or applied research;human;In vivo testing of an electro spun vascular access graft under clinical conditions in an uremic large animal model;ENG;goat;APX_2B;Urogenital or reproductive disorders;NTS_3.1;Induced;APX_2A;APX_2B;Appendix;similar anatomy;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;accomodation and care;cage enrichment;APX_2D;tissue construction;gene and cell-based;NTS_3.1
20173344_03;20173344;Cre<eb>ren van nieuwe bloedvaten voor pati<eb>nten met nierfalen, doormiddel van lokale weefsel constructie;Translational or applied research;human;In vivo testing of an electro spun vascular access graft under clinical conditions in an uremic large animal model;ENG;goat;APX_2B;Urogenital or reproductive disorders;NTS_3.1;Induced;APX_2A;APX_2B;Appendix;similar anatomy;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;accomodation and care;cage enrichment;APX_2D;tissue construction;gene and cell-based;NTS_3.1
20173344_03;20173344;Cre<eb>ren van nieuwe bloedvaten voor pati<eb>nten met nierfalen, doormiddel van lokale weefsel constructie;Translational or applied research;human;In vivo testing of an electro spun vascular access graft under clinical conditions in an uremic large animal model;ENG;goat;APX_2B;Urogenital or reproductive disorders;NTS_3.1;Induced;APX_2A;APX_2B;Appendix;similar anatomy;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;accomodation and care;cage enrichment;APX_2D;tissue construction;gene and cell-based;NTS_3.1
20173344_03;20173344;Cre<eb>ren van nieuwe bloedvaten voor pati<eb>nten met nierfalen, doormiddel van lokale weefsel constructie;Translational or applied research;human;In vivo testing of an electro spun vascular access graft under clinical conditions in an uremic large animal model;ENG;goat;APX_2B;Urogenital or reproductive disorders;NTS_3.1;Induced;APX_2A;APX_2B;Appendix;similar anatomy;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;tissue construction;gene and cell-based;NTS_3.1
20173344_03;20173344;Cre<eb>ren van nieuwe bloedvaten voor pati<eb>nten met nierfalen, doormiddel van lokale weefsel constructie;Translational or applied research;human;In vivo testing of an electro spun vascular access graft under clinical conditions in an uremic large animal model;ENG;goat;APX_2B;Urogenital or reproductive disorders;NTS_3.1;Induced;APX_2A;APX_2B;Appendix;similar anatomy;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;tissue construction;gene and cell-based;NTS_3.1
20173344_03;20173344;Cre<eb>ren van nieuwe bloedvaten voor pati<eb>nten met nierfalen, doormiddel van lokale weefsel constructie;Translational or applied research;human;In vivo testing of an electro spun vascular access graft under clinical conditions in an uremic large animal model;ENG;goat;APX_2B;Urogenital or reproductive disorders;NTS_3.1;Induced;APX_2A;APX_2B;Appendix;similar anatomy;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;tissue construction;gene and cell-based;NTS_3.1
20173344_03;20173344;Cre<eb>ren van nieuwe bloedvaten voor pati<eb>nten met nierfalen, doormiddel van lokale weefsel constructie;Translational or applied research;human;In vivo testing of an electro spun vascular access graft under clinical conditions in an uremic large animal model;ENG;goat;APX_2B;Urogenital or reproductive disorders;NTS_3.1;Induced;APX_2A;APX_2B;Appendix;similar anatomy;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;expertise;APX_2D;tissue construction;gene and cell-based;NTS_3.1
20173344_03;20173344;Cre<eb>ren van nieuwe bloedvaten voor pati<eb>nten met nierfalen, doormiddel van lokale weefsel constructie;Translational or applied research;human;In vivo testing of an electro spun vascular access graft under clinical conditions in an uremic large animal model;ENG;goat;APX_2B;Urogenital or reproductive disorders;NTS_3.1;Induced;APX_2A;APX_2B;Appendix;similar anatomy;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;expertise;APX_2D;tissue construction;gene and cell-based;NTS_3.1
20173344_03;20173344;Cre<eb>ren van nieuwe bloedvaten voor pati<eb>nten met nierfalen, doormiddel van lokale weefsel constructie;Translational or applied research;human;In vivo testing of an electro spun vascular access graft under clinical conditions in an uremic large animal model;ENG;goat;APX_2B;Urogenital or reproductive disorders;NTS_3.1;Induced;APX_2A;APX_2B;Appendix;similar anatomy;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;expertise;APX_2D;tissue construction;gene and cell-based;NTS_3.1
20173344_03;20173344;Cre<eb>ren van nieuwe bloedvaten voor pati<eb>nten met nierfalen, doormiddel van lokale weefsel constructie;Translational or applied research;human;In vivo testing of an electro spun vascular access graft under clinical conditions in an uremic large animal model;ENG;goat;APX_2B;Urogenital or reproductive disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;similar anatomy or organ system;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;accomodation and care;cage enrichment;APX_2D;tissue construction;gene and cell-based;NTS_3.1
20173344_03;20173344;Cre<eb>ren van nieuwe bloedvaten voor pati<eb>nten met nierfalen, doormiddel van lokale weefsel constructie;Translational or applied research;human;In vivo testing of an electro spun vascular access graft under clinical conditions in an uremic large animal model;ENG;goat;APX_2B;Urogenital or reproductive disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;experimental design;optimal combination of readouts;APX_2D;accomodation and care;cage enrichment;APX_2D;tissue construction;gene and cell-based;NTS_3.1
20173344_03;20173344;Cre<eb>ren van nieuwe bloedvaten voor pati<eb>nten met nierfalen, doormiddel van lokale weefsel constructie;Translational or applied research;human;In vivo testing of an electro spun vascular access graft under clinical conditions in an uremic large animal model;ENG;goat;APX_2B;Urogenital or reproductive disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;optimal combination of readouts;APX_2D;accomodation and care;cage enrichment;APX_2D;tissue construction;gene and cell-based;NTS_3.1
20173344_03;20173344;Cre<eb>ren van nieuwe bloedvaten voor pati<eb>nten met nierfalen, doormiddel van lokale weefsel constructie;Translational or applied research;human;In vivo testing of an electro spun vascular access graft under clinical conditions in an uremic large animal model;ENG;goat;APX_2B;Urogenital or reproductive disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;similar anatomy or organ system;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;tissue construction;gene and cell-based;NTS_3.1
20173344_03;20173344;Cre<eb>ren van nieuwe bloedvaten voor pati<eb>nten met nierfalen, doormiddel van lokale weefsel constructie;Translational or applied research;human;In vivo testing of an electro spun vascular access graft under clinical conditions in an uremic large animal model;ENG;goat;APX_2B;Urogenital or reproductive disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;tissue construction;gene and cell-based;NTS_3.1
20173344_03;20173344;Cre<eb>ren van nieuwe bloedvaten voor pati<eb>nten met nierfalen, doormiddel van lokale weefsel constructie;Translational or applied research;human;In vivo testing of an electro spun vascular access graft under clinical conditions in an uremic large animal model;ENG;goat;APX_2B;Urogenital or reproductive disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;tissue construction;gene and cell-based;NTS_3.1
20173344_03;20173344;Cre<eb>ren van nieuwe bloedvaten voor pati<eb>nten met nierfalen, doormiddel van lokale weefsel constructie;Translational or applied research;human;In vivo testing of an electro spun vascular access graft under clinical conditions in an uremic large animal model;ENG;goat;APX_2B;Urogenital or reproductive disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;similar anatomy or organ system;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;expertise;APX_2D;tissue construction;gene and cell-based;NTS_3.1
20173344_03;20173344;Cre<eb>ren van nieuwe bloedvaten voor pati<eb>nten met nierfalen, doormiddel van lokale weefsel constructie;Translational or applied research;human;In vivo testing of an electro spun vascular access graft under clinical conditions in an uremic large animal model;ENG;goat;APX_2B;Urogenital or reproductive disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;expertise;APX_2D;tissue construction;gene and cell-based;NTS_3.1
20173344_03;20173344;Cre<eb>ren van nieuwe bloedvaten voor pati<eb>nten met nierfalen, doormiddel van lokale weefsel constructie;Translational or applied research;human;In vivo testing of an electro spun vascular access graft under clinical conditions in an uremic large animal model;ENG;goat;APX_2B;Urogenital or reproductive disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;expertise;APX_2D;tissue construction;gene and cell-based;NTS_3.1
20173344_03;20173344;Cre<eb>ren van nieuwe bloedvaten voor pati<eb>nten met nierfalen, doormiddel van lokale weefsel constructie;Translational or applied research;human;In vivo testing of an electro spun vascular access graft under clinical conditions in an uremic large animal model;ENG;goat;APX_2B;Urogenital or reproductive disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;similar anatomy or organ system;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;accomodation and care;cage enrichment;APX_2D;tissue construction;gene and cell-based;NTS_3.1
20173344_03;20173344;Cre<eb>ren van nieuwe bloedvaten voor pati<eb>nten met nierfalen, doormiddel van lokale weefsel constructie;Translational or applied research;human;In vivo testing of an electro spun vascular access graft under clinical conditions in an uremic large animal model;ENG;goat;APX_2B;Urogenital or reproductive disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;accomodation and care;cage enrichment;APX_2D;tissue construction;gene and cell-based;NTS_3.1
20173344_03;20173344;Cre<eb>ren van nieuwe bloedvaten voor pati<eb>nten met nierfalen, doormiddel van lokale weefsel constructie;Translational or applied research;human;In vivo testing of an electro spun vascular access graft under clinical conditions in an uremic large animal model;ENG;goat;APX_2B;Urogenital or reproductive disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;accomodation and care;cage enrichment;APX_2D;tissue construction;gene and cell-based;NTS_3.1
20173344_03;20173344;Cre<eb>ren van nieuwe bloedvaten voor pati<eb>nten met nierfalen, doormiddel van lokale weefsel constructie;Translational or applied research;human;In vivo testing of an electro spun vascular access graft under clinical conditions in an uremic large animal model;ENG;goat;APX_2B;Urogenital or reproductive disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;similar anatomy or organ system;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;tissue construction;gene and cell-based;NTS_3.1
20173344_03;20173344;Cre<eb>ren van nieuwe bloedvaten voor pati<eb>nten met nierfalen, doormiddel van lokale weefsel constructie;Translational or applied research;human;In vivo testing of an electro spun vascular access graft under clinical conditions in an uremic large animal model;ENG;goat;APX_2B;Urogenital or reproductive disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;tissue construction;gene and cell-based;NTS_3.1
20173344_03;20173344;Cre<eb>ren van nieuwe bloedvaten voor pati<eb>nten met nierfalen, doormiddel van lokale weefsel constructie;Translational or applied research;human;In vivo testing of an electro spun vascular access graft under clinical conditions in an uremic large animal model;ENG;goat;APX_2B;Urogenital or reproductive disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;tissue construction;gene and cell-based;NTS_3.1
20173344_03;20173344;Cre<eb>ren van nieuwe bloedvaten voor pati<eb>nten met nierfalen, doormiddel van lokale weefsel constructie;Translational or applied research;human;In vivo testing of an electro spun vascular access graft under clinical conditions in an uremic large animal model;ENG;goat;APX_2B;Urogenital or reproductive disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;similar anatomy or organ system;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;expertise;APX_2D;tissue construction;gene and cell-based;NTS_3.1
20173344_03;20173344;Cre<eb>ren van nieuwe bloedvaten voor pati<eb>nten met nierfalen, doormiddel van lokale weefsel constructie;Translational or applied research;human;In vivo testing of an electro spun vascular access graft under clinical conditions in an uremic large animal model;ENG;goat;APX_2B;Urogenital or reproductive disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;expertise;APX_2D;tissue construction;gene and cell-based;NTS_3.1
20173344_03;20173344;Cre<eb>ren van nieuwe bloedvaten voor pati<eb>nten met nierfalen, doormiddel van lokale weefsel constructie;Translational or applied research;human;In vivo testing of an electro spun vascular access graft under clinical conditions in an uremic large animal model;ENG;goat;APX_2B;Urogenital or reproductive disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;expertise;APX_2D;tissue construction;gene and cell-based;NTS_3.1
20173344_03;20173344;Cre<eb>ren van nieuwe bloedvaten voor pati<eb>nten met nierfalen, doormiddel van lokale weefsel constructie;Translational or applied research;human;In vivo testing of an electro spun vascular access graft under clinical conditions in an uremic large animal model;ENG;goat;APX_2B;Urogenital or reproductive disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;accomodation and care;cage enrichment;APX_2D;tissue construction;gene and cell-based;NTS_3.1
20173344_03;20173344;Cre<eb>ren van nieuwe bloedvaten voor pati<eb>nten met nierfalen, doormiddel van lokale weefsel constructie;Translational or applied research;human;In vivo testing of an electro spun vascular access graft under clinical conditions in an uremic large animal model;ENG;goat;APX_2B;Urogenital or reproductive disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;experimental design;optimal combination of readouts;APX_2D;accomodation and care;cage enrichment;APX_2D;tissue construction;gene and cell-based;NTS_3.1
20173344_03;20173344;Cre<eb>ren van nieuwe bloedvaten voor pati<eb>nten met nierfalen, doormiddel van lokale weefsel constructie;Translational or applied research;human;In vivo testing of an electro spun vascular access graft under clinical conditions in an uremic large animal model;ENG;goat;APX_2B;Urogenital or reproductive disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;optimal combination of readouts;APX_2D;accomodation and care;cage enrichment;APX_2D;tissue construction;gene and cell-based;NTS_3.1
20173344_03;20173344;Cre<eb>ren van nieuwe bloedvaten voor pati<eb>nten met nierfalen, doormiddel van lokale weefsel constructie;Translational or applied research;human;In vivo testing of an electro spun vascular access graft under clinical conditions in an uremic large animal model;ENG;goat;APX_2B;Urogenital or reproductive disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;tissue construction;gene and cell-based;NTS_3.1
20173344_03;20173344;Cre<eb>ren van nieuwe bloedvaten voor pati<eb>nten met nierfalen, doormiddel van lokale weefsel constructie;Translational or applied research;human;In vivo testing of an electro spun vascular access graft under clinical conditions in an uremic large animal model;ENG;goat;APX_2B;Urogenital or reproductive disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;tissue construction;gene and cell-based;NTS_3.1
20173344_03;20173344;Cre<eb>ren van nieuwe bloedvaten voor pati<eb>nten met nierfalen, doormiddel van lokale weefsel constructie;Translational or applied research;human;In vivo testing of an electro spun vascular access graft under clinical conditions in an uremic large animal model;ENG;goat;APX_2B;Urogenital or reproductive disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;tissue construction;gene and cell-based;NTS_3.1
20173344_03;20173344;Cre<eb>ren van nieuwe bloedvaten voor pati<eb>nten met nierfalen, doormiddel van lokale weefsel constructie;Translational or applied research;human;In vivo testing of an electro spun vascular access graft under clinical conditions in an uremic large animal model;ENG;goat;APX_2B;Urogenital or reproductive disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;expertise;APX_2D;tissue construction;gene and cell-based;NTS_3.1
20173344_03;20173344;Cre<eb>ren van nieuwe bloedvaten voor pati<eb>nten met nierfalen, doormiddel van lokale weefsel constructie;Translational or applied research;human;In vivo testing of an electro spun vascular access graft under clinical conditions in an uremic large animal model;ENG;goat;APX_2B;Urogenital or reproductive disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;expertise;APX_2D;tissue construction;gene and cell-based;NTS_3.1
20173344_03;20173344;Cre<eb>ren van nieuwe bloedvaten voor pati<eb>nten met nierfalen, doormiddel van lokale weefsel constructie;Translational or applied research;human;In vivo testing of an electro spun vascular access graft under clinical conditions in an uremic large animal model;ENG;goat;APX_2B;Urogenital or reproductive disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;expertise;APX_2D;tissue construction;gene and cell-based;NTS_3.1
20173344_03;20173344;Cre<eb>ren van nieuwe bloedvaten voor pati<eb>nten met nierfalen, doormiddel van lokale weefsel constructie;Translational or applied research;human;In vivo testing of an electro spun vascular access graft under clinical conditions in an uremic large animal model;ENG;goat;APX_2B;Urogenital or reproductive disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;accomodation and care;cage enrichment;APX_2D;tissue construction;gene and cell-based;NTS_3.1
20173344_03;20173344;Cre<eb>ren van nieuwe bloedvaten voor pati<eb>nten met nierfalen, doormiddel van lokale weefsel constructie;Translational or applied research;human;In vivo testing of an electro spun vascular access graft under clinical conditions in an uremic large animal model;ENG;goat;APX_2B;Urogenital or reproductive disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;accomodation and care;cage enrichment;APX_2D;tissue construction;gene and cell-based;NTS_3.1
20173344_03;20173344;Cre<eb>ren van nieuwe bloedvaten voor pati<eb>nten met nierfalen, doormiddel van lokale weefsel constructie;Translational or applied research;human;In vivo testing of an electro spun vascular access graft under clinical conditions in an uremic large animal model;ENG;goat;APX_2B;Urogenital or reproductive disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;accomodation and care;cage enrichment;APX_2D;tissue construction;gene and cell-based;NTS_3.1
20173344_03;20173344;Cre<eb>ren van nieuwe bloedvaten voor pati<eb>nten met nierfalen, doormiddel van lokale weefsel constructie;Translational or applied research;human;In vivo testing of an electro spun vascular access graft under clinical conditions in an uremic large animal model;ENG;goat;APX_2B;Urogenital or reproductive disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;tissue construction;gene and cell-based;NTS_3.1
20173344_03;20173344;Cre<eb>ren van nieuwe bloedvaten voor pati<eb>nten met nierfalen, doormiddel van lokale weefsel constructie;Translational or applied research;human;In vivo testing of an electro spun vascular access graft under clinical conditions in an uremic large animal model;ENG;goat;APX_2B;Urogenital or reproductive disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;tissue construction;gene and cell-based;NTS_3.1
20173344_03;20173344;Cre<eb>ren van nieuwe bloedvaten voor pati<eb>nten met nierfalen, doormiddel van lokale weefsel constructie;Translational or applied research;human;In vivo testing of an electro spun vascular access graft under clinical conditions in an uremic large animal model;ENG;goat;APX_2B;Urogenital or reproductive disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;tissue construction;gene and cell-based;NTS_3.1
20173344_03;20173344;Cre<eb>ren van nieuwe bloedvaten voor pati<eb>nten met nierfalen, doormiddel van lokale weefsel constructie;Translational or applied research;human;In vivo testing of an electro spun vascular access graft under clinical conditions in an uremic large animal model;ENG;goat;APX_2B;Urogenital or reproductive disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;expertise;APX_2D;tissue construction;gene and cell-based;NTS_3.1
20173344_03;20173344;Cre<eb>ren van nieuwe bloedvaten voor pati<eb>nten met nierfalen, doormiddel van lokale weefsel constructie;Translational or applied research;human;In vivo testing of an electro spun vascular access graft under clinical conditions in an uremic large animal model;ENG;goat;APX_2B;Urogenital or reproductive disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;expertise;APX_2D;tissue construction;gene and cell-based;NTS_3.1
20173344_03;20173344;Cre<eb>ren van nieuwe bloedvaten voor pati<eb>nten met nierfalen, doormiddel van lokale weefsel constructie;Translational or applied research;human;In vivo testing of an electro spun vascular access graft under clinical conditions in an uremic large animal model;ENG;goat;APX_2B;Urogenital or reproductive disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;expertise;APX_2D;tissue construction;gene and cell-based;NTS_3.1
20173344_03;20173344;Cre<eb>ren van nieuwe bloedvaten voor pati<eb>nten met nierfalen, doormiddel van lokale weefsel constructie;Translational or applied research;human;In vivo testing of an electro spun vascular access graft under clinical conditions in an uremic large animal model;ENG;goat;APX_2B;Urogenital or reproductive disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;accomodation and care;cage enrichment;APX_2D;tissue construction;gene and cell-based;NTS_3.1
20173344_03;20173344;Cre<eb>ren van nieuwe bloedvaten voor pati<eb>nten met nierfalen, doormiddel van lokale weefsel constructie;Translational or applied research;human;In vivo testing of an electro spun vascular access graft under clinical conditions in an uremic large animal model;ENG;goat;APX_2B;Urogenital or reproductive disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;experimental design;optimal combination of readouts;APX_2D;accomodation and care;cage enrichment;APX_2D;tissue construction;gene and cell-based;NTS_3.1
20173344_03;20173344;Cre<eb>ren van nieuwe bloedvaten voor pati<eb>nten met nierfalen, doormiddel van lokale weefsel constructie;Translational or applied research;human;In vivo testing of an electro spun vascular access graft under clinical conditions in an uremic large animal model;ENG;goat;APX_2B;Urogenital or reproductive disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;optimal combination of readouts;APX_2D;accomodation and care;cage enrichment;APX_2D;tissue construction;gene and cell-based;NTS_3.1
20173344_03;20173344;Cre<eb>ren van nieuwe bloedvaten voor pati<eb>nten met nierfalen, doormiddel van lokale weefsel constructie;Translational or applied research;human;In vivo testing of an electro spun vascular access graft under clinical conditions in an uremic large animal model;ENG;goat;APX_2B;Urogenital or reproductive disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;tissue construction;gene and cell-based;NTS_3.1
20173344_03;20173344;Cre<eb>ren van nieuwe bloedvaten voor pati<eb>nten met nierfalen, doormiddel van lokale weefsel constructie;Translational or applied research;human;In vivo testing of an electro spun vascular access graft under clinical conditions in an uremic large animal model;ENG;goat;APX_2B;Urogenital or reproductive disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;tissue construction;gene and cell-based;NTS_3.1
20173344_03;20173344;Cre<eb>ren van nieuwe bloedvaten voor pati<eb>nten met nierfalen, doormiddel van lokale weefsel constructie;Translational or applied research;human;In vivo testing of an electro spun vascular access graft under clinical conditions in an uremic large animal model;ENG;goat;APX_2B;Urogenital or reproductive disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;tissue construction;gene and cell-based;NTS_3.1
20173344_03;20173344;Cre<eb>ren van nieuwe bloedvaten voor pati<eb>nten met nierfalen, doormiddel van lokale weefsel constructie;Translational or applied research;human;In vivo testing of an electro spun vascular access graft under clinical conditions in an uremic large animal model;ENG;goat;APX_2B;Urogenital or reproductive disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;expertise;APX_2D;tissue construction;gene and cell-based;NTS_3.1
20173344_03;20173344;Cre<eb>ren van nieuwe bloedvaten voor pati<eb>nten met nierfalen, doormiddel van lokale weefsel constructie;Translational or applied research;human;In vivo testing of an electro spun vascular access graft under clinical conditions in an uremic large animal model;ENG;goat;APX_2B;Urogenital or reproductive disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;expertise;APX_2D;tissue construction;gene and cell-based;NTS_3.1
20173344_03;20173344;Cre<eb>ren van nieuwe bloedvaten voor pati<eb>nten met nierfalen, doormiddel van lokale weefsel constructie;Translational or applied research;human;In vivo testing of an electro spun vascular access graft under clinical conditions in an uremic large animal model;ENG;goat;APX_2B;Urogenital or reproductive disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;expertise;APX_2D;tissue construction;gene and cell-based;NTS_3.1
20173344_03;20173344;Cre<eb>ren van nieuwe bloedvaten voor pati<eb>nten met nierfalen, doormiddel van lokale weefsel constructie;Translational or applied research;human;In vivo testing of an electro spun vascular access graft under clinical conditions in an uremic large animal model;ENG;goat;APX_2B;Urogenital or reproductive disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;accomodation and care;cage enrichment;APX_2D;tissue construction;gene and cell-based;NTS_3.1
20173344_03;20173344;Cre<eb>ren van nieuwe bloedvaten voor pati<eb>nten met nierfalen, doormiddel van lokale weefsel constructie;Translational or applied research;human;In vivo testing of an electro spun vascular access graft under clinical conditions in an uremic large animal model;ENG;goat;APX_2B;Urogenital or reproductive disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;accomodation and care;cage enrichment;APX_2D;tissue construction;gene and cell-based;NTS_3.1
20173344_03;20173344;Cre<eb>ren van nieuwe bloedvaten voor pati<eb>nten met nierfalen, doormiddel van lokale weefsel constructie;Translational or applied research;human;In vivo testing of an electro spun vascular access graft under clinical conditions in an uremic large animal model;ENG;goat;APX_2B;Urogenital or reproductive disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;accomodation and care;cage enrichment;APX_2D;tissue construction;gene and cell-based;NTS_3.1
20173344_03;20173344;Cre<eb>ren van nieuwe bloedvaten voor pati<eb>nten met nierfalen, doormiddel van lokale weefsel constructie;Translational or applied research;human;In vivo testing of an electro spun vascular access graft under clinical conditions in an uremic large animal model;ENG;goat;APX_2B;Urogenital or reproductive disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;tissue construction;gene and cell-based;NTS_3.1
20173344_03;20173344;Cre<eb>ren van nieuwe bloedvaten voor pati<eb>nten met nierfalen, doormiddel van lokale weefsel constructie;Translational or applied research;human;In vivo testing of an electro spun vascular access graft under clinical conditions in an uremic large animal model;ENG;goat;APX_2B;Urogenital or reproductive disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;tissue construction;gene and cell-based;NTS_3.1
20173344_03;20173344;Cre<eb>ren van nieuwe bloedvaten voor pati<eb>nten met nierfalen, doormiddel van lokale weefsel constructie;Translational or applied research;human;In vivo testing of an electro spun vascular access graft under clinical conditions in an uremic large animal model;ENG;goat;APX_2B;Urogenital or reproductive disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;tissue construction;gene and cell-based;NTS_3.1
20173344_03;20173344;Cre<eb>ren van nieuwe bloedvaten voor pati<eb>nten met nierfalen, doormiddel van lokale weefsel constructie;Translational or applied research;human;In vivo testing of an electro spun vascular access graft under clinical conditions in an uremic large animal model;ENG;goat;APX_2B;Urogenital or reproductive disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;expertise;APX_2D;tissue construction;gene and cell-based;NTS_3.1
20173344_03;20173344;Cre<eb>ren van nieuwe bloedvaten voor pati<eb>nten met nierfalen, doormiddel van lokale weefsel constructie;Translational or applied research;human;In vivo testing of an electro spun vascular access graft under clinical conditions in an uremic large animal model;ENG;goat;APX_2B;Urogenital or reproductive disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;expertise;APX_2D;tissue construction;gene and cell-based;NTS_3.1
20173344_03;20173344;Cre<eb>ren van nieuwe bloedvaten voor pati<eb>nten met nierfalen, doormiddel van lokale weefsel constructie;Translational or applied research;human;In vivo testing of an electro spun vascular access graft under clinical conditions in an uremic large animal model;ENG;goat;APX_2B;Urogenital or reproductive disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;expertise;APX_2D;tissue construction;gene and cell-based;NTS_3.1
20173344_03;20173344;Cre<eb>ren van nieuwe bloedvaten voor pati<eb>nten met nierfalen, doormiddel van lokale weefsel constructie;Translational or applied research;human;In vivo testing of an electro spun vascular access graft under clinical conditions in an uremic large animal model;ENG;goat;APX_2B;Urogenital or reproductive disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;accomodation and care;cage enrichment;APX_2D;tissue construction;gene and cell-based;NTS_3.1
20173344_03;20173344;Cre<eb>ren van nieuwe bloedvaten voor pati<eb>nten met nierfalen, doormiddel van lokale weefsel constructie;Translational or applied research;human;In vivo testing of an electro spun vascular access graft under clinical conditions in an uremic large animal model;ENG;goat;APX_2B;Urogenital or reproductive disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;experimental design;optimal combination of readouts;APX_2D;accomodation and care;cage enrichment;APX_2D;tissue construction;gene and cell-based;NTS_3.1
20173344_03;20173344;Cre<eb>ren van nieuwe bloedvaten voor pati<eb>nten met nierfalen, doormiddel van lokale weefsel constructie;Translational or applied research;human;In vivo testing of an electro spun vascular access graft under clinical conditions in an uremic large animal model;ENG;goat;APX_2B;Urogenital or reproductive disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;optimal combination of readouts;APX_2D;accomodation and care;cage enrichment;APX_2D;tissue construction;gene and cell-based;NTS_3.1
20173344_03;20173344;Cre<eb>ren van nieuwe bloedvaten voor pati<eb>nten met nierfalen, doormiddel van lokale weefsel constructie;Translational or applied research;human;In vivo testing of an electro spun vascular access graft under clinical conditions in an uremic large animal model;ENG;goat;APX_2B;Urogenital or reproductive disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;tissue construction;gene and cell-based;NTS_3.1
20173344_03;20173344;Cre<eb>ren van nieuwe bloedvaten voor pati<eb>nten met nierfalen, doormiddel van lokale weefsel constructie;Translational or applied research;human;In vivo testing of an electro spun vascular access graft under clinical conditions in an uremic large animal model;ENG;goat;APX_2B;Urogenital or reproductive disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;tissue construction;gene and cell-based;NTS_3.1
20173344_03;20173344;Cre<eb>ren van nieuwe bloedvaten voor pati<eb>nten met nierfalen, doormiddel van lokale weefsel constructie;Translational or applied research;human;In vivo testing of an electro spun vascular access graft under clinical conditions in an uremic large animal model;ENG;goat;APX_2B;Urogenital or reproductive disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;tissue construction;gene and cell-based;NTS_3.1
20173344_03;20173344;Cre<eb>ren van nieuwe bloedvaten voor pati<eb>nten met nierfalen, doormiddel van lokale weefsel constructie;Translational or applied research;human;In vivo testing of an electro spun vascular access graft under clinical conditions in an uremic large animal model;ENG;goat;APX_2B;Urogenital or reproductive disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;expertise;APX_2D;tissue construction;gene and cell-based;NTS_3.1
20173344_03;20173344;Cre<eb>ren van nieuwe bloedvaten voor pati<eb>nten met nierfalen, doormiddel van lokale weefsel constructie;Translational or applied research;human;In vivo testing of an electro spun vascular access graft under clinical conditions in an uremic large animal model;ENG;goat;APX_2B;Urogenital or reproductive disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;expertise;APX_2D;tissue construction;gene and cell-based;NTS_3.1
20173344_03;20173344;Cre<eb>ren van nieuwe bloedvaten voor pati<eb>nten met nierfalen, doormiddel van lokale weefsel constructie;Translational or applied research;human;In vivo testing of an electro spun vascular access graft under clinical conditions in an uremic large animal model;ENG;goat;APX_2B;Urogenital or reproductive disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;expertise;APX_2D;tissue construction;gene and cell-based;NTS_3.1
20173344_03;20173344;Cre<eb>ren van nieuwe bloedvaten voor pati<eb>nten met nierfalen, doormiddel van lokale weefsel constructie;Translational or applied research;human;In vivo testing of an electro spun vascular access graft under clinical conditions in an uremic large animal model;ENG;goat;APX_2B;Urogenital or reproductive disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;accomodation and care;cage enrichment;APX_2D;tissue construction;gene and cell-based;NTS_3.1
20173344_03;20173344;Cre<eb>ren van nieuwe bloedvaten voor pati<eb>nten met nierfalen, doormiddel van lokale weefsel constructie;Translational or applied research;human;In vivo testing of an electro spun vascular access graft under clinical conditions in an uremic large animal model;ENG;goat;APX_2B;Urogenital or reproductive disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;accomodation and care;cage enrichment;APX_2D;tissue construction;gene and cell-based;NTS_3.1
20173344_03;20173344;Cre<eb>ren van nieuwe bloedvaten voor pati<eb>nten met nierfalen, doormiddel van lokale weefsel constructie;Translational or applied research;human;In vivo testing of an electro spun vascular access graft under clinical conditions in an uremic large animal model;ENG;goat;APX_2B;Urogenital or reproductive disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;accomodation and care;cage enrichment;APX_2D;tissue construction;gene and cell-based;NTS_3.1
20173344_03;20173344;Cre<eb>ren van nieuwe bloedvaten voor pati<eb>nten met nierfalen, doormiddel van lokale weefsel constructie;Translational or applied research;human;In vivo testing of an electro spun vascular access graft under clinical conditions in an uremic large animal model;ENG;goat;APX_2B;Urogenital or reproductive disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;tissue construction;gene and cell-based;NTS_3.1
20173344_03;20173344;Cre<eb>ren van nieuwe bloedvaten voor pati<eb>nten met nierfalen, doormiddel van lokale weefsel constructie;Translational or applied research;human;In vivo testing of an electro spun vascular access graft under clinical conditions in an uremic large animal model;ENG;goat;APX_2B;Urogenital or reproductive disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;tissue construction;gene and cell-based;NTS_3.1
20173344_03;20173344;Cre<eb>ren van nieuwe bloedvaten voor pati<eb>nten met nierfalen, doormiddel van lokale weefsel constructie;Translational or applied research;human;In vivo testing of an electro spun vascular access graft under clinical conditions in an uremic large animal model;ENG;goat;APX_2B;Urogenital or reproductive disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;tissue construction;gene and cell-based;NTS_3.1
20173344_03;20173344;Cre<eb>ren van nieuwe bloedvaten voor pati<eb>nten met nierfalen, doormiddel van lokale weefsel constructie;Translational or applied research;human;In vivo testing of an electro spun vascular access graft under clinical conditions in an uremic large animal model;ENG;goat;APX_2B;Urogenital or reproductive disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;expertise;APX_2D;tissue construction;gene and cell-based;NTS_3.1
20173344_03;20173344;Cre<eb>ren van nieuwe bloedvaten voor pati<eb>nten met nierfalen, doormiddel van lokale weefsel constructie;Translational or applied research;human;In vivo testing of an electro spun vascular access graft under clinical conditions in an uremic large animal model;ENG;goat;APX_2B;Urogenital or reproductive disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;expertise;APX_2D;tissue construction;gene and cell-based;NTS_3.1
20173344_03;20173344;Cre<eb>ren van nieuwe bloedvaten voor pati<eb>nten met nierfalen, doormiddel van lokale weefsel constructie;Translational or applied research;human;In vivo testing of an electro spun vascular access graft under clinical conditions in an uremic large animal model;ENG;goat;APX_2B;Urogenital or reproductive disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;expertise;APX_2D;tissue construction;gene and cell-based;NTS_3.1
20173424_01;20173424;In vivo productontwikkeling en training voor minimale invasieve vasulaire hulpmiddelen;Translational or applied research;human;Pig model;ENG;pig;APX_2B;Cardiovascular disorders;NTS_1.3;Naive or healthy;APX_2A;APX_2B;Appendix;similar disease pathology or symptoms;existing model;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;terminal anesthesia;APX_2D;minimal invasive device;diagnostic tool;NTS_3.1
20173424_01;20173424;In vivo productontwikkeling en training voor minimale invasieve vasulaire hulpmiddelen;Translational or applied research;human;Pig model;ENG;pig;APX_2B;Cardiovascular disorders;NTS_1.3;Naive or healthy;APX_2A;APX_2B;Appendix;similar disease pathology or symptoms;existing model;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;terminal anesthesia;APX_2D;minimal invasive device;diagnostic tool;NTS_3.1
20173424_01;20173424;In vivo productontwikkeling en training voor minimale invasieve vasulaire hulpmiddelen;Translational or applied research;human;Pig model;ENG;pig;APX_2B;Cardiovascular disorders;NTS_1.3;Naive or healthy;APX_2A;APX_2B;Appendix;similar disease pathology or symptoms;existing model;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;terminal anesthesia;APX_2D;minimal invasive device;diagnostic tool;NTS_3.1
20173424_01;20173424;In vivo productontwikkeling en training voor minimale invasieve vasulaire hulpmiddelen;Translational or applied research;human;Pig model;ENG;pig;APX_2B;Cardiovascular disorders;NTS_1.3;Naive or healthy;APX_2A;APX_2B;Appendix;similar disease pathology or symptoms;existing model;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;terminal anesthesia;APX_2D;minimal invasive device;diagnostic tool;NTS_3.1
20173424_01;20173424;In vivo productontwikkeling en training voor minimale invasieve vasulaire hulpmiddelen;Translational or applied research;human;Pig model;ENG;pig;APX_2B;Cardiovascular disorders;NTS_1.3;Naive or healthy;APX_2A;APX_2B;Appendix;similar disease pathology or symptoms;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;terminal anesthesia;APX_2D;minimal invasive device;diagnostic tool;NTS_3.1
20173424_01;20173424;In vivo productontwikkeling en training voor minimale invasieve vasulaire hulpmiddelen;Translational or applied research;human;Pig model;ENG;pig;APX_2B;Cardiovascular disorders;NTS_1.3;Naive or healthy;APX_2A;APX_2B;Appendix;similar disease pathology or symptoms;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;terminal anesthesia;APX_2D;minimal invasive device;diagnostic tool;NTS_3.1
20173424_01;20173424;In vivo productontwikkeling en training voor minimale invasieve vasulaire hulpmiddelen;Translational or applied research;human;Pig model;ENG;pig;APX_2B;Cardiovascular disorders;NTS_1.3;Naive or healthy;APX_2A;APX_2B;Appendix;similar disease pathology or symptoms;similar anatomy or organ system;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;terminal anesthesia;APX_2D;minimal invasive device;diagnostic tool;NTS_3.1
20173424_01;20173424;In vivo productontwikkeling en training voor minimale invasieve vasulaire hulpmiddelen;Translational or applied research;human;Pig model;ENG;pig;APX_2B;Cardiovascular disorders;NTS_1.3;Naive or healthy;APX_2A;APX_2B;Appendix;similar disease pathology or symptoms;similar anatomy or organ system;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;terminal anesthesia;APX_2D;minimal invasive device;diagnostic tool;NTS_3.1
20173424_01;20173424;In vivo productontwikkeling en training voor minimale invasieve vasulaire hulpmiddelen;Translational or applied research;human;Pig model;ENG;pig;APX_2B;Cardiovascular disorders;NTS_1.3;Naive or healthy;APX_2A;APX_2B;Appendix;similar disease pathology or symptoms;availability of research tools;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;terminal anesthesia;APX_2D;minimal invasive device;diagnostic tool;NTS_3.1
20173424_01;20173424;In vivo productontwikkeling en training voor minimale invasieve vasulaire hulpmiddelen;Translational or applied research;human;Pig model;ENG;pig;APX_2B;Cardiovascular disorders;NTS_1.3;Naive or healthy;APX_2A;APX_2B;Appendix;similar disease pathology or symptoms;availability of research tools;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;terminal anesthesia;APX_2D;minimal invasive device;diagnostic tool;NTS_3.1
20173424_01;20173424;In vivo productontwikkeling en training voor minimale invasieve vasulaire hulpmiddelen;Translational or applied research;human;Pig model;ENG;pig;APX_2B;Cardiovascular disorders;NTS_1.3;Naive or healthy;APX_2A;APX_2B;Appendix;similar disease pathology or symptoms;availability of research tools;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;terminal anesthesia;APX_2D;minimal invasive device;diagnostic tool;NTS_3.1
20173424_01;20173424;In vivo productontwikkeling en training voor minimale invasieve vasulaire hulpmiddelen;Translational or applied research;human;Pig model;ENG;pig;APX_2B;Cardiovascular disorders;NTS_1.3;Naive or healthy;APX_2A;APX_2B;Appendix;similar disease pathology or symptoms;availability of research tools;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;terminal anesthesia;APX_2D;minimal invasive device;diagnostic tool;NTS_3.1
20173424_01;20173424;In vivo productontwikkeling en training voor minimale invasieve vasulaire hulpmiddelen;Translational or applied research;human;Pig model;ENG;pig;APX_2B;Cardiovascular disorders;NTS_3.1;Naive or healthy;APX_2A;APX_2B;Appendix;similar disease pathology or symptoms;existing model;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;terminal anesthesia;APX_2D;minimal invasive device;diagnostic tool;NTS_3.1
20173424_01;20173424;In vivo productontwikkeling en training voor minimale invasieve vasulaire hulpmiddelen;Translational or applied research;human;Pig model;ENG;pig;APX_2B;Cardiovascular disorders;NTS_3.1;Naive or healthy;APX_2A;APX_2B;Appendix;similar disease pathology or symptoms;existing model;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;terminal anesthesia;APX_2D;minimal invasive device;diagnostic tool;NTS_3.1
20173424_01;20173424;In vivo productontwikkeling en training voor minimale invasieve vasulaire hulpmiddelen;Translational or applied research;human;Pig model;ENG;pig;APX_2B;Cardiovascular disorders;NTS_3.1;Naive or healthy;APX_2A;APX_2B;Appendix;similar disease pathology or symptoms;existing model;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;terminal anesthesia;APX_2D;minimal invasive device;diagnostic tool;NTS_3.1
20173424_01;20173424;In vivo productontwikkeling en training voor minimale invasieve vasulaire hulpmiddelen;Translational or applied research;human;Pig model;ENG;pig;APX_2B;Cardiovascular disorders;NTS_3.1;Naive or healthy;APX_2A;APX_2B;Appendix;similar disease pathology or symptoms;existing model;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;terminal anesthesia;APX_2D;minimal invasive device;diagnostic tool;NTS_3.1
20173424_01;20173424;In vivo productontwikkeling en training voor minimale invasieve vasulaire hulpmiddelen;Translational or applied research;human;Pig model;ENG;pig;APX_2B;Cardiovascular disorders;NTS_3.1;Naive or healthy;APX_2A;APX_2B;Appendix;similar disease pathology or symptoms;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;terminal anesthesia;APX_2D;minimal invasive device;diagnostic tool;NTS_3.1
20173424_01;20173424;In vivo productontwikkeling en training voor minimale invasieve vasulaire hulpmiddelen;Translational or applied research;human;Pig model;ENG;pig;APX_2B;Cardiovascular disorders;NTS_3.1;Naive or healthy;APX_2A;APX_2B;Appendix;similar disease pathology or symptoms;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;terminal anesthesia;APX_2D;minimal invasive device;diagnostic tool;NTS_3.1
20173424_01;20173424;In vivo productontwikkeling en training voor minimale invasieve vasulaire hulpmiddelen;Translational or applied research;human;Pig model;ENG;pig;APX_2B;Cardiovascular disorders;NTS_3.1;Naive or healthy;APX_2A;APX_2B;Appendix;similar disease pathology or symptoms;similar anatomy or organ system;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;terminal anesthesia;APX_2D;minimal invasive device;diagnostic tool;NTS_3.1
20173424_01;20173424;In vivo productontwikkeling en training voor minimale invasieve vasulaire hulpmiddelen;Translational or applied research;human;Pig model;ENG;pig;APX_2B;Cardiovascular disorders;NTS_3.1;Naive or healthy;APX_2A;APX_2B;Appendix;similar disease pathology or symptoms;similar anatomy or organ system;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;terminal anesthesia;APX_2D;minimal invasive device;diagnostic tool;NTS_3.1
20173424_01;20173424;In vivo productontwikkeling en training voor minimale invasieve vasulaire hulpmiddelen;Translational or applied research;human;Pig model;ENG;pig;APX_2B;Cardiovascular disorders;NTS_3.1;Naive or healthy;APX_2A;APX_2B;Appendix;similar disease pathology or symptoms;availability of research tools;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;terminal anesthesia;APX_2D;minimal invasive device;diagnostic tool;NTS_3.1
20173424_01;20173424;In vivo productontwikkeling en training voor minimale invasieve vasulaire hulpmiddelen;Translational or applied research;human;Pig model;ENG;pig;APX_2B;Cardiovascular disorders;NTS_3.1;Naive or healthy;APX_2A;APX_2B;Appendix;similar disease pathology or symptoms;availability of research tools;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;terminal anesthesia;APX_2D;minimal invasive device;diagnostic tool;NTS_3.1
20173424_01;20173424;In vivo productontwikkeling en training voor minimale invasieve vasulaire hulpmiddelen;Translational or applied research;human;Pig model;ENG;pig;APX_2B;Cardiovascular disorders;NTS_3.1;Naive or healthy;APX_2A;APX_2B;Appendix;similar disease pathology or symptoms;availability of research tools;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;terminal anesthesia;APX_2D;minimal invasive device;diagnostic tool;NTS_3.1
20173424_01;20173424;In vivo productontwikkeling en training voor minimale invasieve vasulaire hulpmiddelen;Translational or applied research;human;Pig model;ENG;pig;APX_2B;Cardiovascular disorders;NTS_3.1;Naive or healthy;APX_2A;APX_2B;Appendix;similar disease pathology or symptoms;availability of research tools;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;terminal anesthesia;APX_2D;minimal invasive device;diagnostic tool;NTS_3.1
20173424_02;20173424;In vivo productontwikkeling en training voor minimale invasieve vasulaire hulpmiddelen;Translational or applied research;human;Sheep model;ENG;sheep;APX_2B;Cardiovascular disorders;NTS_1.3;Naive or healthy;APX_2A;APX_2B;Appendix;similar disease pathology or symptoms;existing model;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;terminal anesthesia;APX_2D;minimal invasive device;diagnostic tool;NTS_3.1
20173424_02;20173424;In vivo productontwikkeling en training voor minimale invasieve vasulaire hulpmiddelen;Translational or applied research;human;Sheep model;ENG;sheep;APX_2B;Cardiovascular disorders;NTS_1.3;Naive or healthy;APX_2A;APX_2B;Appendix;similar disease pathology or symptoms;existing model;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;terminal anesthesia;APX_2D;minimal invasive device;diagnostic tool;NTS_3.1
20173424_02;20173424;In vivo productontwikkeling en training voor minimale invasieve vasulaire hulpmiddelen;Translational or applied research;human;Sheep model;ENG;sheep;APX_2B;Cardiovascular disorders;NTS_1.3;Naive or healthy;APX_2A;APX_2B;Appendix;similar disease pathology or symptoms;existing model;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;terminal anesthesia;APX_2D;minimal invasive device;diagnostic tool;NTS_3.1
20173424_02;20173424;In vivo productontwikkeling en training voor minimale invasieve vasulaire hulpmiddelen;Translational or applied research;human;Sheep model;ENG;sheep;APX_2B;Cardiovascular disorders;NTS_1.3;Naive or healthy;APX_2A;APX_2B;Appendix;similar disease pathology or symptoms;existing model;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;terminal anesthesia;APX_2D;minimal invasive device;diagnostic tool;NTS_3.1
20173424_02;20173424;In vivo productontwikkeling en training voor minimale invasieve vasulaire hulpmiddelen;Translational or applied research;human;Sheep model;ENG;sheep;APX_2B;Cardiovascular disorders;NTS_1.3;Naive or healthy;APX_2A;APX_2B;Appendix;similar disease pathology or symptoms;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;terminal anesthesia;APX_2D;minimal invasive device;diagnostic tool;NTS_3.1
20173424_02;20173424;In vivo productontwikkeling en training voor minimale invasieve vasulaire hulpmiddelen;Translational or applied research;human;Sheep model;ENG;sheep;APX_2B;Cardiovascular disorders;NTS_1.3;Naive or healthy;APX_2A;APX_2B;Appendix;similar disease pathology or symptoms;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;terminal anesthesia;APX_2D;minimal invasive device;diagnostic tool;NTS_3.1
20173424_02;20173424;In vivo productontwikkeling en training voor minimale invasieve vasulaire hulpmiddelen;Translational or applied research;human;Sheep model;ENG;sheep;APX_2B;Cardiovascular disorders;NTS_1.3;Naive or healthy;APX_2A;APX_2B;Appendix;similar disease pathology or symptoms;similar anatomy or organ system;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;terminal anesthesia;APX_2D;minimal invasive device;diagnostic tool;NTS_3.1
20173424_02;20173424;In vivo productontwikkeling en training voor minimale invasieve vasulaire hulpmiddelen;Translational or applied research;human;Sheep model;ENG;sheep;APX_2B;Cardiovascular disorders;NTS_1.3;Naive or healthy;APX_2A;APX_2B;Appendix;similar disease pathology or symptoms;similar anatomy or organ system;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;terminal anesthesia;APX_2D;minimal invasive device;diagnostic tool;NTS_3.1
20173424_02;20173424;In vivo productontwikkeling en training voor minimale invasieve vasulaire hulpmiddelen;Translational or applied research;human;Sheep model;ENG;sheep;APX_2B;Cardiovascular disorders;NTS_1.3;Naive or healthy;APX_2A;APX_2B;Appendix;similar disease pathology or symptoms;availability of research tools;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;terminal anesthesia;APX_2D;minimal invasive device;diagnostic tool;NTS_3.1
20173424_02;20173424;In vivo productontwikkeling en training voor minimale invasieve vasulaire hulpmiddelen;Translational or applied research;human;Sheep model;ENG;sheep;APX_2B;Cardiovascular disorders;NTS_1.3;Naive or healthy;APX_2A;APX_2B;Appendix;similar disease pathology or symptoms;availability of research tools;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;terminal anesthesia;APX_2D;minimal invasive device;diagnostic tool;NTS_3.1
20173424_02;20173424;In vivo productontwikkeling en training voor minimale invasieve vasulaire hulpmiddelen;Translational or applied research;human;Sheep model;ENG;sheep;APX_2B;Cardiovascular disorders;NTS_1.3;Naive or healthy;APX_2A;APX_2B;Appendix;similar disease pathology or symptoms;availability of research tools;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;terminal anesthesia;APX_2D;minimal invasive device;diagnostic tool;NTS_3.1
20173424_02;20173424;In vivo productontwikkeling en training voor minimale invasieve vasulaire hulpmiddelen;Translational or applied research;human;Sheep model;ENG;sheep;APX_2B;Cardiovascular disorders;NTS_1.3;Naive or healthy;APX_2A;APX_2B;Appendix;similar disease pathology or symptoms;availability of research tools;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;terminal anesthesia;APX_2D;minimal invasive device;diagnostic tool;NTS_3.1
20173424_02;20173424;In vivo productontwikkeling en training voor minimale invasieve vasulaire hulpmiddelen;Translational or applied research;human;Sheep model;ENG;sheep;APX_2B;Cardiovascular disorders;NTS_1.3;Naive or healthy;APX_2A;APX_2B;Appendix;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;terminal anesthesia;APX_2D;minimal invasive device;diagnostic tool;NTS_3.1
20173424_02;20173424;In vivo productontwikkeling en training voor minimale invasieve vasulaire hulpmiddelen;Translational or applied research;human;Sheep model;ENG;sheep;APX_2B;Cardiovascular disorders;NTS_1.3;Naive or healthy;APX_2A;APX_2B;Appendix;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;terminal anesthesia;APX_2D;minimal invasive device;diagnostic tool;NTS_3.1
20173424_02;20173424;In vivo productontwikkeling en training voor minimale invasieve vasulaire hulpmiddelen;Translational or applied research;human;Sheep model;ENG;sheep;APX_2B;Cardiovascular disorders;NTS_1.3;Naive or healthy;APX_2A;APX_2B;Appendix;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;terminal anesthesia;APX_2D;minimal invasive device;diagnostic tool;NTS_3.1
20173424_02;20173424;In vivo productontwikkeling en training voor minimale invasieve vasulaire hulpmiddelen;Translational or applied research;human;Sheep model;ENG;sheep;APX_2B;Cardiovascular disorders;NTS_1.3;Naive or healthy;APX_2A;APX_2B;Appendix;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;terminal anesthesia;APX_2D;minimal invasive device;diagnostic tool;NTS_3.1
20173424_02;20173424;In vivo productontwikkeling en training voor minimale invasieve vasulaire hulpmiddelen;Translational or applied research;human;Sheep model;ENG;sheep;APX_2B;Cardiovascular disorders;NTS_1.3;Naive or healthy;APX_2A;APX_2B;Appendix;availability of the animal model;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;terminal anesthesia;APX_2D;minimal invasive device;diagnostic tool;NTS_3.1
20173424_02;20173424;In vivo productontwikkeling en training voor minimale invasieve vasulaire hulpmiddelen;Translational or applied research;human;Sheep model;ENG;sheep;APX_2B;Cardiovascular disorders;NTS_1.3;Naive or healthy;APX_2A;APX_2B;Appendix;availability of the animal model;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;terminal anesthesia;APX_2D;minimal invasive device;diagnostic tool;NTS_3.1
20173424_02;20173424;In vivo productontwikkeling en training voor minimale invasieve vasulaire hulpmiddelen;Translational or applied research;human;Sheep model;ENG;sheep;APX_2B;Cardiovascular disorders;NTS_1.3;Naive or healthy;APX_2A;APX_2B;Appendix;availability of the animal model;similar anatomy or organ system;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;terminal anesthesia;APX_2D;minimal invasive device;diagnostic tool;NTS_3.1
20173424_02;20173424;In vivo productontwikkeling en training voor minimale invasieve vasulaire hulpmiddelen;Translational or applied research;human;Sheep model;ENG;sheep;APX_2B;Cardiovascular disorders;NTS_1.3;Naive or healthy;APX_2A;APX_2B;Appendix;availability of the animal model;similar anatomy or organ system;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;terminal anesthesia;APX_2D;minimal invasive device;diagnostic tool;NTS_3.1
20173424_02;20173424;In vivo productontwikkeling en training voor minimale invasieve vasulaire hulpmiddelen;Translational or applied research;human;Sheep model;ENG;sheep;APX_2B;Cardiovascular disorders;NTS_1.3;Naive or healthy;APX_2A;APX_2B;Appendix;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;terminal anesthesia;APX_2D;minimal invasive device;diagnostic tool;NTS_3.1
20173424_02;20173424;In vivo productontwikkeling en training voor minimale invasieve vasulaire hulpmiddelen;Translational or applied research;human;Sheep model;ENG;sheep;APX_2B;Cardiovascular disorders;NTS_1.3;Naive or healthy;APX_2A;APX_2B;Appendix;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;terminal anesthesia;APX_2D;minimal invasive device;diagnostic tool;NTS_3.1
20173424_02;20173424;In vivo productontwikkeling en training voor minimale invasieve vasulaire hulpmiddelen;Translational or applied research;human;Sheep model;ENG;sheep;APX_2B;Cardiovascular disorders;NTS_1.3;Naive or healthy;APX_2A;APX_2B;Appendix;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;terminal anesthesia;APX_2D;minimal invasive device;diagnostic tool;NTS_3.1
20173424_02;20173424;In vivo productontwikkeling en training voor minimale invasieve vasulaire hulpmiddelen;Translational or applied research;human;Sheep model;ENG;sheep;APX_2B;Cardiovascular disorders;NTS_1.3;Naive or healthy;APX_2A;APX_2B;Appendix;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;terminal anesthesia;APX_2D;minimal invasive device;diagnostic tool;NTS_3.1
20173424_02;20173424;In vivo productontwikkeling en training voor minimale invasieve vasulaire hulpmiddelen;Translational or applied research;human;Sheep model;ENG;sheep;APX_2B;Cardiovascular disorders;NTS_3.1;Naive or healthy;APX_2A;APX_2B;Appendix;similar disease pathology or symptoms;existing model;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;terminal anesthesia;APX_2D;minimal invasive device;diagnostic tool;NTS_3.1
20173424_02;20173424;In vivo productontwikkeling en training voor minimale invasieve vasulaire hulpmiddelen;Translational or applied research;human;Sheep model;ENG;sheep;APX_2B;Cardiovascular disorders;NTS_3.1;Naive or healthy;APX_2A;APX_2B;Appendix;similar disease pathology or symptoms;existing model;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;terminal anesthesia;APX_2D;minimal invasive device;diagnostic tool;NTS_3.1
20173424_02;20173424;In vivo productontwikkeling en training voor minimale invasieve vasulaire hulpmiddelen;Translational or applied research;human;Sheep model;ENG;sheep;APX_2B;Cardiovascular disorders;NTS_3.1;Naive or healthy;APX_2A;APX_2B;Appendix;similar disease pathology or symptoms;existing model;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;terminal anesthesia;APX_2D;minimal invasive device;diagnostic tool;NTS_3.1
20173424_02;20173424;In vivo productontwikkeling en training voor minimale invasieve vasulaire hulpmiddelen;Translational or applied research;human;Sheep model;ENG;sheep;APX_2B;Cardiovascular disorders;NTS_3.1;Naive or healthy;APX_2A;APX_2B;Appendix;similar disease pathology or symptoms;existing model;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;terminal anesthesia;APX_2D;minimal invasive device;diagnostic tool;NTS_3.1
20173424_02;20173424;In vivo productontwikkeling en training voor minimale invasieve vasulaire hulpmiddelen;Translational or applied research;human;Sheep model;ENG;sheep;APX_2B;Cardiovascular disorders;NTS_3.1;Naive or healthy;APX_2A;APX_2B;Appendix;similar disease pathology or symptoms;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;terminal anesthesia;APX_2D;minimal invasive device;diagnostic tool;NTS_3.1
20173424_02;20173424;In vivo productontwikkeling en training voor minimale invasieve vasulaire hulpmiddelen;Translational or applied research;human;Sheep model;ENG;sheep;APX_2B;Cardiovascular disorders;NTS_3.1;Naive or healthy;APX_2A;APX_2B;Appendix;similar disease pathology or symptoms;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;terminal anesthesia;APX_2D;minimal invasive device;diagnostic tool;NTS_3.1
20173424_02;20173424;In vivo productontwikkeling en training voor minimale invasieve vasulaire hulpmiddelen;Translational or applied research;human;Sheep model;ENG;sheep;APX_2B;Cardiovascular disorders;NTS_3.1;Naive or healthy;APX_2A;APX_2B;Appendix;similar disease pathology or symptoms;similar anatomy or organ system;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;terminal anesthesia;APX_2D;minimal invasive device;diagnostic tool;NTS_3.1
20173424_02;20173424;In vivo productontwikkeling en training voor minimale invasieve vasulaire hulpmiddelen;Translational or applied research;human;Sheep model;ENG;sheep;APX_2B;Cardiovascular disorders;NTS_3.1;Naive or healthy;APX_2A;APX_2B;Appendix;similar disease pathology or symptoms;similar anatomy or organ system;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;terminal anesthesia;APX_2D;minimal invasive device;diagnostic tool;NTS_3.1
20173424_02;20173424;In vivo productontwikkeling en training voor minimale invasieve vasulaire hulpmiddelen;Translational or applied research;human;Sheep model;ENG;sheep;APX_2B;Cardiovascular disorders;NTS_3.1;Naive or healthy;APX_2A;APX_2B;Appendix;similar disease pathology or symptoms;availability of research tools;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;terminal anesthesia;APX_2D;minimal invasive device;diagnostic tool;NTS_3.1
20173424_02;20173424;In vivo productontwikkeling en training voor minimale invasieve vasulaire hulpmiddelen;Translational or applied research;human;Sheep model;ENG;sheep;APX_2B;Cardiovascular disorders;NTS_3.1;Naive or healthy;APX_2A;APX_2B;Appendix;similar disease pathology or symptoms;availability of research tools;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;terminal anesthesia;APX_2D;minimal invasive device;diagnostic tool;NTS_3.1
20173424_02;20173424;In vivo productontwikkeling en training voor minimale invasieve vasulaire hulpmiddelen;Translational or applied research;human;Sheep model;ENG;sheep;APX_2B;Cardiovascular disorders;NTS_3.1;Naive or healthy;APX_2A;APX_2B;Appendix;similar disease pathology or symptoms;availability of research tools;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;terminal anesthesia;APX_2D;minimal invasive device;diagnostic tool;NTS_3.1
20173424_02;20173424;In vivo productontwikkeling en training voor minimale invasieve vasulaire hulpmiddelen;Translational or applied research;human;Sheep model;ENG;sheep;APX_2B;Cardiovascular disorders;NTS_3.1;Naive or healthy;APX_2A;APX_2B;Appendix;similar disease pathology or symptoms;availability of research tools;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;terminal anesthesia;APX_2D;minimal invasive device;diagnostic tool;NTS_3.1
20173424_02;20173424;In vivo productontwikkeling en training voor minimale invasieve vasulaire hulpmiddelen;Translational or applied research;human;Sheep model;ENG;sheep;APX_2B;Cardiovascular disorders;NTS_3.1;Naive or healthy;APX_2A;APX_2B;Appendix;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;terminal anesthesia;APX_2D;minimal invasive device;diagnostic tool;NTS_3.1
20173424_02;20173424;In vivo productontwikkeling en training voor minimale invasieve vasulaire hulpmiddelen;Translational or applied research;human;Sheep model;ENG;sheep;APX_2B;Cardiovascular disorders;NTS_3.1;Naive or healthy;APX_2A;APX_2B;Appendix;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;terminal anesthesia;APX_2D;minimal invasive device;diagnostic tool;NTS_3.1
20173424_02;20173424;In vivo productontwikkeling en training voor minimale invasieve vasulaire hulpmiddelen;Translational or applied research;human;Sheep model;ENG;sheep;APX_2B;Cardiovascular disorders;NTS_3.1;Naive or healthy;APX_2A;APX_2B;Appendix;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;terminal anesthesia;APX_2D;minimal invasive device;diagnostic tool;NTS_3.1
20173424_02;20173424;In vivo productontwikkeling en training voor minimale invasieve vasulaire hulpmiddelen;Translational or applied research;human;Sheep model;ENG;sheep;APX_2B;Cardiovascular disorders;NTS_3.1;Naive or healthy;APX_2A;APX_2B;Appendix;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;terminal anesthesia;APX_2D;minimal invasive device;diagnostic tool;NTS_3.1
20173424_02;20173424;In vivo productontwikkeling en training voor minimale invasieve vasulaire hulpmiddelen;Translational or applied research;human;Sheep model;ENG;sheep;APX_2B;Cardiovascular disorders;NTS_3.1;Naive or healthy;APX_2A;APX_2B;Appendix;availability of the animal model;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;terminal anesthesia;APX_2D;minimal invasive device;diagnostic tool;NTS_3.1
20173424_02;20173424;In vivo productontwikkeling en training voor minimale invasieve vasulaire hulpmiddelen;Translational or applied research;human;Sheep model;ENG;sheep;APX_2B;Cardiovascular disorders;NTS_3.1;Naive or healthy;APX_2A;APX_2B;Appendix;availability of the animal model;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;terminal anesthesia;APX_2D;minimal invasive device;diagnostic tool;NTS_3.1
20173424_02;20173424;In vivo productontwikkeling en training voor minimale invasieve vasulaire hulpmiddelen;Translational or applied research;human;Sheep model;ENG;sheep;APX_2B;Cardiovascular disorders;NTS_3.1;Naive or healthy;APX_2A;APX_2B;Appendix;availability of the animal model;similar anatomy or organ system;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;terminal anesthesia;APX_2D;minimal invasive device;diagnostic tool;NTS_3.1
20173424_02;20173424;In vivo productontwikkeling en training voor minimale invasieve vasulaire hulpmiddelen;Translational or applied research;human;Sheep model;ENG;sheep;APX_2B;Cardiovascular disorders;NTS_3.1;Naive or healthy;APX_2A;APX_2B;Appendix;availability of the animal model;similar anatomy or organ system;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;terminal anesthesia;APX_2D;minimal invasive device;diagnostic tool;NTS_3.1
20173424_02;20173424;In vivo productontwikkeling en training voor minimale invasieve vasulaire hulpmiddelen;Translational or applied research;human;Sheep model;ENG;sheep;APX_2B;Cardiovascular disorders;NTS_3.1;Naive or healthy;APX_2A;APX_2B;Appendix;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;terminal anesthesia;APX_2D;minimal invasive device;diagnostic tool;NTS_3.1
20173424_02;20173424;In vivo productontwikkeling en training voor minimale invasieve vasulaire hulpmiddelen;Translational or applied research;human;Sheep model;ENG;sheep;APX_2B;Cardiovascular disorders;NTS_3.1;Naive or healthy;APX_2A;APX_2B;Appendix;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;terminal anesthesia;APX_2D;minimal invasive device;diagnostic tool;NTS_3.1
20173424_02;20173424;In vivo productontwikkeling en training voor minimale invasieve vasulaire hulpmiddelen;Translational or applied research;human;Sheep model;ENG;sheep;APX_2B;Cardiovascular disorders;NTS_3.1;Naive or healthy;APX_2A;APX_2B;Appendix;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;terminal anesthesia;APX_2D;minimal invasive device;diagnostic tool;NTS_3.1
20173424_02;20173424;In vivo productontwikkeling en training voor minimale invasieve vasulaire hulpmiddelen;Translational or applied research;human;Sheep model;ENG;sheep;APX_2B;Cardiovascular disorders;NTS_3.1;Naive or healthy;APX_2A;APX_2B;Appendix;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;terminal anesthesia;APX_2D;minimal invasive device;diagnostic tool;NTS_3.1
20173566_01;20173566;Een niet invasieve ablatie therapie door middel van ultrageluid;Translational or applied research;human;HIFU for (peripheral) vascular disease;ENG;pig;NTS_3.3;Cardiovascular disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;similar anatomy or organ system;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;ultrasound;medical device;NTS_3.1
20173566_01;20173566;Een niet invasieve ablatie therapie door middel van ultrageluid;Translational or applied research;human;HIFU for (peripheral) vascular disease;ENG;pig;NTS_3.3;Cardiovascular disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;ultrasound;medical device;NTS_3.1
20173566_01;20173566;Een niet invasieve ablatie therapie door middel van ultrageluid;Translational or applied research;human;HIFU for (peripheral) vascular disease;ENG;pig;NTS_3.3;Cardiovascular disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;similar anatomy or organ system;APX_2B;intervention related;APX_2A;MEC requirement;allowing clinical trial;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;ultrasound;medical device;NTS_3.1
20173566_01;20173566;Een niet invasieve ablatie therapie door middel van ultrageluid;Translational or applied research;human;HIFU for (peripheral) vascular disease;ENG;pig;NTS_3.3;Cardiovascular disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;ultrasound;medical device;NTS_3.1
20173566_01;20173566;Een niet invasieve ablatie therapie door middel van ultrageluid;Translational or applied research;human;HIFU for (peripheral) vascular disease;ENG;pig;NTS_3.3;Cardiovascular disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;ultrasound;medical device;NTS_3.1
20173566_01;20173566;Een niet invasieve ablatie therapie door middel van ultrageluid;Translational or applied research;human;HIFU for (peripheral) vascular disease;ENG;pig;NTS_3.3;Cardiovascular disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;MEC requirement;allowing clinical trial;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;ultrasound;medical device;NTS_3.1
20173566_01;20173566;Een niet invasieve ablatie therapie door middel van ultrageluid;Translational or applied research;human;HIFU for (peripheral) vascular disease;ENG;pig;NTS_3.3;Cardiovascular disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;ultrasound;medical device;NTS_3.1
20173566_01;20173566;Een niet invasieve ablatie therapie door middel van ultrageluid;Translational or applied research;human;HIFU for (peripheral) vascular disease;ENG;pig;NTS_3.3;Cardiovascular disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;ultrasound;medical device;NTS_3.1
20173566_01;20173566;Een niet invasieve ablatie therapie door middel van ultrageluid;Translational or applied research;human;HIFU for (peripheral) vascular disease;ENG;pig;NTS_3.3;Cardiovascular disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;MEC requirement;allowing clinical trial;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;ultrasound;medical device;NTS_3.1
20173566_01;20173566;Een niet invasieve ablatie therapie door middel van ultrageluid;Translational or applied research;human;HIFU for (peripheral) vascular disease;ENG;pig;NTS_3.3;Cardiovascular disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;ultrasound;medical device;NTS_3.1
20173566_01;20173566;Een niet invasieve ablatie therapie door middel van ultrageluid;Translational or applied research;human;HIFU for (peripheral) vascular disease;ENG;pig;NTS_3.3;Cardiovascular disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;ultrasound;medical device;NTS_3.1
20173566_01;20173566;Een niet invasieve ablatie therapie door middel van ultrageluid;Translational or applied research;human;HIFU for (peripheral) vascular disease;ENG;pig;NTS_3.3;Cardiovascular disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;MEC requirement;allowing clinical trial;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;ultrasound;medical device;NTS_3.1
20173566_01;20173566;Een niet invasieve ablatie therapie door middel van ultrageluid;Translational or applied research;human;HIFU for (peripheral) vascular disease;ENG;pig;NTS_3.3;Cardiovascular disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;similar anatomy or organ system;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;ultrasound;medical device;NTS_3.1
20173566_01;20173566;Een niet invasieve ablatie therapie door middel van ultrageluid;Translational or applied research;human;HIFU for (peripheral) vascular disease;ENG;pig;NTS_3.3;Cardiovascular disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;ultrasound;medical device;NTS_3.1
20173566_01;20173566;Een niet invasieve ablatie therapie door middel van ultrageluid;Translational or applied research;human;HIFU for (peripheral) vascular disease;ENG;pig;NTS_3.3;Cardiovascular disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;similar anatomy or organ system;APX_2B;intervention related;APX_2A;MEC requirement;allowing clinical trial;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;ultrasound;medical device;NTS_3.1
20173566_01;20173566;Een niet invasieve ablatie therapie door middel van ultrageluid;Translational or applied research;human;HIFU for (peripheral) vascular disease;ENG;pig;NTS_3.3;Cardiovascular disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;ultrasound;medical device;NTS_3.1
20173566_01;20173566;Een niet invasieve ablatie therapie door middel van ultrageluid;Translational or applied research;human;HIFU for (peripheral) vascular disease;ENG;pig;NTS_3.3;Cardiovascular disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;ultrasound;medical device;NTS_3.1
20173566_01;20173566;Een niet invasieve ablatie therapie door middel van ultrageluid;Translational or applied research;human;HIFU for (peripheral) vascular disease;ENG;pig;NTS_3.3;Cardiovascular disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;MEC requirement;allowing clinical trial;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;ultrasound;medical device;NTS_3.1
20173566_01;20173566;Een niet invasieve ablatie therapie door middel van ultrageluid;Translational or applied research;human;HIFU for (peripheral) vascular disease;ENG;pig;NTS_3.3;Cardiovascular disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;ultrasound;medical device;NTS_3.1
20173566_01;20173566;Een niet invasieve ablatie therapie door middel van ultrageluid;Translational or applied research;human;HIFU for (peripheral) vascular disease;ENG;pig;NTS_3.3;Cardiovascular disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;ultrasound;medical device;NTS_3.1
20173566_01;20173566;Een niet invasieve ablatie therapie door middel van ultrageluid;Translational or applied research;human;HIFU for (peripheral) vascular disease;ENG;pig;NTS_3.3;Cardiovascular disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;MEC requirement;allowing clinical trial;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;ultrasound;medical device;NTS_3.1
20173566_01;20173566;Een niet invasieve ablatie therapie door middel van ultrageluid;Translational or applied research;human;HIFU for (peripheral) vascular disease;ENG;pig;NTS_3.3;Cardiovascular disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;ultrasound;medical device;NTS_3.1
20173566_01;20173566;Een niet invasieve ablatie therapie door middel van ultrageluid;Translational or applied research;human;HIFU for (peripheral) vascular disease;ENG;pig;NTS_3.3;Cardiovascular disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;ultrasound;medical device;NTS_3.1
20173566_01;20173566;Een niet invasieve ablatie therapie door middel van ultrageluid;Translational or applied research;human;HIFU for (peripheral) vascular disease;ENG;pig;NTS_3.3;Cardiovascular disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;MEC requirement;allowing clinical trial;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;ultrasound;medical device;NTS_3.1
20173566_01;20173566;Een niet invasieve ablatie therapie door middel van ultrageluid;Translational or applied research;human;HIFU for (peripheral) vascular disease;ENG;pig;NTS_3.3;Cardiovascular disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;similar anatomy or organ system;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;ultrasound;medical device;NTS_3.1
20173566_01;20173566;Een niet invasieve ablatie therapie door middel van ultrageluid;Translational or applied research;human;HIFU for (peripheral) vascular disease;ENG;pig;NTS_3.3;Cardiovascular disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;ultrasound;medical device;NTS_3.1
20173566_01;20173566;Een niet invasieve ablatie therapie door middel van ultrageluid;Translational or applied research;human;HIFU for (peripheral) vascular disease;ENG;pig;NTS_3.3;Cardiovascular disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;similar anatomy or organ system;APX_2B;intervention related;APX_2A;MEC requirement;allowing clinical trial;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;ultrasound;medical device;NTS_3.1
20173566_01;20173566;Een niet invasieve ablatie therapie door middel van ultrageluid;Translational or applied research;human;HIFU for (peripheral) vascular disease;ENG;pig;NTS_3.3;Cardiovascular disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;ultrasound;medical device;NTS_3.1
20173566_01;20173566;Een niet invasieve ablatie therapie door middel van ultrageluid;Translational or applied research;human;HIFU for (peripheral) vascular disease;ENG;pig;NTS_3.3;Cardiovascular disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;ultrasound;medical device;NTS_3.1
20173566_01;20173566;Een niet invasieve ablatie therapie door middel van ultrageluid;Translational or applied research;human;HIFU for (peripheral) vascular disease;ENG;pig;NTS_3.3;Cardiovascular disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;MEC requirement;allowing clinical trial;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;ultrasound;medical device;NTS_3.1
20173566_01;20173566;Een niet invasieve ablatie therapie door middel van ultrageluid;Translational or applied research;human;HIFU for (peripheral) vascular disease;ENG;pig;NTS_3.3;Cardiovascular disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;ultrasound;medical device;NTS_3.1
20173566_01;20173566;Een niet invasieve ablatie therapie door middel van ultrageluid;Translational or applied research;human;HIFU for (peripheral) vascular disease;ENG;pig;NTS_3.3;Cardiovascular disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;ultrasound;medical device;NTS_3.1
20173566_01;20173566;Een niet invasieve ablatie therapie door middel van ultrageluid;Translational or applied research;human;HIFU for (peripheral) vascular disease;ENG;pig;NTS_3.3;Cardiovascular disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;MEC requirement;allowing clinical trial;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;ultrasound;medical device;NTS_3.1
20173566_01;20173566;Een niet invasieve ablatie therapie door middel van ultrageluid;Translational or applied research;human;HIFU for (peripheral) vascular disease;ENG;pig;NTS_3.3;Cardiovascular disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;ultrasound;medical device;NTS_3.1
20173566_01;20173566;Een niet invasieve ablatie therapie door middel van ultrageluid;Translational or applied research;human;HIFU for (peripheral) vascular disease;ENG;pig;NTS_3.3;Cardiovascular disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;ultrasound;medical device;NTS_3.1
20173566_01;20173566;Een niet invasieve ablatie therapie door middel van ultrageluid;Translational or applied research;human;HIFU for (peripheral) vascular disease;ENG;pig;NTS_3.3;Cardiovascular disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;MEC requirement;allowing clinical trial;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;ultrasound;medical device;NTS_3.1
20173566_01;20173566;Een niet invasieve ablatie therapie door middel van ultrageluid;Translational or applied research;human;HIFU for (peripheral) vascular disease;ENG;pig;NTS_3.3;Cardiovascular disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;similar anatomy or organ system;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;ultrasound;medical device;NTS_3.1
20173566_01;20173566;Een niet invasieve ablatie therapie door middel van ultrageluid;Translational or applied research;human;HIFU for (peripheral) vascular disease;ENG;pig;NTS_3.3;Cardiovascular disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;ultrasound;medical device;NTS_3.1
20173566_01;20173566;Een niet invasieve ablatie therapie door middel van ultrageluid;Translational or applied research;human;HIFU for (peripheral) vascular disease;ENG;pig;NTS_3.3;Cardiovascular disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;similar anatomy or organ system;APX_2B;intervention related;APX_2A;MEC requirement;allowing clinical trial;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;ultrasound;medical device;NTS_3.1
20173566_01;20173566;Een niet invasieve ablatie therapie door middel van ultrageluid;Translational or applied research;human;HIFU for (peripheral) vascular disease;ENG;pig;NTS_3.3;Cardiovascular disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;ultrasound;medical device;NTS_3.1
20173566_01;20173566;Een niet invasieve ablatie therapie door middel van ultrageluid;Translational or applied research;human;HIFU for (peripheral) vascular disease;ENG;pig;NTS_3.3;Cardiovascular disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;ultrasound;medical device;NTS_3.1
20173566_01;20173566;Een niet invasieve ablatie therapie door middel van ultrageluid;Translational or applied research;human;HIFU for (peripheral) vascular disease;ENG;pig;NTS_3.3;Cardiovascular disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;MEC requirement;allowing clinical trial;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;ultrasound;medical device;NTS_3.1
20173566_01;20173566;Een niet invasieve ablatie therapie door middel van ultrageluid;Translational or applied research;human;HIFU for (peripheral) vascular disease;ENG;pig;NTS_3.3;Cardiovascular disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;ultrasound;medical device;NTS_3.1
20173566_01;20173566;Een niet invasieve ablatie therapie door middel van ultrageluid;Translational or applied research;human;HIFU for (peripheral) vascular disease;ENG;pig;NTS_3.3;Cardiovascular disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;ultrasound;medical device;NTS_3.1
20173566_01;20173566;Een niet invasieve ablatie therapie door middel van ultrageluid;Translational or applied research;human;HIFU for (peripheral) vascular disease;ENG;pig;NTS_3.3;Cardiovascular disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;MEC requirement;allowing clinical trial;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;ultrasound;medical device;NTS_3.1
20173566_01;20173566;Een niet invasieve ablatie therapie door middel van ultrageluid;Translational or applied research;human;HIFU for (peripheral) vascular disease;ENG;pig;NTS_3.3;Cardiovascular disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;ultrasound;medical device;NTS_3.1
20173566_01;20173566;Een niet invasieve ablatie therapie door middel van ultrageluid;Translational or applied research;human;HIFU for (peripheral) vascular disease;ENG;pig;NTS_3.3;Cardiovascular disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;ultrasound;medical device;NTS_3.1
20173566_01;20173566;Een niet invasieve ablatie therapie door middel van ultrageluid;Translational or applied research;human;HIFU for (peripheral) vascular disease;ENG;pig;NTS_3.3;Cardiovascular disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;MEC requirement;allowing clinical trial;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;ultrasound;medical device;NTS_3.1
20173566_02;20173566;Een niet invasieve ablatie therapie door middel van ultrageluid;Translational or applied research;human;HIFU for treatment of hypertension;ENG;pig;NTS_3.3;Cardiovascular disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;similar anatomy or organ system;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;ultrasound;medical device;NTS_3.1
20173566_02;20173566;Een niet invasieve ablatie therapie door middel van ultrageluid;Translational or applied research;human;HIFU for treatment of hypertension;ENG;pig;NTS_3.3;Cardiovascular disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;ultrasound;medical device;NTS_3.1
20173566_02;20173566;Een niet invasieve ablatie therapie door middel van ultrageluid;Translational or applied research;human;HIFU for treatment of hypertension;ENG;pig;NTS_3.3;Cardiovascular disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;similar anatomy or organ system;APX_2B;intervention related;APX_2A;MEC requirement;allowing clinical trial;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;ultrasound;medical device;NTS_3.1
20173566_02;20173566;Een niet invasieve ablatie therapie door middel van ultrageluid;Translational or applied research;human;HIFU for treatment of hypertension;ENG;pig;NTS_3.3;Cardiovascular disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;ultrasound;medical device;NTS_3.1
20173566_02;20173566;Een niet invasieve ablatie therapie door middel van ultrageluid;Translational or applied research;human;HIFU for treatment of hypertension;ENG;pig;NTS_3.3;Cardiovascular disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;ultrasound;medical device;NTS_3.1
20173566_02;20173566;Een niet invasieve ablatie therapie door middel van ultrageluid;Translational or applied research;human;HIFU for treatment of hypertension;ENG;pig;NTS_3.3;Cardiovascular disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;MEC requirement;allowing clinical trial;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;ultrasound;medical device;NTS_3.1
20173566_02;20173566;Een niet invasieve ablatie therapie door middel van ultrageluid;Translational or applied research;human;HIFU for treatment of hypertension;ENG;pig;NTS_3.3;Cardiovascular disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;ultrasound;medical device;NTS_3.1
20173566_02;20173566;Een niet invasieve ablatie therapie door middel van ultrageluid;Translational or applied research;human;HIFU for treatment of hypertension;ENG;pig;NTS_3.3;Cardiovascular disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;ultrasound;medical device;NTS_3.1
20173566_02;20173566;Een niet invasieve ablatie therapie door middel van ultrageluid;Translational or applied research;human;HIFU for treatment of hypertension;ENG;pig;NTS_3.3;Cardiovascular disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;MEC requirement;allowing clinical trial;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;ultrasound;medical device;NTS_3.1
20173566_02;20173566;Een niet invasieve ablatie therapie door middel van ultrageluid;Translational or applied research;human;HIFU for treatment of hypertension;ENG;pig;NTS_3.3;Cardiovascular disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;ultrasound;medical device;NTS_3.1
20173566_02;20173566;Een niet invasieve ablatie therapie door middel van ultrageluid;Translational or applied research;human;HIFU for treatment of hypertension;ENG;pig;NTS_3.3;Cardiovascular disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;ultrasound;medical device;NTS_3.1
20173566_02;20173566;Een niet invasieve ablatie therapie door middel van ultrageluid;Translational or applied research;human;HIFU for treatment of hypertension;ENG;pig;NTS_3.3;Cardiovascular disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;MEC requirement;allowing clinical trial;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;ultrasound;medical device;NTS_3.1
20173566_02;20173566;Een niet invasieve ablatie therapie door middel van ultrageluid;Translational or applied research;human;HIFU for treatment of hypertension;ENG;pig;NTS_3.3;Cardiovascular disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;similar anatomy or organ system;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;ultrasound;medical device;NTS_3.1
20173566_02;20173566;Een niet invasieve ablatie therapie door middel van ultrageluid;Translational or applied research;human;HIFU for treatment of hypertension;ENG;pig;NTS_3.3;Cardiovascular disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;ultrasound;medical device;NTS_3.1
20173566_02;20173566;Een niet invasieve ablatie therapie door middel van ultrageluid;Translational or applied research;human;HIFU for treatment of hypertension;ENG;pig;NTS_3.3;Cardiovascular disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;similar anatomy or organ system;APX_2B;intervention related;APX_2A;MEC requirement;allowing clinical trial;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;ultrasound;medical device;NTS_3.1
20173566_02;20173566;Een niet invasieve ablatie therapie door middel van ultrageluid;Translational or applied research;human;HIFU for treatment of hypertension;ENG;pig;NTS_3.3;Cardiovascular disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;ultrasound;medical device;NTS_3.1
20173566_02;20173566;Een niet invasieve ablatie therapie door middel van ultrageluid;Translational or applied research;human;HIFU for treatment of hypertension;ENG;pig;NTS_3.3;Cardiovascular disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;ultrasound;medical device;NTS_3.1
20173566_02;20173566;Een niet invasieve ablatie therapie door middel van ultrageluid;Translational or applied research;human;HIFU for treatment of hypertension;ENG;pig;NTS_3.3;Cardiovascular disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;MEC requirement;allowing clinical trial;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;ultrasound;medical device;NTS_3.1
20173566_02;20173566;Een niet invasieve ablatie therapie door middel van ultrageluid;Translational or applied research;human;HIFU for treatment of hypertension;ENG;pig;NTS_3.3;Cardiovascular disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;ultrasound;medical device;NTS_3.1
20173566_02;20173566;Een niet invasieve ablatie therapie door middel van ultrageluid;Translational or applied research;human;HIFU for treatment of hypertension;ENG;pig;NTS_3.3;Cardiovascular disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;ultrasound;medical device;NTS_3.1
20173566_02;20173566;Een niet invasieve ablatie therapie door middel van ultrageluid;Translational or applied research;human;HIFU for treatment of hypertension;ENG;pig;NTS_3.3;Cardiovascular disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;MEC requirement;allowing clinical trial;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;ultrasound;medical device;NTS_3.1
20173566_02;20173566;Een niet invasieve ablatie therapie door middel van ultrageluid;Translational or applied research;human;HIFU for treatment of hypertension;ENG;pig;NTS_3.3;Cardiovascular disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;ultrasound;medical device;NTS_3.1
20173566_02;20173566;Een niet invasieve ablatie therapie door middel van ultrageluid;Translational or applied research;human;HIFU for treatment of hypertension;ENG;pig;NTS_3.3;Cardiovascular disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;ultrasound;medical device;NTS_3.1
20173566_02;20173566;Een niet invasieve ablatie therapie door middel van ultrageluid;Translational or applied research;human;HIFU for treatment of hypertension;ENG;pig;NTS_3.3;Cardiovascular disorders;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;MEC requirement;allowing clinical trial;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;ultrasound;medical device;NTS_3.1
20173566_02;20173566;Een niet invasieve ablatie therapie door middel van ultrageluid;Translational or applied research;human;HIFU for treatment of hypertension;ENG;pig;NTS_3.3;Cardiovascular disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;similar anatomy or organ system;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;ultrasound;medical device;NTS_3.1
20173566_02;20173566;Een niet invasieve ablatie therapie door middel van ultrageluid;Translational or applied research;human;HIFU for treatment of hypertension;ENG;pig;NTS_3.3;Cardiovascular disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;ultrasound;medical device;NTS_3.1
20173566_02;20173566;Een niet invasieve ablatie therapie door middel van ultrageluid;Translational or applied research;human;HIFU for treatment of hypertension;ENG;pig;NTS_3.3;Cardiovascular disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;similar anatomy or organ system;APX_2B;intervention related;APX_2A;MEC requirement;allowing clinical trial;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;ultrasound;medical device;NTS_3.1
20173566_02;20173566;Een niet invasieve ablatie therapie door middel van ultrageluid;Translational or applied research;human;HIFU for treatment of hypertension;ENG;pig;NTS_3.3;Cardiovascular disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;ultrasound;medical device;NTS_3.1
20173566_02;20173566;Een niet invasieve ablatie therapie door middel van ultrageluid;Translational or applied research;human;HIFU for treatment of hypertension;ENG;pig;NTS_3.3;Cardiovascular disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;ultrasound;medical device;NTS_3.1
20173566_02;20173566;Een niet invasieve ablatie therapie door middel van ultrageluid;Translational or applied research;human;HIFU for treatment of hypertension;ENG;pig;NTS_3.3;Cardiovascular disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;MEC requirement;allowing clinical trial;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;ultrasound;medical device;NTS_3.1
20173566_02;20173566;Een niet invasieve ablatie therapie door middel van ultrageluid;Translational or applied research;human;HIFU for treatment of hypertension;ENG;pig;NTS_3.3;Cardiovascular disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;ultrasound;medical device;NTS_3.1
20173566_02;20173566;Een niet invasieve ablatie therapie door middel van ultrageluid;Translational or applied research;human;HIFU for treatment of hypertension;ENG;pig;NTS_3.3;Cardiovascular disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;ultrasound;medical device;NTS_3.1
20173566_02;20173566;Een niet invasieve ablatie therapie door middel van ultrageluid;Translational or applied research;human;HIFU for treatment of hypertension;ENG;pig;NTS_3.3;Cardiovascular disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;MEC requirement;allowing clinical trial;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;ultrasound;medical device;NTS_3.1
20173566_02;20173566;Een niet invasieve ablatie therapie door middel van ultrageluid;Translational or applied research;human;HIFU for treatment of hypertension;ENG;pig;NTS_3.3;Cardiovascular disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;ultrasound;medical device;NTS_3.1
20173566_02;20173566;Een niet invasieve ablatie therapie door middel van ultrageluid;Translational or applied research;human;HIFU for treatment of hypertension;ENG;pig;NTS_3.3;Cardiovascular disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;ultrasound;medical device;NTS_3.1
20173566_02;20173566;Een niet invasieve ablatie therapie door middel van ultrageluid;Translational or applied research;human;HIFU for treatment of hypertension;ENG;pig;NTS_3.3;Cardiovascular disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;similar disease pathology or symptoms;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;MEC requirement;allowing clinical trial;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;ultrasound;medical device;NTS_3.1
20173566_02;20173566;Een niet invasieve ablatie therapie door middel van ultrageluid;Translational or applied research;human;HIFU for treatment of hypertension;ENG;pig;NTS_3.3;Cardiovascular disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;similar anatomy or organ system;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;ultrasound;medical device;NTS_3.1
20173566_02;20173566;Een niet invasieve ablatie therapie door middel van ultrageluid;Translational or applied research;human;HIFU for treatment of hypertension;ENG;pig;NTS_3.3;Cardiovascular disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;ultrasound;medical device;NTS_3.1
20173566_02;20173566;Een niet invasieve ablatie therapie door middel van ultrageluid;Translational or applied research;human;HIFU for treatment of hypertension;ENG;pig;NTS_3.3;Cardiovascular disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;similar anatomy or organ system;APX_2B;intervention related;APX_2A;MEC requirement;allowing clinical trial;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;ultrasound;medical device;NTS_3.1
20173566_02;20173566;Een niet invasieve ablatie therapie door middel van ultrageluid;Translational or applied research;human;HIFU for treatment of hypertension;ENG;pig;NTS_3.3;Cardiovascular disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;ultrasound;medical device;NTS_3.1
20173566_02;20173566;Een niet invasieve ablatie therapie door middel van ultrageluid;Translational or applied research;human;HIFU for treatment of hypertension;ENG;pig;NTS_3.3;Cardiovascular disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;ultrasound;medical device;NTS_3.1
20173566_02;20173566;Een niet invasieve ablatie therapie door middel van ultrageluid;Translational or applied research;human;HIFU for treatment of hypertension;ENG;pig;NTS_3.3;Cardiovascular disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;MEC requirement;allowing clinical trial;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;ultrasound;medical device;NTS_3.1
20173566_02;20173566;Een niet invasieve ablatie therapie door middel van ultrageluid;Translational or applied research;human;HIFU for treatment of hypertension;ENG;pig;NTS_3.3;Cardiovascular disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;ultrasound;medical device;NTS_3.1
20173566_02;20173566;Een niet invasieve ablatie therapie door middel van ultrageluid;Translational or applied research;human;HIFU for treatment of hypertension;ENG;pig;NTS_3.3;Cardiovascular disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;ultrasound;medical device;NTS_3.1
20173566_02;20173566;Een niet invasieve ablatie therapie door middel van ultrageluid;Translational or applied research;human;HIFU for treatment of hypertension;ENG;pig;NTS_3.3;Cardiovascular disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;MEC requirement;allowing clinical trial;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;ultrasound;medical device;NTS_3.1
20173566_02;20173566;Een niet invasieve ablatie therapie door middel van ultrageluid;Translational or applied research;human;HIFU for treatment of hypertension;ENG;pig;NTS_3.3;Cardiovascular disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;ultrasound;medical device;NTS_3.1
20173566_02;20173566;Een niet invasieve ablatie therapie door middel van ultrageluid;Translational or applied research;human;HIFU for treatment of hypertension;ENG;pig;NTS_3.3;Cardiovascular disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;ultrasound;medical device;NTS_3.1
20173566_02;20173566;Een niet invasieve ablatie therapie door middel van ultrageluid;Translational or applied research;human;HIFU for treatment of hypertension;ENG;pig;NTS_3.3;Cardiovascular disorders;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;MEC requirement;allowing clinical trial;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;expertise;APX_2D;ultrasound;medical device;NTS_3.1
20173827_01;20173827;Onderzoek naar de behandeling van het syndroom van Leigh;Translational or applied research;human;Breeding;ENG;mouse;NTS_3.3;Endocrine or metabolism disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;similar disease pathology or symptoms;APX_2B;not reported;APX_2A;no alternative model;obtain required information or material;APX_2D;experimental design;use of one or both sexes;APX_2D;reduction of discomfort;experimental design;APX_2D;transgenic breeding;gene and cell-based;APX_2A
20173827_01;20173827;Onderzoek naar de behandeling van het syndroom van Leigh;Translational or applied research;human;Breeding;ENG;mouse;NTS_3.3;Endocrine or metabolism disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;similar disease pathology or symptoms;APX_2B;not reported;APX_2A;no alternative model;obtain required information or material;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;experimental design;APX_2D;transgenic breeding;gene and cell-based;APX_2A
20173827_01;20173827;Onderzoek naar de behandeling van het syndroom van Leigh;Translational or applied research;human;Breeding;ENG;mouse;NTS_3.3;Endocrine or metabolism disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2B;not reported;APX_2A;no alternative model;obtain required information or material;APX_2D;experimental design;use of one or both sexes;APX_2D;reduction of discomfort;experimental design;APX_2D;transgenic breeding;gene and cell-based;APX_2A
20173827_01;20173827;Onderzoek naar de behandeling van het syndroom van Leigh;Translational or applied research;human;Breeding;ENG;mouse;NTS_3.3;Endocrine or metabolism disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2B;not reported;APX_2A;no alternative model;obtain required information or material;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;experimental design;APX_2D;transgenic breeding;gene and cell-based;APX_2A
20173827_01;20173827;Onderzoek naar de behandeling van het syndroom van Leigh;Translational or applied research;human;Breeding;ENG;mouse;NTS_3.3;Endocrine or metabolism disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;similar disease pathology or symptoms;APX_2B;not reported;APX_2A;no alternative model;obtain required information or material;APX_2D;experimental design;use of one or both sexes;APX_2D;reduction of discomfort;experimental design;APX_2D;transgenic breeding;gene and cell-based;APX_2A
20173827_01;20173827;Onderzoek naar de behandeling van het syndroom van Leigh;Translational or applied research;human;Breeding;ENG;mouse;NTS_3.3;Endocrine or metabolism disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;similar disease pathology or symptoms;APX_2B;not reported;APX_2A;no alternative model;obtain required information or material;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;experimental design;APX_2D;transgenic breeding;gene and cell-based;APX_2A
20173827_01;20173827;Onderzoek naar de behandeling van het syndroom van Leigh;Translational or applied research;human;Breeding;ENG;mouse;NTS_3.3;Endocrine or metabolism disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2B;not reported;APX_2A;no alternative model;obtain required information or material;APX_2D;experimental design;use of one or both sexes;APX_2D;reduction of discomfort;experimental design;APX_2D;transgenic breeding;gene and cell-based;APX_2A
20173827_01;20173827;Onderzoek naar de behandeling van het syndroom van Leigh;Translational or applied research;human;Breeding;ENG;mouse;NTS_3.3;Endocrine or metabolism disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2B;not reported;APX_2A;no alternative model;obtain required information or material;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;experimental design;APX_2D;transgenic breeding;gene and cell-based;APX_2A
20173827_02;20173827;Onderzoek naar de behandeling van het syndroom van Leigh;Translational or applied research;human;Pharmacokinetic studies;ENG;mouse;NTS_3.3;Endocrine or metabolism disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;similar disease pathology or symptoms;PPL_3.1;intervention related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;substantiated statistics;sample size calculation;APX_2D;reduction of discomfort;route of administration;APX_2D;<U+0085>. compounds;small molecular compounds;APX_2A
20173827_02;20173827;Onderzoek naar de behandeling van het syndroom van Leigh;Translational or applied research;human;Pharmacokinetic studies;ENG;mouse;NTS_3.3;Endocrine or metabolism disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;similar disease pathology or symptoms;PPL_3.1;intervention related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;literature review;optimal combination of readouts;APX_2D;reduction of discomfort;route of administration;APX_2D;<U+0085>. compounds;small molecular compounds;APX_2A
20173827_02;20173827;Onderzoek naar de behandeling van het syndroom van Leigh;Translational or applied research;human;Pharmacokinetic studies;ENG;mouse;NTS_3.3;Endocrine or metabolism disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;similar disease pathology or symptoms;PPL_3.1;intervention related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;experimental design;use of one or both sexes;APX_2D;reduction of discomfort;route of administration;APX_2D;<U+0085>. compounds;small molecular compounds;APX_2A
20173827_02;20173827;Onderzoek naar de behandeling van het syndroom van Leigh;Translational or applied research;human;Pharmacokinetic studies;ENG;mouse;NTS_3.3;Endocrine or metabolism disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar disease pathology or symptoms;PPL_3.1;intervention related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;substantiated statistics;sample size calculation;APX_2D;reduction of discomfort;route of administration;APX_2D;<U+0085>. compounds;small molecular compounds;APX_2A
20173827_02;20173827;Onderzoek naar de behandeling van het syndroom van Leigh;Translational or applied research;human;Pharmacokinetic studies;ENG;mouse;NTS_3.3;Endocrine or metabolism disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar disease pathology or symptoms;PPL_3.1;intervention related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;literature review;optimal combination of readouts;APX_2D;reduction of discomfort;route of administration;APX_2D;<U+0085>. compounds;small molecular compounds;APX_2A
20173827_02;20173827;Onderzoek naar de behandeling van het syndroom van Leigh;Translational or applied research;human;Pharmacokinetic studies;ENG;mouse;NTS_3.3;Endocrine or metabolism disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar disease pathology or symptoms;PPL_3.1;intervention related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;experimental design;use of one or both sexes;APX_2D;reduction of discomfort;route of administration;APX_2D;<U+0085>. compounds;small molecular compounds;APX_2A
20173827_02;20173827;Onderzoek naar de behandeling van het syndroom van Leigh;Translational or applied research;human;Pharmacokinetic studies;ENG;mouse;NTS_3.3;Endocrine or metabolism disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;similar disease pathology or symptoms;PPL_3.1;intervention related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;substantiated statistics;sample size calculation;APX_2D;reduction of discomfort;route of administration;APX_2D;<U+0085>. compounds;small molecular compounds;APX_2A
20173827_02;20173827;Onderzoek naar de behandeling van het syndroom van Leigh;Translational or applied research;human;Pharmacokinetic studies;ENG;mouse;NTS_3.3;Endocrine or metabolism disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;similar disease pathology or symptoms;PPL_3.1;intervention related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;literature review;optimal combination of readouts;APX_2D;reduction of discomfort;route of administration;APX_2D;<U+0085>. compounds;small molecular compounds;APX_2A
20173827_02;20173827;Onderzoek naar de behandeling van het syndroom van Leigh;Translational or applied research;human;Pharmacokinetic studies;ENG;mouse;NTS_3.3;Endocrine or metabolism disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;similar disease pathology or symptoms;PPL_3.1;intervention related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;experimental design;use of one or both sexes;APX_2D;reduction of discomfort;route of administration;APX_2D;<U+0085>. compounds;small molecular compounds;APX_2A
20173827_02;20173827;Onderzoek naar de behandeling van het syndroom van Leigh;Translational or applied research;human;Pharmacokinetic studies;ENG;mouse;NTS_3.3;Endocrine or metabolism disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar disease pathology or symptoms;PPL_3.1;intervention related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;substantiated statistics;sample size calculation;APX_2D;reduction of discomfort;route of administration;APX_2D;<U+0085>. compounds;small molecular compounds;APX_2A
20173827_02;20173827;Onderzoek naar de behandeling van het syndroom van Leigh;Translational or applied research;human;Pharmacokinetic studies;ENG;mouse;NTS_3.3;Endocrine or metabolism disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar disease pathology or symptoms;PPL_3.1;intervention related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;literature review;optimal combination of readouts;APX_2D;reduction of discomfort;route of administration;APX_2D;<U+0085>. compounds;small molecular compounds;APX_2A
20173827_02;20173827;Onderzoek naar de behandeling van het syndroom van Leigh;Translational or applied research;human;Pharmacokinetic studies;ENG;mouse;NTS_3.3;Endocrine or metabolism disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar disease pathology or symptoms;PPL_3.1;intervention related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;experimental design;use of one or both sexes;APX_2D;reduction of discomfort;route of administration;APX_2D;<U+0085>. compounds;small molecular compounds;APX_2A
20173827_03;20173827;Onderzoek naar de behandeling van het syndroom van Leigh;Translational or applied research;human;Efficacy studies;ENG;mouse;NTS_3.3;Endocrine or metabolism disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;no alternative model;obtain required information or material;APX_2D;substantiated statistics;sample size calculation;APX_2D;reduction of discomfort;route of administration;APX_2D;<U+0085>. compounds;small molecular compounds;APX_2A
20173827_03;20173827;Onderzoek naar de behandeling van het syndroom van Leigh;Translational or applied research;human;Efficacy studies;ENG;mouse;NTS_3.3;Endocrine or metabolism disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;no alternative model;obtain required information or material;APX_2D;literature review;optimal combination of readouts;APX_2D;reduction of discomfort;route of administration;APX_2D;<U+0085>. compounds;small molecular compounds;APX_2A
20173827_03;20173827;Onderzoek naar de behandeling van het syndroom van Leigh;Translational or applied research;human;Efficacy studies;ENG;mouse;NTS_3.3;Endocrine or metabolism disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;no alternative model;obtain required information or material;APX_2D;experimental design;use of one or both sexes;APX_2D;reduction of discomfort;route of administration;APX_2D;<U+0085>. compounds;small molecular compounds;APX_2A
20173827_03;20173827;Onderzoek naar de behandeling van het syndroom van Leigh;Translational or applied research;human;Efficacy studies;ENG;mouse;NTS_3.3;Endocrine or metabolism disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;no alternative model;obtain required information or material;APX_2D;substantiated statistics;sample size calculation;APX_2D;reduction of discomfort;route of administration;APX_2D;<U+0085>. compounds;small molecular compounds;APX_2A
20173827_03;20173827;Onderzoek naar de behandeling van het syndroom van Leigh;Translational or applied research;human;Efficacy studies;ENG;mouse;NTS_3.3;Endocrine or metabolism disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;no alternative model;obtain required information or material;APX_2D;literature review;optimal combination of readouts;APX_2D;reduction of discomfort;route of administration;APX_2D;<U+0085>. compounds;small molecular compounds;APX_2A
20173827_03;20173827;Onderzoek naar de behandeling van het syndroom van Leigh;Translational or applied research;human;Efficacy studies;ENG;mouse;NTS_3.3;Endocrine or metabolism disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;no alternative model;obtain required information or material;APX_2D;experimental design;use of one or both sexes;APX_2D;reduction of discomfort;route of administration;APX_2D;<U+0085>. compounds;small molecular compounds;APX_2A
20173827_03;20173827;Onderzoek naar de behandeling van het syndroom van Leigh;Translational or applied research;human;Efficacy studies;ENG;mouse;NTS_3.3;Endocrine or metabolism disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;no alternative model;obtain required information or material;APX_2D;substantiated statistics;sample size calculation;APX_2D;reduction of discomfort;route of administration;APX_2D;<U+0085>. compounds;small molecular compounds;APX_2A
20173827_03;20173827;Onderzoek naar de behandeling van het syndroom van Leigh;Translational or applied research;human;Efficacy studies;ENG;mouse;NTS_3.3;Endocrine or metabolism disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;no alternative model;obtain required information or material;APX_2D;literature review;optimal combination of readouts;APX_2D;reduction of discomfort;route of administration;APX_2D;<U+0085>. compounds;small molecular compounds;APX_2A
20173827_03;20173827;Onderzoek naar de behandeling van het syndroom van Leigh;Translational or applied research;human;Efficacy studies;ENG;mouse;NTS_3.3;Endocrine or metabolism disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;no alternative model;obtain required information or material;APX_2D;experimental design;use of one or both sexes;APX_2D;reduction of discomfort;route of administration;APX_2D;<U+0085>. compounds;small molecular compounds;APX_2A
20173827_03;20173827;Onderzoek naar de behandeling van het syndroom van Leigh;Translational or applied research;human;Efficacy studies;ENG;mouse;NTS_3.3;Endocrine or metabolism disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;no alternative model;obtain required information or material;APX_2D;substantiated statistics;sample size calculation;APX_2D;reduction of discomfort;route of administration;APX_2D;<U+0085>. compounds;small molecular compounds;APX_2A
20173827_03;20173827;Onderzoek naar de behandeling van het syndroom van Leigh;Translational or applied research;human;Efficacy studies;ENG;mouse;NTS_3.3;Endocrine or metabolism disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;no alternative model;obtain required information or material;APX_2D;literature review;optimal combination of readouts;APX_2D;reduction of discomfort;route of administration;APX_2D;<U+0085>. compounds;small molecular compounds;APX_2A
20173827_03;20173827;Onderzoek naar de behandeling van het syndroom van Leigh;Translational or applied research;human;Efficacy studies;ENG;mouse;NTS_3.3;Endocrine or metabolism disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;no alternative model;obtain required information or material;APX_2D;experimental design;use of one or both sexes;APX_2D;reduction of discomfort;route of administration;APX_2D;<U+0085>. compounds;small molecular compounds;APX_2A
20173827_03;20173827;Onderzoek naar de behandeling van het syndroom van Leigh;Translational or applied research;human;Efficacy studies;ENG;mouse;NTS_3.3;Endocrine or metabolism disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;no alternative model;obtain required information or material;APX_2D;substantiated statistics;sample size calculation;APX_2D;reduction of discomfort;route of administration;APX_2D;<U+0085>. compounds;small molecular compounds;APX_2A
20173827_03;20173827;Onderzoek naar de behandeling van het syndroom van Leigh;Translational or applied research;human;Efficacy studies;ENG;mouse;NTS_3.3;Endocrine or metabolism disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;no alternative model;obtain required information or material;APX_2D;literature review;optimal combination of readouts;APX_2D;reduction of discomfort;route of administration;APX_2D;<U+0085>. compounds;small molecular compounds;APX_2A
20173827_03;20173827;Onderzoek naar de behandeling van het syndroom van Leigh;Translational or applied research;human;Efficacy studies;ENG;mouse;NTS_3.3;Endocrine or metabolism disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;no alternative model;obtain required information or material;APX_2D;experimental design;use of one or both sexes;APX_2D;reduction of discomfort;route of administration;APX_2D;<U+0085>. compounds;small molecular compounds;APX_2A
20173827_03;20173827;Onderzoek naar de behandeling van het syndroom van Leigh;Translational or applied research;human;Efficacy studies;ENG;mouse;NTS_3.3;Endocrine or metabolism disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;no alternative model;obtain required information or material;APX_2D;substantiated statistics;sample size calculation;APX_2D;reduction of discomfort;route of administration;APX_2D;<U+0085>. compounds;small molecular compounds;APX_2A
20173827_03;20173827;Onderzoek naar de behandeling van het syndroom van Leigh;Translational or applied research;human;Efficacy studies;ENG;mouse;NTS_3.3;Endocrine or metabolism disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;no alternative model;obtain required information or material;APX_2D;literature review;optimal combination of readouts;APX_2D;reduction of discomfort;route of administration;APX_2D;<U+0085>. compounds;small molecular compounds;APX_2A
20173827_03;20173827;Onderzoek naar de behandeling van het syndroom van Leigh;Translational or applied research;human;Efficacy studies;ENG;mouse;NTS_3.3;Endocrine or metabolism disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;no alternative model;obtain required information or material;APX_2D;experimental design;use of one or both sexes;APX_2D;reduction of discomfort;route of administration;APX_2D;<U+0085>. compounds;small molecular compounds;APX_2A
20173827_03;20173827;Onderzoek naar de behandeling van het syndroom van Leigh;Translational or applied research;human;Efficacy studies;ENG;mouse;NTS_3.3;Endocrine or metabolism disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;no alternative model;obtain required information or material;APX_2D;substantiated statistics;sample size calculation;APX_2D;reduction of discomfort;route of administration;APX_2D;<U+0085>. compounds;small molecular compounds;APX_2A
20173827_03;20173827;Onderzoek naar de behandeling van het syndroom van Leigh;Translational or applied research;human;Efficacy studies;ENG;mouse;NTS_3.3;Endocrine or metabolism disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;no alternative model;obtain required information or material;APX_2D;literature review;optimal combination of readouts;APX_2D;reduction of discomfort;route of administration;APX_2D;<U+0085>. compounds;small molecular compounds;APX_2A
20173827_03;20173827;Onderzoek naar de behandeling van het syndroom van Leigh;Translational or applied research;human;Efficacy studies;ENG;mouse;NTS_3.3;Endocrine or metabolism disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;no alternative model;obtain required information or material;APX_2D;experimental design;use of one or both sexes;APX_2D;reduction of discomfort;route of administration;APX_2D;<U+0085>. compounds;small molecular compounds;APX_2A
20173827_03;20173827;Onderzoek naar de behandeling van het syndroom van Leigh;Translational or applied research;human;Efficacy studies;ENG;mouse;NTS_3.3;Endocrine or metabolism disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;no alternative model;obtain required information or material;APX_2D;substantiated statistics;sample size calculation;APX_2D;reduction of discomfort;route of administration;APX_2D;<U+0085>. compounds;small molecular compounds;APX_2A
20173827_03;20173827;Onderzoek naar de behandeling van het syndroom van Leigh;Translational or applied research;human;Efficacy studies;ENG;mouse;NTS_3.3;Endocrine or metabolism disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;no alternative model;obtain required information or material;APX_2D;literature review;optimal combination of readouts;APX_2D;reduction of discomfort;route of administration;APX_2D;<U+0085>. compounds;small molecular compounds;APX_2A
20173827_03;20173827;Onderzoek naar de behandeling van het syndroom van Leigh;Translational or applied research;human;Efficacy studies;ENG;mouse;NTS_3.3;Endocrine or metabolism disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;no alternative model;obtain required information or material;APX_2D;experimental design;use of one or both sexes;APX_2D;reduction of discomfort;route of administration;APX_2D;<U+0085>. compounds;small molecular compounds;APX_2A
20173827_04;20173827;Onderzoek naar de behandeling van het syndroom van Leigh;Translational or applied research;human;Imaging studies;ENG;mouse;NTS_3.3;Endocrine or metabolism disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;no alternative model;obtain required information or material;APX_2D;substantiated statistics;sample size calculation;APX_2D;reduction of discomfort;route of administration;APX_2D;<U+0085>. compounds;small molecular compounds;APX_2A
20173827_04;20173827;Onderzoek naar de behandeling van het syndroom van Leigh;Translational or applied research;human;Imaging studies;ENG;mouse;NTS_3.3;Endocrine or metabolism disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;no alternative model;obtain required information or material;APX_2D;literature review;optimal combination of readouts;APX_2D;reduction of discomfort;route of administration;APX_2D;<U+0085>. compounds;small molecular compounds;APX_2A
20173827_04;20173827;Onderzoek naar de behandeling van het syndroom van Leigh;Translational or applied research;human;Imaging studies;ENG;mouse;NTS_3.3;Endocrine or metabolism disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;no alternative model;obtain required information or material;APX_2D;experimental design;use of one or both sexes;APX_2D;reduction of discomfort;route of administration;APX_2D;<U+0085>. compounds;small molecular compounds;APX_2A
20173827_04;20173827;Onderzoek naar de behandeling van het syndroom van Leigh;Translational or applied research;human;Imaging studies;ENG;mouse;NTS_3.3;Endocrine or metabolism disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;no alternative model;obtain required information or material;APX_2D;substantiated statistics;sample size calculation;APX_2D;reduction of discomfort;route of administration;APX_2D;<U+0085>. compounds;small molecular compounds;APX_2A
20173827_04;20173827;Onderzoek naar de behandeling van het syndroom van Leigh;Translational or applied research;human;Imaging studies;ENG;mouse;NTS_3.3;Endocrine or metabolism disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;no alternative model;obtain required information or material;APX_2D;literature review;optimal combination of readouts;APX_2D;reduction of discomfort;route of administration;APX_2D;<U+0085>. compounds;small molecular compounds;APX_2A
20173827_04;20173827;Onderzoek naar de behandeling van het syndroom van Leigh;Translational or applied research;human;Imaging studies;ENG;mouse;NTS_3.3;Endocrine or metabolism disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;no alternative model;obtain required information or material;APX_2D;experimental design;use of one or both sexes;APX_2D;reduction of discomfort;route of administration;APX_2D;<U+0085>. compounds;small molecular compounds;APX_2A
20173827_04;20173827;Onderzoek naar de behandeling van het syndroom van Leigh;Translational or applied research;human;Imaging studies;ENG;mouse;NTS_3.3;Endocrine or metabolism disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;no alternative model;obtain required information or material;APX_2D;substantiated statistics;sample size calculation;APX_2D;reduction of discomfort;route of administration;APX_2D;<U+0085>. compounds;small molecular compounds;APX_2A
20173827_04;20173827;Onderzoek naar de behandeling van het syndroom van Leigh;Translational or applied research;human;Imaging studies;ENG;mouse;NTS_3.3;Endocrine or metabolism disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;no alternative model;obtain required information or material;APX_2D;literature review;optimal combination of readouts;APX_2D;reduction of discomfort;route of administration;APX_2D;<U+0085>. compounds;small molecular compounds;APX_2A
20173827_04;20173827;Onderzoek naar de behandeling van het syndroom van Leigh;Translational or applied research;human;Imaging studies;ENG;mouse;NTS_3.3;Endocrine or metabolism disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;no alternative model;obtain required information or material;APX_2D;experimental design;use of one or both sexes;APX_2D;reduction of discomfort;route of administration;APX_2D;<U+0085>. compounds;small molecular compounds;APX_2A
20173827_04;20173827;Onderzoek naar de behandeling van het syndroom van Leigh;Translational or applied research;human;Imaging studies;ENG;mouse;NTS_3.3;Endocrine or metabolism disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;no alternative model;obtain required information or material;APX_2D;substantiated statistics;sample size calculation;APX_2D;reduction of discomfort;route of administration;APX_2D;<U+0085>. compounds;small molecular compounds;APX_2A
20173827_04;20173827;Onderzoek naar de behandeling van het syndroom van Leigh;Translational or applied research;human;Imaging studies;ENG;mouse;NTS_3.3;Endocrine or metabolism disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;no alternative model;obtain required information or material;APX_2D;literature review;optimal combination of readouts;APX_2D;reduction of discomfort;route of administration;APX_2D;<U+0085>. compounds;small molecular compounds;APX_2A
20173827_04;20173827;Onderzoek naar de behandeling van het syndroom van Leigh;Translational or applied research;human;Imaging studies;ENG;mouse;NTS_3.3;Endocrine or metabolism disorders;NTS_1.3;Genetically modified;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;no alternative model;obtain required information or material;APX_2D;experimental design;use of one or both sexes;APX_2D;reduction of discomfort;route of administration;APX_2D;<U+0085>. compounds;small molecular compounds;APX_2A
20173827_04;20173827;Onderzoek naar de behandeling van het syndroom van Leigh;Translational or applied research;human;Imaging studies;ENG;mouse;NTS_3.3;Endocrine or metabolism disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;no alternative model;obtain required information or material;APX_2D;substantiated statistics;sample size calculation;APX_2D;reduction of discomfort;route of administration;APX_2D;<U+0085>. compounds;small molecular compounds;APX_2A
20173827_04;20173827;Onderzoek naar de behandeling van het syndroom van Leigh;Translational or applied research;human;Imaging studies;ENG;mouse;NTS_3.3;Endocrine or metabolism disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;no alternative model;obtain required information or material;APX_2D;literature review;optimal combination of readouts;APX_2D;reduction of discomfort;route of administration;APX_2D;<U+0085>. compounds;small molecular compounds;APX_2A
20173827_04;20173827;Onderzoek naar de behandeling van het syndroom van Leigh;Translational or applied research;human;Imaging studies;ENG;mouse;NTS_3.3;Endocrine or metabolism disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;no alternative model;obtain required information or material;APX_2D;experimental design;use of one or both sexes;APX_2D;reduction of discomfort;route of administration;APX_2D;<U+0085>. compounds;small molecular compounds;APX_2A
20173827_04;20173827;Onderzoek naar de behandeling van het syndroom van Leigh;Translational or applied research;human;Imaging studies;ENG;mouse;NTS_3.3;Endocrine or metabolism disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;no alternative model;obtain required information or material;APX_2D;substantiated statistics;sample size calculation;APX_2D;reduction of discomfort;route of administration;APX_2D;<U+0085>. compounds;small molecular compounds;APX_2A
20173827_04;20173827;Onderzoek naar de behandeling van het syndroom van Leigh;Translational or applied research;human;Imaging studies;ENG;mouse;NTS_3.3;Endocrine or metabolism disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;no alternative model;obtain required information or material;APX_2D;literature review;optimal combination of readouts;APX_2D;reduction of discomfort;route of administration;APX_2D;<U+0085>. compounds;small molecular compounds;APX_2A
20173827_04;20173827;Onderzoek naar de behandeling van het syndroom van Leigh;Translational or applied research;human;Imaging studies;ENG;mouse;NTS_3.3;Endocrine or metabolism disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.1;Main Text;similar disease pathology or symptoms;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;no alternative model;obtain required information or material;APX_2D;experimental design;use of one or both sexes;APX_2D;reduction of discomfort;route of administration;APX_2D;<U+0085>. compounds;small molecular compounds;APX_2A
20173827_04;20173827;Onderzoek naar de behandeling van het syndroom van Leigh;Translational or applied research;human;Imaging studies;ENG;mouse;NTS_3.3;Endocrine or metabolism disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;no alternative model;obtain required information or material;APX_2D;substantiated statistics;sample size calculation;APX_2D;reduction of discomfort;route of administration;APX_2D;<U+0085>. compounds;small molecular compounds;APX_2A
20173827_04;20173827;Onderzoek naar de behandeling van het syndroom van Leigh;Translational or applied research;human;Imaging studies;ENG;mouse;NTS_3.3;Endocrine or metabolism disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;no alternative model;obtain required information or material;APX_2D;literature review;optimal combination of readouts;APX_2D;reduction of discomfort;route of administration;APX_2D;<U+0085>. compounds;small molecular compounds;APX_2A
20173827_04;20173827;Onderzoek naar de behandeling van het syndroom van Leigh;Translational or applied research;human;Imaging studies;ENG;mouse;NTS_3.3;Endocrine or metabolism disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;no alternative model;obtain required information or material;APX_2D;experimental design;use of one or both sexes;APX_2D;reduction of discomfort;route of administration;APX_2D;<U+0085>. compounds;small molecular compounds;APX_2A
20173827_04;20173827;Onderzoek naar de behandeling van het syndroom van Leigh;Translational or applied research;human;Imaging studies;ENG;mouse;NTS_3.3;Endocrine or metabolism disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;no alternative model;obtain required information or material;APX_2D;substantiated statistics;sample size calculation;APX_2D;reduction of discomfort;route of administration;APX_2D;<U+0085>. compounds;small molecular compounds;APX_2A
20173827_04;20173827;Onderzoek naar de behandeling van het syndroom van Leigh;Translational or applied research;human;Imaging studies;ENG;mouse;NTS_3.3;Endocrine or metabolism disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;no alternative model;obtain required information or material;APX_2D;literature review;optimal combination of readouts;APX_2D;reduction of discomfort;route of administration;APX_2D;<U+0085>. compounds;small molecular compounds;APX_2A
20173827_04;20173827;Onderzoek naar de behandeling van het syndroom van Leigh;Translational or applied research;human;Imaging studies;ENG;mouse;NTS_3.3;Endocrine or metabolism disorders;NTS_3.1;Genetically modified;APX_2A;PPL_3.1;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;no alternative model;obtain required information or material;APX_2D;experimental design;use of one or both sexes;APX_2D;reduction of discomfort;route of administration;APX_2D;<U+0085>. compounds;small molecular compounds;APX_2A
20173828_01;20173828;Onderzoek naar de capaciteit van vezelversterkt calciumfosfaat cementen om zwaarbelaste botdefecten te genezen;Translational or applied research;human;Assessment of the performance of bone substitutes under load-bearing conditions;ENG;rabbit;NTS_3.3;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;literature review;relevant information;APX_2D;methods used in procedures;lowest possible species;APX_2D;bone replacement;medical device;NTS_3.1
20173828_01;20173828;Onderzoek naar de capaciteit van vezelversterkt calciumfosfaat cementen om zwaarbelaste botdefecten te genezen;Translational or applied research;human;Assessment of the performance of bone substitutes under load-bearing conditions;ENG;rabbit;NTS_3.3;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;literature review;relevant information;APX_2D;methods used in procedures;lowest possible species;APX_2D;bone replacement;medical device;NTS_3.1
20173828_01;20173828;Onderzoek naar de capaciteit van vezelversterkt calciumfosfaat cementen om zwaarbelaste botdefecten te genezen;Translational or applied research;human;Assessment of the performance of bone substitutes under load-bearing conditions;ENG;rabbit;NTS_3.3;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;lowest possible species;APX_2D;bone replacement;medical device;NTS_3.1
20173828_01;20173828;Onderzoek naar de capaciteit van vezelversterkt calciumfosfaat cementen om zwaarbelaste botdefecten te genezen;Translational or applied research;human;Assessment of the performance of bone substitutes under load-bearing conditions;ENG;rabbit;NTS_3.3;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;lowest possible species;APX_2D;bone replacement;medical device;NTS_3.1
20173828_01;20173828;Onderzoek naar de capaciteit van vezelversterkt calciumfosfaat cementen om zwaarbelaste botdefecten te genezen;Translational or applied research;human;Assessment of the performance of bone substitutes under load-bearing conditions;ENG;rabbit;NTS_3.3;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;methods used in procedures;lowest possible species;APX_2D;bone replacement;medical device;NTS_3.1
20173828_01;20173828;Onderzoek naar de capaciteit van vezelversterkt calciumfosfaat cementen om zwaarbelaste botdefecten te genezen;Translational or applied research;human;Assessment of the performance of bone substitutes under load-bearing conditions;ENG;rabbit;NTS_3.3;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;substantiated statistics;statistical power calculation;APX_2D;methods used in procedures;lowest possible species;APX_2D;bone replacement;medical device;NTS_3.1
20173828_01;20173828;Onderzoek naar de capaciteit van vezelversterkt calciumfosfaat cementen om zwaarbelaste botdefecten te genezen;Translational or applied research;human;Assessment of the performance of bone substitutes under load-bearing conditions;ENG;rabbit;NTS_3.3;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;literature review;relevant information;APX_2D;reduction of discomfort;equipment;APX_2D;bone replacement;medical device;NTS_3.1
20173828_01;20173828;Onderzoek naar de capaciteit van vezelversterkt calciumfosfaat cementen om zwaarbelaste botdefecten te genezen;Translational or applied research;human;Assessment of the performance of bone substitutes under load-bearing conditions;ENG;rabbit;NTS_3.3;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;literature review;relevant information;APX_2D;reduction of discomfort;equipment;APX_2D;bone replacement;medical device;NTS_3.1
20173828_01;20173828;Onderzoek naar de capaciteit van vezelversterkt calciumfosfaat cementen om zwaarbelaste botdefecten te genezen;Translational or applied research;human;Assessment of the performance of bone substitutes under load-bearing conditions;ENG;rabbit;NTS_3.3;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;equipment;APX_2D;bone replacement;medical device;NTS_3.1
20173828_01;20173828;Onderzoek naar de capaciteit van vezelversterkt calciumfosfaat cementen om zwaarbelaste botdefecten te genezen;Translational or applied research;human;Assessment of the performance of bone substitutes under load-bearing conditions;ENG;rabbit;NTS_3.3;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;equipment;APX_2D;bone replacement;medical device;NTS_3.1
20173828_01;20173828;Onderzoek naar de capaciteit van vezelversterkt calciumfosfaat cementen om zwaarbelaste botdefecten te genezen;Translational or applied research;human;Assessment of the performance of bone substitutes under load-bearing conditions;ENG;rabbit;NTS_3.3;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;equipment;APX_2D;bone replacement;medical device;NTS_3.1
20173828_01;20173828;Onderzoek naar de capaciteit van vezelversterkt calciumfosfaat cementen om zwaarbelaste botdefecten te genezen;Translational or applied research;human;Assessment of the performance of bone substitutes under load-bearing conditions;ENG;rabbit;NTS_3.3;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;equipment;APX_2D;bone replacement;medical device;NTS_3.1
20173828_01;20173828;Onderzoek naar de capaciteit van vezelversterkt calciumfosfaat cementen om zwaarbelaste botdefecten te genezen;Translational or applied research;human;Assessment of the performance of bone substitutes under load-bearing conditions;ENG;rabbit;NTS_3.3;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;literature review;relevant information;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;NTS_3.1
20173828_01;20173828;Onderzoek naar de capaciteit van vezelversterkt calciumfosfaat cementen om zwaarbelaste botdefecten te genezen;Translational or applied research;human;Assessment of the performance of bone substitutes under load-bearing conditions;ENG;rabbit;NTS_3.3;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;literature review;relevant information;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;NTS_3.1
20173828_01;20173828;Onderzoek naar de capaciteit van vezelversterkt calciumfosfaat cementen om zwaarbelaste botdefecten te genezen;Translational or applied research;human;Assessment of the performance of bone substitutes under load-bearing conditions;ENG;rabbit;NTS_3.3;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;NTS_3.1
20173828_01;20173828;Onderzoek naar de capaciteit van vezelversterkt calciumfosfaat cementen om zwaarbelaste botdefecten te genezen;Translational or applied research;human;Assessment of the performance of bone substitutes under load-bearing conditions;ENG;rabbit;NTS_3.3;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;NTS_3.1
20173828_01;20173828;Onderzoek naar de capaciteit van vezelversterkt calciumfosfaat cementen om zwaarbelaste botdefecten te genezen;Translational or applied research;human;Assessment of the performance of bone substitutes under load-bearing conditions;ENG;rabbit;NTS_3.3;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;NTS_3.1
20173828_01;20173828;Onderzoek naar de capaciteit van vezelversterkt calciumfosfaat cementen om zwaarbelaste botdefecten te genezen;Translational or applied research;human;Assessment of the performance of bone substitutes under load-bearing conditions;ENG;rabbit;NTS_3.3;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;substantiated statistics;statistical power calculation;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;NTS_3.1
20173828_01;20173828;Onderzoek naar de capaciteit van vezelversterkt calciumfosfaat cementen om zwaarbelaste botdefecten te genezen;Translational or applied research;human;Assessment of the performance of bone substitutes under load-bearing conditions;ENG;rabbit;NTS_3.3;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;literature review;relevant information;APX_2D;accomodation and care;cage enrichment;APX_2D;bone replacement;medical device;NTS_3.1
20173828_01;20173828;Onderzoek naar de capaciteit van vezelversterkt calciumfosfaat cementen om zwaarbelaste botdefecten te genezen;Translational or applied research;human;Assessment of the performance of bone substitutes under load-bearing conditions;ENG;rabbit;NTS_3.3;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;literature review;relevant information;APX_2D;accomodation and care;cage enrichment;APX_2D;bone replacement;medical device;NTS_3.1
20173828_01;20173828;Onderzoek naar de capaciteit van vezelversterkt calciumfosfaat cementen om zwaarbelaste botdefecten te genezen;Translational or applied research;human;Assessment of the performance of bone substitutes under load-bearing conditions;ENG;rabbit;NTS_3.3;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;accomodation and care;cage enrichment;APX_2D;bone replacement;medical device;NTS_3.1
20173828_01;20173828;Onderzoek naar de capaciteit van vezelversterkt calciumfosfaat cementen om zwaarbelaste botdefecten te genezen;Translational or applied research;human;Assessment of the performance of bone substitutes under load-bearing conditions;ENG;rabbit;NTS_3.3;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;accomodation and care;cage enrichment;APX_2D;bone replacement;medical device;NTS_3.1
20173828_01;20173828;Onderzoek naar de capaciteit van vezelversterkt calciumfosfaat cementen om zwaarbelaste botdefecten te genezen;Translational or applied research;human;Assessment of the performance of bone substitutes under load-bearing conditions;ENG;rabbit;NTS_3.3;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;accomodation and care;cage enrichment;APX_2D;bone replacement;medical device;NTS_3.1
20173828_01;20173828;Onderzoek naar de capaciteit van vezelversterkt calciumfosfaat cementen om zwaarbelaste botdefecten te genezen;Translational or applied research;human;Assessment of the performance of bone substitutes under load-bearing conditions;ENG;rabbit;NTS_3.3;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;substantiated statistics;statistical power calculation;APX_2D;accomodation and care;cage enrichment;APX_2D;bone replacement;medical device;NTS_3.1
20173828_01;20173828;Onderzoek naar de capaciteit van vezelversterkt calciumfosfaat cementen om zwaarbelaste botdefecten te genezen;Translational or applied research;human;Assessment of the performance of bone substitutes under load-bearing conditions;ENG;rabbit;NTS_3.3;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;literature review;relevant information;APX_2D;methods used in procedures;lowest possible species;APX_2D;bone replacement;medical device;NTS_3.1
20173828_01;20173828;Onderzoek naar de capaciteit van vezelversterkt calciumfosfaat cementen om zwaarbelaste botdefecten te genezen;Translational or applied research;human;Assessment of the performance of bone substitutes under load-bearing conditions;ENG;rabbit;NTS_3.3;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;literature review;relevant information;APX_2D;methods used in procedures;lowest possible species;APX_2D;bone replacement;medical device;NTS_3.1
20173828_01;20173828;Onderzoek naar de capaciteit van vezelversterkt calciumfosfaat cementen om zwaarbelaste botdefecten te genezen;Translational or applied research;human;Assessment of the performance of bone substitutes under load-bearing conditions;ENG;rabbit;NTS_3.3;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;lowest possible species;APX_2D;bone replacement;medical device;NTS_3.1
20173828_01;20173828;Onderzoek naar de capaciteit van vezelversterkt calciumfosfaat cementen om zwaarbelaste botdefecten te genezen;Translational or applied research;human;Assessment of the performance of bone substitutes under load-bearing conditions;ENG;rabbit;NTS_3.3;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;lowest possible species;APX_2D;bone replacement;medical device;NTS_3.1
20173828_01;20173828;Onderzoek naar de capaciteit van vezelversterkt calciumfosfaat cementen om zwaarbelaste botdefecten te genezen;Translational or applied research;human;Assessment of the performance of bone substitutes under load-bearing conditions;ENG;rabbit;NTS_3.3;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;methods used in procedures;lowest possible species;APX_2D;bone replacement;medical device;NTS_3.1
20173828_01;20173828;Onderzoek naar de capaciteit van vezelversterkt calciumfosfaat cementen om zwaarbelaste botdefecten te genezen;Translational or applied research;human;Assessment of the performance of bone substitutes under load-bearing conditions;ENG;rabbit;NTS_3.3;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;substantiated statistics;statistical power calculation;APX_2D;methods used in procedures;lowest possible species;APX_2D;bone replacement;medical device;NTS_3.1
20173828_01;20173828;Onderzoek naar de capaciteit van vezelversterkt calciumfosfaat cementen om zwaarbelaste botdefecten te genezen;Translational or applied research;human;Assessment of the performance of bone substitutes under load-bearing conditions;ENG;rabbit;NTS_3.3;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;literature review;relevant information;APX_2D;reduction of discomfort;equipment;APX_2D;bone replacement;medical device;NTS_3.1
20173828_01;20173828;Onderzoek naar de capaciteit van vezelversterkt calciumfosfaat cementen om zwaarbelaste botdefecten te genezen;Translational or applied research;human;Assessment of the performance of bone substitutes under load-bearing conditions;ENG;rabbit;NTS_3.3;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;literature review;relevant information;APX_2D;reduction of discomfort;equipment;APX_2D;bone replacement;medical device;NTS_3.1
20173828_01;20173828;Onderzoek naar de capaciteit van vezelversterkt calciumfosfaat cementen om zwaarbelaste botdefecten te genezen;Translational or applied research;human;Assessment of the performance of bone substitutes under load-bearing conditions;ENG;rabbit;NTS_3.3;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;equipment;APX_2D;bone replacement;medical device;NTS_3.1
20173828_01;20173828;Onderzoek naar de capaciteit van vezelversterkt calciumfosfaat cementen om zwaarbelaste botdefecten te genezen;Translational or applied research;human;Assessment of the performance of bone substitutes under load-bearing conditions;ENG;rabbit;NTS_3.3;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;equipment;APX_2D;bone replacement;medical device;NTS_3.1
20173828_01;20173828;Onderzoek naar de capaciteit van vezelversterkt calciumfosfaat cementen om zwaarbelaste botdefecten te genezen;Translational or applied research;human;Assessment of the performance of bone substitutes under load-bearing conditions;ENG;rabbit;NTS_3.3;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;equipment;APX_2D;bone replacement;medical device;NTS_3.1
20173828_01;20173828;Onderzoek naar de capaciteit van vezelversterkt calciumfosfaat cementen om zwaarbelaste botdefecten te genezen;Translational or applied research;human;Assessment of the performance of bone substitutes under load-bearing conditions;ENG;rabbit;NTS_3.3;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;equipment;APX_2D;bone replacement;medical device;NTS_3.1
20173828_01;20173828;Onderzoek naar de capaciteit van vezelversterkt calciumfosfaat cementen om zwaarbelaste botdefecten te genezen;Translational or applied research;human;Assessment of the performance of bone substitutes under load-bearing conditions;ENG;rabbit;NTS_3.3;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;literature review;relevant information;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;NTS_3.1
20173828_01;20173828;Onderzoek naar de capaciteit van vezelversterkt calciumfosfaat cementen om zwaarbelaste botdefecten te genezen;Translational or applied research;human;Assessment of the performance of bone substitutes under load-bearing conditions;ENG;rabbit;NTS_3.3;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;literature review;relevant information;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;NTS_3.1
20173828_01;20173828;Onderzoek naar de capaciteit van vezelversterkt calciumfosfaat cementen om zwaarbelaste botdefecten te genezen;Translational or applied research;human;Assessment of the performance of bone substitutes under load-bearing conditions;ENG;rabbit;NTS_3.3;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;NTS_3.1
20173828_01;20173828;Onderzoek naar de capaciteit van vezelversterkt calciumfosfaat cementen om zwaarbelaste botdefecten te genezen;Translational or applied research;human;Assessment of the performance of bone substitutes under load-bearing conditions;ENG;rabbit;NTS_3.3;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;NTS_3.1
20173828_01;20173828;Onderzoek naar de capaciteit van vezelversterkt calciumfosfaat cementen om zwaarbelaste botdefecten te genezen;Translational or applied research;human;Assessment of the performance of bone substitutes under load-bearing conditions;ENG;rabbit;NTS_3.3;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;NTS_3.1
20173828_01;20173828;Onderzoek naar de capaciteit van vezelversterkt calciumfosfaat cementen om zwaarbelaste botdefecten te genezen;Translational or applied research;human;Assessment of the performance of bone substitutes under load-bearing conditions;ENG;rabbit;NTS_3.3;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;substantiated statistics;statistical power calculation;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;NTS_3.1
20173828_01;20173828;Onderzoek naar de capaciteit van vezelversterkt calciumfosfaat cementen om zwaarbelaste botdefecten te genezen;Translational or applied research;human;Assessment of the performance of bone substitutes under load-bearing conditions;ENG;rabbit;NTS_3.3;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;literature review;relevant information;APX_2D;accomodation and care;cage enrichment;APX_2D;bone replacement;medical device;NTS_3.1
20173828_01;20173828;Onderzoek naar de capaciteit van vezelversterkt calciumfosfaat cementen om zwaarbelaste botdefecten te genezen;Translational or applied research;human;Assessment of the performance of bone substitutes under load-bearing conditions;ENG;rabbit;NTS_3.3;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;literature review;relevant information;APX_2D;accomodation and care;cage enrichment;APX_2D;bone replacement;medical device;NTS_3.1
20173828_01;20173828;Onderzoek naar de capaciteit van vezelversterkt calciumfosfaat cementen om zwaarbelaste botdefecten te genezen;Translational or applied research;human;Assessment of the performance of bone substitutes under load-bearing conditions;ENG;rabbit;NTS_3.3;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;accomodation and care;cage enrichment;APX_2D;bone replacement;medical device;NTS_3.1
20173828_01;20173828;Onderzoek naar de capaciteit van vezelversterkt calciumfosfaat cementen om zwaarbelaste botdefecten te genezen;Translational or applied research;human;Assessment of the performance of bone substitutes under load-bearing conditions;ENG;rabbit;NTS_3.3;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;accomodation and care;cage enrichment;APX_2D;bone replacement;medical device;NTS_3.1
20173828_01;20173828;Onderzoek naar de capaciteit van vezelversterkt calciumfosfaat cementen om zwaarbelaste botdefecten te genezen;Translational or applied research;human;Assessment of the performance of bone substitutes under load-bearing conditions;ENG;rabbit;NTS_3.3;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;accomodation and care;cage enrichment;APX_2D;bone replacement;medical device;NTS_3.1
20173828_01;20173828;Onderzoek naar de capaciteit van vezelversterkt calciumfosfaat cementen om zwaarbelaste botdefecten te genezen;Translational or applied research;human;Assessment of the performance of bone substitutes under load-bearing conditions;ENG;rabbit;NTS_3.3;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;substantiated statistics;statistical power calculation;APX_2D;accomodation and care;cage enrichment;APX_2D;bone replacement;medical device;NTS_3.1
20173828_01;20173828;Onderzoek naar de capaciteit van vezelversterkt calciumfosfaat cementen om zwaarbelaste botdefecten te genezen;Translational or applied research;human;Assessment of the performance of bone substitutes under load-bearing conditions;ENG;rabbit;NTS_3.3;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;literature review;relevant information;APX_2D;methods used in procedures;lowest possible species;APX_2D;bone replacement;medical device;NTS_3.1
20173828_01;20173828;Onderzoek naar de capaciteit van vezelversterkt calciumfosfaat cementen om zwaarbelaste botdefecten te genezen;Translational or applied research;human;Assessment of the performance of bone substitutes under load-bearing conditions;ENG;rabbit;NTS_3.3;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;literature review;relevant information;APX_2D;methods used in procedures;lowest possible species;APX_2D;bone replacement;medical device;NTS_3.1
20173828_01;20173828;Onderzoek naar de capaciteit van vezelversterkt calciumfosfaat cementen om zwaarbelaste botdefecten te genezen;Translational or applied research;human;Assessment of the performance of bone substitutes under load-bearing conditions;ENG;rabbit;NTS_3.3;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;lowest possible species;APX_2D;bone replacement;medical device;NTS_3.1
20173828_01;20173828;Onderzoek naar de capaciteit van vezelversterkt calciumfosfaat cementen om zwaarbelaste botdefecten te genezen;Translational or applied research;human;Assessment of the performance of bone substitutes under load-bearing conditions;ENG;rabbit;NTS_3.3;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;lowest possible species;APX_2D;bone replacement;medical device;NTS_3.1
20173828_01;20173828;Onderzoek naar de capaciteit van vezelversterkt calciumfosfaat cementen om zwaarbelaste botdefecten te genezen;Translational or applied research;human;Assessment of the performance of bone substitutes under load-bearing conditions;ENG;rabbit;NTS_3.3;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;methods used in procedures;lowest possible species;APX_2D;bone replacement;medical device;NTS_3.1
20173828_01;20173828;Onderzoek naar de capaciteit van vezelversterkt calciumfosfaat cementen om zwaarbelaste botdefecten te genezen;Translational or applied research;human;Assessment of the performance of bone substitutes under load-bearing conditions;ENG;rabbit;NTS_3.3;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;substantiated statistics;statistical power calculation;APX_2D;methods used in procedures;lowest possible species;APX_2D;bone replacement;medical device;NTS_3.1
20173828_01;20173828;Onderzoek naar de capaciteit van vezelversterkt calciumfosfaat cementen om zwaarbelaste botdefecten te genezen;Translational or applied research;human;Assessment of the performance of bone substitutes under load-bearing conditions;ENG;rabbit;NTS_3.3;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;literature review;relevant information;APX_2D;reduction of discomfort;equipment;APX_2D;bone replacement;medical device;NTS_3.1
20173828_01;20173828;Onderzoek naar de capaciteit van vezelversterkt calciumfosfaat cementen om zwaarbelaste botdefecten te genezen;Translational or applied research;human;Assessment of the performance of bone substitutes under load-bearing conditions;ENG;rabbit;NTS_3.3;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;literature review;relevant information;APX_2D;reduction of discomfort;equipment;APX_2D;bone replacement;medical device;NTS_3.1
20173828_01;20173828;Onderzoek naar de capaciteit van vezelversterkt calciumfosfaat cementen om zwaarbelaste botdefecten te genezen;Translational or applied research;human;Assessment of the performance of bone substitutes under load-bearing conditions;ENG;rabbit;NTS_3.3;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;equipment;APX_2D;bone replacement;medical device;NTS_3.1
20173828_01;20173828;Onderzoek naar de capaciteit van vezelversterkt calciumfosfaat cementen om zwaarbelaste botdefecten te genezen;Translational or applied research;human;Assessment of the performance of bone substitutes under load-bearing conditions;ENG;rabbit;NTS_3.3;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;equipment;APX_2D;bone replacement;medical device;NTS_3.1
20173828_01;20173828;Onderzoek naar de capaciteit van vezelversterkt calciumfosfaat cementen om zwaarbelaste botdefecten te genezen;Translational or applied research;human;Assessment of the performance of bone substitutes under load-bearing conditions;ENG;rabbit;NTS_3.3;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;equipment;APX_2D;bone replacement;medical device;NTS_3.1
20173828_01;20173828;Onderzoek naar de capaciteit van vezelversterkt calciumfosfaat cementen om zwaarbelaste botdefecten te genezen;Translational or applied research;human;Assessment of the performance of bone substitutes under load-bearing conditions;ENG;rabbit;NTS_3.3;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;equipment;APX_2D;bone replacement;medical device;NTS_3.1
20173828_01;20173828;Onderzoek naar de capaciteit van vezelversterkt calciumfosfaat cementen om zwaarbelaste botdefecten te genezen;Translational or applied research;human;Assessment of the performance of bone substitutes under load-bearing conditions;ENG;rabbit;NTS_3.3;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;literature review;relevant information;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;NTS_3.1
20173828_01;20173828;Onderzoek naar de capaciteit van vezelversterkt calciumfosfaat cementen om zwaarbelaste botdefecten te genezen;Translational or applied research;human;Assessment of the performance of bone substitutes under load-bearing conditions;ENG;rabbit;NTS_3.3;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;literature review;relevant information;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;NTS_3.1
20173828_01;20173828;Onderzoek naar de capaciteit van vezelversterkt calciumfosfaat cementen om zwaarbelaste botdefecten te genezen;Translational or applied research;human;Assessment of the performance of bone substitutes under load-bearing conditions;ENG;rabbit;NTS_3.3;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;NTS_3.1
20173828_01;20173828;Onderzoek naar de capaciteit van vezelversterkt calciumfosfaat cementen om zwaarbelaste botdefecten te genezen;Translational or applied research;human;Assessment of the performance of bone substitutes under load-bearing conditions;ENG;rabbit;NTS_3.3;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;NTS_3.1
20173828_01;20173828;Onderzoek naar de capaciteit van vezelversterkt calciumfosfaat cementen om zwaarbelaste botdefecten te genezen;Translational or applied research;human;Assessment of the performance of bone substitutes under load-bearing conditions;ENG;rabbit;NTS_3.3;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;NTS_3.1
20173828_01;20173828;Onderzoek naar de capaciteit van vezelversterkt calciumfosfaat cementen om zwaarbelaste botdefecten te genezen;Translational or applied research;human;Assessment of the performance of bone substitutes under load-bearing conditions;ENG;rabbit;NTS_3.3;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;substantiated statistics;statistical power calculation;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;NTS_3.1
20173828_01;20173828;Onderzoek naar de capaciteit van vezelversterkt calciumfosfaat cementen om zwaarbelaste botdefecten te genezen;Translational or applied research;human;Assessment of the performance of bone substitutes under load-bearing conditions;ENG;rabbit;NTS_3.3;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;literature review;relevant information;APX_2D;accomodation and care;cage enrichment;APX_2D;bone replacement;medical device;NTS_3.1
20173828_01;20173828;Onderzoek naar de capaciteit van vezelversterkt calciumfosfaat cementen om zwaarbelaste botdefecten te genezen;Translational or applied research;human;Assessment of the performance of bone substitutes under load-bearing conditions;ENG;rabbit;NTS_3.3;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;literature review;relevant information;APX_2D;accomodation and care;cage enrichment;APX_2D;bone replacement;medical device;NTS_3.1
20173828_01;20173828;Onderzoek naar de capaciteit van vezelversterkt calciumfosfaat cementen om zwaarbelaste botdefecten te genezen;Translational or applied research;human;Assessment of the performance of bone substitutes under load-bearing conditions;ENG;rabbit;NTS_3.3;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;accomodation and care;cage enrichment;APX_2D;bone replacement;medical device;NTS_3.1
20173828_01;20173828;Onderzoek naar de capaciteit van vezelversterkt calciumfosfaat cementen om zwaarbelaste botdefecten te genezen;Translational or applied research;human;Assessment of the performance of bone substitutes under load-bearing conditions;ENG;rabbit;NTS_3.3;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;accomodation and care;cage enrichment;APX_2D;bone replacement;medical device;NTS_3.1
20173828_01;20173828;Onderzoek naar de capaciteit van vezelversterkt calciumfosfaat cementen om zwaarbelaste botdefecten te genezen;Translational or applied research;human;Assessment of the performance of bone substitutes under load-bearing conditions;ENG;rabbit;NTS_3.3;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;accomodation and care;cage enrichment;APX_2D;bone replacement;medical device;NTS_3.1
20173828_01;20173828;Onderzoek naar de capaciteit van vezelversterkt calciumfosfaat cementen om zwaarbelaste botdefecten te genezen;Translational or applied research;human;Assessment of the performance of bone substitutes under load-bearing conditions;ENG;rabbit;NTS_3.3;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;substantiated statistics;statistical power calculation;APX_2D;accomodation and care;cage enrichment;APX_2D;bone replacement;medical device;NTS_3.1
20173828_01;20173828;Onderzoek naar de capaciteit van vezelversterkt calciumfosfaat cementen om zwaarbelaste botdefecten te genezen;Translational or applied research;human;Assessment of the performance of bone substitutes under load-bearing conditions;ENG;rabbit;NTS_3.3;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;availability of research tools;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;literature review;relevant information;APX_2D;methods used in procedures;lowest possible species;APX_2D;bone replacement;medical device;NTS_3.1
20173828_01;20173828;Onderzoek naar de capaciteit van vezelversterkt calciumfosfaat cementen om zwaarbelaste botdefecten te genezen;Translational or applied research;human;Assessment of the performance of bone substitutes under load-bearing conditions;ENG;rabbit;NTS_3.3;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;literature review;relevant information;APX_2D;methods used in procedures;lowest possible species;APX_2D;bone replacement;medical device;NTS_3.1
20173828_01;20173828;Onderzoek naar de capaciteit van vezelversterkt calciumfosfaat cementen om zwaarbelaste botdefecten te genezen;Translational or applied research;human;Assessment of the performance of bone substitutes under load-bearing conditions;ENG;rabbit;NTS_3.3;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;availability of research tools;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;lowest possible species;APX_2D;bone replacement;medical device;NTS_3.1
20173828_01;20173828;Onderzoek naar de capaciteit van vezelversterkt calciumfosfaat cementen om zwaarbelaste botdefecten te genezen;Translational or applied research;human;Assessment of the performance of bone substitutes under load-bearing conditions;ENG;rabbit;NTS_3.3;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;lowest possible species;APX_2D;bone replacement;medical device;NTS_3.1
20173828_01;20173828;Onderzoek naar de capaciteit van vezelversterkt calciumfosfaat cementen om zwaarbelaste botdefecten te genezen;Translational or applied research;human;Assessment of the performance of bone substitutes under load-bearing conditions;ENG;rabbit;NTS_3.3;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;availability of research tools;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;methods used in procedures;lowest possible species;APX_2D;bone replacement;medical device;NTS_3.1
20173828_01;20173828;Onderzoek naar de capaciteit van vezelversterkt calciumfosfaat cementen om zwaarbelaste botdefecten te genezen;Translational or applied research;human;Assessment of the performance of bone substitutes under load-bearing conditions;ENG;rabbit;NTS_3.3;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;substantiated statistics;statistical power calculation;APX_2D;methods used in procedures;lowest possible species;APX_2D;bone replacement;medical device;NTS_3.1
20173828_01;20173828;Onderzoek naar de capaciteit van vezelversterkt calciumfosfaat cementen om zwaarbelaste botdefecten te genezen;Translational or applied research;human;Assessment of the performance of bone substitutes under load-bearing conditions;ENG;rabbit;NTS_3.3;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;availability of research tools;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;literature review;relevant information;APX_2D;reduction of discomfort;equipment;APX_2D;bone replacement;medical device;NTS_3.1
20173828_01;20173828;Onderzoek naar de capaciteit van vezelversterkt calciumfosfaat cementen om zwaarbelaste botdefecten te genezen;Translational or applied research;human;Assessment of the performance of bone substitutes under load-bearing conditions;ENG;rabbit;NTS_3.3;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;literature review;relevant information;APX_2D;reduction of discomfort;equipment;APX_2D;bone replacement;medical device;NTS_3.1
20173828_01;20173828;Onderzoek naar de capaciteit van vezelversterkt calciumfosfaat cementen om zwaarbelaste botdefecten te genezen;Translational or applied research;human;Assessment of the performance of bone substitutes under load-bearing conditions;ENG;rabbit;NTS_3.3;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;availability of research tools;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;equipment;APX_2D;bone replacement;medical device;NTS_3.1
20173828_01;20173828;Onderzoek naar de capaciteit van vezelversterkt calciumfosfaat cementen om zwaarbelaste botdefecten te genezen;Translational or applied research;human;Assessment of the performance of bone substitutes under load-bearing conditions;ENG;rabbit;NTS_3.3;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;equipment;APX_2D;bone replacement;medical device;NTS_3.1
20173828_01;20173828;Onderzoek naar de capaciteit van vezelversterkt calciumfosfaat cementen om zwaarbelaste botdefecten te genezen;Translational or applied research;human;Assessment of the performance of bone substitutes under load-bearing conditions;ENG;rabbit;NTS_3.3;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;availability of research tools;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;equipment;APX_2D;bone replacement;medical device;NTS_3.1
20173828_01;20173828;Onderzoek naar de capaciteit van vezelversterkt calciumfosfaat cementen om zwaarbelaste botdefecten te genezen;Translational or applied research;human;Assessment of the performance of bone substitutes under load-bearing conditions;ENG;rabbit;NTS_3.3;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;equipment;APX_2D;bone replacement;medical device;NTS_3.1
20173828_01;20173828;Onderzoek naar de capaciteit van vezelversterkt calciumfosfaat cementen om zwaarbelaste botdefecten te genezen;Translational or applied research;human;Assessment of the performance of bone substitutes under load-bearing conditions;ENG;rabbit;NTS_3.3;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;availability of research tools;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;literature review;relevant information;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;NTS_3.1
20173828_01;20173828;Onderzoek naar de capaciteit van vezelversterkt calciumfosfaat cementen om zwaarbelaste botdefecten te genezen;Translational or applied research;human;Assessment of the performance of bone substitutes under load-bearing conditions;ENG;rabbit;NTS_3.3;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;literature review;relevant information;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;NTS_3.1
20173828_01;20173828;Onderzoek naar de capaciteit van vezelversterkt calciumfosfaat cementen om zwaarbelaste botdefecten te genezen;Translational or applied research;human;Assessment of the performance of bone substitutes under load-bearing conditions;ENG;rabbit;NTS_3.3;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;availability of research tools;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;NTS_3.1
20173828_01;20173828;Onderzoek naar de capaciteit van vezelversterkt calciumfosfaat cementen om zwaarbelaste botdefecten te genezen;Translational or applied research;human;Assessment of the performance of bone substitutes under load-bearing conditions;ENG;rabbit;NTS_3.3;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;NTS_3.1
20173828_01;20173828;Onderzoek naar de capaciteit van vezelversterkt calciumfosfaat cementen om zwaarbelaste botdefecten te genezen;Translational or applied research;human;Assessment of the performance of bone substitutes under load-bearing conditions;ENG;rabbit;NTS_3.3;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;availability of research tools;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;NTS_3.1
20173828_01;20173828;Onderzoek naar de capaciteit van vezelversterkt calciumfosfaat cementen om zwaarbelaste botdefecten te genezen;Translational or applied research;human;Assessment of the performance of bone substitutes under load-bearing conditions;ENG;rabbit;NTS_3.3;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;substantiated statistics;statistical power calculation;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;NTS_3.1
20173828_01;20173828;Onderzoek naar de capaciteit van vezelversterkt calciumfosfaat cementen om zwaarbelaste botdefecten te genezen;Translational or applied research;human;Assessment of the performance of bone substitutes under load-bearing conditions;ENG;rabbit;NTS_3.3;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;availability of research tools;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;literature review;relevant information;APX_2D;accomodation and care;cage enrichment;APX_2D;bone replacement;medical device;NTS_3.1
20173828_01;20173828;Onderzoek naar de capaciteit van vezelversterkt calciumfosfaat cementen om zwaarbelaste botdefecten te genezen;Translational or applied research;human;Assessment of the performance of bone substitutes under load-bearing conditions;ENG;rabbit;NTS_3.3;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;literature review;relevant information;APX_2D;accomodation and care;cage enrichment;APX_2D;bone replacement;medical device;NTS_3.1
20173828_01;20173828;Onderzoek naar de capaciteit van vezelversterkt calciumfosfaat cementen om zwaarbelaste botdefecten te genezen;Translational or applied research;human;Assessment of the performance of bone substitutes under load-bearing conditions;ENG;rabbit;NTS_3.3;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;availability of research tools;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;accomodation and care;cage enrichment;APX_2D;bone replacement;medical device;NTS_3.1
20173828_01;20173828;Onderzoek naar de capaciteit van vezelversterkt calciumfosfaat cementen om zwaarbelaste botdefecten te genezen;Translational or applied research;human;Assessment of the performance of bone substitutes under load-bearing conditions;ENG;rabbit;NTS_3.3;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;accomodation and care;cage enrichment;APX_2D;bone replacement;medical device;NTS_3.1
20173828_01;20173828;Onderzoek naar de capaciteit van vezelversterkt calciumfosfaat cementen om zwaarbelaste botdefecten te genezen;Translational or applied research;human;Assessment of the performance of bone substitutes under load-bearing conditions;ENG;rabbit;NTS_3.3;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;availability of research tools;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;accomodation and care;cage enrichment;APX_2D;bone replacement;medical device;NTS_3.1
20173828_01;20173828;Onderzoek naar de capaciteit van vezelversterkt calciumfosfaat cementen om zwaarbelaste botdefecten te genezen;Translational or applied research;human;Assessment of the performance of bone substitutes under load-bearing conditions;ENG;rabbit;NTS_3.3;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;substantiated statistics;statistical power calculation;APX_2D;accomodation and care;cage enrichment;APX_2D;bone replacement;medical device;NTS_3.1
20173828_01;20173828;Onderzoek naar de capaciteit van vezelversterkt calciumfosfaat cementen om zwaarbelaste botdefecten te genezen;Translational or applied research;human;Assessment of the performance of bone substitutes under load-bearing conditions;ENG;rabbit;NTS_3.3;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;literature review;relevant information;APX_2D;methods used in procedures;lowest possible species;APX_2D;bone replacement;medical device;NTS_3.1
20173828_01;20173828;Onderzoek naar de capaciteit van vezelversterkt calciumfosfaat cementen om zwaarbelaste botdefecten te genezen;Translational or applied research;human;Assessment of the performance of bone substitutes under load-bearing conditions;ENG;rabbit;NTS_3.3;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;literature review;relevant information;APX_2D;methods used in procedures;lowest possible species;APX_2D;bone replacement;medical device;NTS_3.1
20173828_01;20173828;Onderzoek naar de capaciteit van vezelversterkt calciumfosfaat cementen om zwaarbelaste botdefecten te genezen;Translational or applied research;human;Assessment of the performance of bone substitutes under load-bearing conditions;ENG;rabbit;NTS_3.3;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;lowest possible species;APX_2D;bone replacement;medical device;NTS_3.1
20173828_01;20173828;Onderzoek naar de capaciteit van vezelversterkt calciumfosfaat cementen om zwaarbelaste botdefecten te genezen;Translational or applied research;human;Assessment of the performance of bone substitutes under load-bearing conditions;ENG;rabbit;NTS_3.3;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;lowest possible species;APX_2D;bone replacement;medical device;NTS_3.1
20173828_01;20173828;Onderzoek naar de capaciteit van vezelversterkt calciumfosfaat cementen om zwaarbelaste botdefecten te genezen;Translational or applied research;human;Assessment of the performance of bone substitutes under load-bearing conditions;ENG;rabbit;NTS_3.3;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;methods used in procedures;lowest possible species;APX_2D;bone replacement;medical device;NTS_3.1
20173828_01;20173828;Onderzoek naar de capaciteit van vezelversterkt calciumfosfaat cementen om zwaarbelaste botdefecten te genezen;Translational or applied research;human;Assessment of the performance of bone substitutes under load-bearing conditions;ENG;rabbit;NTS_3.3;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;substantiated statistics;statistical power calculation;APX_2D;methods used in procedures;lowest possible species;APX_2D;bone replacement;medical device;NTS_3.1
20173828_01;20173828;Onderzoek naar de capaciteit van vezelversterkt calciumfosfaat cementen om zwaarbelaste botdefecten te genezen;Translational or applied research;human;Assessment of the performance of bone substitutes under load-bearing conditions;ENG;rabbit;NTS_3.3;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;literature review;relevant information;APX_2D;reduction of discomfort;equipment;APX_2D;bone replacement;medical device;NTS_3.1
20173828_01;20173828;Onderzoek naar de capaciteit van vezelversterkt calciumfosfaat cementen om zwaarbelaste botdefecten te genezen;Translational or applied research;human;Assessment of the performance of bone substitutes under load-bearing conditions;ENG;rabbit;NTS_3.3;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;literature review;relevant information;APX_2D;reduction of discomfort;equipment;APX_2D;bone replacement;medical device;NTS_3.1
20173828_01;20173828;Onderzoek naar de capaciteit van vezelversterkt calciumfosfaat cementen om zwaarbelaste botdefecten te genezen;Translational or applied research;human;Assessment of the performance of bone substitutes under load-bearing conditions;ENG;rabbit;NTS_3.3;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;equipment;APX_2D;bone replacement;medical device;NTS_3.1
20173828_01;20173828;Onderzoek naar de capaciteit van vezelversterkt calciumfosfaat cementen om zwaarbelaste botdefecten te genezen;Translational or applied research;human;Assessment of the performance of bone substitutes under load-bearing conditions;ENG;rabbit;NTS_3.3;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;equipment;APX_2D;bone replacement;medical device;NTS_3.1
20173828_01;20173828;Onderzoek naar de capaciteit van vezelversterkt calciumfosfaat cementen om zwaarbelaste botdefecten te genezen;Translational or applied research;human;Assessment of the performance of bone substitutes under load-bearing conditions;ENG;rabbit;NTS_3.3;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;equipment;APX_2D;bone replacement;medical device;NTS_3.1
20173828_01;20173828;Onderzoek naar de capaciteit van vezelversterkt calciumfosfaat cementen om zwaarbelaste botdefecten te genezen;Translational or applied research;human;Assessment of the performance of bone substitutes under load-bearing conditions;ENG;rabbit;NTS_3.3;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;equipment;APX_2D;bone replacement;medical device;NTS_3.1
20173828_01;20173828;Onderzoek naar de capaciteit van vezelversterkt calciumfosfaat cementen om zwaarbelaste botdefecten te genezen;Translational or applied research;human;Assessment of the performance of bone substitutes under load-bearing conditions;ENG;rabbit;NTS_3.3;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;literature review;relevant information;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;NTS_3.1
20173828_01;20173828;Onderzoek naar de capaciteit van vezelversterkt calciumfosfaat cementen om zwaarbelaste botdefecten te genezen;Translational or applied research;human;Assessment of the performance of bone substitutes under load-bearing conditions;ENG;rabbit;NTS_3.3;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;literature review;relevant information;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;NTS_3.1
20173828_01;20173828;Onderzoek naar de capaciteit van vezelversterkt calciumfosfaat cementen om zwaarbelaste botdefecten te genezen;Translational or applied research;human;Assessment of the performance of bone substitutes under load-bearing conditions;ENG;rabbit;NTS_3.3;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;NTS_3.1
20173828_01;20173828;Onderzoek naar de capaciteit van vezelversterkt calciumfosfaat cementen om zwaarbelaste botdefecten te genezen;Translational or applied research;human;Assessment of the performance of bone substitutes under load-bearing conditions;ENG;rabbit;NTS_3.3;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;NTS_3.1
20173828_01;20173828;Onderzoek naar de capaciteit van vezelversterkt calciumfosfaat cementen om zwaarbelaste botdefecten te genezen;Translational or applied research;human;Assessment of the performance of bone substitutes under load-bearing conditions;ENG;rabbit;NTS_3.3;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;NTS_3.1
20173828_01;20173828;Onderzoek naar de capaciteit van vezelversterkt calciumfosfaat cementen om zwaarbelaste botdefecten te genezen;Translational or applied research;human;Assessment of the performance of bone substitutes under load-bearing conditions;ENG;rabbit;NTS_3.3;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;substantiated statistics;statistical power calculation;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;NTS_3.1
20173828_01;20173828;Onderzoek naar de capaciteit van vezelversterkt calciumfosfaat cementen om zwaarbelaste botdefecten te genezen;Translational or applied research;human;Assessment of the performance of bone substitutes under load-bearing conditions;ENG;rabbit;NTS_3.3;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;literature review;relevant information;APX_2D;accomodation and care;cage enrichment;APX_2D;bone replacement;medical device;NTS_3.1
20173828_01;20173828;Onderzoek naar de capaciteit van vezelversterkt calciumfosfaat cementen om zwaarbelaste botdefecten te genezen;Translational or applied research;human;Assessment of the performance of bone substitutes under load-bearing conditions;ENG;rabbit;NTS_3.3;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;literature review;relevant information;APX_2D;accomodation and care;cage enrichment;APX_2D;bone replacement;medical device;NTS_3.1
20173828_01;20173828;Onderzoek naar de capaciteit van vezelversterkt calciumfosfaat cementen om zwaarbelaste botdefecten te genezen;Translational or applied research;human;Assessment of the performance of bone substitutes under load-bearing conditions;ENG;rabbit;NTS_3.3;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;accomodation and care;cage enrichment;APX_2D;bone replacement;medical device;NTS_3.1
20173828_01;20173828;Onderzoek naar de capaciteit van vezelversterkt calciumfosfaat cementen om zwaarbelaste botdefecten te genezen;Translational or applied research;human;Assessment of the performance of bone substitutes under load-bearing conditions;ENG;rabbit;NTS_3.3;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;accomodation and care;cage enrichment;APX_2D;bone replacement;medical device;NTS_3.1
20173828_01;20173828;Onderzoek naar de capaciteit van vezelversterkt calciumfosfaat cementen om zwaarbelaste botdefecten te genezen;Translational or applied research;human;Assessment of the performance of bone substitutes under load-bearing conditions;ENG;rabbit;NTS_3.3;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;accomodation and care;cage enrichment;APX_2D;bone replacement;medical device;NTS_3.1
20173828_01;20173828;Onderzoek naar de capaciteit van vezelversterkt calciumfosfaat cementen om zwaarbelaste botdefecten te genezen;Translational or applied research;human;Assessment of the performance of bone substitutes under load-bearing conditions;ENG;rabbit;NTS_3.3;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;substantiated statistics;statistical power calculation;APX_2D;accomodation and care;cage enrichment;APX_2D;bone replacement;medical device;NTS_3.1
20173828_01;20173828;Onderzoek naar de capaciteit van vezelversterkt calciumfosfaat cementen om zwaarbelaste botdefecten te genezen;Translational or applied research;human;Assessment of the performance of bone substitutes under load-bearing conditions;ENG;rabbit;NTS_3.3;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;literature review;relevant information;APX_2D;methods used in procedures;lowest possible species;APX_2D;bone replacement;medical device;NTS_3.1
20173828_01;20173828;Onderzoek naar de capaciteit van vezelversterkt calciumfosfaat cementen om zwaarbelaste botdefecten te genezen;Translational or applied research;human;Assessment of the performance of bone substitutes under load-bearing conditions;ENG;rabbit;NTS_3.3;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;literature review;relevant information;APX_2D;methods used in procedures;lowest possible species;APX_2D;bone replacement;medical device;NTS_3.1
20173828_01;20173828;Onderzoek naar de capaciteit van vezelversterkt calciumfosfaat cementen om zwaarbelaste botdefecten te genezen;Translational or applied research;human;Assessment of the performance of bone substitutes under load-bearing conditions;ENG;rabbit;NTS_3.3;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;lowest possible species;APX_2D;bone replacement;medical device;NTS_3.1
20173828_01;20173828;Onderzoek naar de capaciteit van vezelversterkt calciumfosfaat cementen om zwaarbelaste botdefecten te genezen;Translational or applied research;human;Assessment of the performance of bone substitutes under load-bearing conditions;ENG;rabbit;NTS_3.3;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;lowest possible species;APX_2D;bone replacement;medical device;NTS_3.1
20173828_01;20173828;Onderzoek naar de capaciteit van vezelversterkt calciumfosfaat cementen om zwaarbelaste botdefecten te genezen;Translational or applied research;human;Assessment of the performance of bone substitutes under load-bearing conditions;ENG;rabbit;NTS_3.3;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;methods used in procedures;lowest possible species;APX_2D;bone replacement;medical device;NTS_3.1
20173828_01;20173828;Onderzoek naar de capaciteit van vezelversterkt calciumfosfaat cementen om zwaarbelaste botdefecten te genezen;Translational or applied research;human;Assessment of the performance of bone substitutes under load-bearing conditions;ENG;rabbit;NTS_3.3;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;substantiated statistics;statistical power calculation;APX_2D;methods used in procedures;lowest possible species;APX_2D;bone replacement;medical device;NTS_3.1
20173828_01;20173828;Onderzoek naar de capaciteit van vezelversterkt calciumfosfaat cementen om zwaarbelaste botdefecten te genezen;Translational or applied research;human;Assessment of the performance of bone substitutes under load-bearing conditions;ENG;rabbit;NTS_3.3;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;literature review;relevant information;APX_2D;reduction of discomfort;equipment;APX_2D;bone replacement;medical device;NTS_3.1
20173828_01;20173828;Onderzoek naar de capaciteit van vezelversterkt calciumfosfaat cementen om zwaarbelaste botdefecten te genezen;Translational or applied research;human;Assessment of the performance of bone substitutes under load-bearing conditions;ENG;rabbit;NTS_3.3;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;literature review;relevant information;APX_2D;reduction of discomfort;equipment;APX_2D;bone replacement;medical device;NTS_3.1
20173828_01;20173828;Onderzoek naar de capaciteit van vezelversterkt calciumfosfaat cementen om zwaarbelaste botdefecten te genezen;Translational or applied research;human;Assessment of the performance of bone substitutes under load-bearing conditions;ENG;rabbit;NTS_3.3;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;equipment;APX_2D;bone replacement;medical device;NTS_3.1
20173828_01;20173828;Onderzoek naar de capaciteit van vezelversterkt calciumfosfaat cementen om zwaarbelaste botdefecten te genezen;Translational or applied research;human;Assessment of the performance of bone substitutes under load-bearing conditions;ENG;rabbit;NTS_3.3;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;equipment;APX_2D;bone replacement;medical device;NTS_3.1
20173828_01;20173828;Onderzoek naar de capaciteit van vezelversterkt calciumfosfaat cementen om zwaarbelaste botdefecten te genezen;Translational or applied research;human;Assessment of the performance of bone substitutes under load-bearing conditions;ENG;rabbit;NTS_3.3;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;equipment;APX_2D;bone replacement;medical device;NTS_3.1
20173828_01;20173828;Onderzoek naar de capaciteit van vezelversterkt calciumfosfaat cementen om zwaarbelaste botdefecten te genezen;Translational or applied research;human;Assessment of the performance of bone substitutes under load-bearing conditions;ENG;rabbit;NTS_3.3;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;equipment;APX_2D;bone replacement;medical device;NTS_3.1
20173828_01;20173828;Onderzoek naar de capaciteit van vezelversterkt calciumfosfaat cementen om zwaarbelaste botdefecten te genezen;Translational or applied research;human;Assessment of the performance of bone substitutes under load-bearing conditions;ENG;rabbit;NTS_3.3;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;literature review;relevant information;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;NTS_3.1
20173828_01;20173828;Onderzoek naar de capaciteit van vezelversterkt calciumfosfaat cementen om zwaarbelaste botdefecten te genezen;Translational or applied research;human;Assessment of the performance of bone substitutes under load-bearing conditions;ENG;rabbit;NTS_3.3;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;literature review;relevant information;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;NTS_3.1
20173828_01;20173828;Onderzoek naar de capaciteit van vezelversterkt calciumfosfaat cementen om zwaarbelaste botdefecten te genezen;Translational or applied research;human;Assessment of the performance of bone substitutes under load-bearing conditions;ENG;rabbit;NTS_3.3;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;NTS_3.1
20173828_01;20173828;Onderzoek naar de capaciteit van vezelversterkt calciumfosfaat cementen om zwaarbelaste botdefecten te genezen;Translational or applied research;human;Assessment of the performance of bone substitutes under load-bearing conditions;ENG;rabbit;NTS_3.3;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;NTS_3.1
20173828_01;20173828;Onderzoek naar de capaciteit van vezelversterkt calciumfosfaat cementen om zwaarbelaste botdefecten te genezen;Translational or applied research;human;Assessment of the performance of bone substitutes under load-bearing conditions;ENG;rabbit;NTS_3.3;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;NTS_3.1
20173828_01;20173828;Onderzoek naar de capaciteit van vezelversterkt calciumfosfaat cementen om zwaarbelaste botdefecten te genezen;Translational or applied research;human;Assessment of the performance of bone substitutes under load-bearing conditions;ENG;rabbit;NTS_3.3;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;substantiated statistics;statistical power calculation;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;NTS_3.1
20173828_01;20173828;Onderzoek naar de capaciteit van vezelversterkt calciumfosfaat cementen om zwaarbelaste botdefecten te genezen;Translational or applied research;human;Assessment of the performance of bone substitutes under load-bearing conditions;ENG;rabbit;NTS_3.3;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;literature review;relevant information;APX_2D;accomodation and care;cage enrichment;APX_2D;bone replacement;medical device;NTS_3.1
20173828_01;20173828;Onderzoek naar de capaciteit van vezelversterkt calciumfosfaat cementen om zwaarbelaste botdefecten te genezen;Translational or applied research;human;Assessment of the performance of bone substitutes under load-bearing conditions;ENG;rabbit;NTS_3.3;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;literature review;relevant information;APX_2D;accomodation and care;cage enrichment;APX_2D;bone replacement;medical device;NTS_3.1
20173828_01;20173828;Onderzoek naar de capaciteit van vezelversterkt calciumfosfaat cementen om zwaarbelaste botdefecten te genezen;Translational or applied research;human;Assessment of the performance of bone substitutes under load-bearing conditions;ENG;rabbit;NTS_3.3;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;accomodation and care;cage enrichment;APX_2D;bone replacement;medical device;NTS_3.1
20173828_01;20173828;Onderzoek naar de capaciteit van vezelversterkt calciumfosfaat cementen om zwaarbelaste botdefecten te genezen;Translational or applied research;human;Assessment of the performance of bone substitutes under load-bearing conditions;ENG;rabbit;NTS_3.3;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;accomodation and care;cage enrichment;APX_2D;bone replacement;medical device;NTS_3.1
20173828_01;20173828;Onderzoek naar de capaciteit van vezelversterkt calciumfosfaat cementen om zwaarbelaste botdefecten te genezen;Translational or applied research;human;Assessment of the performance of bone substitutes under load-bearing conditions;ENG;rabbit;NTS_3.3;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;accomodation and care;cage enrichment;APX_2D;bone replacement;medical device;NTS_3.1
20173828_01;20173828;Onderzoek naar de capaciteit van vezelversterkt calciumfosfaat cementen om zwaarbelaste botdefecten te genezen;Translational or applied research;human;Assessment of the performance of bone substitutes under load-bearing conditions;ENG;rabbit;NTS_3.3;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;similar anatomy or organ system;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;substantiated statistics;statistical power calculation;APX_2D;accomodation and care;cage enrichment;APX_2D;bone replacement;medical device;NTS_3.1
20173828_01;20173828;Onderzoek naar de capaciteit van vezelversterkt calciumfosfaat cementen om zwaarbelaste botdefecten te genezen;Translational or applied research;human;Assessment of the performance of bone substitutes under load-bearing conditions;ENG;rabbit;NTS_3.3;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;literature review;relevant information;APX_2D;methods used in procedures;lowest possible species;APX_2D;bone replacement;medical device;NTS_3.1
20173828_01;20173828;Onderzoek naar de capaciteit van vezelversterkt calciumfosfaat cementen om zwaarbelaste botdefecten te genezen;Translational or applied research;human;Assessment of the performance of bone substitutes under load-bearing conditions;ENG;rabbit;NTS_3.3;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;literature review;relevant information;APX_2D;methods used in procedures;lowest possible species;APX_2D;bone replacement;medical device;NTS_3.1
20173828_01;20173828;Onderzoek naar de capaciteit van vezelversterkt calciumfosfaat cementen om zwaarbelaste botdefecten te genezen;Translational or applied research;human;Assessment of the performance of bone substitutes under load-bearing conditions;ENG;rabbit;NTS_3.3;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;lowest possible species;APX_2D;bone replacement;medical device;NTS_3.1
20173828_01;20173828;Onderzoek naar de capaciteit van vezelversterkt calciumfosfaat cementen om zwaarbelaste botdefecten te genezen;Translational or applied research;human;Assessment of the performance of bone substitutes under load-bearing conditions;ENG;rabbit;NTS_3.3;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;lowest possible species;APX_2D;bone replacement;medical device;NTS_3.1
20173828_01;20173828;Onderzoek naar de capaciteit van vezelversterkt calciumfosfaat cementen om zwaarbelaste botdefecten te genezen;Translational or applied research;human;Assessment of the performance of bone substitutes under load-bearing conditions;ENG;rabbit;NTS_3.3;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;methods used in procedures;lowest possible species;APX_2D;bone replacement;medical device;NTS_3.1
20173828_01;20173828;Onderzoek naar de capaciteit van vezelversterkt calciumfosfaat cementen om zwaarbelaste botdefecten te genezen;Translational or applied research;human;Assessment of the performance of bone substitutes under load-bearing conditions;ENG;rabbit;NTS_3.3;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;substantiated statistics;statistical power calculation;APX_2D;methods used in procedures;lowest possible species;APX_2D;bone replacement;medical device;NTS_3.1
20173828_01;20173828;Onderzoek naar de capaciteit van vezelversterkt calciumfosfaat cementen om zwaarbelaste botdefecten te genezen;Translational or applied research;human;Assessment of the performance of bone substitutes under load-bearing conditions;ENG;rabbit;NTS_3.3;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;literature review;relevant information;APX_2D;reduction of discomfort;equipment;APX_2D;bone replacement;medical device;NTS_3.1
20173828_01;20173828;Onderzoek naar de capaciteit van vezelversterkt calciumfosfaat cementen om zwaarbelaste botdefecten te genezen;Translational or applied research;human;Assessment of the performance of bone substitutes under load-bearing conditions;ENG;rabbit;NTS_3.3;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;literature review;relevant information;APX_2D;reduction of discomfort;equipment;APX_2D;bone replacement;medical device;NTS_3.1
20173828_01;20173828;Onderzoek naar de capaciteit van vezelversterkt calciumfosfaat cementen om zwaarbelaste botdefecten te genezen;Translational or applied research;human;Assessment of the performance of bone substitutes under load-bearing conditions;ENG;rabbit;NTS_3.3;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;equipment;APX_2D;bone replacement;medical device;NTS_3.1
20173828_01;20173828;Onderzoek naar de capaciteit van vezelversterkt calciumfosfaat cementen om zwaarbelaste botdefecten te genezen;Translational or applied research;human;Assessment of the performance of bone substitutes under load-bearing conditions;ENG;rabbit;NTS_3.3;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;equipment;APX_2D;bone replacement;medical device;NTS_3.1
20173828_01;20173828;Onderzoek naar de capaciteit van vezelversterkt calciumfosfaat cementen om zwaarbelaste botdefecten te genezen;Translational or applied research;human;Assessment of the performance of bone substitutes under load-bearing conditions;ENG;rabbit;NTS_3.3;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;equipment;APX_2D;bone replacement;medical device;NTS_3.1
20173828_01;20173828;Onderzoek naar de capaciteit van vezelversterkt calciumfosfaat cementen om zwaarbelaste botdefecten te genezen;Translational or applied research;human;Assessment of the performance of bone substitutes under load-bearing conditions;ENG;rabbit;NTS_3.3;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;equipment;APX_2D;bone replacement;medical device;NTS_3.1
20173828_01;20173828;Onderzoek naar de capaciteit van vezelversterkt calciumfosfaat cementen om zwaarbelaste botdefecten te genezen;Translational or applied research;human;Assessment of the performance of bone substitutes under load-bearing conditions;ENG;rabbit;NTS_3.3;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;literature review;relevant information;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;NTS_3.1
20173828_01;20173828;Onderzoek naar de capaciteit van vezelversterkt calciumfosfaat cementen om zwaarbelaste botdefecten te genezen;Translational or applied research;human;Assessment of the performance of bone substitutes under load-bearing conditions;ENG;rabbit;NTS_3.3;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;literature review;relevant information;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;NTS_3.1
20173828_01;20173828;Onderzoek naar de capaciteit van vezelversterkt calciumfosfaat cementen om zwaarbelaste botdefecten te genezen;Translational or applied research;human;Assessment of the performance of bone substitutes under load-bearing conditions;ENG;rabbit;NTS_3.3;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;NTS_3.1
20173828_01;20173828;Onderzoek naar de capaciteit van vezelversterkt calciumfosfaat cementen om zwaarbelaste botdefecten te genezen;Translational or applied research;human;Assessment of the performance of bone substitutes under load-bearing conditions;ENG;rabbit;NTS_3.3;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;NTS_3.1
20173828_01;20173828;Onderzoek naar de capaciteit van vezelversterkt calciumfosfaat cementen om zwaarbelaste botdefecten te genezen;Translational or applied research;human;Assessment of the performance of bone substitutes under load-bearing conditions;ENG;rabbit;NTS_3.3;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;NTS_3.1
20173828_01;20173828;Onderzoek naar de capaciteit van vezelversterkt calciumfosfaat cementen om zwaarbelaste botdefecten te genezen;Translational or applied research;human;Assessment of the performance of bone substitutes under load-bearing conditions;ENG;rabbit;NTS_3.3;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;substantiated statistics;statistical power calculation;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;NTS_3.1
20173828_01;20173828;Onderzoek naar de capaciteit van vezelversterkt calciumfosfaat cementen om zwaarbelaste botdefecten te genezen;Translational or applied research;human;Assessment of the performance of bone substitutes under load-bearing conditions;ENG;rabbit;NTS_3.3;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;literature review;relevant information;APX_2D;accomodation and care;cage enrichment;APX_2D;bone replacement;medical device;NTS_3.1
20173828_01;20173828;Onderzoek naar de capaciteit van vezelversterkt calciumfosfaat cementen om zwaarbelaste botdefecten te genezen;Translational or applied research;human;Assessment of the performance of bone substitutes under load-bearing conditions;ENG;rabbit;NTS_3.3;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;literature review;relevant information;APX_2D;accomodation and care;cage enrichment;APX_2D;bone replacement;medical device;NTS_3.1
20173828_01;20173828;Onderzoek naar de capaciteit van vezelversterkt calciumfosfaat cementen om zwaarbelaste botdefecten te genezen;Translational or applied research;human;Assessment of the performance of bone substitutes under load-bearing conditions;ENG;rabbit;NTS_3.3;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;accomodation and care;cage enrichment;APX_2D;bone replacement;medical device;NTS_3.1
20173828_01;20173828;Onderzoek naar de capaciteit van vezelversterkt calciumfosfaat cementen om zwaarbelaste botdefecten te genezen;Translational or applied research;human;Assessment of the performance of bone substitutes under load-bearing conditions;ENG;rabbit;NTS_3.3;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;accomodation and care;cage enrichment;APX_2D;bone replacement;medical device;NTS_3.1
20173828_01;20173828;Onderzoek naar de capaciteit van vezelversterkt calciumfosfaat cementen om zwaarbelaste botdefecten te genezen;Translational or applied research;human;Assessment of the performance of bone substitutes under load-bearing conditions;ENG;rabbit;NTS_3.3;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;accomodation and care;cage enrichment;APX_2D;bone replacement;medical device;NTS_3.1
20173828_01;20173828;Onderzoek naar de capaciteit van vezelversterkt calciumfosfaat cementen om zwaarbelaste botdefecten te genezen;Translational or applied research;human;Assessment of the performance of bone substitutes under load-bearing conditions;ENG;rabbit;NTS_3.3;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;substantiated statistics;statistical power calculation;APX_2D;accomodation and care;cage enrichment;APX_2D;bone replacement;medical device;NTS_3.1
20173828_01;20173828;Onderzoek naar de capaciteit van vezelversterkt calciumfosfaat cementen om zwaarbelaste botdefecten te genezen;Translational or applied research;human;Assessment of the performance of bone substitutes under load-bearing conditions;ENG;rabbit;NTS_3.3;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;availability of research tools;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;literature review;relevant information;APX_2D;methods used in procedures;lowest possible species;APX_2D;bone replacement;medical device;NTS_3.1
20173828_01;20173828;Onderzoek naar de capaciteit van vezelversterkt calciumfosfaat cementen om zwaarbelaste botdefecten te genezen;Translational or applied research;human;Assessment of the performance of bone substitutes under load-bearing conditions;ENG;rabbit;NTS_3.3;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;literature review;relevant information;APX_2D;methods used in procedures;lowest possible species;APX_2D;bone replacement;medical device;NTS_3.1
20173828_01;20173828;Onderzoek naar de capaciteit van vezelversterkt calciumfosfaat cementen om zwaarbelaste botdefecten te genezen;Translational or applied research;human;Assessment of the performance of bone substitutes under load-bearing conditions;ENG;rabbit;NTS_3.3;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;availability of research tools;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;lowest possible species;APX_2D;bone replacement;medical device;NTS_3.1
20173828_01;20173828;Onderzoek naar de capaciteit van vezelversterkt calciumfosfaat cementen om zwaarbelaste botdefecten te genezen;Translational or applied research;human;Assessment of the performance of bone substitutes under load-bearing conditions;ENG;rabbit;NTS_3.3;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;lowest possible species;APX_2D;bone replacement;medical device;NTS_3.1
20173828_01;20173828;Onderzoek naar de capaciteit van vezelversterkt calciumfosfaat cementen om zwaarbelaste botdefecten te genezen;Translational or applied research;human;Assessment of the performance of bone substitutes under load-bearing conditions;ENG;rabbit;NTS_3.3;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;availability of research tools;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;methods used in procedures;lowest possible species;APX_2D;bone replacement;medical device;NTS_3.1
20173828_01;20173828;Onderzoek naar de capaciteit van vezelversterkt calciumfosfaat cementen om zwaarbelaste botdefecten te genezen;Translational or applied research;human;Assessment of the performance of bone substitutes under load-bearing conditions;ENG;rabbit;NTS_3.3;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;substantiated statistics;statistical power calculation;APX_2D;methods used in procedures;lowest possible species;APX_2D;bone replacement;medical device;NTS_3.1
20173828_01;20173828;Onderzoek naar de capaciteit van vezelversterkt calciumfosfaat cementen om zwaarbelaste botdefecten te genezen;Translational or applied research;human;Assessment of the performance of bone substitutes under load-bearing conditions;ENG;rabbit;NTS_3.3;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;availability of research tools;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;literature review;relevant information;APX_2D;reduction of discomfort;equipment;APX_2D;bone replacement;medical device;NTS_3.1
20173828_01;20173828;Onderzoek naar de capaciteit van vezelversterkt calciumfosfaat cementen om zwaarbelaste botdefecten te genezen;Translational or applied research;human;Assessment of the performance of bone substitutes under load-bearing conditions;ENG;rabbit;NTS_3.3;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;literature review;relevant information;APX_2D;reduction of discomfort;equipment;APX_2D;bone replacement;medical device;NTS_3.1
20173828_01;20173828;Onderzoek naar de capaciteit van vezelversterkt calciumfosfaat cementen om zwaarbelaste botdefecten te genezen;Translational or applied research;human;Assessment of the performance of bone substitutes under load-bearing conditions;ENG;rabbit;NTS_3.3;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;availability of research tools;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;equipment;APX_2D;bone replacement;medical device;NTS_3.1
20173828_01;20173828;Onderzoek naar de capaciteit van vezelversterkt calciumfosfaat cementen om zwaarbelaste botdefecten te genezen;Translational or applied research;human;Assessment of the performance of bone substitutes under load-bearing conditions;ENG;rabbit;NTS_3.3;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;equipment;APX_2D;bone replacement;medical device;NTS_3.1
20173828_01;20173828;Onderzoek naar de capaciteit van vezelversterkt calciumfosfaat cementen om zwaarbelaste botdefecten te genezen;Translational or applied research;human;Assessment of the performance of bone substitutes under load-bearing conditions;ENG;rabbit;NTS_3.3;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;availability of research tools;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;equipment;APX_2D;bone replacement;medical device;NTS_3.1
20173828_01;20173828;Onderzoek naar de capaciteit van vezelversterkt calciumfosfaat cementen om zwaarbelaste botdefecten te genezen;Translational or applied research;human;Assessment of the performance of bone substitutes under load-bearing conditions;ENG;rabbit;NTS_3.3;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;equipment;APX_2D;bone replacement;medical device;NTS_3.1
20173828_01;20173828;Onderzoek naar de capaciteit van vezelversterkt calciumfosfaat cementen om zwaarbelaste botdefecten te genezen;Translational or applied research;human;Assessment of the performance of bone substitutes under load-bearing conditions;ENG;rabbit;NTS_3.3;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;availability of research tools;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;literature review;relevant information;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;NTS_3.1
20173828_01;20173828;Onderzoek naar de capaciteit van vezelversterkt calciumfosfaat cementen om zwaarbelaste botdefecten te genezen;Translational or applied research;human;Assessment of the performance of bone substitutes under load-bearing conditions;ENG;rabbit;NTS_3.3;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;literature review;relevant information;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;NTS_3.1
20173828_01;20173828;Onderzoek naar de capaciteit van vezelversterkt calciumfosfaat cementen om zwaarbelaste botdefecten te genezen;Translational or applied research;human;Assessment of the performance of bone substitutes under load-bearing conditions;ENG;rabbit;NTS_3.3;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;availability of research tools;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;NTS_3.1
20173828_01;20173828;Onderzoek naar de capaciteit van vezelversterkt calciumfosfaat cementen om zwaarbelaste botdefecten te genezen;Translational or applied research;human;Assessment of the performance of bone substitutes under load-bearing conditions;ENG;rabbit;NTS_3.3;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;NTS_3.1
20173828_01;20173828;Onderzoek naar de capaciteit van vezelversterkt calciumfosfaat cementen om zwaarbelaste botdefecten te genezen;Translational or applied research;human;Assessment of the performance of bone substitutes under load-bearing conditions;ENG;rabbit;NTS_3.3;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;availability of research tools;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;NTS_3.1
20173828_01;20173828;Onderzoek naar de capaciteit van vezelversterkt calciumfosfaat cementen om zwaarbelaste botdefecten te genezen;Translational or applied research;human;Assessment of the performance of bone substitutes under load-bearing conditions;ENG;rabbit;NTS_3.3;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;substantiated statistics;statistical power calculation;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;NTS_3.1
20173828_01;20173828;Onderzoek naar de capaciteit van vezelversterkt calciumfosfaat cementen om zwaarbelaste botdefecten te genezen;Translational or applied research;human;Assessment of the performance of bone substitutes under load-bearing conditions;ENG;rabbit;NTS_3.3;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;availability of research tools;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;literature review;relevant information;APX_2D;accomodation and care;cage enrichment;APX_2D;bone replacement;medical device;NTS_3.1
20173828_01;20173828;Onderzoek naar de capaciteit van vezelversterkt calciumfosfaat cementen om zwaarbelaste botdefecten te genezen;Translational or applied research;human;Assessment of the performance of bone substitutes under load-bearing conditions;ENG;rabbit;NTS_3.3;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;literature review;relevant information;APX_2D;accomodation and care;cage enrichment;APX_2D;bone replacement;medical device;NTS_3.1
20173828_01;20173828;Onderzoek naar de capaciteit van vezelversterkt calciumfosfaat cementen om zwaarbelaste botdefecten te genezen;Translational or applied research;human;Assessment of the performance of bone substitutes under load-bearing conditions;ENG;rabbit;NTS_3.3;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;availability of research tools;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;accomodation and care;cage enrichment;APX_2D;bone replacement;medical device;NTS_3.1
20173828_01;20173828;Onderzoek naar de capaciteit van vezelversterkt calciumfosfaat cementen om zwaarbelaste botdefecten te genezen;Translational or applied research;human;Assessment of the performance of bone substitutes under load-bearing conditions;ENG;rabbit;NTS_3.3;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;accomodation and care;cage enrichment;APX_2D;bone replacement;medical device;NTS_3.1
20173828_01;20173828;Onderzoek naar de capaciteit van vezelversterkt calciumfosfaat cementen om zwaarbelaste botdefecten te genezen;Translational or applied research;human;Assessment of the performance of bone substitutes under load-bearing conditions;ENG;rabbit;NTS_3.3;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;availability of research tools;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;accomodation and care;cage enrichment;APX_2D;bone replacement;medical device;NTS_3.1
20173828_01;20173828;Onderzoek naar de capaciteit van vezelversterkt calciumfosfaat cementen om zwaarbelaste botdefecten te genezen;Translational or applied research;human;Assessment of the performance of bone substitutes under load-bearing conditions;ENG;rabbit;NTS_3.3;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;substantiated statistics;statistical power calculation;APX_2D;accomodation and care;cage enrichment;APX_2D;bone replacement;medical device;NTS_3.1
20173828_02;20173828;Onderzoek naar de capaciteit van vezelversterkt calciumfosfaat cementen om zwaarbelaste botdefecten te genezen;Translational or applied research;human;Evaluation of implant stability upon embedding in a bone substitute;ENG;rabbit;NTS_3.3;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;literature review;relevant information;APX_2D;methods used in procedures;lowest possible species;APX_2D;bone replacement;medical device;NTS_3.1
20173828_02;20173828;Onderzoek naar de capaciteit van vezelversterkt calciumfosfaat cementen om zwaarbelaste botdefecten te genezen;Translational or applied research;human;Evaluation of implant stability upon embedding in a bone substitute;ENG;rabbit;NTS_3.3;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;lowest possible species;APX_2D;bone replacement;medical device;NTS_3.1
20173828_02;20173828;Onderzoek naar de capaciteit van vezelversterkt calciumfosfaat cementen om zwaarbelaste botdefecten te genezen;Translational or applied research;human;Evaluation of implant stability upon embedding in a bone substitute;ENG;rabbit;NTS_3.3;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;methods used in procedures;lowest possible species;APX_2D;bone replacement;medical device;NTS_3.1
20173828_02;20173828;Onderzoek naar de capaciteit van vezelversterkt calciumfosfaat cementen om zwaarbelaste botdefecten te genezen;Translational or applied research;human;Evaluation of implant stability upon embedding in a bone substitute;ENG;rabbit;NTS_3.3;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;literature review;relevant information;APX_2D;methods used in procedures;lowest possible species;APX_2D;bone replacement;medical device;NTS_3.1
20173828_02;20173828;Onderzoek naar de capaciteit van vezelversterkt calciumfosfaat cementen om zwaarbelaste botdefecten te genezen;Translational or applied research;human;Evaluation of implant stability upon embedding in a bone substitute;ENG;rabbit;NTS_3.3;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;lowest possible species;APX_2D;bone replacement;medical device;NTS_3.1
20173828_02;20173828;Onderzoek naar de capaciteit van vezelversterkt calciumfosfaat cementen om zwaarbelaste botdefecten te genezen;Translational or applied research;human;Evaluation of implant stability upon embedding in a bone substitute;ENG;rabbit;NTS_3.3;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;substantiated statistics;statistical power calculation;APX_2D;methods used in procedures;lowest possible species;APX_2D;bone replacement;medical device;NTS_3.1
20173828_02;20173828;Onderzoek naar de capaciteit van vezelversterkt calciumfosfaat cementen om zwaarbelaste botdefecten te genezen;Translational or applied research;human;Evaluation of implant stability upon embedding in a bone substitute;ENG;rabbit;NTS_3.3;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;literature review;relevant information;APX_2D;reduction of discomfort;equipment;APX_2D;bone replacement;medical device;NTS_3.1
20173828_02;20173828;Onderzoek naar de capaciteit van vezelversterkt calciumfosfaat cementen om zwaarbelaste botdefecten te genezen;Translational or applied research;human;Evaluation of implant stability upon embedding in a bone substitute;ENG;rabbit;NTS_3.3;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;equipment;APX_2D;bone replacement;medical device;NTS_3.1
20173828_02;20173828;Onderzoek naar de capaciteit van vezelversterkt calciumfosfaat cementen om zwaarbelaste botdefecten te genezen;Translational or applied research;human;Evaluation of implant stability upon embedding in a bone substitute;ENG;rabbit;NTS_3.3;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;equipment;APX_2D;bone replacement;medical device;NTS_3.1
20173828_02;20173828;Onderzoek naar de capaciteit van vezelversterkt calciumfosfaat cementen om zwaarbelaste botdefecten te genezen;Translational or applied research;human;Evaluation of implant stability upon embedding in a bone substitute;ENG;rabbit;NTS_3.3;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;literature review;relevant information;APX_2D;reduction of discomfort;equipment;APX_2D;bone replacement;medical device;NTS_3.1
20173828_02;20173828;Onderzoek naar de capaciteit van vezelversterkt calciumfosfaat cementen om zwaarbelaste botdefecten te genezen;Translational or applied research;human;Evaluation of implant stability upon embedding in a bone substitute;ENG;rabbit;NTS_3.3;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;equipment;APX_2D;bone replacement;medical device;NTS_3.1
20173828_02;20173828;Onderzoek naar de capaciteit van vezelversterkt calciumfosfaat cementen om zwaarbelaste botdefecten te genezen;Translational or applied research;human;Evaluation of implant stability upon embedding in a bone substitute;ENG;rabbit;NTS_3.3;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;equipment;APX_2D;bone replacement;medical device;NTS_3.1
20173828_02;20173828;Onderzoek naar de capaciteit van vezelversterkt calciumfosfaat cementen om zwaarbelaste botdefecten te genezen;Translational or applied research;human;Evaluation of implant stability upon embedding in a bone substitute;ENG;rabbit;NTS_3.3;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;literature review;relevant information;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;NTS_3.1
20173828_02;20173828;Onderzoek naar de capaciteit van vezelversterkt calciumfosfaat cementen om zwaarbelaste botdefecten te genezen;Translational or applied research;human;Evaluation of implant stability upon embedding in a bone substitute;ENG;rabbit;NTS_3.3;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;NTS_3.1
20173828_02;20173828;Onderzoek naar de capaciteit van vezelversterkt calciumfosfaat cementen om zwaarbelaste botdefecten te genezen;Translational or applied research;human;Evaluation of implant stability upon embedding in a bone substitute;ENG;rabbit;NTS_3.3;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;NTS_3.1
20173828_02;20173828;Onderzoek naar de capaciteit van vezelversterkt calciumfosfaat cementen om zwaarbelaste botdefecten te genezen;Translational or applied research;human;Evaluation of implant stability upon embedding in a bone substitute;ENG;rabbit;NTS_3.3;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;literature review;relevant information;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;NTS_3.1
20173828_02;20173828;Onderzoek naar de capaciteit van vezelversterkt calciumfosfaat cementen om zwaarbelaste botdefecten te genezen;Translational or applied research;human;Evaluation of implant stability upon embedding in a bone substitute;ENG;rabbit;NTS_3.3;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;NTS_3.1
20173828_02;20173828;Onderzoek naar de capaciteit van vezelversterkt calciumfosfaat cementen om zwaarbelaste botdefecten te genezen;Translational or applied research;human;Evaluation of implant stability upon embedding in a bone substitute;ENG;rabbit;NTS_3.3;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;substantiated statistics;statistical power calculation;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;NTS_3.1
20173828_02;20173828;Onderzoek naar de capaciteit van vezelversterkt calciumfosfaat cementen om zwaarbelaste botdefecten te genezen;Translational or applied research;human;Evaluation of implant stability upon embedding in a bone substitute;ENG;rabbit;NTS_3.3;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;literature review;relevant information;APX_2D;accomodation and care;cage enrichment;APX_2D;bone replacement;medical device;NTS_3.1
20173828_02;20173828;Onderzoek naar de capaciteit van vezelversterkt calciumfosfaat cementen om zwaarbelaste botdefecten te genezen;Translational or applied research;human;Evaluation of implant stability upon embedding in a bone substitute;ENG;rabbit;NTS_3.3;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;accomodation and care;cage enrichment;APX_2D;bone replacement;medical device;NTS_3.1
20173828_02;20173828;Onderzoek naar de capaciteit van vezelversterkt calciumfosfaat cementen om zwaarbelaste botdefecten te genezen;Translational or applied research;human;Evaluation of implant stability upon embedding in a bone substitute;ENG;rabbit;NTS_3.3;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;accomodation and care;cage enrichment;APX_2D;bone replacement;medical device;NTS_3.1
20173828_02;20173828;Onderzoek naar de capaciteit van vezelversterkt calciumfosfaat cementen om zwaarbelaste botdefecten te genezen;Translational or applied research;human;Evaluation of implant stability upon embedding in a bone substitute;ENG;rabbit;NTS_3.3;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;literature review;relevant information;APX_2D;accomodation and care;cage enrichment;APX_2D;bone replacement;medical device;NTS_3.1
20173828_02;20173828;Onderzoek naar de capaciteit van vezelversterkt calciumfosfaat cementen om zwaarbelaste botdefecten te genezen;Translational or applied research;human;Evaluation of implant stability upon embedding in a bone substitute;ENG;rabbit;NTS_3.3;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;accomodation and care;cage enrichment;APX_2D;bone replacement;medical device;NTS_3.1
20173828_02;20173828;Onderzoek naar de capaciteit van vezelversterkt calciumfosfaat cementen om zwaarbelaste botdefecten te genezen;Translational or applied research;human;Evaluation of implant stability upon embedding in a bone substitute;ENG;rabbit;NTS_3.3;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;substantiated statistics;statistical power calculation;APX_2D;accomodation and care;cage enrichment;APX_2D;bone replacement;medical device;NTS_3.1
20173828_02;20173828;Onderzoek naar de capaciteit van vezelversterkt calciumfosfaat cementen om zwaarbelaste botdefecten te genezen;Translational or applied research;human;Evaluation of implant stability upon embedding in a bone substitute;ENG;rabbit;NTS_3.3;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;availability of research tools;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;literature review;relevant information;APX_2D;methods used in procedures;lowest possible species;APX_2D;bone replacement;medical device;NTS_3.1
20173828_02;20173828;Onderzoek naar de capaciteit van vezelversterkt calciumfosfaat cementen om zwaarbelaste botdefecten te genezen;Translational or applied research;human;Evaluation of implant stability upon embedding in a bone substitute;ENG;rabbit;NTS_3.3;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;availability of research tools;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;lowest possible species;APX_2D;bone replacement;medical device;NTS_3.1
20173828_02;20173828;Onderzoek naar de capaciteit van vezelversterkt calciumfosfaat cementen om zwaarbelaste botdefecten te genezen;Translational or applied research;human;Evaluation of implant stability upon embedding in a bone substitute;ENG;rabbit;NTS_3.3;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;availability of research tools;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;methods used in procedures;lowest possible species;APX_2D;bone replacement;medical device;NTS_3.1
20173828_02;20173828;Onderzoek naar de capaciteit van vezelversterkt calciumfosfaat cementen om zwaarbelaste botdefecten te genezen;Translational or applied research;human;Evaluation of implant stability upon embedding in a bone substitute;ENG;rabbit;NTS_3.3;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;literature review;relevant information;APX_2D;methods used in procedures;lowest possible species;APX_2D;bone replacement;medical device;NTS_3.1
20173828_02;20173828;Onderzoek naar de capaciteit van vezelversterkt calciumfosfaat cementen om zwaarbelaste botdefecten te genezen;Translational or applied research;human;Evaluation of implant stability upon embedding in a bone substitute;ENG;rabbit;NTS_3.3;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;lowest possible species;APX_2D;bone replacement;medical device;NTS_3.1
20173828_02;20173828;Onderzoek naar de capaciteit van vezelversterkt calciumfosfaat cementen om zwaarbelaste botdefecten te genezen;Translational or applied research;human;Evaluation of implant stability upon embedding in a bone substitute;ENG;rabbit;NTS_3.3;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;substantiated statistics;statistical power calculation;APX_2D;methods used in procedures;lowest possible species;APX_2D;bone replacement;medical device;NTS_3.1
20173828_02;20173828;Onderzoek naar de capaciteit van vezelversterkt calciumfosfaat cementen om zwaarbelaste botdefecten te genezen;Translational or applied research;human;Evaluation of implant stability upon embedding in a bone substitute;ENG;rabbit;NTS_3.3;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;availability of research tools;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;literature review;relevant information;APX_2D;reduction of discomfort;equipment;APX_2D;bone replacement;medical device;NTS_3.1
20173828_02;20173828;Onderzoek naar de capaciteit van vezelversterkt calciumfosfaat cementen om zwaarbelaste botdefecten te genezen;Translational or applied research;human;Evaluation of implant stability upon embedding in a bone substitute;ENG;rabbit;NTS_3.3;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;availability of research tools;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;equipment;APX_2D;bone replacement;medical device;NTS_3.1
20173828_02;20173828;Onderzoek naar de capaciteit van vezelversterkt calciumfosfaat cementen om zwaarbelaste botdefecten te genezen;Translational or applied research;human;Evaluation of implant stability upon embedding in a bone substitute;ENG;rabbit;NTS_3.3;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;availability of research tools;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;equipment;APX_2D;bone replacement;medical device;NTS_3.1
20173828_02;20173828;Onderzoek naar de capaciteit van vezelversterkt calciumfosfaat cementen om zwaarbelaste botdefecten te genezen;Translational or applied research;human;Evaluation of implant stability upon embedding in a bone substitute;ENG;rabbit;NTS_3.3;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;literature review;relevant information;APX_2D;reduction of discomfort;equipment;APX_2D;bone replacement;medical device;NTS_3.1
20173828_02;20173828;Onderzoek naar de capaciteit van vezelversterkt calciumfosfaat cementen om zwaarbelaste botdefecten te genezen;Translational or applied research;human;Evaluation of implant stability upon embedding in a bone substitute;ENG;rabbit;NTS_3.3;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;equipment;APX_2D;bone replacement;medical device;NTS_3.1
20173828_02;20173828;Onderzoek naar de capaciteit van vezelversterkt calciumfosfaat cementen om zwaarbelaste botdefecten te genezen;Translational or applied research;human;Evaluation of implant stability upon embedding in a bone substitute;ENG;rabbit;NTS_3.3;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;equipment;APX_2D;bone replacement;medical device;NTS_3.1
20173828_02;20173828;Onderzoek naar de capaciteit van vezelversterkt calciumfosfaat cementen om zwaarbelaste botdefecten te genezen;Translational or applied research;human;Evaluation of implant stability upon embedding in a bone substitute;ENG;rabbit;NTS_3.3;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;availability of research tools;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;literature review;relevant information;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;NTS_3.1
20173828_02;20173828;Onderzoek naar de capaciteit van vezelversterkt calciumfosfaat cementen om zwaarbelaste botdefecten te genezen;Translational or applied research;human;Evaluation of implant stability upon embedding in a bone substitute;ENG;rabbit;NTS_3.3;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;availability of research tools;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;NTS_3.1
20173828_02;20173828;Onderzoek naar de capaciteit van vezelversterkt calciumfosfaat cementen om zwaarbelaste botdefecten te genezen;Translational or applied research;human;Evaluation of implant stability upon embedding in a bone substitute;ENG;rabbit;NTS_3.3;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;availability of research tools;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;NTS_3.1
20173828_02;20173828;Onderzoek naar de capaciteit van vezelversterkt calciumfosfaat cementen om zwaarbelaste botdefecten te genezen;Translational or applied research;human;Evaluation of implant stability upon embedding in a bone substitute;ENG;rabbit;NTS_3.3;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;literature review;relevant information;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;NTS_3.1
20173828_02;20173828;Onderzoek naar de capaciteit van vezelversterkt calciumfosfaat cementen om zwaarbelaste botdefecten te genezen;Translational or applied research;human;Evaluation of implant stability upon embedding in a bone substitute;ENG;rabbit;NTS_3.3;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;NTS_3.1
20173828_02;20173828;Onderzoek naar de capaciteit van vezelversterkt calciumfosfaat cementen om zwaarbelaste botdefecten te genezen;Translational or applied research;human;Evaluation of implant stability upon embedding in a bone substitute;ENG;rabbit;NTS_3.3;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;substantiated statistics;statistical power calculation;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;NTS_3.1
20173828_02;20173828;Onderzoek naar de capaciteit van vezelversterkt calciumfosfaat cementen om zwaarbelaste botdefecten te genezen;Translational or applied research;human;Evaluation of implant stability upon embedding in a bone substitute;ENG;rabbit;NTS_3.3;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;availability of research tools;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;literature review;relevant information;APX_2D;accomodation and care;cage enrichment;APX_2D;bone replacement;medical device;NTS_3.1
20173828_02;20173828;Onderzoek naar de capaciteit van vezelversterkt calciumfosfaat cementen om zwaarbelaste botdefecten te genezen;Translational or applied research;human;Evaluation of implant stability upon embedding in a bone substitute;ENG;rabbit;NTS_3.3;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;availability of research tools;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;accomodation and care;cage enrichment;APX_2D;bone replacement;medical device;NTS_3.1
20173828_02;20173828;Onderzoek naar de capaciteit van vezelversterkt calciumfosfaat cementen om zwaarbelaste botdefecten te genezen;Translational or applied research;human;Evaluation of implant stability upon embedding in a bone substitute;ENG;rabbit;NTS_3.3;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;availability of research tools;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;accomodation and care;cage enrichment;APX_2D;bone replacement;medical device;NTS_3.1
20173828_02;20173828;Onderzoek naar de capaciteit van vezelversterkt calciumfosfaat cementen om zwaarbelaste botdefecten te genezen;Translational or applied research;human;Evaluation of implant stability upon embedding in a bone substitute;ENG;rabbit;NTS_3.3;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;literature review;relevant information;APX_2D;accomodation and care;cage enrichment;APX_2D;bone replacement;medical device;NTS_3.1
20173828_02;20173828;Onderzoek naar de capaciteit van vezelversterkt calciumfosfaat cementen om zwaarbelaste botdefecten te genezen;Translational or applied research;human;Evaluation of implant stability upon embedding in a bone substitute;ENG;rabbit;NTS_3.3;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;accomodation and care;cage enrichment;APX_2D;bone replacement;medical device;NTS_3.1
20173828_02;20173828;Onderzoek naar de capaciteit van vezelversterkt calciumfosfaat cementen om zwaarbelaste botdefecten te genezen;Translational or applied research;human;Evaluation of implant stability upon embedding in a bone substitute;ENG;rabbit;NTS_3.3;Musculoskeletal disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;substantiated statistics;statistical power calculation;APX_2D;accomodation and care;cage enrichment;APX_2D;bone replacement;medical device;NTS_3.1
20173828_02;20173828;Onderzoek naar de capaciteit van vezelversterkt calciumfosfaat cementen om zwaarbelaste botdefecten te genezen;Translational or applied research;human;Evaluation of implant stability upon embedding in a bone substitute;ENG;rabbit;NTS_3.3;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;literature review;relevant information;APX_2D;methods used in procedures;lowest possible species;APX_2D;bone replacement;medical device;NTS_3.1
20173828_02;20173828;Onderzoek naar de capaciteit van vezelversterkt calciumfosfaat cementen om zwaarbelaste botdefecten te genezen;Translational or applied research;human;Evaluation of implant stability upon embedding in a bone substitute;ENG;rabbit;NTS_3.3;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;lowest possible species;APX_2D;bone replacement;medical device;NTS_3.1
20173828_02;20173828;Onderzoek naar de capaciteit van vezelversterkt calciumfosfaat cementen om zwaarbelaste botdefecten te genezen;Translational or applied research;human;Evaluation of implant stability upon embedding in a bone substitute;ENG;rabbit;NTS_3.3;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;methods used in procedures;lowest possible species;APX_2D;bone replacement;medical device;NTS_3.1
20173828_02;20173828;Onderzoek naar de capaciteit van vezelversterkt calciumfosfaat cementen om zwaarbelaste botdefecten te genezen;Translational or applied research;human;Evaluation of implant stability upon embedding in a bone substitute;ENG;rabbit;NTS_3.3;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;literature review;relevant information;APX_2D;methods used in procedures;lowest possible species;APX_2D;bone replacement;medical device;NTS_3.1
20173828_02;20173828;Onderzoek naar de capaciteit van vezelversterkt calciumfosfaat cementen om zwaarbelaste botdefecten te genezen;Translational or applied research;human;Evaluation of implant stability upon embedding in a bone substitute;ENG;rabbit;NTS_3.3;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;lowest possible species;APX_2D;bone replacement;medical device;NTS_3.1
20173828_02;20173828;Onderzoek naar de capaciteit van vezelversterkt calciumfosfaat cementen om zwaarbelaste botdefecten te genezen;Translational or applied research;human;Evaluation of implant stability upon embedding in a bone substitute;ENG;rabbit;NTS_3.3;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;substantiated statistics;statistical power calculation;APX_2D;methods used in procedures;lowest possible species;APX_2D;bone replacement;medical device;NTS_3.1
20173828_02;20173828;Onderzoek naar de capaciteit van vezelversterkt calciumfosfaat cementen om zwaarbelaste botdefecten te genezen;Translational or applied research;human;Evaluation of implant stability upon embedding in a bone substitute;ENG;rabbit;NTS_3.3;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;literature review;relevant information;APX_2D;reduction of discomfort;equipment;APX_2D;bone replacement;medical device;NTS_3.1
20173828_02;20173828;Onderzoek naar de capaciteit van vezelversterkt calciumfosfaat cementen om zwaarbelaste botdefecten te genezen;Translational or applied research;human;Evaluation of implant stability upon embedding in a bone substitute;ENG;rabbit;NTS_3.3;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;equipment;APX_2D;bone replacement;medical device;NTS_3.1
20173828_02;20173828;Onderzoek naar de capaciteit van vezelversterkt calciumfosfaat cementen om zwaarbelaste botdefecten te genezen;Translational or applied research;human;Evaluation of implant stability upon embedding in a bone substitute;ENG;rabbit;NTS_3.3;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;equipment;APX_2D;bone replacement;medical device;NTS_3.1
20173828_02;20173828;Onderzoek naar de capaciteit van vezelversterkt calciumfosfaat cementen om zwaarbelaste botdefecten te genezen;Translational or applied research;human;Evaluation of implant stability upon embedding in a bone substitute;ENG;rabbit;NTS_3.3;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;literature review;relevant information;APX_2D;reduction of discomfort;equipment;APX_2D;bone replacement;medical device;NTS_3.1
20173828_02;20173828;Onderzoek naar de capaciteit van vezelversterkt calciumfosfaat cementen om zwaarbelaste botdefecten te genezen;Translational or applied research;human;Evaluation of implant stability upon embedding in a bone substitute;ENG;rabbit;NTS_3.3;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;equipment;APX_2D;bone replacement;medical device;NTS_3.1
20173828_02;20173828;Onderzoek naar de capaciteit van vezelversterkt calciumfosfaat cementen om zwaarbelaste botdefecten te genezen;Translational or applied research;human;Evaluation of implant stability upon embedding in a bone substitute;ENG;rabbit;NTS_3.3;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;equipment;APX_2D;bone replacement;medical device;NTS_3.1
20173828_02;20173828;Onderzoek naar de capaciteit van vezelversterkt calciumfosfaat cementen om zwaarbelaste botdefecten te genezen;Translational or applied research;human;Evaluation of implant stability upon embedding in a bone substitute;ENG;rabbit;NTS_3.3;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;literature review;relevant information;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;NTS_3.1
20173828_02;20173828;Onderzoek naar de capaciteit van vezelversterkt calciumfosfaat cementen om zwaarbelaste botdefecten te genezen;Translational or applied research;human;Evaluation of implant stability upon embedding in a bone substitute;ENG;rabbit;NTS_3.3;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;NTS_3.1
20173828_02;20173828;Onderzoek naar de capaciteit van vezelversterkt calciumfosfaat cementen om zwaarbelaste botdefecten te genezen;Translational or applied research;human;Evaluation of implant stability upon embedding in a bone substitute;ENG;rabbit;NTS_3.3;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;NTS_3.1
20173828_02;20173828;Onderzoek naar de capaciteit van vezelversterkt calciumfosfaat cementen om zwaarbelaste botdefecten te genezen;Translational or applied research;human;Evaluation of implant stability upon embedding in a bone substitute;ENG;rabbit;NTS_3.3;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;literature review;relevant information;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;NTS_3.1
20173828_02;20173828;Onderzoek naar de capaciteit van vezelversterkt calciumfosfaat cementen om zwaarbelaste botdefecten te genezen;Translational or applied research;human;Evaluation of implant stability upon embedding in a bone substitute;ENG;rabbit;NTS_3.3;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;NTS_3.1
20173828_02;20173828;Onderzoek naar de capaciteit van vezelversterkt calciumfosfaat cementen om zwaarbelaste botdefecten te genezen;Translational or applied research;human;Evaluation of implant stability upon embedding in a bone substitute;ENG;rabbit;NTS_3.3;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;substantiated statistics;statistical power calculation;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;NTS_3.1
20173828_02;20173828;Onderzoek naar de capaciteit van vezelversterkt calciumfosfaat cementen om zwaarbelaste botdefecten te genezen;Translational or applied research;human;Evaluation of implant stability upon embedding in a bone substitute;ENG;rabbit;NTS_3.3;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;literature review;relevant information;APX_2D;accomodation and care;cage enrichment;APX_2D;bone replacement;medical device;NTS_3.1
20173828_02;20173828;Onderzoek naar de capaciteit van vezelversterkt calciumfosfaat cementen om zwaarbelaste botdefecten te genezen;Translational or applied research;human;Evaluation of implant stability upon embedding in a bone substitute;ENG;rabbit;NTS_3.3;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;accomodation and care;cage enrichment;APX_2D;bone replacement;medical device;NTS_3.1
20173828_02;20173828;Onderzoek naar de capaciteit van vezelversterkt calciumfosfaat cementen om zwaarbelaste botdefecten te genezen;Translational or applied research;human;Evaluation of implant stability upon embedding in a bone substitute;ENG;rabbit;NTS_3.3;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;accomodation and care;cage enrichment;APX_2D;bone replacement;medical device;NTS_3.1
20173828_02;20173828;Onderzoek naar de capaciteit van vezelversterkt calciumfosfaat cementen om zwaarbelaste botdefecten te genezen;Translational or applied research;human;Evaluation of implant stability upon embedding in a bone substitute;ENG;rabbit;NTS_3.3;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;literature review;relevant information;APX_2D;accomodation and care;cage enrichment;APX_2D;bone replacement;medical device;NTS_3.1
20173828_02;20173828;Onderzoek naar de capaciteit van vezelversterkt calciumfosfaat cementen om zwaarbelaste botdefecten te genezen;Translational or applied research;human;Evaluation of implant stability upon embedding in a bone substitute;ENG;rabbit;NTS_3.3;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;accomodation and care;cage enrichment;APX_2D;bone replacement;medical device;NTS_3.1
20173828_02;20173828;Onderzoek naar de capaciteit van vezelversterkt calciumfosfaat cementen om zwaarbelaste botdefecten te genezen;Translational or applied research;human;Evaluation of implant stability upon embedding in a bone substitute;ENG;rabbit;NTS_3.3;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;substantiated statistics;statistical power calculation;APX_2D;accomodation and care;cage enrichment;APX_2D;bone replacement;medical device;NTS_3.1
20173828_02;20173828;Onderzoek naar de capaciteit van vezelversterkt calciumfosfaat cementen om zwaarbelaste botdefecten te genezen;Translational or applied research;human;Evaluation of implant stability upon embedding in a bone substitute;ENG;rabbit;NTS_3.3;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;availability of research tools;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;literature review;relevant information;APX_2D;methods used in procedures;lowest possible species;APX_2D;bone replacement;medical device;NTS_3.1
20173828_02;20173828;Onderzoek naar de capaciteit van vezelversterkt calciumfosfaat cementen om zwaarbelaste botdefecten te genezen;Translational or applied research;human;Evaluation of implant stability upon embedding in a bone substitute;ENG;rabbit;NTS_3.3;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;availability of research tools;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;lowest possible species;APX_2D;bone replacement;medical device;NTS_3.1
20173828_02;20173828;Onderzoek naar de capaciteit van vezelversterkt calciumfosfaat cementen om zwaarbelaste botdefecten te genezen;Translational or applied research;human;Evaluation of implant stability upon embedding in a bone substitute;ENG;rabbit;NTS_3.3;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;availability of research tools;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;methods used in procedures;lowest possible species;APX_2D;bone replacement;medical device;NTS_3.1
20173828_02;20173828;Onderzoek naar de capaciteit van vezelversterkt calciumfosfaat cementen om zwaarbelaste botdefecten te genezen;Translational or applied research;human;Evaluation of implant stability upon embedding in a bone substitute;ENG;rabbit;NTS_3.3;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;literature review;relevant information;APX_2D;methods used in procedures;lowest possible species;APX_2D;bone replacement;medical device;NTS_3.1
20173828_02;20173828;Onderzoek naar de capaciteit van vezelversterkt calciumfosfaat cementen om zwaarbelaste botdefecten te genezen;Translational or applied research;human;Evaluation of implant stability upon embedding in a bone substitute;ENG;rabbit;NTS_3.3;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;lowest possible species;APX_2D;bone replacement;medical device;NTS_3.1
20173828_02;20173828;Onderzoek naar de capaciteit van vezelversterkt calciumfosfaat cementen om zwaarbelaste botdefecten te genezen;Translational or applied research;human;Evaluation of implant stability upon embedding in a bone substitute;ENG;rabbit;NTS_3.3;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;substantiated statistics;statistical power calculation;APX_2D;methods used in procedures;lowest possible species;APX_2D;bone replacement;medical device;NTS_3.1
20173828_02;20173828;Onderzoek naar de capaciteit van vezelversterkt calciumfosfaat cementen om zwaarbelaste botdefecten te genezen;Translational or applied research;human;Evaluation of implant stability upon embedding in a bone substitute;ENG;rabbit;NTS_3.3;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;availability of research tools;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;literature review;relevant information;APX_2D;reduction of discomfort;equipment;APX_2D;bone replacement;medical device;NTS_3.1
20173828_02;20173828;Onderzoek naar de capaciteit van vezelversterkt calciumfosfaat cementen om zwaarbelaste botdefecten te genezen;Translational or applied research;human;Evaluation of implant stability upon embedding in a bone substitute;ENG;rabbit;NTS_3.3;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;availability of research tools;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;equipment;APX_2D;bone replacement;medical device;NTS_3.1
20173828_02;20173828;Onderzoek naar de capaciteit van vezelversterkt calciumfosfaat cementen om zwaarbelaste botdefecten te genezen;Translational or applied research;human;Evaluation of implant stability upon embedding in a bone substitute;ENG;rabbit;NTS_3.3;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;availability of research tools;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;equipment;APX_2D;bone replacement;medical device;NTS_3.1
20173828_02;20173828;Onderzoek naar de capaciteit van vezelversterkt calciumfosfaat cementen om zwaarbelaste botdefecten te genezen;Translational or applied research;human;Evaluation of implant stability upon embedding in a bone substitute;ENG;rabbit;NTS_3.3;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;literature review;relevant information;APX_2D;reduction of discomfort;equipment;APX_2D;bone replacement;medical device;NTS_3.1
20173828_02;20173828;Onderzoek naar de capaciteit van vezelversterkt calciumfosfaat cementen om zwaarbelaste botdefecten te genezen;Translational or applied research;human;Evaluation of implant stability upon embedding in a bone substitute;ENG;rabbit;NTS_3.3;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;reduction of discomfort;equipment;APX_2D;bone replacement;medical device;NTS_3.1
20173828_02;20173828;Onderzoek naar de capaciteit van vezelversterkt calciumfosfaat cementen om zwaarbelaste botdefecten te genezen;Translational or applied research;human;Evaluation of implant stability upon embedding in a bone substitute;ENG;rabbit;NTS_3.3;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;substantiated statistics;statistical power calculation;APX_2D;reduction of discomfort;equipment;APX_2D;bone replacement;medical device;NTS_3.1
20173828_02;20173828;Onderzoek naar de capaciteit van vezelversterkt calciumfosfaat cementen om zwaarbelaste botdefecten te genezen;Translational or applied research;human;Evaluation of implant stability upon embedding in a bone substitute;ENG;rabbit;NTS_3.3;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;availability of research tools;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;literature review;relevant information;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;NTS_3.1
20173828_02;20173828;Onderzoek naar de capaciteit van vezelversterkt calciumfosfaat cementen om zwaarbelaste botdefecten te genezen;Translational or applied research;human;Evaluation of implant stability upon embedding in a bone substitute;ENG;rabbit;NTS_3.3;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;availability of research tools;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;NTS_3.1
20173828_02;20173828;Onderzoek naar de capaciteit van vezelversterkt calciumfosfaat cementen om zwaarbelaste botdefecten te genezen;Translational or applied research;human;Evaluation of implant stability upon embedding in a bone substitute;ENG;rabbit;NTS_3.3;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;availability of research tools;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;NTS_3.1
20173828_02;20173828;Onderzoek naar de capaciteit van vezelversterkt calciumfosfaat cementen om zwaarbelaste botdefecten te genezen;Translational or applied research;human;Evaluation of implant stability upon embedding in a bone substitute;ENG;rabbit;NTS_3.3;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;literature review;relevant information;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;NTS_3.1
20173828_02;20173828;Onderzoek naar de capaciteit van vezelversterkt calciumfosfaat cementen om zwaarbelaste botdefecten te genezen;Translational or applied research;human;Evaluation of implant stability upon embedding in a bone substitute;ENG;rabbit;NTS_3.3;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;NTS_3.1
20173828_02;20173828;Onderzoek naar de capaciteit van vezelversterkt calciumfosfaat cementen om zwaarbelaste botdefecten te genezen;Translational or applied research;human;Evaluation of implant stability upon embedding in a bone substitute;ENG;rabbit;NTS_3.3;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;substantiated statistics;statistical power calculation;APX_2D;methods used in procedures;expertise;APX_2D;bone replacement;medical device;NTS_3.1
20173828_02;20173828;Onderzoek naar de capaciteit van vezelversterkt calciumfosfaat cementen om zwaarbelaste botdefecten te genezen;Translational or applied research;human;Evaluation of implant stability upon embedding in a bone substitute;ENG;rabbit;NTS_3.3;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;availability of research tools;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;literature review;relevant information;APX_2D;accomodation and care;cage enrichment;APX_2D;bone replacement;medical device;NTS_3.1
20173828_02;20173828;Onderzoek naar de capaciteit van vezelversterkt calciumfosfaat cementen om zwaarbelaste botdefecten te genezen;Translational or applied research;human;Evaluation of implant stability upon embedding in a bone substitute;ENG;rabbit;NTS_3.3;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;availability of research tools;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;accomodation and care;cage enrichment;APX_2D;bone replacement;medical device;NTS_3.1
20173828_02;20173828;Onderzoek naar de capaciteit van vezelversterkt calciumfosfaat cementen om zwaarbelaste botdefecten te genezen;Translational or applied research;human;Evaluation of implant stability upon embedding in a bone substitute;ENG;rabbit;NTS_3.3;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;availability of research tools;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;statistical power calculation;APX_2D;accomodation and care;cage enrichment;APX_2D;bone replacement;medical device;NTS_3.1
20173828_02;20173828;Onderzoek naar de capaciteit van vezelversterkt calciumfosfaat cementen om zwaarbelaste botdefecten te genezen;Translational or applied research;human;Evaluation of implant stability upon embedding in a bone substitute;ENG;rabbit;NTS_3.3;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;literature review;relevant information;APX_2D;accomodation and care;cage enrichment;APX_2D;bone replacement;medical device;NTS_3.1
20173828_02;20173828;Onderzoek naar de capaciteit van vezelversterkt calciumfosfaat cementen om zwaarbelaste botdefecten te genezen;Translational or applied research;human;Evaluation of implant stability upon embedding in a bone substitute;ENG;rabbit;NTS_3.3;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;accomodation and care;cage enrichment;APX_2D;bone replacement;medical device;NTS_3.1
20173828_02;20173828;Onderzoek naar de capaciteit van vezelversterkt calciumfosfaat cementen om zwaarbelaste botdefecten te genezen;Translational or applied research;human;Evaluation of implant stability upon embedding in a bone substitute;ENG;rabbit;NTS_3.3;Musculoskeletal disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;substantiated statistics;statistical power calculation;APX_2D;accomodation and care;cage enrichment;APX_2D;bone replacement;medical device;NTS_3.1
20173846_01;20173846;Werkingsmechanismen van hersenstimulatie therapien na een experimentele hersenberoerte;Translational or applied research;human;Phase 0: Preparation phase to optimize and establish stimulation, imaging, stroke and behavioral techniques;ENG;rat;NTS_3.3;Cardiovascular disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;electrical stimulation;medical device;NTS_3.1
20173846_01;20173846;Werkingsmechanismen van hersenstimulatie therapien na een experimentele hersenberoerte;Translational or applied research;human;Phase 0: Preparation phase to optimize and establish stimulation, imaging, stroke and behavioral techniques;ENG;rat;NTS_3.3;Cardiovascular disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;electrical stimulation;medical device;NTS_3.1
20173846_01;20173846;Werkingsmechanismen van hersenstimulatie therapien na een experimentele hersenberoerte;Translational or applied research;human;Phase 0: Preparation phase to optimize and establish stimulation, imaging, stroke and behavioral techniques;ENG;rat;NTS_3.3;Cardiovascular disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;electrical stimulation;medical device;NTS_3.1
20173846_01;20173846;Werkingsmechanismen van hersenstimulatie therapien na een experimentele hersenberoerte;Translational or applied research;human;Phase 0: Preparation phase to optimize and establish stimulation, imaging, stroke and behavioral techniques;ENG;rat;NTS_3.3;Cardiovascular disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;electrical stimulation;medical device;NTS_3.1
20173846_01;20173846;Werkingsmechanismen van hersenstimulatie therapien na een experimentele hersenberoerte;Translational or applied research;human;Phase 0: Preparation phase to optimize and establish stimulation, imaging, stroke and behavioral techniques;ENG;rat;NTS_3.3;Cardiovascular disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;accomodation and care;social housing;APX_2D;electrical stimulation;medical device;NTS_3.1
20173846_01;20173846;Werkingsmechanismen van hersenstimulatie therapien na een experimentele hersenberoerte;Translational or applied research;human;Phase 0: Preparation phase to optimize and establish stimulation, imaging, stroke and behavioral techniques;ENG;rat;NTS_3.3;Cardiovascular disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;accomodation and care;social housing;APX_2D;electrical stimulation;medical device;NTS_3.1
20173846_01;20173846;Werkingsmechanismen van hersenstimulatie therapien na een experimentele hersenberoerte;Translational or applied research;human;Phase 0: Preparation phase to optimize and establish stimulation, imaging, stroke and behavioral techniques;ENG;rat;NTS_3.3;Cardiovascular disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;accomodation and care;social housing;APX_2D;electrical stimulation;medical device;NTS_3.1
20173846_01;20173846;Werkingsmechanismen van hersenstimulatie therapien na een experimentele hersenberoerte;Translational or applied research;human;Phase 0: Preparation phase to optimize and establish stimulation, imaging, stroke and behavioral techniques;ENG;rat;NTS_3.3;Cardiovascular disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;expertise;experience with model or methodology;APX_2D;accomodation and care;social housing;APX_2D;electrical stimulation;medical device;NTS_3.1
20173846_01;20173846;Werkingsmechanismen van hersenstimulatie therapien na een experimentele hersenberoerte;Translational or applied research;human;Phase 0: Preparation phase to optimize and establish stimulation, imaging, stroke and behavioral techniques;ENG;rat;NTS_3.3;Cardiovascular disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;electrical stimulation;medical device;NTS_3.1
20173846_01;20173846;Werkingsmechanismen van hersenstimulatie therapien na een experimentele hersenberoerte;Translational or applied research;human;Phase 0: Preparation phase to optimize and establish stimulation, imaging, stroke and behavioral techniques;ENG;rat;NTS_3.3;Cardiovascular disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;electrical stimulation;medical device;NTS_3.1
20173846_01;20173846;Werkingsmechanismen van hersenstimulatie therapien na een experimentele hersenberoerte;Translational or applied research;human;Phase 0: Preparation phase to optimize and establish stimulation, imaging, stroke and behavioral techniques;ENG;rat;NTS_3.3;Cardiovascular disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;electrical stimulation;medical device;NTS_3.1
20173846_01;20173846;Werkingsmechanismen van hersenstimulatie therapien na een experimentele hersenberoerte;Translational or applied research;human;Phase 0: Preparation phase to optimize and establish stimulation, imaging, stroke and behavioral techniques;ENG;rat;NTS_3.3;Cardiovascular disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;electrical stimulation;medical device;NTS_3.1
20173846_01;20173846;Werkingsmechanismen van hersenstimulatie therapien na een experimentele hersenberoerte;Translational or applied research;human;Phase 0: Preparation phase to optimize and establish stimulation, imaging, stroke and behavioral techniques;ENG;rat;NTS_3.3;Cardiovascular disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;accomodation and care;social housing;APX_2D;electrical stimulation;medical device;NTS_3.1
20173846_01;20173846;Werkingsmechanismen van hersenstimulatie therapien na een experimentele hersenberoerte;Translational or applied research;human;Phase 0: Preparation phase to optimize and establish stimulation, imaging, stroke and behavioral techniques;ENG;rat;NTS_3.3;Cardiovascular disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;accomodation and care;social housing;APX_2D;electrical stimulation;medical device;NTS_3.1
20173846_01;20173846;Werkingsmechanismen van hersenstimulatie therapien na een experimentele hersenberoerte;Translational or applied research;human;Phase 0: Preparation phase to optimize and establish stimulation, imaging, stroke and behavioral techniques;ENG;rat;NTS_3.3;Cardiovascular disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;accomodation and care;social housing;APX_2D;electrical stimulation;medical device;NTS_3.1
20173846_01;20173846;Werkingsmechanismen van hersenstimulatie therapien na een experimentele hersenberoerte;Translational or applied research;human;Phase 0: Preparation phase to optimize and establish stimulation, imaging, stroke and behavioral techniques;ENG;rat;NTS_3.3;Cardiovascular disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;expertise;experience with model or methodology;APX_2D;accomodation and care;social housing;APX_2D;electrical stimulation;medical device;NTS_3.1
20173846_01;20173846;Werkingsmechanismen van hersenstimulatie therapien na een experimentele hersenberoerte;Translational or applied research;human;Phase 0: Preparation phase to optimize and establish stimulation, imaging, stroke and behavioral techniques;ENG;rat;NTS_3.3;Cardiovascular disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;electrical stimulation;medical device;NTS_3.1
20173846_01;20173846;Werkingsmechanismen van hersenstimulatie therapien na een experimentele hersenberoerte;Translational or applied research;human;Phase 0: Preparation phase to optimize and establish stimulation, imaging, stroke and behavioral techniques;ENG;rat;NTS_3.3;Cardiovascular disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;electrical stimulation;medical device;NTS_3.1
20173846_01;20173846;Werkingsmechanismen van hersenstimulatie therapien na een experimentele hersenberoerte;Translational or applied research;human;Phase 0: Preparation phase to optimize and establish stimulation, imaging, stroke and behavioral techniques;ENG;rat;NTS_3.3;Cardiovascular disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;electrical stimulation;medical device;NTS_3.1
20173846_01;20173846;Werkingsmechanismen van hersenstimulatie therapien na een experimentele hersenberoerte;Translational or applied research;human;Phase 0: Preparation phase to optimize and establish stimulation, imaging, stroke and behavioral techniques;ENG;rat;NTS_3.3;Cardiovascular disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;electrical stimulation;medical device;NTS_3.1
20173846_01;20173846;Werkingsmechanismen van hersenstimulatie therapien na een experimentele hersenberoerte;Translational or applied research;human;Phase 0: Preparation phase to optimize and establish stimulation, imaging, stroke and behavioral techniques;ENG;rat;NTS_3.3;Cardiovascular disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;accomodation and care;social housing;APX_2D;electrical stimulation;medical device;NTS_3.1
20173846_01;20173846;Werkingsmechanismen van hersenstimulatie therapien na een experimentele hersenberoerte;Translational or applied research;human;Phase 0: Preparation phase to optimize and establish stimulation, imaging, stroke and behavioral techniques;ENG;rat;NTS_3.3;Cardiovascular disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;accomodation and care;social housing;APX_2D;electrical stimulation;medical device;NTS_3.1
20173846_01;20173846;Werkingsmechanismen van hersenstimulatie therapien na een experimentele hersenberoerte;Translational or applied research;human;Phase 0: Preparation phase to optimize and establish stimulation, imaging, stroke and behavioral techniques;ENG;rat;NTS_3.3;Cardiovascular disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;accomodation and care;social housing;APX_2D;electrical stimulation;medical device;NTS_3.1
20173846_01;20173846;Werkingsmechanismen van hersenstimulatie therapien na een experimentele hersenberoerte;Translational or applied research;human;Phase 0: Preparation phase to optimize and establish stimulation, imaging, stroke and behavioral techniques;ENG;rat;NTS_3.3;Cardiovascular disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;expertise;experience with model or methodology;APX_2D;accomodation and care;social housing;APX_2D;electrical stimulation;medical device;NTS_3.1
20173846_01;20173846;Werkingsmechanismen van hersenstimulatie therapien na een experimentele hersenberoerte;Translational or applied research;human;Phase 0: Preparation phase to optimize and establish stimulation, imaging, stroke and behavioral techniques;ENG;rat;NTS_3.3;Cardiovascular disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;electrical stimulation;medical device;NTS_3.1
20173846_01;20173846;Werkingsmechanismen van hersenstimulatie therapien na een experimentele hersenberoerte;Translational or applied research;human;Phase 0: Preparation phase to optimize and establish stimulation, imaging, stroke and behavioral techniques;ENG;rat;NTS_3.3;Cardiovascular disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;electrical stimulation;medical device;NTS_3.1
20173846_01;20173846;Werkingsmechanismen van hersenstimulatie therapien na een experimentele hersenberoerte;Translational or applied research;human;Phase 0: Preparation phase to optimize and establish stimulation, imaging, stroke and behavioral techniques;ENG;rat;NTS_3.3;Cardiovascular disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;electrical stimulation;medical device;NTS_3.1
20173846_01;20173846;Werkingsmechanismen van hersenstimulatie therapien na een experimentele hersenberoerte;Translational or applied research;human;Phase 0: Preparation phase to optimize and establish stimulation, imaging, stroke and behavioral techniques;ENG;rat;NTS_3.3;Cardiovascular disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;electrical stimulation;medical device;NTS_3.1
20173846_01;20173846;Werkingsmechanismen van hersenstimulatie therapien na een experimentele hersenberoerte;Translational or applied research;human;Phase 0: Preparation phase to optimize and establish stimulation, imaging, stroke and behavioral techniques;ENG;rat;NTS_3.3;Cardiovascular disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;accomodation and care;social housing;APX_2D;electrical stimulation;medical device;NTS_3.1
20173846_01;20173846;Werkingsmechanismen van hersenstimulatie therapien na een experimentele hersenberoerte;Translational or applied research;human;Phase 0: Preparation phase to optimize and establish stimulation, imaging, stroke and behavioral techniques;ENG;rat;NTS_3.3;Cardiovascular disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;optimal combination of readouts;APX_2D;accomodation and care;social housing;APX_2D;electrical stimulation;medical device;NTS_3.1
20173846_01;20173846;Werkingsmechanismen van hersenstimulatie therapien na een experimentele hersenberoerte;Translational or applied research;human;Phase 0: Preparation phase to optimize and establish stimulation, imaging, stroke and behavioral techniques;ENG;rat;NTS_3.3;Cardiovascular disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;accomodation and care;social housing;APX_2D;electrical stimulation;medical device;NTS_3.1
20173846_01;20173846;Werkingsmechanismen van hersenstimulatie therapien na een experimentele hersenberoerte;Translational or applied research;human;Phase 0: Preparation phase to optimize and establish stimulation, imaging, stroke and behavioral techniques;ENG;rat;NTS_3.3;Cardiovascular disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;expertise;experience with model or methodology;APX_2D;accomodation and care;social housing;APX_2D;electrical stimulation;medical device;NTS_3.1
20173846_02;20173846;Werkingsmechanismen van hersenstimulatie therapien na een experimentele hersenberoerte;Translational or applied research;human;Phase 1: XXXX manipulation and MRI in healthy rats and rats with experimental stroke;ENG;rat;NTS_3.3;Cardiovascular disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;electrical stimulation;medical device;NTS_3.1
20173846_02;20173846;Werkingsmechanismen van hersenstimulatie therapien na een experimentele hersenberoerte;Translational or applied research;human;Phase 1: XXXX manipulation and MRI in healthy rats and rats with experimental stroke;ENG;rat;NTS_3.3;Cardiovascular disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;drug;small molecular compounds;APX_2A
20173846_02;20173846;Werkingsmechanismen van hersenstimulatie therapien na een experimentele hersenberoerte;Translational or applied research;human;Phase 1: XXXX manipulation and MRI in healthy rats and rats with experimental stroke;ENG;rat;NTS_3.3;Cardiovascular disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;electrical stimulation;medical device;NTS_3.1
20173846_02;20173846;Werkingsmechanismen van hersenstimulatie therapien na een experimentele hersenberoerte;Translational or applied research;human;Phase 1: XXXX manipulation and MRI in healthy rats and rats with experimental stroke;ENG;rat;NTS_3.3;Cardiovascular disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;drug;small molecular compounds;APX_2A
20173846_02;20173846;Werkingsmechanismen van hersenstimulatie therapien na een experimentele hersenberoerte;Translational or applied research;human;Phase 1: XXXX manipulation and MRI in healthy rats and rats with experimental stroke;ENG;rat;NTS_3.3;Cardiovascular disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;accomodation and care;social housing;APX_2D;electrical stimulation;medical device;NTS_3.1
20173846_02;20173846;Werkingsmechanismen van hersenstimulatie therapien na een experimentele hersenberoerte;Translational or applied research;human;Phase 1: XXXX manipulation and MRI in healthy rats and rats with experimental stroke;ENG;rat;NTS_3.3;Cardiovascular disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;accomodation and care;social housing;APX_2D;drug;small molecular compounds;APX_2A
20173846_02;20173846;Werkingsmechanismen van hersenstimulatie therapien na een experimentele hersenberoerte;Translational or applied research;human;Phase 1: XXXX manipulation and MRI in healthy rats and rats with experimental stroke;ENG;rat;NTS_3.3;Cardiovascular disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;expertise;experience with model or methodology;APX_2D;accomodation and care;social housing;APX_2D;electrical stimulation;medical device;NTS_3.1
20173846_02;20173846;Werkingsmechanismen van hersenstimulatie therapien na een experimentele hersenberoerte;Translational or applied research;human;Phase 1: XXXX manipulation and MRI in healthy rats and rats with experimental stroke;ENG;rat;NTS_3.3;Cardiovascular disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;expertise;experience with model or methodology;APX_2D;accomodation and care;social housing;APX_2D;drug;small molecular compounds;APX_2A
20173846_02;20173846;Werkingsmechanismen van hersenstimulatie therapien na een experimentele hersenberoerte;Translational or applied research;human;Phase 1: XXXX manipulation and MRI in healthy rats and rats with experimental stroke;ENG;rat;NTS_3.3;Cardiovascular disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;electrical stimulation;medical device;NTS_3.1
20173846_02;20173846;Werkingsmechanismen van hersenstimulatie therapien na een experimentele hersenberoerte;Translational or applied research;human;Phase 1: XXXX manipulation and MRI in healthy rats and rats with experimental stroke;ENG;rat;NTS_3.3;Cardiovascular disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;drug;small molecular compounds;APX_2A
20173846_02;20173846;Werkingsmechanismen van hersenstimulatie therapien na een experimentele hersenberoerte;Translational or applied research;human;Phase 1: XXXX manipulation and MRI in healthy rats and rats with experimental stroke;ENG;rat;NTS_3.3;Cardiovascular disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;electrical stimulation;medical device;NTS_3.1
20173846_02;20173846;Werkingsmechanismen van hersenstimulatie therapien na een experimentele hersenberoerte;Translational or applied research;human;Phase 1: XXXX manipulation and MRI in healthy rats and rats with experimental stroke;ENG;rat;NTS_3.3;Cardiovascular disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;drug;small molecular compounds;APX_2A
20173846_02;20173846;Werkingsmechanismen van hersenstimulatie therapien na een experimentele hersenberoerte;Translational or applied research;human;Phase 1: XXXX manipulation and MRI in healthy rats and rats with experimental stroke;ENG;rat;NTS_3.3;Cardiovascular disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;accomodation and care;social housing;APX_2D;electrical stimulation;medical device;NTS_3.1
20173846_02;20173846;Werkingsmechanismen van hersenstimulatie therapien na een experimentele hersenberoerte;Translational or applied research;human;Phase 1: XXXX manipulation and MRI in healthy rats and rats with experimental stroke;ENG;rat;NTS_3.3;Cardiovascular disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;accomodation and care;social housing;APX_2D;drug;small molecular compounds;APX_2A
20173846_02;20173846;Werkingsmechanismen van hersenstimulatie therapien na een experimentele hersenberoerte;Translational or applied research;human;Phase 1: XXXX manipulation and MRI in healthy rats and rats with experimental stroke;ENG;rat;NTS_3.3;Cardiovascular disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;expertise;experience with model or methodology;APX_2D;accomodation and care;social housing;APX_2D;electrical stimulation;medical device;NTS_3.1
20173846_02;20173846;Werkingsmechanismen van hersenstimulatie therapien na een experimentele hersenberoerte;Translational or applied research;human;Phase 1: XXXX manipulation and MRI in healthy rats and rats with experimental stroke;ENG;rat;NTS_3.3;Cardiovascular disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;expertise;experience with model or methodology;APX_2D;accomodation and care;social housing;APX_2D;drug;small molecular compounds;APX_2A
20173846_02;20173846;Werkingsmechanismen van hersenstimulatie therapien na een experimentele hersenberoerte;Translational or applied research;human;Phase 1: XXXX manipulation and MRI in healthy rats and rats with experimental stroke;ENG;rat;NTS_3.3;Cardiovascular disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;electrical stimulation;medical device;NTS_3.1
20173846_02;20173846;Werkingsmechanismen van hersenstimulatie therapien na een experimentele hersenberoerte;Translational or applied research;human;Phase 1: XXXX manipulation and MRI in healthy rats and rats with experimental stroke;ENG;rat;NTS_3.3;Cardiovascular disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;drug;small molecular compounds;APX_2A
20173846_02;20173846;Werkingsmechanismen van hersenstimulatie therapien na een experimentele hersenberoerte;Translational or applied research;human;Phase 1: XXXX manipulation and MRI in healthy rats and rats with experimental stroke;ENG;rat;NTS_3.3;Cardiovascular disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;electrical stimulation;medical device;NTS_3.1
20173846_02;20173846;Werkingsmechanismen van hersenstimulatie therapien na een experimentele hersenberoerte;Translational or applied research;human;Phase 1: XXXX manipulation and MRI in healthy rats and rats with experimental stroke;ENG;rat;NTS_3.3;Cardiovascular disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;drug;small molecular compounds;APX_2A
20173846_02;20173846;Werkingsmechanismen van hersenstimulatie therapien na een experimentele hersenberoerte;Translational or applied research;human;Phase 1: XXXX manipulation and MRI in healthy rats and rats with experimental stroke;ENG;rat;NTS_3.3;Cardiovascular disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;accomodation and care;social housing;APX_2D;electrical stimulation;medical device;NTS_3.1
20173846_02;20173846;Werkingsmechanismen van hersenstimulatie therapien na een experimentele hersenberoerte;Translational or applied research;human;Phase 1: XXXX manipulation and MRI in healthy rats and rats with experimental stroke;ENG;rat;NTS_3.3;Cardiovascular disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;accomodation and care;social housing;APX_2D;drug;small molecular compounds;APX_2A
20173846_02;20173846;Werkingsmechanismen van hersenstimulatie therapien na een experimentele hersenberoerte;Translational or applied research;human;Phase 1: XXXX manipulation and MRI in healthy rats and rats with experimental stroke;ENG;rat;NTS_3.3;Cardiovascular disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;expertise;experience with model or methodology;APX_2D;accomodation and care;social housing;APX_2D;electrical stimulation;medical device;NTS_3.1
20173846_02;20173846;Werkingsmechanismen van hersenstimulatie therapien na een experimentele hersenberoerte;Translational or applied research;human;Phase 1: XXXX manipulation and MRI in healthy rats and rats with experimental stroke;ENG;rat;NTS_3.3;Cardiovascular disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;expertise;experience with model or methodology;APX_2D;accomodation and care;social housing;APX_2D;drug;small molecular compounds;APX_2A
20173846_02;20173846;Werkingsmechanismen van hersenstimulatie therapien na een experimentele hersenberoerte;Translational or applied research;human;Phase 1: XXXX manipulation and MRI in healthy rats and rats with experimental stroke;ENG;rat;NTS_3.3;Cardiovascular disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;electrical stimulation;medical device;NTS_3.1
20173846_02;20173846;Werkingsmechanismen van hersenstimulatie therapien na een experimentele hersenberoerte;Translational or applied research;human;Phase 1: XXXX manipulation and MRI in healthy rats and rats with experimental stroke;ENG;rat;NTS_3.3;Cardiovascular disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;drug;small molecular compounds;APX_2A
20173846_02;20173846;Werkingsmechanismen van hersenstimulatie therapien na een experimentele hersenberoerte;Translational or applied research;human;Phase 1: XXXX manipulation and MRI in healthy rats and rats with experimental stroke;ENG;rat;NTS_3.3;Cardiovascular disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;electrical stimulation;medical device;NTS_3.1
20173846_02;20173846;Werkingsmechanismen van hersenstimulatie therapien na een experimentele hersenberoerte;Translational or applied research;human;Phase 1: XXXX manipulation and MRI in healthy rats and rats with experimental stroke;ENG;rat;NTS_3.3;Cardiovascular disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;drug;small molecular compounds;APX_2A
20173846_02;20173846;Werkingsmechanismen van hersenstimulatie therapien na een experimentele hersenberoerte;Translational or applied research;human;Phase 1: XXXX manipulation and MRI in healthy rats and rats with experimental stroke;ENG;rat;NTS_3.3;Cardiovascular disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;accomodation and care;social housing;APX_2D;electrical stimulation;medical device;NTS_3.1
20173846_02;20173846;Werkingsmechanismen van hersenstimulatie therapien na een experimentele hersenberoerte;Translational or applied research;human;Phase 1: XXXX manipulation and MRI in healthy rats and rats with experimental stroke;ENG;rat;NTS_3.3;Cardiovascular disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;accomodation and care;social housing;APX_2D;drug;small molecular compounds;APX_2A
20173846_02;20173846;Werkingsmechanismen van hersenstimulatie therapien na een experimentele hersenberoerte;Translational or applied research;human;Phase 1: XXXX manipulation and MRI in healthy rats and rats with experimental stroke;ENG;rat;NTS_3.3;Cardiovascular disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;expertise;experience with model or methodology;APX_2D;accomodation and care;social housing;APX_2D;electrical stimulation;medical device;NTS_3.1
20173846_02;20173846;Werkingsmechanismen van hersenstimulatie therapien na een experimentele hersenberoerte;Translational or applied research;human;Phase 1: XXXX manipulation and MRI in healthy rats and rats with experimental stroke;ENG;rat;NTS_3.3;Cardiovascular disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;expertise;experience with model or methodology;APX_2D;accomodation and care;social housing;APX_2D;drug;small molecular compounds;APX_2A
20173846_03;20173846;Werkingsmechanismen van hersenstimulatie therapien na een experimentele hersenberoerte;Translational or applied research;human;Phase 2: Brain stimulation and multiparametric MRI in healthy rats and rats with experimental stroke;ENG;rat;NTS_3.3;Cardiovascular disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;electrical stimulation;medical device;NTS_3.1
20173846_03;20173846;Werkingsmechanismen van hersenstimulatie therapien na een experimentele hersenberoerte;Translational or applied research;human;Phase 2: Brain stimulation and multiparametric MRI in healthy rats and rats with experimental stroke;ENG;rat;NTS_3.3;Cardiovascular disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;electrical stimulation;medical device;NTS_3.1
20173846_03;20173846;Werkingsmechanismen van hersenstimulatie therapien na een experimentele hersenberoerte;Translational or applied research;human;Phase 2: Brain stimulation and multiparametric MRI in healthy rats and rats with experimental stroke;ENG;rat;NTS_3.3;Cardiovascular disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;accomodation and care;social housing;APX_2D;electrical stimulation;medical device;NTS_3.1
20173846_03;20173846;Werkingsmechanismen van hersenstimulatie therapien na een experimentele hersenberoerte;Translational or applied research;human;Phase 2: Brain stimulation and multiparametric MRI in healthy rats and rats with experimental stroke;ENG;rat;NTS_3.3;Cardiovascular disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;expertise;experience with model or methodology;APX_2D;accomodation and care;social housing;APX_2D;electrical stimulation;medical device;NTS_3.1
20173846_03;20173846;Werkingsmechanismen van hersenstimulatie therapien na een experimentele hersenberoerte;Translational or applied research;human;Phase 2: Brain stimulation and multiparametric MRI in healthy rats and rats with experimental stroke;ENG;rat;NTS_3.3;Cardiovascular disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;electrical stimulation;medical device;NTS_3.1
20173846_03;20173846;Werkingsmechanismen van hersenstimulatie therapien na een experimentele hersenberoerte;Translational or applied research;human;Phase 2: Brain stimulation and multiparametric MRI in healthy rats and rats with experimental stroke;ENG;rat;NTS_3.3;Cardiovascular disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;electrical stimulation;medical device;NTS_3.1
20173846_03;20173846;Werkingsmechanismen van hersenstimulatie therapien na een experimentele hersenberoerte;Translational or applied research;human;Phase 2: Brain stimulation and multiparametric MRI in healthy rats and rats with experimental stroke;ENG;rat;NTS_3.3;Cardiovascular disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;accomodation and care;social housing;APX_2D;electrical stimulation;medical device;NTS_3.1
20173846_03;20173846;Werkingsmechanismen van hersenstimulatie therapien na een experimentele hersenberoerte;Translational or applied research;human;Phase 2: Brain stimulation and multiparametric MRI in healthy rats and rats with experimental stroke;ENG;rat;NTS_3.3;Cardiovascular disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;expertise;experience with model or methodology;APX_2D;accomodation and care;social housing;APX_2D;electrical stimulation;medical device;NTS_3.1
20173846_03;20173846;Werkingsmechanismen van hersenstimulatie therapien na een experimentele hersenberoerte;Translational or applied research;human;Phase 2: Brain stimulation and multiparametric MRI in healthy rats and rats with experimental stroke;ENG;rat;NTS_3.3;Cardiovascular disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;electrical stimulation;medical device;NTS_3.1
20173846_03;20173846;Werkingsmechanismen van hersenstimulatie therapien na een experimentele hersenberoerte;Translational or applied research;human;Phase 2: Brain stimulation and multiparametric MRI in healthy rats and rats with experimental stroke;ENG;rat;NTS_3.3;Cardiovascular disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;electrical stimulation;medical device;NTS_3.1
20173846_03;20173846;Werkingsmechanismen van hersenstimulatie therapien na een experimentele hersenberoerte;Translational or applied research;human;Phase 2: Brain stimulation and multiparametric MRI in healthy rats and rats with experimental stroke;ENG;rat;NTS_3.3;Cardiovascular disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;accomodation and care;social housing;APX_2D;electrical stimulation;medical device;NTS_3.1
20173846_03;20173846;Werkingsmechanismen van hersenstimulatie therapien na een experimentele hersenberoerte;Translational or applied research;human;Phase 2: Brain stimulation and multiparametric MRI in healthy rats and rats with experimental stroke;ENG;rat;NTS_3.3;Cardiovascular disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;expertise;experience with model or methodology;APX_2D;accomodation and care;social housing;APX_2D;electrical stimulation;medical device;NTS_3.1
20173846_03;20173846;Werkingsmechanismen van hersenstimulatie therapien na een experimentele hersenberoerte;Translational or applied research;human;Phase 2: Brain stimulation and multiparametric MRI in healthy rats and rats with experimental stroke;ENG;rat;NTS_3.3;Cardiovascular disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;electrical stimulation;medical device;NTS_3.1
20173846_03;20173846;Werkingsmechanismen van hersenstimulatie therapien na een experimentele hersenberoerte;Translational or applied research;human;Phase 2: Brain stimulation and multiparametric MRI in healthy rats and rats with experimental stroke;ENG;rat;NTS_3.3;Cardiovascular disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;electrical stimulation;medical device;NTS_3.1
20173846_03;20173846;Werkingsmechanismen van hersenstimulatie therapien na een experimentele hersenberoerte;Translational or applied research;human;Phase 2: Brain stimulation and multiparametric MRI in healthy rats and rats with experimental stroke;ENG;rat;NTS_3.3;Cardiovascular disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;accomodation and care;social housing;APX_2D;electrical stimulation;medical device;NTS_3.1
20173846_03;20173846;Werkingsmechanismen van hersenstimulatie therapien na een experimentele hersenberoerte;Translational or applied research;human;Phase 2: Brain stimulation and multiparametric MRI in healthy rats and rats with experimental stroke;ENG;rat;NTS_3.3;Cardiovascular disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;expertise;experience with model or methodology;APX_2D;accomodation and care;social housing;APX_2D;electrical stimulation;medical device;NTS_3.1
20173846_04;20173846;Werkingsmechanismen van hersenstimulatie therapien na een experimentele hersenberoerte;Translational or applied research;human;Phase 3: Working mechanisms of brain stimulation and multiparametric MRI in healthy rats and rats with experimental stroke.;ENG;rat;NTS_3.3;Cardiovascular disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;electrical stimulation;medical device;NTS_3.1
20173846_04;20173846;Werkingsmechanismen van hersenstimulatie therapien na een experimentele hersenberoerte;Translational or applied research;human;Phase 3: Working mechanisms of brain stimulation and multiparametric MRI in healthy rats and rats with experimental stroke.;ENG;rat;NTS_3.3;Cardiovascular disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;electrical stimulation;medical device;NTS_3.1
20173846_04;20173846;Werkingsmechanismen van hersenstimulatie therapien na een experimentele hersenberoerte;Translational or applied research;human;Phase 3: Working mechanisms of brain stimulation and multiparametric MRI in healthy rats and rats with experimental stroke.;ENG;rat;NTS_3.3;Cardiovascular disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;accomodation and care;social housing;APX_2D;electrical stimulation;medical device;NTS_3.1
20173846_04;20173846;Werkingsmechanismen van hersenstimulatie therapien na een experimentele hersenberoerte;Translational or applied research;human;Phase 3: Working mechanisms of brain stimulation and multiparametric MRI in healthy rats and rats with experimental stroke.;ENG;rat;NTS_3.3;Cardiovascular disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;expertise;experience with model or methodology;APX_2D;accomodation and care;social housing;APX_2D;electrical stimulation;medical device;NTS_3.1
20173846_04;20173846;Werkingsmechanismen van hersenstimulatie therapien na een experimentele hersenberoerte;Translational or applied research;human;Phase 3: Working mechanisms of brain stimulation and multiparametric MRI in healthy rats and rats with experimental stroke.;ENG;rat;NTS_3.3;Cardiovascular disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;electrical stimulation;medical device;NTS_3.1
20173846_04;20173846;Werkingsmechanismen van hersenstimulatie therapien na een experimentele hersenberoerte;Translational or applied research;human;Phase 3: Working mechanisms of brain stimulation and multiparametric MRI in healthy rats and rats with experimental stroke.;ENG;rat;NTS_3.3;Cardiovascular disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;electrical stimulation;medical device;NTS_3.1
20173846_04;20173846;Werkingsmechanismen van hersenstimulatie therapien na een experimentele hersenberoerte;Translational or applied research;human;Phase 3: Working mechanisms of brain stimulation and multiparametric MRI in healthy rats and rats with experimental stroke.;ENG;rat;NTS_3.3;Cardiovascular disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;accomodation and care;social housing;APX_2D;electrical stimulation;medical device;NTS_3.1
20173846_04;20173846;Werkingsmechanismen van hersenstimulatie therapien na een experimentele hersenberoerte;Translational or applied research;human;Phase 3: Working mechanisms of brain stimulation and multiparametric MRI in healthy rats and rats with experimental stroke.;ENG;rat;NTS_3.3;Cardiovascular disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;expertise;experience with model or methodology;APX_2D;accomodation and care;social housing;APX_2D;electrical stimulation;medical device;NTS_3.1
20173846_04;20173846;Werkingsmechanismen van hersenstimulatie therapien na een experimentele hersenberoerte;Translational or applied research;human;Phase 3: Working mechanisms of brain stimulation and multiparametric MRI in healthy rats and rats with experimental stroke.;ENG;rat;NTS_3.3;Cardiovascular disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;electrical stimulation;medical device;NTS_3.1
20173846_04;20173846;Werkingsmechanismen van hersenstimulatie therapien na een experimentele hersenberoerte;Translational or applied research;human;Phase 3: Working mechanisms of brain stimulation and multiparametric MRI in healthy rats and rats with experimental stroke.;ENG;rat;NTS_3.3;Cardiovascular disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;electrical stimulation;medical device;NTS_3.1
20173846_04;20173846;Werkingsmechanismen van hersenstimulatie therapien na een experimentele hersenberoerte;Translational or applied research;human;Phase 3: Working mechanisms of brain stimulation and multiparametric MRI in healthy rats and rats with experimental stroke.;ENG;rat;NTS_3.3;Cardiovascular disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;accomodation and care;social housing;APX_2D;electrical stimulation;medical device;NTS_3.1
20173846_04;20173846;Werkingsmechanismen van hersenstimulatie therapien na een experimentele hersenberoerte;Translational or applied research;human;Phase 3: Working mechanisms of brain stimulation and multiparametric MRI in healthy rats and rats with experimental stroke.;ENG;rat;NTS_3.3;Cardiovascular disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;expertise;experience with model or methodology;APX_2D;accomodation and care;social housing;APX_2D;electrical stimulation;medical device;NTS_3.1
20173846_04;20173846;Werkingsmechanismen van hersenstimulatie therapien na een experimentele hersenberoerte;Translational or applied research;human;Phase 3: Working mechanisms of brain stimulation and multiparametric MRI in healthy rats and rats with experimental stroke.;ENG;rat;NTS_3.3;Cardiovascular disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;electrical stimulation;medical device;NTS_3.1
20173846_04;20173846;Werkingsmechanismen van hersenstimulatie therapien na een experimentele hersenberoerte;Translational or applied research;human;Phase 3: Working mechanisms of brain stimulation and multiparametric MRI in healthy rats and rats with experimental stroke.;ENG;rat;NTS_3.3;Cardiovascular disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;electrical stimulation;medical device;NTS_3.1
20173846_04;20173846;Werkingsmechanismen van hersenstimulatie therapien na een experimentele hersenberoerte;Translational or applied research;human;Phase 3: Working mechanisms of brain stimulation and multiparametric MRI in healthy rats and rats with experimental stroke.;ENG;rat;NTS_3.3;Cardiovascular disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;accomodation and care;social housing;APX_2D;electrical stimulation;medical device;NTS_3.1
20173846_04;20173846;Werkingsmechanismen van hersenstimulatie therapien na een experimentele hersenberoerte;Translational or applied research;human;Phase 3: Working mechanisms of brain stimulation and multiparametric MRI in healthy rats and rats with experimental stroke.;ENG;rat;NTS_3.3;Cardiovascular disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;expertise;experience with model or methodology;APX_2D;accomodation and care;social housing;APX_2D;electrical stimulation;medical device;NTS_3.1
20173885_01;20173885;De eigenschappen van biologische medicijnen in proefdieren voorspellen met verschillende beeldvormingstechnieken;Translational or applied research;human;Implementation of specific cancer animal models;ENG;mouse;APX_2B;Cancer;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;literature review;relevant information;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;cell lines xenografted;gene and cell-based;APX_2A
20173885_01;20173885;De eigenschappen van biologische medicijnen in proefdieren voorspellen met verschillende beeldvormingstechnieken;Translational or applied research;human;Implementation of specific cancer animal models;ENG;mouse;APX_2B;Cancer;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;literature review;relevant information;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;cell lines xenografted;gene and cell-based;APX_2A
20173885_01;20173885;De eigenschappen van biologische medicijnen in proefdieren voorspellen met verschillende beeldvormingstechnieken;Translational or applied research;human;Implementation of specific cancer animal models;ENG;mouse;APX_2B;Cancer;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;consult (bio)statistician;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;cell lines xenografted;gene and cell-based;APX_2A
20173885_01;20173885;De eigenschappen van biologische medicijnen in proefdieren voorspellen met verschillende beeldvormingstechnieken;Translational or applied research;human;Implementation of specific cancer animal models;ENG;mouse;APX_2B;Cancer;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;substantiated statistics;consult (bio)statistician;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;cell lines xenografted;gene and cell-based;APX_2A
20173885_01;20173885;De eigenschappen van biologische medicijnen in proefdieren voorspellen met verschillende beeldvormingstechnieken;Translational or applied research;human;Implementation of specific cancer animal models;ENG;mouse;APX_2B;Cancer;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;literature review;relevant information;APX_2D;accomodation and care;social housing;APX_2D;cell lines xenografted;gene and cell-based;APX_2A
20173885_01;20173885;De eigenschappen van biologische medicijnen in proefdieren voorspellen met verschillende beeldvormingstechnieken;Translational or applied research;human;Implementation of specific cancer animal models;ENG;mouse;APX_2B;Cancer;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;literature review;relevant information;APX_2D;accomodation and care;social housing;APX_2D;cell lines xenografted;gene and cell-based;APX_2A
20173885_01;20173885;De eigenschappen van biologische medicijnen in proefdieren voorspellen met verschillende beeldvormingstechnieken;Translational or applied research;human;Implementation of specific cancer animal models;ENG;mouse;APX_2B;Cancer;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;consult (bio)statistician;APX_2D;accomodation and care;social housing;APX_2D;cell lines xenografted;gene and cell-based;APX_2A
20173885_01;20173885;De eigenschappen van biologische medicijnen in proefdieren voorspellen met verschillende beeldvormingstechnieken;Translational or applied research;human;Implementation of specific cancer animal models;ENG;mouse;APX_2B;Cancer;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;substantiated statistics;consult (bio)statistician;APX_2D;accomodation and care;social housing;APX_2D;cell lines xenografted;gene and cell-based;APX_2A
20173885_01;20173885;De eigenschappen van biologische medicijnen in proefdieren voorspellen met verschillende beeldvormingstechnieken;Translational or applied research;human;Implementation of specific cancer animal models;ENG;mouse;APX_2B;Cancer;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;literature review;relevant information;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;cell lines xenografted;gene and cell-based;APX_2A
20173885_01;20173885;De eigenschappen van biologische medicijnen in proefdieren voorspellen met verschillende beeldvormingstechnieken;Translational or applied research;human;Implementation of specific cancer animal models;ENG;mouse;APX_2B;Cancer;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;literature review;relevant information;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;cell lines xenografted;gene and cell-based;APX_2A
20173885_01;20173885;De eigenschappen van biologische medicijnen in proefdieren voorspellen met verschillende beeldvormingstechnieken;Translational or applied research;human;Implementation of specific cancer animal models;ENG;mouse;APX_2B;Cancer;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;consult (bio)statistician;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;cell lines xenografted;gene and cell-based;APX_2A
20173885_01;20173885;De eigenschappen van biologische medicijnen in proefdieren voorspellen met verschillende beeldvormingstechnieken;Translational or applied research;human;Implementation of specific cancer animal models;ENG;mouse;APX_2B;Cancer;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;substantiated statistics;consult (bio)statistician;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;cell lines xenografted;gene and cell-based;APX_2A
20173885_01;20173885;De eigenschappen van biologische medicijnen in proefdieren voorspellen met verschillende beeldvormingstechnieken;Translational or applied research;human;Implementation of specific cancer animal models;ENG;mouse;APX_2B;Cancer;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;literature review;relevant information;APX_2D;accomodation and care;social housing;APX_2D;cell lines xenografted;gene and cell-based;APX_2A
20173885_01;20173885;De eigenschappen van biologische medicijnen in proefdieren voorspellen met verschillende beeldvormingstechnieken;Translational or applied research;human;Implementation of specific cancer animal models;ENG;mouse;APX_2B;Cancer;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;literature review;relevant information;APX_2D;accomodation and care;social housing;APX_2D;cell lines xenografted;gene and cell-based;APX_2A
20173885_01;20173885;De eigenschappen van biologische medicijnen in proefdieren voorspellen met verschillende beeldvormingstechnieken;Translational or applied research;human;Implementation of specific cancer animal models;ENG;mouse;APX_2B;Cancer;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;consult (bio)statistician;APX_2D;accomodation and care;social housing;APX_2D;cell lines xenografted;gene and cell-based;APX_2A
20173885_01;20173885;De eigenschappen van biologische medicijnen in proefdieren voorspellen met verschillende beeldvormingstechnieken;Translational or applied research;human;Implementation of specific cancer animal models;ENG;mouse;APX_2B;Cancer;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;substantiated statistics;consult (bio)statistician;APX_2D;accomodation and care;social housing;APX_2D;cell lines xenografted;gene and cell-based;APX_2A
20173885_01;20173885;De eigenschappen van biologische medicijnen in proefdieren voorspellen met verschillende beeldvormingstechnieken;Translational or applied research;human;Implementation of specific cancer animal models;ENG;mouse;APX_2B;Cancer;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;literature review;relevant information;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;cell lines xenografted;gene and cell-based;APX_2A
20173885_01;20173885;De eigenschappen van biologische medicijnen in proefdieren voorspellen met verschillende beeldvormingstechnieken;Translational or applied research;human;Implementation of specific cancer animal models;ENG;mouse;APX_2B;Cancer;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;literature review;relevant information;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;cell lines xenografted;gene and cell-based;APX_2A
20173885_01;20173885;De eigenschappen van biologische medicijnen in proefdieren voorspellen met verschillende beeldvormingstechnieken;Translational or applied research;human;Implementation of specific cancer animal models;ENG;mouse;APX_2B;Cancer;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;consult (bio)statistician;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;cell lines xenografted;gene and cell-based;APX_2A
20173885_01;20173885;De eigenschappen van biologische medicijnen in proefdieren voorspellen met verschillende beeldvormingstechnieken;Translational or applied research;human;Implementation of specific cancer animal models;ENG;mouse;APX_2B;Cancer;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;substantiated statistics;consult (bio)statistician;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;cell lines xenografted;gene and cell-based;APX_2A
20173885_01;20173885;De eigenschappen van biologische medicijnen in proefdieren voorspellen met verschillende beeldvormingstechnieken;Translational or applied research;human;Implementation of specific cancer animal models;ENG;mouse;APX_2B;Cancer;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;literature review;relevant information;APX_2D;accomodation and care;social housing;APX_2D;cell lines xenografted;gene and cell-based;APX_2A
20173885_01;20173885;De eigenschappen van biologische medicijnen in proefdieren voorspellen met verschillende beeldvormingstechnieken;Translational or applied research;human;Implementation of specific cancer animal models;ENG;mouse;APX_2B;Cancer;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;literature review;relevant information;APX_2D;accomodation and care;social housing;APX_2D;cell lines xenografted;gene and cell-based;APX_2A
20173885_01;20173885;De eigenschappen van biologische medicijnen in proefdieren voorspellen met verschillende beeldvormingstechnieken;Translational or applied research;human;Implementation of specific cancer animal models;ENG;mouse;APX_2B;Cancer;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;consult (bio)statistician;APX_2D;accomodation and care;social housing;APX_2D;cell lines xenografted;gene and cell-based;APX_2A
20173885_01;20173885;De eigenschappen van biologische medicijnen in proefdieren voorspellen met verschillende beeldvormingstechnieken;Translational or applied research;human;Implementation of specific cancer animal models;ENG;mouse;APX_2B;Cancer;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;substantiated statistics;consult (bio)statistician;APX_2D;accomodation and care;social housing;APX_2D;cell lines xenografted;gene and cell-based;APX_2A
20173885_01;20173885;De eigenschappen van biologische medicijnen in proefdieren voorspellen met verschillende beeldvormingstechnieken;Translational or applied research;human;Implementation of specific cancer animal models;ENG;mouse;APX_2B;Cancer;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;literature review;relevant information;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;cell lines xenografted;gene and cell-based;APX_2A
20173885_01;20173885;De eigenschappen van biologische medicijnen in proefdieren voorspellen met verschillende beeldvormingstechnieken;Translational or applied research;human;Implementation of specific cancer animal models;ENG;mouse;APX_2B;Cancer;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;literature review;relevant information;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;cell lines xenografted;gene and cell-based;APX_2A
20173885_01;20173885;De eigenschappen van biologische medicijnen in proefdieren voorspellen met verschillende beeldvormingstechnieken;Translational or applied research;human;Implementation of specific cancer animal models;ENG;mouse;APX_2B;Cancer;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;consult (bio)statistician;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;cell lines xenografted;gene and cell-based;APX_2A
20173885_01;20173885;De eigenschappen van biologische medicijnen in proefdieren voorspellen met verschillende beeldvormingstechnieken;Translational or applied research;human;Implementation of specific cancer animal models;ENG;mouse;APX_2B;Cancer;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;substantiated statistics;consult (bio)statistician;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;cell lines xenografted;gene and cell-based;APX_2A
20173885_01;20173885;De eigenschappen van biologische medicijnen in proefdieren voorspellen met verschillende beeldvormingstechnieken;Translational or applied research;human;Implementation of specific cancer animal models;ENG;mouse;APX_2B;Cancer;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;literature review;relevant information;APX_2D;accomodation and care;social housing;APX_2D;cell lines xenografted;gene and cell-based;APX_2A
20173885_01;20173885;De eigenschappen van biologische medicijnen in proefdieren voorspellen met verschillende beeldvormingstechnieken;Translational or applied research;human;Implementation of specific cancer animal models;ENG;mouse;APX_2B;Cancer;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;literature review;relevant information;APX_2D;accomodation and care;social housing;APX_2D;cell lines xenografted;gene and cell-based;APX_2A
20173885_01;20173885;De eigenschappen van biologische medicijnen in proefdieren voorspellen met verschillende beeldvormingstechnieken;Translational or applied research;human;Implementation of specific cancer animal models;ENG;mouse;APX_2B;Cancer;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;consult (bio)statistician;APX_2D;accomodation and care;social housing;APX_2D;cell lines xenografted;gene and cell-based;APX_2A
20173885_01;20173885;De eigenschappen van biologische medicijnen in proefdieren voorspellen met verschillende beeldvormingstechnieken;Translational or applied research;human;Implementation of specific cancer animal models;ENG;mouse;APX_2B;Cancer;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;substantiated statistics;consult (bio)statistician;APX_2D;accomodation and care;social housing;APX_2D;cell lines xenografted;gene and cell-based;APX_2A
20173885_02;20173885;De eigenschappen van biologische medicijnen in proefdieren voorspellen met verschillende beeldvormingstechnieken;Translational or applied research;human;Implementation of specific druk induced interstitial lung disease animal model and evaluation of biomarkers;ENG;rat;APX_2B;Cancer;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;availability of research tools;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;expert collaborations;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;biomarker identification;diagnostic tool;APX_2A
20173885_02;20173885;De eigenschappen van biologische medicijnen in proefdieren voorspellen met verschillende beeldvormingstechnieken;Translational or applied research;human;Implementation of specific druk induced interstitial lung disease animal model and evaluation of biomarkers;ENG;rat;APX_2B;Cancer;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;expertise;expert collaborations;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;biomarker identification;diagnostic tool;APX_2A
20173885_02;20173885;De eigenschappen van biologische medicijnen in proefdieren voorspellen met verschillende beeldvormingstechnieken;Translational or applied research;human;Implementation of specific druk induced interstitial lung disease animal model and evaluation of biomarkers;ENG;rat;APX_2B;Cancer;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;availability of research tools;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;literature review;relevant information;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;biomarker identification;diagnostic tool;APX_2A
20173885_02;20173885;De eigenschappen van biologische medicijnen in proefdieren voorspellen met verschillende beeldvormingstechnieken;Translational or applied research;human;Implementation of specific druk induced interstitial lung disease animal model and evaluation of biomarkers;ENG;rat;APX_2B;Cancer;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;literature review;relevant information;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;biomarker identification;diagnostic tool;APX_2A
20173885_02;20173885;De eigenschappen van biologische medicijnen in proefdieren voorspellen met verschillende beeldvormingstechnieken;Translational or applied research;human;Implementation of specific druk induced interstitial lung disease animal model and evaluation of biomarkers;ENG;rat;APX_2B;Cancer;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;availability of research tools;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;consult (bio)statistician;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;biomarker identification;diagnostic tool;APX_2A
20173885_02;20173885;De eigenschappen van biologische medicijnen in proefdieren voorspellen met verschillende beeldvormingstechnieken;Translational or applied research;human;Implementation of specific druk induced interstitial lung disease animal model and evaluation of biomarkers;ENG;rat;APX_2B;Cancer;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;substantiated statistics;consult (bio)statistician;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;biomarker identification;diagnostic tool;APX_2A
20173885_02;20173885;De eigenschappen van biologische medicijnen in proefdieren voorspellen met verschillende beeldvormingstechnieken;Translational or applied research;human;Implementation of specific druk induced interstitial lung disease animal model and evaluation of biomarkers;ENG;rat;APX_2B;Cancer;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;availability of research tools;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;expert collaborations;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;biomarker identification;diagnostic tool;APX_2A
20173885_02;20173885;De eigenschappen van biologische medicijnen in proefdieren voorspellen met verschillende beeldvormingstechnieken;Translational or applied research;human;Implementation of specific druk induced interstitial lung disease animal model and evaluation of biomarkers;ENG;rat;APX_2B;Cancer;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;expertise;expert collaborations;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;biomarker identification;diagnostic tool;APX_2A
20173885_02;20173885;De eigenschappen van biologische medicijnen in proefdieren voorspellen met verschillende beeldvormingstechnieken;Translational or applied research;human;Implementation of specific druk induced interstitial lung disease animal model and evaluation of biomarkers;ENG;rat;APX_2B;Cancer;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;availability of research tools;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;literature review;relevant information;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;biomarker identification;diagnostic tool;APX_2A
20173885_02;20173885;De eigenschappen van biologische medicijnen in proefdieren voorspellen met verschillende beeldvormingstechnieken;Translational or applied research;human;Implementation of specific druk induced interstitial lung disease animal model and evaluation of biomarkers;ENG;rat;APX_2B;Cancer;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;literature review;relevant information;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;biomarker identification;diagnostic tool;APX_2A
20173885_02;20173885;De eigenschappen van biologische medicijnen in proefdieren voorspellen met verschillende beeldvormingstechnieken;Translational or applied research;human;Implementation of specific druk induced interstitial lung disease animal model and evaluation of biomarkers;ENG;rat;APX_2B;Cancer;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;availability of research tools;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;consult (bio)statistician;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;biomarker identification;diagnostic tool;APX_2A
20173885_02;20173885;De eigenschappen van biologische medicijnen in proefdieren voorspellen met verschillende beeldvormingstechnieken;Translational or applied research;human;Implementation of specific druk induced interstitial lung disease animal model and evaluation of biomarkers;ENG;rat;APX_2B;Cancer;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;substantiated statistics;consult (bio)statistician;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;biomarker identification;diagnostic tool;APX_2A
20173885_02;20173885;De eigenschappen van biologische medicijnen in proefdieren voorspellen met verschillende beeldvormingstechnieken;Translational or applied research;human;Implementation of specific druk induced interstitial lung disease animal model and evaluation of biomarkers;ENG;rat;APX_2B;Cancer;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;availability of research tools;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;expert collaborations;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;biomarker identification;diagnostic tool;APX_2A
20173885_02;20173885;De eigenschappen van biologische medicijnen in proefdieren voorspellen met verschillende beeldvormingstechnieken;Translational or applied research;human;Implementation of specific druk induced interstitial lung disease animal model and evaluation of biomarkers;ENG;rat;APX_2B;Cancer;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;expertise;expert collaborations;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;biomarker identification;diagnostic tool;APX_2A
20173885_02;20173885;De eigenschappen van biologische medicijnen in proefdieren voorspellen met verschillende beeldvormingstechnieken;Translational or applied research;human;Implementation of specific druk induced interstitial lung disease animal model and evaluation of biomarkers;ENG;rat;APX_2B;Cancer;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;availability of research tools;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;literature review;relevant information;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;biomarker identification;diagnostic tool;APX_2A
20173885_02;20173885;De eigenschappen van biologische medicijnen in proefdieren voorspellen met verschillende beeldvormingstechnieken;Translational or applied research;human;Implementation of specific druk induced interstitial lung disease animal model and evaluation of biomarkers;ENG;rat;APX_2B;Cancer;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;literature review;relevant information;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;biomarker identification;diagnostic tool;APX_2A
20173885_02;20173885;De eigenschappen van biologische medicijnen in proefdieren voorspellen met verschillende beeldvormingstechnieken;Translational or applied research;human;Implementation of specific druk induced interstitial lung disease animal model and evaluation of biomarkers;ENG;rat;APX_2B;Cancer;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;availability of research tools;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;consult (bio)statistician;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;biomarker identification;diagnostic tool;APX_2A
20173885_02;20173885;De eigenschappen van biologische medicijnen in proefdieren voorspellen met verschillende beeldvormingstechnieken;Translational or applied research;human;Implementation of specific druk induced interstitial lung disease animal model and evaluation of biomarkers;ENG;rat;APX_2B;Cancer;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;substantiated statistics;consult (bio)statistician;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;biomarker identification;diagnostic tool;APX_2A
20173885_02;20173885;De eigenschappen van biologische medicijnen in proefdieren voorspellen met verschillende beeldvormingstechnieken;Translational or applied research;human;Implementation of specific druk induced interstitial lung disease animal model and evaluation of biomarkers;ENG;rat;APX_2B;Cancer;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;availability of research tools;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;expert collaborations;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;biomarker identification;diagnostic tool;APX_2A
20173885_02;20173885;De eigenschappen van biologische medicijnen in proefdieren voorspellen met verschillende beeldvormingstechnieken;Translational or applied research;human;Implementation of specific druk induced interstitial lung disease animal model and evaluation of biomarkers;ENG;rat;APX_2B;Cancer;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;expertise;expert collaborations;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;biomarker identification;diagnostic tool;APX_2A
20173885_02;20173885;De eigenschappen van biologische medicijnen in proefdieren voorspellen met verschillende beeldvormingstechnieken;Translational or applied research;human;Implementation of specific druk induced interstitial lung disease animal model and evaluation of biomarkers;ENG;rat;APX_2B;Cancer;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;availability of research tools;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;literature review;relevant information;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;biomarker identification;diagnostic tool;APX_2A
20173885_02;20173885;De eigenschappen van biologische medicijnen in proefdieren voorspellen met verschillende beeldvormingstechnieken;Translational or applied research;human;Implementation of specific druk induced interstitial lung disease animal model and evaluation of biomarkers;ENG;rat;APX_2B;Cancer;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;literature review;relevant information;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;biomarker identification;diagnostic tool;APX_2A
20173885_02;20173885;De eigenschappen van biologische medicijnen in proefdieren voorspellen met verschillende beeldvormingstechnieken;Translational or applied research;human;Implementation of specific druk induced interstitial lung disease animal model and evaluation of biomarkers;ENG;rat;APX_2B;Cancer;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;availability of research tools;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;consult (bio)statistician;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;biomarker identification;diagnostic tool;APX_2A
20173885_02;20173885;De eigenschappen van biologische medicijnen in proefdieren voorspellen met verschillende beeldvormingstechnieken;Translational or applied research;human;Implementation of specific druk induced interstitial lung disease animal model and evaluation of biomarkers;ENG;rat;APX_2B;Cancer;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;availability of research tools;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;substantiated statistics;consult (bio)statistician;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;biomarker identification;diagnostic tool;APX_2A
20173885_03;20173885;De eigenschappen van biologische medicijnen in proefdieren voorspellen met verschillende beeldvormingstechnieken;Translational or applied research;human;Evaluation of the stability of new PET?SPECT chelates;ENG;mouse;APX_2B;Cancer;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;literature review;relevant information;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;radiolabeled biologics;diagnostic tool;APX_2A
20173885_03;20173885;De eigenschappen van biologische medicijnen in proefdieren voorspellen met verschillende beeldvormingstechnieken;Translational or applied research;human;Evaluation of the stability of new PET?SPECT chelates;ENG;mouse;APX_2B;Cancer;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;literature review;relevant information;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;radiolabeled biologics;diagnostic tool;APX_2A
20173885_03;20173885;De eigenschappen van biologische medicijnen in proefdieren voorspellen met verschillende beeldvormingstechnieken;Translational or applied research;human;Evaluation of the stability of new PET?SPECT chelates;ENG;mouse;APX_2B;Cancer;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;consult (bio)statistician;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;radiolabeled biologics;diagnostic tool;APX_2A
20173885_03;20173885;De eigenschappen van biologische medicijnen in proefdieren voorspellen met verschillende beeldvormingstechnieken;Translational or applied research;human;Evaluation of the stability of new PET?SPECT chelates;ENG;mouse;APX_2B;Cancer;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;substantiated statistics;consult (bio)statistician;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;radiolabeled biologics;diagnostic tool;APX_2A
20173885_03;20173885;De eigenschappen van biologische medicijnen in proefdieren voorspellen met verschillende beeldvormingstechnieken;Translational or applied research;human;Evaluation of the stability of new PET?SPECT chelates;ENG;mouse;APX_2B;Cancer;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;literature review;relevant information;APX_2D;accomodation and care;social housing;APX_2D;radiolabeled biologics;diagnostic tool;APX_2A
20173885_03;20173885;De eigenschappen van biologische medicijnen in proefdieren voorspellen met verschillende beeldvormingstechnieken;Translational or applied research;human;Evaluation of the stability of new PET?SPECT chelates;ENG;mouse;APX_2B;Cancer;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;literature review;relevant information;APX_2D;accomodation and care;social housing;APX_2D;radiolabeled biologics;diagnostic tool;APX_2A
20173885_03;20173885;De eigenschappen van biologische medicijnen in proefdieren voorspellen met verschillende beeldvormingstechnieken;Translational or applied research;human;Evaluation of the stability of new PET?SPECT chelates;ENG;mouse;APX_2B;Cancer;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;consult (bio)statistician;APX_2D;accomodation and care;social housing;APX_2D;radiolabeled biologics;diagnostic tool;APX_2A
20173885_03;20173885;De eigenschappen van biologische medicijnen in proefdieren voorspellen met verschillende beeldvormingstechnieken;Translational or applied research;human;Evaluation of the stability of new PET?SPECT chelates;ENG;mouse;APX_2B;Cancer;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;substantiated statistics;consult (bio)statistician;APX_2D;accomodation and care;social housing;APX_2D;radiolabeled biologics;diagnostic tool;APX_2A
20173885_03;20173885;De eigenschappen van biologische medicijnen in proefdieren voorspellen met verschillende beeldvormingstechnieken;Translational or applied research;human;Evaluation of the stability of new PET?SPECT chelates;ENG;mouse;APX_2B;Cancer;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;literature review;relevant information;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;radiolabeled biologics;diagnostic tool;APX_2A
20173885_03;20173885;De eigenschappen van biologische medicijnen in proefdieren voorspellen met verschillende beeldvormingstechnieken;Translational or applied research;human;Evaluation of the stability of new PET?SPECT chelates;ENG;mouse;APX_2B;Cancer;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;literature review;relevant information;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;radiolabeled biologics;diagnostic tool;APX_2A
20173885_03;20173885;De eigenschappen van biologische medicijnen in proefdieren voorspellen met verschillende beeldvormingstechnieken;Translational or applied research;human;Evaluation of the stability of new PET?SPECT chelates;ENG;mouse;APX_2B;Cancer;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;consult (bio)statistician;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;radiolabeled biologics;diagnostic tool;APX_2A
20173885_03;20173885;De eigenschappen van biologische medicijnen in proefdieren voorspellen met verschillende beeldvormingstechnieken;Translational or applied research;human;Evaluation of the stability of new PET?SPECT chelates;ENG;mouse;APX_2B;Cancer;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;substantiated statistics;consult (bio)statistician;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;radiolabeled biologics;diagnostic tool;APX_2A
20173885_03;20173885;De eigenschappen van biologische medicijnen in proefdieren voorspellen met verschillende beeldvormingstechnieken;Translational or applied research;human;Evaluation of the stability of new PET?SPECT chelates;ENG;mouse;APX_2B;Cancer;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;literature review;relevant information;APX_2D;accomodation and care;social housing;APX_2D;radiolabeled biologics;diagnostic tool;APX_2A
20173885_03;20173885;De eigenschappen van biologische medicijnen in proefdieren voorspellen met verschillende beeldvormingstechnieken;Translational or applied research;human;Evaluation of the stability of new PET?SPECT chelates;ENG;mouse;APX_2B;Cancer;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;literature review;relevant information;APX_2D;accomodation and care;social housing;APX_2D;radiolabeled biologics;diagnostic tool;APX_2A
20173885_03;20173885;De eigenschappen van biologische medicijnen in proefdieren voorspellen met verschillende beeldvormingstechnieken;Translational or applied research;human;Evaluation of the stability of new PET?SPECT chelates;ENG;mouse;APX_2B;Cancer;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;consult (bio)statistician;APX_2D;accomodation and care;social housing;APX_2D;radiolabeled biologics;diagnostic tool;APX_2A
20173885_03;20173885;De eigenschappen van biologische medicijnen in proefdieren voorspellen met verschillende beeldvormingstechnieken;Translational or applied research;human;Evaluation of the stability of new PET?SPECT chelates;ENG;mouse;APX_2B;Cancer;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;substantiated statistics;consult (bio)statistician;APX_2D;accomodation and care;social housing;APX_2D;radiolabeled biologics;diagnostic tool;APX_2A
20173885_03;20173885;De eigenschappen van biologische medicijnen in proefdieren voorspellen met verschillende beeldvormingstechnieken;Translational or applied research;human;Evaluation of the stability of new PET?SPECT chelates;ENG;mouse;APX_2B;Cancer;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;literature review;relevant information;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;radiolabeled biologics;diagnostic tool;APX_2A
20173885_03;20173885;De eigenschappen van biologische medicijnen in proefdieren voorspellen met verschillende beeldvormingstechnieken;Translational or applied research;human;Evaluation of the stability of new PET?SPECT chelates;ENG;mouse;APX_2B;Cancer;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;literature review;relevant information;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;radiolabeled biologics;diagnostic tool;APX_2A
20173885_03;20173885;De eigenschappen van biologische medicijnen in proefdieren voorspellen met verschillende beeldvormingstechnieken;Translational or applied research;human;Evaluation of the stability of new PET?SPECT chelates;ENG;mouse;APX_2B;Cancer;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;consult (bio)statistician;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;radiolabeled biologics;diagnostic tool;APX_2A
20173885_03;20173885;De eigenschappen van biologische medicijnen in proefdieren voorspellen met verschillende beeldvormingstechnieken;Translational or applied research;human;Evaluation of the stability of new PET?SPECT chelates;ENG;mouse;APX_2B;Cancer;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;substantiated statistics;consult (bio)statistician;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;radiolabeled biologics;diagnostic tool;APX_2A
20173885_03;20173885;De eigenschappen van biologische medicijnen in proefdieren voorspellen met verschillende beeldvormingstechnieken;Translational or applied research;human;Evaluation of the stability of new PET?SPECT chelates;ENG;mouse;APX_2B;Cancer;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;literature review;relevant information;APX_2D;accomodation and care;social housing;APX_2D;radiolabeled biologics;diagnostic tool;APX_2A
20173885_03;20173885;De eigenschappen van biologische medicijnen in proefdieren voorspellen met verschillende beeldvormingstechnieken;Translational or applied research;human;Evaluation of the stability of new PET?SPECT chelates;ENG;mouse;APX_2B;Cancer;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;literature review;relevant information;APX_2D;accomodation and care;social housing;APX_2D;radiolabeled biologics;diagnostic tool;APX_2A
20173885_03;20173885;De eigenschappen van biologische medicijnen in proefdieren voorspellen met verschillende beeldvormingstechnieken;Translational or applied research;human;Evaluation of the stability of new PET?SPECT chelates;ENG;mouse;APX_2B;Cancer;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;consult (bio)statistician;APX_2D;accomodation and care;social housing;APX_2D;radiolabeled biologics;diagnostic tool;APX_2A
20173885_03;20173885;De eigenschappen van biologische medicijnen in proefdieren voorspellen met verschillende beeldvormingstechnieken;Translational or applied research;human;Evaluation of the stability of new PET?SPECT chelates;ENG;mouse;APX_2B;Cancer;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;substantiated statistics;consult (bio)statistician;APX_2D;accomodation and care;social housing;APX_2D;radiolabeled biologics;diagnostic tool;APX_2A
20173885_03;20173885;De eigenschappen van biologische medicijnen in proefdieren voorspellen met verschillende beeldvormingstechnieken;Translational or applied research;human;Evaluation of the stability of new PET?SPECT chelates;ENG;mouse;APX_2B;Cancer;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;literature review;relevant information;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;radiolabeled biologics;diagnostic tool;APX_2A
20173885_03;20173885;De eigenschappen van biologische medicijnen in proefdieren voorspellen met verschillende beeldvormingstechnieken;Translational or applied research;human;Evaluation of the stability of new PET?SPECT chelates;ENG;mouse;APX_2B;Cancer;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;literature review;relevant information;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;radiolabeled biologics;diagnostic tool;APX_2A
20173885_03;20173885;De eigenschappen van biologische medicijnen in proefdieren voorspellen met verschillende beeldvormingstechnieken;Translational or applied research;human;Evaluation of the stability of new PET?SPECT chelates;ENG;mouse;APX_2B;Cancer;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;consult (bio)statistician;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;radiolabeled biologics;diagnostic tool;APX_2A
20173885_03;20173885;De eigenschappen van biologische medicijnen in proefdieren voorspellen met verschillende beeldvormingstechnieken;Translational or applied research;human;Evaluation of the stability of new PET?SPECT chelates;ENG;mouse;APX_2B;Cancer;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;substantiated statistics;consult (bio)statistician;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;radiolabeled biologics;diagnostic tool;APX_2A
20173885_03;20173885;De eigenschappen van biologische medicijnen in proefdieren voorspellen met verschillende beeldvormingstechnieken;Translational or applied research;human;Evaluation of the stability of new PET?SPECT chelates;ENG;mouse;APX_2B;Cancer;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;literature review;relevant information;APX_2D;accomodation and care;social housing;APX_2D;radiolabeled biologics;diagnostic tool;APX_2A
20173885_03;20173885;De eigenschappen van biologische medicijnen in proefdieren voorspellen met verschillende beeldvormingstechnieken;Translational or applied research;human;Evaluation of the stability of new PET?SPECT chelates;ENG;mouse;APX_2B;Cancer;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;literature review;relevant information;APX_2D;accomodation and care;social housing;APX_2D;radiolabeled biologics;diagnostic tool;APX_2A
20173885_03;20173885;De eigenschappen van biologische medicijnen in proefdieren voorspellen met verschillende beeldvormingstechnieken;Translational or applied research;human;Evaluation of the stability of new PET?SPECT chelates;ENG;mouse;APX_2B;Cancer;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;consult (bio)statistician;APX_2D;accomodation and care;social housing;APX_2D;radiolabeled biologics;diagnostic tool;APX_2A
20173885_03;20173885;De eigenschappen van biologische medicijnen in proefdieren voorspellen met verschillende beeldvormingstechnieken;Translational or applied research;human;Evaluation of the stability of new PET?SPECT chelates;ENG;mouse;APX_2B;Cancer;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;substantiated statistics;consult (bio)statistician;APX_2D;accomodation and care;social housing;APX_2D;radiolabeled biologics;diagnostic tool;APX_2A
20173885_04;20173885;De eigenschappen van biologische medicijnen in proefdieren voorspellen met verschillende beeldvormingstechnieken;Translational or applied research;human;Evaluation of the use of advanced imaging techniques sto study pharmacokinetics in vivo fate and subcellular localization in novel biologics in rats;ENG;rat;APX_2B;Cancer;NTS_1.3;Naive or healthy;APX_2A;APX_2A;Appendix;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;literature review;relevant information;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;imaging biologics;diagnostic tool;APX_2A
20173885_04;20173885;De eigenschappen van biologische medicijnen in proefdieren voorspellen met verschillende beeldvormingstechnieken;Translational or applied research;human;Evaluation of the use of advanced imaging techniques sto study pharmacokinetics in vivo fate and subcellular localization in novel biologics in rats;ENG;rat;APX_2B;Cancer;NTS_1.3;Naive or healthy;APX_2A;APX_2A;Appendix;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;literature review;relevant information;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;imaging biologics;diagnostic tool;APX_2A
20173885_04;20173885;De eigenschappen van biologische medicijnen in proefdieren voorspellen met verschillende beeldvormingstechnieken;Translational or applied research;human;Evaluation of the use of advanced imaging techniques sto study pharmacokinetics in vivo fate and subcellular localization in novel biologics in rats;ENG;rat;APX_2B;Cancer;NTS_1.3;Naive or healthy;APX_2A;APX_2A;Appendix;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;consult (bio)statistician;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;imaging biologics;diagnostic tool;APX_2A
20173885_04;20173885;De eigenschappen van biologische medicijnen in proefdieren voorspellen met verschillende beeldvormingstechnieken;Translational or applied research;human;Evaluation of the use of advanced imaging techniques sto study pharmacokinetics in vivo fate and subcellular localization in novel biologics in rats;ENG;rat;APX_2B;Cancer;NTS_1.3;Naive or healthy;APX_2A;APX_2A;Appendix;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;substantiated statistics;consult (bio)statistician;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;imaging biologics;diagnostic tool;APX_2A
20173885_04;20173885;De eigenschappen van biologische medicijnen in proefdieren voorspellen met verschillende beeldvormingstechnieken;Translational or applied research;human;Evaluation of the use of advanced imaging techniques sto study pharmacokinetics in vivo fate and subcellular localization in novel biologics in rats;ENG;rat;APX_2B;Cancer;NTS_1.3;Naive or healthy;APX_2A;APX_2A;Appendix;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;literature review;relevant information;APX_2D;accomodation and care;social housing;APX_2D;imaging biologics;diagnostic tool;APX_2A
20173885_04;20173885;De eigenschappen van biologische medicijnen in proefdieren voorspellen met verschillende beeldvormingstechnieken;Translational or applied research;human;Evaluation of the use of advanced imaging techniques sto study pharmacokinetics in vivo fate and subcellular localization in novel biologics in rats;ENG;rat;APX_2B;Cancer;NTS_1.3;Naive or healthy;APX_2A;APX_2A;Appendix;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;literature review;relevant information;APX_2D;accomodation and care;social housing;APX_2D;imaging biologics;diagnostic tool;APX_2A
20173885_04;20173885;De eigenschappen van biologische medicijnen in proefdieren voorspellen met verschillende beeldvormingstechnieken;Translational or applied research;human;Evaluation of the use of advanced imaging techniques sto study pharmacokinetics in vivo fate and subcellular localization in novel biologics in rats;ENG;rat;APX_2B;Cancer;NTS_1.3;Naive or healthy;APX_2A;APX_2A;Appendix;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;consult (bio)statistician;APX_2D;accomodation and care;social housing;APX_2D;imaging biologics;diagnostic tool;APX_2A
20173885_04;20173885;De eigenschappen van biologische medicijnen in proefdieren voorspellen met verschillende beeldvormingstechnieken;Translational or applied research;human;Evaluation of the use of advanced imaging techniques sto study pharmacokinetics in vivo fate and subcellular localization in novel biologics in rats;ENG;rat;APX_2B;Cancer;NTS_1.3;Naive or healthy;APX_2A;APX_2A;Appendix;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;substantiated statistics;consult (bio)statistician;APX_2D;accomodation and care;social housing;APX_2D;imaging biologics;diagnostic tool;APX_2A
20173885_04;20173885;De eigenschappen van biologische medicijnen in proefdieren voorspellen met verschillende beeldvormingstechnieken;Translational or applied research;human;Evaluation of the use of advanced imaging techniques sto study pharmacokinetics in vivo fate and subcellular localization in novel biologics in rats;ENG;rat;APX_2B;Cancer;NTS_1.3;Naive or healthy;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;literature review;relevant information;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;imaging biologics;diagnostic tool;APX_2A
20173885_04;20173885;De eigenschappen van biologische medicijnen in proefdieren voorspellen met verschillende beeldvormingstechnieken;Translational or applied research;human;Evaluation of the use of advanced imaging techniques sto study pharmacokinetics in vivo fate and subcellular localization in novel biologics in rats;ENG;rat;APX_2B;Cancer;NTS_1.3;Naive or healthy;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;literature review;relevant information;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;imaging biologics;diagnostic tool;APX_2A
20173885_04;20173885;De eigenschappen van biologische medicijnen in proefdieren voorspellen met verschillende beeldvormingstechnieken;Translational or applied research;human;Evaluation of the use of advanced imaging techniques sto study pharmacokinetics in vivo fate and subcellular localization in novel biologics in rats;ENG;rat;APX_2B;Cancer;NTS_1.3;Naive or healthy;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;consult (bio)statistician;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;imaging biologics;diagnostic tool;APX_2A
20173885_04;20173885;De eigenschappen van biologische medicijnen in proefdieren voorspellen met verschillende beeldvormingstechnieken;Translational or applied research;human;Evaluation of the use of advanced imaging techniques sto study pharmacokinetics in vivo fate and subcellular localization in novel biologics in rats;ENG;rat;APX_2B;Cancer;NTS_1.3;Naive or healthy;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;substantiated statistics;consult (bio)statistician;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;imaging biologics;diagnostic tool;APX_2A
20173885_04;20173885;De eigenschappen van biologische medicijnen in proefdieren voorspellen met verschillende beeldvormingstechnieken;Translational or applied research;human;Evaluation of the use of advanced imaging techniques sto study pharmacokinetics in vivo fate and subcellular localization in novel biologics in rats;ENG;rat;APX_2B;Cancer;NTS_1.3;Naive or healthy;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;literature review;relevant information;APX_2D;accomodation and care;social housing;APX_2D;imaging biologics;diagnostic tool;APX_2A
20173885_04;20173885;De eigenschappen van biologische medicijnen in proefdieren voorspellen met verschillende beeldvormingstechnieken;Translational or applied research;human;Evaluation of the use of advanced imaging techniques sto study pharmacokinetics in vivo fate and subcellular localization in novel biologics in rats;ENG;rat;APX_2B;Cancer;NTS_1.3;Naive or healthy;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;literature review;relevant information;APX_2D;accomodation and care;social housing;APX_2D;imaging biologics;diagnostic tool;APX_2A
20173885_04;20173885;De eigenschappen van biologische medicijnen in proefdieren voorspellen met verschillende beeldvormingstechnieken;Translational or applied research;human;Evaluation of the use of advanced imaging techniques sto study pharmacokinetics in vivo fate and subcellular localization in novel biologics in rats;ENG;rat;APX_2B;Cancer;NTS_1.3;Naive or healthy;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;consult (bio)statistician;APX_2D;accomodation and care;social housing;APX_2D;imaging biologics;diagnostic tool;APX_2A
20173885_04;20173885;De eigenschappen van biologische medicijnen in proefdieren voorspellen met verschillende beeldvormingstechnieken;Translational or applied research;human;Evaluation of the use of advanced imaging techniques sto study pharmacokinetics in vivo fate and subcellular localization in novel biologics in rats;ENG;rat;APX_2B;Cancer;NTS_1.3;Naive or healthy;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;substantiated statistics;consult (bio)statistician;APX_2D;accomodation and care;social housing;APX_2D;imaging biologics;diagnostic tool;APX_2A
20173885_04;20173885;De eigenschappen van biologische medicijnen in proefdieren voorspellen met verschillende beeldvormingstechnieken;Translational or applied research;human;Evaluation of the use of advanced imaging techniques sto study pharmacokinetics in vivo fate and subcellular localization in novel biologics in rats;ENG;rat;APX_2B;Cancer;NTS_3.1;Naive or healthy;APX_2A;APX_2A;Appendix;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;literature review;relevant information;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;imaging biologics;diagnostic tool;APX_2A
20173885_04;20173885;De eigenschappen van biologische medicijnen in proefdieren voorspellen met verschillende beeldvormingstechnieken;Translational or applied research;human;Evaluation of the use of advanced imaging techniques sto study pharmacokinetics in vivo fate and subcellular localization in novel biologics in rats;ENG;rat;APX_2B;Cancer;NTS_3.1;Naive or healthy;APX_2A;APX_2A;Appendix;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;literature review;relevant information;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;imaging biologics;diagnostic tool;APX_2A
20173885_04;20173885;De eigenschappen van biologische medicijnen in proefdieren voorspellen met verschillende beeldvormingstechnieken;Translational or applied research;human;Evaluation of the use of advanced imaging techniques sto study pharmacokinetics in vivo fate and subcellular localization in novel biologics in rats;ENG;rat;APX_2B;Cancer;NTS_3.1;Naive or healthy;APX_2A;APX_2A;Appendix;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;consult (bio)statistician;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;imaging biologics;diagnostic tool;APX_2A
20173885_04;20173885;De eigenschappen van biologische medicijnen in proefdieren voorspellen met verschillende beeldvormingstechnieken;Translational or applied research;human;Evaluation of the use of advanced imaging techniques sto study pharmacokinetics in vivo fate and subcellular localization in novel biologics in rats;ENG;rat;APX_2B;Cancer;NTS_3.1;Naive or healthy;APX_2A;APX_2A;Appendix;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;substantiated statistics;consult (bio)statistician;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;imaging biologics;diagnostic tool;APX_2A
20173885_04;20173885;De eigenschappen van biologische medicijnen in proefdieren voorspellen met verschillende beeldvormingstechnieken;Translational or applied research;human;Evaluation of the use of advanced imaging techniques sto study pharmacokinetics in vivo fate and subcellular localization in novel biologics in rats;ENG;rat;APX_2B;Cancer;NTS_3.1;Naive or healthy;APX_2A;APX_2A;Appendix;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;literature review;relevant information;APX_2D;accomodation and care;social housing;APX_2D;imaging biologics;diagnostic tool;APX_2A
20173885_04;20173885;De eigenschappen van biologische medicijnen in proefdieren voorspellen met verschillende beeldvormingstechnieken;Translational or applied research;human;Evaluation of the use of advanced imaging techniques sto study pharmacokinetics in vivo fate and subcellular localization in novel biologics in rats;ENG;rat;APX_2B;Cancer;NTS_3.1;Naive or healthy;APX_2A;APX_2A;Appendix;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;literature review;relevant information;APX_2D;accomodation and care;social housing;APX_2D;imaging biologics;diagnostic tool;APX_2A
20173885_04;20173885;De eigenschappen van biologische medicijnen in proefdieren voorspellen met verschillende beeldvormingstechnieken;Translational or applied research;human;Evaluation of the use of advanced imaging techniques sto study pharmacokinetics in vivo fate and subcellular localization in novel biologics in rats;ENG;rat;APX_2B;Cancer;NTS_3.1;Naive or healthy;APX_2A;APX_2A;Appendix;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;consult (bio)statistician;APX_2D;accomodation and care;social housing;APX_2D;imaging biologics;diagnostic tool;APX_2A
20173885_04;20173885;De eigenschappen van biologische medicijnen in proefdieren voorspellen met verschillende beeldvormingstechnieken;Translational or applied research;human;Evaluation of the use of advanced imaging techniques sto study pharmacokinetics in vivo fate and subcellular localization in novel biologics in rats;ENG;rat;APX_2B;Cancer;NTS_3.1;Naive or healthy;APX_2A;APX_2A;Appendix;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;substantiated statistics;consult (bio)statistician;APX_2D;accomodation and care;social housing;APX_2D;imaging biologics;diagnostic tool;APX_2A
20173885_04;20173885;De eigenschappen van biologische medicijnen in proefdieren voorspellen met verschillende beeldvormingstechnieken;Translational or applied research;human;Evaluation of the use of advanced imaging techniques sto study pharmacokinetics in vivo fate and subcellular localization in novel biologics in rats;ENG;rat;APX_2B;Cancer;NTS_3.1;Naive or healthy;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;literature review;relevant information;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;imaging biologics;diagnostic tool;APX_2A
20173885_04;20173885;De eigenschappen van biologische medicijnen in proefdieren voorspellen met verschillende beeldvormingstechnieken;Translational or applied research;human;Evaluation of the use of advanced imaging techniques sto study pharmacokinetics in vivo fate and subcellular localization in novel biologics in rats;ENG;rat;APX_2B;Cancer;NTS_3.1;Naive or healthy;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;literature review;relevant information;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;imaging biologics;diagnostic tool;APX_2A
20173885_04;20173885;De eigenschappen van biologische medicijnen in proefdieren voorspellen met verschillende beeldvormingstechnieken;Translational or applied research;human;Evaluation of the use of advanced imaging techniques sto study pharmacokinetics in vivo fate and subcellular localization in novel biologics in rats;ENG;rat;APX_2B;Cancer;NTS_3.1;Naive or healthy;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;consult (bio)statistician;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;imaging biologics;diagnostic tool;APX_2A
20173885_04;20173885;De eigenschappen van biologische medicijnen in proefdieren voorspellen met verschillende beeldvormingstechnieken;Translational or applied research;human;Evaluation of the use of advanced imaging techniques sto study pharmacokinetics in vivo fate and subcellular localization in novel biologics in rats;ENG;rat;APX_2B;Cancer;NTS_3.1;Naive or healthy;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;substantiated statistics;consult (bio)statistician;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;imaging biologics;diagnostic tool;APX_2A
20173885_04;20173885;De eigenschappen van biologische medicijnen in proefdieren voorspellen met verschillende beeldvormingstechnieken;Translational or applied research;human;Evaluation of the use of advanced imaging techniques sto study pharmacokinetics in vivo fate and subcellular localization in novel biologics in rats;ENG;rat;APX_2B;Cancer;NTS_3.1;Naive or healthy;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;literature review;relevant information;APX_2D;accomodation and care;social housing;APX_2D;imaging biologics;diagnostic tool;APX_2A
20173885_04;20173885;De eigenschappen van biologische medicijnen in proefdieren voorspellen met verschillende beeldvormingstechnieken;Translational or applied research;human;Evaluation of the use of advanced imaging techniques sto study pharmacokinetics in vivo fate and subcellular localization in novel biologics in rats;ENG;rat;APX_2B;Cancer;NTS_3.1;Naive or healthy;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;literature review;relevant information;APX_2D;accomodation and care;social housing;APX_2D;imaging biologics;diagnostic tool;APX_2A
20173885_04;20173885;De eigenschappen van biologische medicijnen in proefdieren voorspellen met verschillende beeldvormingstechnieken;Translational or applied research;human;Evaluation of the use of advanced imaging techniques sto study pharmacokinetics in vivo fate and subcellular localization in novel biologics in rats;ENG;rat;APX_2B;Cancer;NTS_3.1;Naive or healthy;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;consult (bio)statistician;APX_2D;accomodation and care;social housing;APX_2D;imaging biologics;diagnostic tool;APX_2A
20173885_04;20173885;De eigenschappen van biologische medicijnen in proefdieren voorspellen met verschillende beeldvormingstechnieken;Translational or applied research;human;Evaluation of the use of advanced imaging techniques sto study pharmacokinetics in vivo fate and subcellular localization in novel biologics in rats;ENG;rat;APX_2B;Cancer;NTS_3.1;Naive or healthy;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;availability of research tools;APX_2B;intervention related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;substantiated statistics;consult (bio)statistician;APX_2D;accomodation and care;social housing;APX_2D;imaging biologics;diagnostic tool;APX_2A
20173885_05;20173885;De eigenschappen van biologische medicijnen in proefdieren voorspellen met verschillende beeldvormingstechnieken;Translational or applied research;human;Evaluation of possibilities to investigate the pharmacodynamics of novel biologiscs with advanced imaging techniques;ENG;mouse;APX_2B;Cancer;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;reported as fact;existing model;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;antibody;biologics;APX_2A
20173885_05;20173885;De eigenschappen van biologische medicijnen in proefdieren voorspellen met verschillende beeldvormingstechnieken;Translational or applied research;human;Evaluation of possibilities to investigate the pharmacodynamics of novel biologiscs with advanced imaging techniques;ENG;mouse;APX_2B;Cancer;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;reported as fact;existing model;APX_2B;intervention related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;antibody;biologics;APX_2A
20173885_05;20173885;De eigenschappen van biologische medicijnen in proefdieren voorspellen met verschillende beeldvormingstechnieken;Translational or applied research;human;Evaluation of possibilities to investigate the pharmacodynamics of novel biologiscs with advanced imaging techniques;ENG;mouse;APX_2B;Cancer;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;reported as fact;existing model;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;literature review;relevant information;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;antibody;biologics;APX_2A
20173885_05;20173885;De eigenschappen van biologische medicijnen in proefdieren voorspellen met verschillende beeldvormingstechnieken;Translational or applied research;human;Evaluation of possibilities to investigate the pharmacodynamics of novel biologiscs with advanced imaging techniques;ENG;mouse;APX_2B;Cancer;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;reported as fact;existing model;APX_2B;intervention related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;literature review;relevant information;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;antibody;biologics;APX_2A
20173885_05;20173885;De eigenschappen van biologische medicijnen in proefdieren voorspellen met verschillende beeldvormingstechnieken;Translational or applied research;human;Evaluation of possibilities to investigate the pharmacodynamics of novel biologiscs with advanced imaging techniques;ENG;mouse;APX_2B;Cancer;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;reported as fact;existing model;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;consult (bio)statistician;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;antibody;biologics;APX_2A
20173885_05;20173885;De eigenschappen van biologische medicijnen in proefdieren voorspellen met verschillende beeldvormingstechnieken;Translational or applied research;human;Evaluation of possibilities to investigate the pharmacodynamics of novel biologiscs with advanced imaging techniques;ENG;mouse;APX_2B;Cancer;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;reported as fact;existing model;APX_2B;intervention related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;substantiated statistics;consult (bio)statistician;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;antibody;biologics;APX_2A
20173885_05;20173885;De eigenschappen van biologische medicijnen in proefdieren voorspellen met verschillende beeldvormingstechnieken;Translational or applied research;human;Evaluation of possibilities to investigate the pharmacodynamics of novel biologiscs with advanced imaging techniques;ENG;mouse;APX_2B;Cancer;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;reported as fact;existing model;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;accomodation and care;social housing;APX_2D;antibody;biologics;APX_2A
20173885_05;20173885;De eigenschappen van biologische medicijnen in proefdieren voorspellen met verschillende beeldvormingstechnieken;Translational or applied research;human;Evaluation of possibilities to investigate the pharmacodynamics of novel biologiscs with advanced imaging techniques;ENG;mouse;APX_2B;Cancer;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;reported as fact;existing model;APX_2B;intervention related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;expertise;experience with model or methodology;APX_2D;accomodation and care;social housing;APX_2D;antibody;biologics;APX_2A
20173885_05;20173885;De eigenschappen van biologische medicijnen in proefdieren voorspellen met verschillende beeldvormingstechnieken;Translational or applied research;human;Evaluation of possibilities to investigate the pharmacodynamics of novel biologiscs with advanced imaging techniques;ENG;mouse;APX_2B;Cancer;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;reported as fact;existing model;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;literature review;relevant information;APX_2D;accomodation and care;social housing;APX_2D;antibody;biologics;APX_2A
20173885_05;20173885;De eigenschappen van biologische medicijnen in proefdieren voorspellen met verschillende beeldvormingstechnieken;Translational or applied research;human;Evaluation of possibilities to investigate the pharmacodynamics of novel biologiscs with advanced imaging techniques;ENG;mouse;APX_2B;Cancer;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;reported as fact;existing model;APX_2B;intervention related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;literature review;relevant information;APX_2D;accomodation and care;social housing;APX_2D;antibody;biologics;APX_2A
20173885_05;20173885;De eigenschappen van biologische medicijnen in proefdieren voorspellen met verschillende beeldvormingstechnieken;Translational or applied research;human;Evaluation of possibilities to investigate the pharmacodynamics of novel biologiscs with advanced imaging techniques;ENG;mouse;APX_2B;Cancer;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;reported as fact;existing model;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;consult (bio)statistician;APX_2D;accomodation and care;social housing;APX_2D;antibody;biologics;APX_2A
20173885_05;20173885;De eigenschappen van biologische medicijnen in proefdieren voorspellen met verschillende beeldvormingstechnieken;Translational or applied research;human;Evaluation of possibilities to investigate the pharmacodynamics of novel biologiscs with advanced imaging techniques;ENG;mouse;APX_2B;Cancer;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;reported as fact;existing model;APX_2B;intervention related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;substantiated statistics;consult (bio)statistician;APX_2D;accomodation and care;social housing;APX_2D;antibody;biologics;APX_2A
20173885_05;20173885;De eigenschappen van biologische medicijnen in proefdieren voorspellen met verschillende beeldvormingstechnieken;Translational or applied research;human;Evaluation of possibilities to investigate the pharmacodynamics of novel biologiscs with advanced imaging techniques;ENG;mouse;APX_2B;Cancer;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;antibody;biologics;APX_2A
20173885_05;20173885;De eigenschappen van biologische medicijnen in proefdieren voorspellen met verschillende beeldvormingstechnieken;Translational or applied research;human;Evaluation of possibilities to investigate the pharmacodynamics of novel biologiscs with advanced imaging techniques;ENG;mouse;APX_2B;Cancer;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;antibody;biologics;APX_2A
20173885_05;20173885;De eigenschappen van biologische medicijnen in proefdieren voorspellen met verschillende beeldvormingstechnieken;Translational or applied research;human;Evaluation of possibilities to investigate the pharmacodynamics of novel biologiscs with advanced imaging techniques;ENG;mouse;APX_2B;Cancer;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;literature review;relevant information;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;antibody;biologics;APX_2A
20173885_05;20173885;De eigenschappen van biologische medicijnen in proefdieren voorspellen met verschillende beeldvormingstechnieken;Translational or applied research;human;Evaluation of possibilities to investigate the pharmacodynamics of novel biologiscs with advanced imaging techniques;ENG;mouse;APX_2B;Cancer;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;literature review;relevant information;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;antibody;biologics;APX_2A
20173885_05;20173885;De eigenschappen van biologische medicijnen in proefdieren voorspellen met verschillende beeldvormingstechnieken;Translational or applied research;human;Evaluation of possibilities to investigate the pharmacodynamics of novel biologiscs with advanced imaging techniques;ENG;mouse;APX_2B;Cancer;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;consult (bio)statistician;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;antibody;biologics;APX_2A
20173885_05;20173885;De eigenschappen van biologische medicijnen in proefdieren voorspellen met verschillende beeldvormingstechnieken;Translational or applied research;human;Evaluation of possibilities to investigate the pharmacodynamics of novel biologiscs with advanced imaging techniques;ENG;mouse;APX_2B;Cancer;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;substantiated statistics;consult (bio)statistician;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;antibody;biologics;APX_2A
20173885_05;20173885;De eigenschappen van biologische medicijnen in proefdieren voorspellen met verschillende beeldvormingstechnieken;Translational or applied research;human;Evaluation of possibilities to investigate the pharmacodynamics of novel biologiscs with advanced imaging techniques;ENG;mouse;APX_2B;Cancer;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;accomodation and care;social housing;APX_2D;antibody;biologics;APX_2A
20173885_05;20173885;De eigenschappen van biologische medicijnen in proefdieren voorspellen met verschillende beeldvormingstechnieken;Translational or applied research;human;Evaluation of possibilities to investigate the pharmacodynamics of novel biologiscs with advanced imaging techniques;ENG;mouse;APX_2B;Cancer;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;expertise;experience with model or methodology;APX_2D;accomodation and care;social housing;APX_2D;antibody;biologics;APX_2A
20173885_05;20173885;De eigenschappen van biologische medicijnen in proefdieren voorspellen met verschillende beeldvormingstechnieken;Translational or applied research;human;Evaluation of possibilities to investigate the pharmacodynamics of novel biologiscs with advanced imaging techniques;ENG;mouse;APX_2B;Cancer;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;literature review;relevant information;APX_2D;accomodation and care;social housing;APX_2D;antibody;biologics;APX_2A
20173885_05;20173885;De eigenschappen van biologische medicijnen in proefdieren voorspellen met verschillende beeldvormingstechnieken;Translational or applied research;human;Evaluation of possibilities to investigate the pharmacodynamics of novel biologiscs with advanced imaging techniques;ENG;mouse;APX_2B;Cancer;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;literature review;relevant information;APX_2D;accomodation and care;social housing;APX_2D;antibody;biologics;APX_2A
20173885_05;20173885;De eigenschappen van biologische medicijnen in proefdieren voorspellen met verschillende beeldvormingstechnieken;Translational or applied research;human;Evaluation of possibilities to investigate the pharmacodynamics of novel biologiscs with advanced imaging techniques;ENG;mouse;APX_2B;Cancer;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;consult (bio)statistician;APX_2D;accomodation and care;social housing;APX_2D;antibody;biologics;APX_2A
20173885_05;20173885;De eigenschappen van biologische medicijnen in proefdieren voorspellen met verschillende beeldvormingstechnieken;Translational or applied research;human;Evaluation of possibilities to investigate the pharmacodynamics of novel biologiscs with advanced imaging techniques;ENG;mouse;APX_2B;Cancer;NTS_1.3;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;substantiated statistics;consult (bio)statistician;APX_2D;accomodation and care;social housing;APX_2D;antibody;biologics;APX_2A
20173885_05;20173885;De eigenschappen van biologische medicijnen in proefdieren voorspellen met verschillende beeldvormingstechnieken;Translational or applied research;human;Evaluation of possibilities to investigate the pharmacodynamics of novel biologiscs with advanced imaging techniques;ENG;mouse;APX_2B;Cancer;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;antibody;biologics;APX_2A
20173885_05;20173885;De eigenschappen van biologische medicijnen in proefdieren voorspellen met verschillende beeldvormingstechnieken;Translational or applied research;human;Evaluation of possibilities to investigate the pharmacodynamics of novel biologiscs with advanced imaging techniques;ENG;mouse;APX_2B;Cancer;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;antibody;biologics;APX_2A
20173885_05;20173885;De eigenschappen van biologische medicijnen in proefdieren voorspellen met verschillende beeldvormingstechnieken;Translational or applied research;human;Evaluation of possibilities to investigate the pharmacodynamics of novel biologiscs with advanced imaging techniques;ENG;mouse;APX_2B;Cancer;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;literature review;relevant information;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;antibody;biologics;APX_2A
20173885_05;20173885;De eigenschappen van biologische medicijnen in proefdieren voorspellen met verschillende beeldvormingstechnieken;Translational or applied research;human;Evaluation of possibilities to investigate the pharmacodynamics of novel biologiscs with advanced imaging techniques;ENG;mouse;APX_2B;Cancer;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;literature review;relevant information;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;antibody;biologics;APX_2A
20173885_05;20173885;De eigenschappen van biologische medicijnen in proefdieren voorspellen met verschillende beeldvormingstechnieken;Translational or applied research;human;Evaluation of possibilities to investigate the pharmacodynamics of novel biologiscs with advanced imaging techniques;ENG;mouse;APX_2B;Cancer;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;consult (bio)statistician;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;antibody;biologics;APX_2A
20173885_05;20173885;De eigenschappen van biologische medicijnen in proefdieren voorspellen met verschillende beeldvormingstechnieken;Translational or applied research;human;Evaluation of possibilities to investigate the pharmacodynamics of novel biologiscs with advanced imaging techniques;ENG;mouse;APX_2B;Cancer;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;substantiated statistics;consult (bio)statistician;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;antibody;biologics;APX_2A
20173885_05;20173885;De eigenschappen van biologische medicijnen in proefdieren voorspellen met verschillende beeldvormingstechnieken;Translational or applied research;human;Evaluation of possibilities to investigate the pharmacodynamics of novel biologiscs with advanced imaging techniques;ENG;mouse;APX_2B;Cancer;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;accomodation and care;social housing;APX_2D;antibody;biologics;APX_2A
20173885_05;20173885;De eigenschappen van biologische medicijnen in proefdieren voorspellen met verschillende beeldvormingstechnieken;Translational or applied research;human;Evaluation of possibilities to investigate the pharmacodynamics of novel biologiscs with advanced imaging techniques;ENG;mouse;APX_2B;Cancer;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;expertise;experience with model or methodology;APX_2D;accomodation and care;social housing;APX_2D;antibody;biologics;APX_2A
20173885_05;20173885;De eigenschappen van biologische medicijnen in proefdieren voorspellen met verschillende beeldvormingstechnieken;Translational or applied research;human;Evaluation of possibilities to investigate the pharmacodynamics of novel biologiscs with advanced imaging techniques;ENG;mouse;APX_2B;Cancer;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;literature review;relevant information;APX_2D;accomodation and care;social housing;APX_2D;antibody;biologics;APX_2A
20173885_05;20173885;De eigenschappen van biologische medicijnen in proefdieren voorspellen met verschillende beeldvormingstechnieken;Translational or applied research;human;Evaluation of possibilities to investigate the pharmacodynamics of novel biologiscs with advanced imaging techniques;ENG;mouse;APX_2B;Cancer;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;literature review;relevant information;APX_2D;accomodation and care;social housing;APX_2D;antibody;biologics;APX_2A
20173885_05;20173885;De eigenschappen van biologische medicijnen in proefdieren voorspellen met verschillende beeldvormingstechnieken;Translational or applied research;human;Evaluation of possibilities to investigate the pharmacodynamics of novel biologiscs with advanced imaging techniques;ENG;mouse;APX_2B;Cancer;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;consult (bio)statistician;APX_2D;accomodation and care;social housing;APX_2D;antibody;biologics;APX_2A
20173885_05;20173885;De eigenschappen van biologische medicijnen in proefdieren voorspellen met verschillende beeldvormingstechnieken;Translational or applied research;human;Evaluation of possibilities to investigate the pharmacodynamics of novel biologiscs with advanced imaging techniques;ENG;mouse;APX_2B;Cancer;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;substantiated statistics;consult (bio)statistician;APX_2D;accomodation and care;social housing;APX_2D;antibody;biologics;APX_2A
20173885_05;20173885;De eigenschappen van biologische medicijnen in proefdieren voorspellen met verschillende beeldvormingstechnieken;Translational or applied research;human;Evaluation of possibilities to investigate the pharmacodynamics of novel biologiscs with advanced imaging techniques;ENG;mouse;APX_2B;Cancer;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;reported as fact;existing model;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;antibody;biologics;APX_2A
20173885_05;20173885;De eigenschappen van biologische medicijnen in proefdieren voorspellen met verschillende beeldvormingstechnieken;Translational or applied research;human;Evaluation of possibilities to investigate the pharmacodynamics of novel biologiscs with advanced imaging techniques;ENG;mouse;APX_2B;Cancer;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;reported as fact;existing model;APX_2B;intervention related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;antibody;biologics;APX_2A
20173885_05;20173885;De eigenschappen van biologische medicijnen in proefdieren voorspellen met verschillende beeldvormingstechnieken;Translational or applied research;human;Evaluation of possibilities to investigate the pharmacodynamics of novel biologiscs with advanced imaging techniques;ENG;mouse;APX_2B;Cancer;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;reported as fact;existing model;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;literature review;relevant information;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;antibody;biologics;APX_2A
20173885_05;20173885;De eigenschappen van biologische medicijnen in proefdieren voorspellen met verschillende beeldvormingstechnieken;Translational or applied research;human;Evaluation of possibilities to investigate the pharmacodynamics of novel biologiscs with advanced imaging techniques;ENG;mouse;APX_2B;Cancer;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;reported as fact;existing model;APX_2B;intervention related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;literature review;relevant information;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;antibody;biologics;APX_2A
20173885_05;20173885;De eigenschappen van biologische medicijnen in proefdieren voorspellen met verschillende beeldvormingstechnieken;Translational or applied research;human;Evaluation of possibilities to investigate the pharmacodynamics of novel biologiscs with advanced imaging techniques;ENG;mouse;APX_2B;Cancer;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;reported as fact;existing model;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;consult (bio)statistician;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;antibody;biologics;APX_2A
20173885_05;20173885;De eigenschappen van biologische medicijnen in proefdieren voorspellen met verschillende beeldvormingstechnieken;Translational or applied research;human;Evaluation of possibilities to investigate the pharmacodynamics of novel biologiscs with advanced imaging techniques;ENG;mouse;APX_2B;Cancer;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;reported as fact;existing model;APX_2B;intervention related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;substantiated statistics;consult (bio)statistician;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;antibody;biologics;APX_2A
20173885_05;20173885;De eigenschappen van biologische medicijnen in proefdieren voorspellen met verschillende beeldvormingstechnieken;Translational or applied research;human;Evaluation of possibilities to investigate the pharmacodynamics of novel biologiscs with advanced imaging techniques;ENG;mouse;APX_2B;Cancer;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;reported as fact;existing model;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;accomodation and care;social housing;APX_2D;antibody;biologics;APX_2A
20173885_05;20173885;De eigenschappen van biologische medicijnen in proefdieren voorspellen met verschillende beeldvormingstechnieken;Translational or applied research;human;Evaluation of possibilities to investigate the pharmacodynamics of novel biologiscs with advanced imaging techniques;ENG;mouse;APX_2B;Cancer;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;reported as fact;existing model;APX_2B;intervention related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;expertise;experience with model or methodology;APX_2D;accomodation and care;social housing;APX_2D;antibody;biologics;APX_2A
20173885_05;20173885;De eigenschappen van biologische medicijnen in proefdieren voorspellen met verschillende beeldvormingstechnieken;Translational or applied research;human;Evaluation of possibilities to investigate the pharmacodynamics of novel biologiscs with advanced imaging techniques;ENG;mouse;APX_2B;Cancer;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;reported as fact;existing model;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;literature review;relevant information;APX_2D;accomodation and care;social housing;APX_2D;antibody;biologics;APX_2A
20173885_05;20173885;De eigenschappen van biologische medicijnen in proefdieren voorspellen met verschillende beeldvormingstechnieken;Translational or applied research;human;Evaluation of possibilities to investigate the pharmacodynamics of novel biologiscs with advanced imaging techniques;ENG;mouse;APX_2B;Cancer;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;reported as fact;existing model;APX_2B;intervention related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;literature review;relevant information;APX_2D;accomodation and care;social housing;APX_2D;antibody;biologics;APX_2A
20173885_05;20173885;De eigenschappen van biologische medicijnen in proefdieren voorspellen met verschillende beeldvormingstechnieken;Translational or applied research;human;Evaluation of possibilities to investigate the pharmacodynamics of novel biologiscs with advanced imaging techniques;ENG;mouse;APX_2B;Cancer;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;reported as fact;existing model;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;consult (bio)statistician;APX_2D;accomodation and care;social housing;APX_2D;antibody;biologics;APX_2A
20173885_05;20173885;De eigenschappen van biologische medicijnen in proefdieren voorspellen met verschillende beeldvormingstechnieken;Translational or applied research;human;Evaluation of possibilities to investigate the pharmacodynamics of novel biologiscs with advanced imaging techniques;ENG;mouse;APX_2B;Cancer;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;reported as fact;existing model;APX_2B;intervention related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;substantiated statistics;consult (bio)statistician;APX_2D;accomodation and care;social housing;APX_2D;antibody;biologics;APX_2A
20173885_05;20173885;De eigenschappen van biologische medicijnen in proefdieren voorspellen met verschillende beeldvormingstechnieken;Translational or applied research;human;Evaluation of possibilities to investigate the pharmacodynamics of novel biologiscs with advanced imaging techniques;ENG;mouse;APX_2B;Cancer;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;antibody;biologics;APX_2A
20173885_05;20173885;De eigenschappen van biologische medicijnen in proefdieren voorspellen met verschillende beeldvormingstechnieken;Translational or applied research;human;Evaluation of possibilities to investigate the pharmacodynamics of novel biologiscs with advanced imaging techniques;ENG;mouse;APX_2B;Cancer;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;antibody;biologics;APX_2A
20173885_05;20173885;De eigenschappen van biologische medicijnen in proefdieren voorspellen met verschillende beeldvormingstechnieken;Translational or applied research;human;Evaluation of possibilities to investigate the pharmacodynamics of novel biologiscs with advanced imaging techniques;ENG;mouse;APX_2B;Cancer;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;literature review;relevant information;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;antibody;biologics;APX_2A
20173885_05;20173885;De eigenschappen van biologische medicijnen in proefdieren voorspellen met verschillende beeldvormingstechnieken;Translational or applied research;human;Evaluation of possibilities to investigate the pharmacodynamics of novel biologiscs with advanced imaging techniques;ENG;mouse;APX_2B;Cancer;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;literature review;relevant information;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;antibody;biologics;APX_2A
20173885_05;20173885;De eigenschappen van biologische medicijnen in proefdieren voorspellen met verschillende beeldvormingstechnieken;Translational or applied research;human;Evaluation of possibilities to investigate the pharmacodynamics of novel biologiscs with advanced imaging techniques;ENG;mouse;APX_2B;Cancer;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;consult (bio)statistician;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;antibody;biologics;APX_2A
20173885_05;20173885;De eigenschappen van biologische medicijnen in proefdieren voorspellen met verschillende beeldvormingstechnieken;Translational or applied research;human;Evaluation of possibilities to investigate the pharmacodynamics of novel biologiscs with advanced imaging techniques;ENG;mouse;APX_2B;Cancer;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;substantiated statistics;consult (bio)statistician;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;antibody;biologics;APX_2A
20173885_05;20173885;De eigenschappen van biologische medicijnen in proefdieren voorspellen met verschillende beeldvormingstechnieken;Translational or applied research;human;Evaluation of possibilities to investigate the pharmacodynamics of novel biologiscs with advanced imaging techniques;ENG;mouse;APX_2B;Cancer;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;accomodation and care;social housing;APX_2D;antibody;biologics;APX_2A
20173885_05;20173885;De eigenschappen van biologische medicijnen in proefdieren voorspellen met verschillende beeldvormingstechnieken;Translational or applied research;human;Evaluation of possibilities to investigate the pharmacodynamics of novel biologiscs with advanced imaging techniques;ENG;mouse;APX_2B;Cancer;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;expertise;experience with model or methodology;APX_2D;accomodation and care;social housing;APX_2D;antibody;biologics;APX_2A
20173885_05;20173885;De eigenschappen van biologische medicijnen in proefdieren voorspellen met verschillende beeldvormingstechnieken;Translational or applied research;human;Evaluation of possibilities to investigate the pharmacodynamics of novel biologiscs with advanced imaging techniques;ENG;mouse;APX_2B;Cancer;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;literature review;relevant information;APX_2D;accomodation and care;social housing;APX_2D;antibody;biologics;APX_2A
20173885_05;20173885;De eigenschappen van biologische medicijnen in proefdieren voorspellen met verschillende beeldvormingstechnieken;Translational or applied research;human;Evaluation of possibilities to investigate the pharmacodynamics of novel biologiscs with advanced imaging techniques;ENG;mouse;APX_2B;Cancer;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;literature review;relevant information;APX_2D;accomodation and care;social housing;APX_2D;antibody;biologics;APX_2A
20173885_05;20173885;De eigenschappen van biologische medicijnen in proefdieren voorspellen met verschillende beeldvormingstechnieken;Translational or applied research;human;Evaluation of possibilities to investigate the pharmacodynamics of novel biologiscs with advanced imaging techniques;ENG;mouse;APX_2B;Cancer;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;consult (bio)statistician;APX_2D;accomodation and care;social housing;APX_2D;antibody;biologics;APX_2A
20173885_05;20173885;De eigenschappen van biologische medicijnen in proefdieren voorspellen met verschillende beeldvormingstechnieken;Translational or applied research;human;Evaluation of possibilities to investigate the pharmacodynamics of novel biologiscs with advanced imaging techniques;ENG;mouse;APX_2B;Cancer;NTS_3.1;Induced;APX_2A;APX_2A;Appendix;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;substantiated statistics;consult (bio)statistician;APX_2D;accomodation and care;social housing;APX_2D;antibody;biologics;APX_2A
20173885_05;20173885;De eigenschappen van biologische medicijnen in proefdieren voorspellen met verschillende beeldvormingstechnieken;Translational or applied research;human;Evaluation of possibilities to investigate the pharmacodynamics of novel biologiscs with advanced imaging techniques;ENG;mouse;APX_2B;Cancer;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;antibody;biologics;APX_2A
20173885_05;20173885;De eigenschappen van biologische medicijnen in proefdieren voorspellen met verschillende beeldvormingstechnieken;Translational or applied research;human;Evaluation of possibilities to investigate the pharmacodynamics of novel biologiscs with advanced imaging techniques;ENG;mouse;APX_2B;Cancer;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;expertise;experience with model or methodology;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;antibody;biologics;APX_2A
20173885_05;20173885;De eigenschappen van biologische medicijnen in proefdieren voorspellen met verschillende beeldvormingstechnieken;Translational or applied research;human;Evaluation of possibilities to investigate the pharmacodynamics of novel biologiscs with advanced imaging techniques;ENG;mouse;APX_2B;Cancer;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;literature review;relevant information;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;antibody;biologics;APX_2A
20173885_05;20173885;De eigenschappen van biologische medicijnen in proefdieren voorspellen met verschillende beeldvormingstechnieken;Translational or applied research;human;Evaluation of possibilities to investigate the pharmacodynamics of novel biologiscs with advanced imaging techniques;ENG;mouse;APX_2B;Cancer;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;literature review;relevant information;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;antibody;biologics;APX_2A
20173885_05;20173885;De eigenschappen van biologische medicijnen in proefdieren voorspellen met verschillende beeldvormingstechnieken;Translational or applied research;human;Evaluation of possibilities to investigate the pharmacodynamics of novel biologiscs with advanced imaging techniques;ENG;mouse;APX_2B;Cancer;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;consult (bio)statistician;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;antibody;biologics;APX_2A
20173885_05;20173885;De eigenschappen van biologische medicijnen in proefdieren voorspellen met verschillende beeldvormingstechnieken;Translational or applied research;human;Evaluation of possibilities to investigate the pharmacodynamics of novel biologiscs with advanced imaging techniques;ENG;mouse;APX_2B;Cancer;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;substantiated statistics;consult (bio)statistician;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;antibody;biologics;APX_2A
20173885_05;20173885;De eigenschappen van biologische medicijnen in proefdieren voorspellen met verschillende beeldvormingstechnieken;Translational or applied research;human;Evaluation of possibilities to investigate the pharmacodynamics of novel biologiscs with advanced imaging techniques;ENG;mouse;APX_2B;Cancer;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;expertise;experience with model or methodology;APX_2D;accomodation and care;social housing;APX_2D;antibody;biologics;APX_2A
20173885_05;20173885;De eigenschappen van biologische medicijnen in proefdieren voorspellen met verschillende beeldvormingstechnieken;Translational or applied research;human;Evaluation of possibilities to investigate the pharmacodynamics of novel biologiscs with advanced imaging techniques;ENG;mouse;APX_2B;Cancer;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;expertise;experience with model or methodology;APX_2D;accomodation and care;social housing;APX_2D;antibody;biologics;APX_2A
20173885_05;20173885;De eigenschappen van biologische medicijnen in proefdieren voorspellen met verschillende beeldvormingstechnieken;Translational or applied research;human;Evaluation of possibilities to investigate the pharmacodynamics of novel biologiscs with advanced imaging techniques;ENG;mouse;APX_2B;Cancer;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;literature review;relevant information;APX_2D;accomodation and care;social housing;APX_2D;antibody;biologics;APX_2A
20173885_05;20173885;De eigenschappen van biologische medicijnen in proefdieren voorspellen met verschillende beeldvormingstechnieken;Translational or applied research;human;Evaluation of possibilities to investigate the pharmacodynamics of novel biologiscs with advanced imaging techniques;ENG;mouse;APX_2B;Cancer;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;literature review;relevant information;APX_2D;accomodation and care;social housing;APX_2D;antibody;biologics;APX_2A
20173885_05;20173885;De eigenschappen van biologische medicijnen in proefdieren voorspellen met verschillende beeldvormingstechnieken;Translational or applied research;human;Evaluation of possibilities to investigate the pharmacodynamics of novel biologiscs with advanced imaging techniques;ENG;mouse;APX_2B;Cancer;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;substantiated statistics;consult (bio)statistician;APX_2D;accomodation and care;social housing;APX_2D;antibody;biologics;APX_2A
20173885_05;20173885;De eigenschappen van biologische medicijnen in proefdieren voorspellen met verschillende beeldvormingstechnieken;Translational or applied research;human;Evaluation of possibilities to investigate the pharmacodynamics of novel biologiscs with advanced imaging techniques;ENG;mouse;APX_2B;Cancer;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;no alternative model;kinetics or biodistribution;APX_2D;substantiated statistics;consult (bio)statistician;APX_2D;accomodation and care;social housing;APX_2D;antibody;biologics;APX_2A
20173905_01;20173905;In stand houden van een uniek panel van humane tumoren;Translational or applied research;human;Instandhouden;NLD;mouse;NTS_3.3;Cancer;NTS_1.3;Induced;APX_2A;PPL_3.1;Main Text;lack of equivalent;availability of research tools;APX_2B;disease pathology related;APX_2A;not reported;not reported;APX_2D;not reported;not reported;APX_2D;other;not reported;APX_2D;tumor implants;gene and cell-based;APX_2A
20173905_01;20173905;In stand houden van een uniek panel van humane tumoren;Translational or applied research;human;Instandhouden;NLD;mouse;NTS_3.3;Cancer;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;similar disease pathology or symptoms;availability of research tools;APX_2B;disease pathology related;APX_2A;not reported;not reported;APX_2D;not reported;not reported;APX_2D;other;not reported;APX_2D;tumor implants;gene and cell-based;APX_2A
20173905_01;20173905;In stand houden van een uniek panel van humane tumoren;Translational or applied research;human;Instandhouden;NLD;mouse;NTS_3.3;Cancer;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;availability of research tools;APX_2B;disease pathology related;APX_2A;not reported;not reported;APX_2D;not reported;not reported;APX_2D;other;not reported;APX_2D;tumor implants;gene and cell-based;APX_2A
20173905_01;20173905;In stand houden van een uniek panel van humane tumoren;Translational or applied research;human;Instandhouden;NLD;mouse;NTS_3.3;Cancer;NTS_3.1;Induced;APX_2A;PPL_3.1;Main Text;lack of equivalent;availability of research tools;APX_2B;disease pathology related;APX_2A;not reported;not reported;APX_2D;not reported;not reported;APX_2D;other;not reported;APX_2D;tumor implants;gene and cell-based;APX_2A
20173905_01;20173905;In stand houden van een uniek panel van humane tumoren;Translational or applied research;human;Instandhouden;NLD;mouse;NTS_3.3;Cancer;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;similar disease pathology or symptoms;availability of research tools;APX_2B;disease pathology related;APX_2A;not reported;not reported;APX_2D;not reported;not reported;APX_2D;other;not reported;APX_2D;tumor implants;gene and cell-based;APX_2A
20173905_01;20173905;In stand houden van een uniek panel van humane tumoren;Translational or applied research;human;Instandhouden;NLD;mouse;NTS_3.3;Cancer;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;availability of research tools;APX_2B;disease pathology related;APX_2A;not reported;not reported;APX_2D;not reported;not reported;APX_2D;other;not reported;APX_2D;tumor implants;gene and cell-based;APX_2A
20173964_01;20173964;Wat maakt gewrichtsdistractie zo succesvol in het herstellen van artrose?;Translational or applied research;human;Groove model (+/- distraction);ENG;dog;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;other;not reported;APX_2D;joint distraction;medical device;APX_2A
20173964_01;20173964;Wat maakt gewrichtsdistractie zo succesvol in het herstellen van artrose?;Translational or applied research;human;Groove model (+/- distraction);ENG;dog;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;optimal combination of readouts;APX_2D;other;not reported;APX_2D;joint distraction;medical device;APX_2A
20173964_01;20173964;Wat maakt gewrichtsdistractie zo succesvol in het herstellen van artrose?;Translational or applied research;human;Groove model (+/- distraction);ENG;dog;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;other;not reported;APX_2D;joint distraction;medical device;APX_2A
20173964_01;20173964;Wat maakt gewrichtsdistractie zo succesvol in het herstellen van artrose?;Translational or applied research;human;Groove model (+/- distraction);ENG;dog;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;optimal combination of readouts;APX_2D;other;not reported;APX_2D;joint distraction;medical device;APX_2A
20173964_01;20173964;Wat maakt gewrichtsdistractie zo succesvol in het herstellen van artrose?;Translational or applied research;human;Groove model (+/- distraction);ENG;dog;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;other;not reported;APX_2D;joint distraction;medical device;APX_2A
20173964_01;20173964;Wat maakt gewrichtsdistractie zo succesvol in het herstellen van artrose?;Translational or applied research;human;Groove model (+/- distraction);ENG;dog;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;optimal combination of readouts;APX_2D;other;not reported;APX_2D;joint distraction;medical device;APX_2A
20173964_01;20173964;Wat maakt gewrichtsdistractie zo succesvol in het herstellen van artrose?;Translational or applied research;human;Groove model (+/- distraction);ENG;dog;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;other;not reported;APX_2D;joint distraction;medical device;APX_2A
20173964_01;20173964;Wat maakt gewrichtsdistractie zo succesvol in het herstellen van artrose?;Translational or applied research;human;Groove model (+/- distraction);ENG;dog;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;optimal combination of readouts;APX_2D;other;not reported;APX_2D;joint distraction;medical device;APX_2A
20173964_01;20173964;Wat maakt gewrichtsdistractie zo succesvol in het herstellen van artrose?;Translational or applied research;human;Groove model (+/- distraction);ENG;dog;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;other;not reported;APX_2D;joint distraction;medical device;APX_2A
20173964_01;20173964;Wat maakt gewrichtsdistractie zo succesvol in het herstellen van artrose?;Translational or applied research;human;Groove model (+/- distraction);ENG;dog;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;optimal combination of readouts;APX_2D;other;not reported;APX_2D;joint distraction;medical device;APX_2A
20173964_01;20173964;Wat maakt gewrichtsdistractie zo succesvol in het herstellen van artrose?;Translational or applied research;human;Groove model (+/- distraction);ENG;dog;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;other;not reported;APX_2D;joint distraction;medical device;APX_2A
20173964_01;20173964;Wat maakt gewrichtsdistractie zo succesvol in het herstellen van artrose?;Translational or applied research;human;Groove model (+/- distraction);ENG;dog;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;optimal combination of readouts;APX_2D;other;not reported;APX_2D;joint distraction;medical device;APX_2A
20173964_01;20173964;Wat maakt gewrichtsdistractie zo succesvol in het herstellen van artrose?;Translational or applied research;human;Groove model (+/- distraction);ENG;dog;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;other;not reported;APX_2D;joint distraction;medical device;APX_2A
20173964_01;20173964;Wat maakt gewrichtsdistractie zo succesvol in het herstellen van artrose?;Translational or applied research;human;Groove model (+/- distraction);ENG;dog;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;optimal combination of readouts;APX_2D;other;not reported;APX_2D;joint distraction;medical device;APX_2A
20173964_01;20173964;Wat maakt gewrichtsdistractie zo succesvol in het herstellen van artrose?;Translational or applied research;human;Groove model (+/- distraction);ENG;dog;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;other;not reported;APX_2D;joint distraction;medical device;APX_2A
20173964_01;20173964;Wat maakt gewrichtsdistractie zo succesvol in het herstellen van artrose?;Translational or applied research;human;Groove model (+/- distraction);ENG;dog;NTS_3.3;Immune disorders;NTS_1.3;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;optimal combination of readouts;APX_2D;other;not reported;APX_2D;joint distraction;medical device;APX_2A
20173964_01;20173964;Wat maakt gewrichtsdistractie zo succesvol in het herstellen van artrose?;Translational or applied research;human;Groove model (+/- distraction);ENG;dog;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;other;not reported;APX_2D;joint distraction;medical device;APX_2A
20173964_01;20173964;Wat maakt gewrichtsdistractie zo succesvol in het herstellen van artrose?;Translational or applied research;human;Groove model (+/- distraction);ENG;dog;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;optimal combination of readouts;APX_2D;other;not reported;APX_2D;joint distraction;medical device;APX_2A
20173964_01;20173964;Wat maakt gewrichtsdistractie zo succesvol in het herstellen van artrose?;Translational or applied research;human;Groove model (+/- distraction);ENG;dog;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;other;not reported;APX_2D;joint distraction;medical device;APX_2A
20173964_01;20173964;Wat maakt gewrichtsdistractie zo succesvol in het herstellen van artrose?;Translational or applied research;human;Groove model (+/- distraction);ENG;dog;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;optimal combination of readouts;APX_2D;other;not reported;APX_2D;joint distraction;medical device;APX_2A
20173964_01;20173964;Wat maakt gewrichtsdistractie zo succesvol in het herstellen van artrose?;Translational or applied research;human;Groove model (+/- distraction);ENG;dog;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;other;not reported;APX_2D;joint distraction;medical device;APX_2A
20173964_01;20173964;Wat maakt gewrichtsdistractie zo succesvol in het herstellen van artrose?;Translational or applied research;human;Groove model (+/- distraction);ENG;dog;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;optimal combination of readouts;APX_2D;other;not reported;APX_2D;joint distraction;medical device;APX_2A
20173964_01;20173964;Wat maakt gewrichtsdistractie zo succesvol in het herstellen van artrose?;Translational or applied research;human;Groove model (+/- distraction);ENG;dog;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;other;not reported;APX_2D;joint distraction;medical device;APX_2A
20173964_01;20173964;Wat maakt gewrichtsdistractie zo succesvol in het herstellen van artrose?;Translational or applied research;human;Groove model (+/- distraction);ENG;dog;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;optimal combination of readouts;APX_2D;other;not reported;APX_2D;joint distraction;medical device;APX_2A
20173964_01;20173964;Wat maakt gewrichtsdistractie zo succesvol in het herstellen van artrose?;Translational or applied research;human;Groove model (+/- distraction);ENG;dog;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;other;not reported;APX_2D;joint distraction;medical device;APX_2A
20173964_01;20173964;Wat maakt gewrichtsdistractie zo succesvol in het herstellen van artrose?;Translational or applied research;human;Groove model (+/- distraction);ENG;dog;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;existing model;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;optimal combination of readouts;APX_2D;other;not reported;APX_2D;joint distraction;medical device;APX_2A
20173964_01;20173964;Wat maakt gewrichtsdistractie zo succesvol in het herstellen van artrose?;Translational or applied research;human;Groove model (+/- distraction);ENG;dog;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;other;not reported;APX_2D;joint distraction;medical device;APX_2A
20173964_01;20173964;Wat maakt gewrichtsdistractie zo succesvol in het herstellen van artrose?;Translational or applied research;human;Groove model (+/- distraction);ENG;dog;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;existing model;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;optimal combination of readouts;APX_2D;other;not reported;APX_2D;joint distraction;medical device;APX_2A
20173964_01;20173964;Wat maakt gewrichtsdistractie zo succesvol in het herstellen van artrose?;Translational or applied research;human;Groove model (+/- distraction);ENG;dog;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;other;not reported;APX_2D;joint distraction;medical device;APX_2A
20173964_01;20173964;Wat maakt gewrichtsdistractie zo succesvol in het herstellen van artrose?;Translational or applied research;human;Groove model (+/- distraction);ENG;dog;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;optimal combination of readouts;APX_2D;other;not reported;APX_2D;joint distraction;medical device;APX_2A
20173964_01;20173964;Wat maakt gewrichtsdistractie zo succesvol in het herstellen van artrose?;Translational or applied research;human;Groove model (+/- distraction);ENG;dog;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;other;not reported;APX_2D;joint distraction;medical device;APX_2A
20173964_01;20173964;Wat maakt gewrichtsdistractie zo succesvol in het herstellen van artrose?;Translational or applied research;human;Groove model (+/- distraction);ENG;dog;NTS_3.3;Immune disorders;NTS_3.1;Induced;APX_2A;PPL_3.4.2;Main Text;availability of the animal model;similar disease pathology or symptoms;APX_2B;disease pathology related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;optimal combination of readouts;APX_2D;other;not reported;APX_2D;joint distraction;medical device;APX_2A
20174167_01;20174167;Reuma en vermoeidheid;Translational or applied research;human;Gedragstesten voor meten van fysieke en mentale vermoeidheid;NLD;rat;NTS_3.3;Immune disorders;NTS_1.3;Genetically modified and induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;sensitivity;PPL_3.1;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;method of induction;APX_2D;reduction of discomfort;duration of the study;APX_2D;biomarker identification;diagnostic tool;APX_2A
20174167_01;20174167;Reuma en vermoeidheid;Translational or applied research;human;Gedragstesten voor meten van fysieke en mentale vermoeidheid;NLD;rat;NTS_3.3;Immune disorders;NTS_1.3;Genetically modified and induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;sensitivity;PPL_3.1;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;use of one or both sexes;APX_2D;reduction of discomfort;duration of the study;APX_2D;biomarker identification;diagnostic tool;APX_2A
20174167_01;20174167;Reuma en vermoeidheid;Translational or applied research;human;Gedragstesten voor meten van fysieke en mentale vermoeidheid;NLD;rat;NTS_3.3;Immune disorders;NTS_1.3;Genetically modified and induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;sensitivity;PPL_3.1;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;method of induction;APX_2D;methods used in procedures;expertise;APX_2D;biomarker identification;diagnostic tool;APX_2A
20174167_01;20174167;Reuma en vermoeidheid;Translational or applied research;human;Gedragstesten voor meten van fysieke en mentale vermoeidheid;NLD;rat;NTS_3.3;Immune disorders;NTS_1.3;Genetically modified and induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;sensitivity;PPL_3.1;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;use of one or both sexes;APX_2D;methods used in procedures;expertise;APX_2D;biomarker identification;diagnostic tool;APX_2A
20174167_01;20174167;Reuma en vermoeidheid;Translational or applied research;human;Gedragstesten voor meten van fysieke en mentale vermoeidheid;NLD;rat;NTS_3.3;Immune disorders;NTS_1.3;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;sensitivity;PPL_3.1;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;method of induction;APX_2D;reduction of discomfort;duration of the study;APX_2D;biomarker identification;diagnostic tool;APX_2A
20174167_01;20174167;Reuma en vermoeidheid;Translational or applied research;human;Gedragstesten voor meten van fysieke en mentale vermoeidheid;NLD;rat;NTS_3.3;Immune disorders;NTS_1.3;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;sensitivity;PPL_3.1;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;use of one or both sexes;APX_2D;reduction of discomfort;duration of the study;APX_2D;biomarker identification;diagnostic tool;APX_2A
20174167_01;20174167;Reuma en vermoeidheid;Translational or applied research;human;Gedragstesten voor meten van fysieke en mentale vermoeidheid;NLD;rat;NTS_3.3;Immune disorders;NTS_1.3;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;sensitivity;PPL_3.1;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;method of induction;APX_2D;methods used in procedures;expertise;APX_2D;biomarker identification;diagnostic tool;APX_2A
20174167_01;20174167;Reuma en vermoeidheid;Translational or applied research;human;Gedragstesten voor meten van fysieke en mentale vermoeidheid;NLD;rat;NTS_3.3;Immune disorders;NTS_1.3;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;sensitivity;PPL_3.1;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;use of one or both sexes;APX_2D;methods used in procedures;expertise;APX_2D;biomarker identification;diagnostic tool;APX_2A
20174167_01;20174167;Reuma en vermoeidheid;Translational or applied research;human;Gedragstesten voor meten van fysieke en mentale vermoeidheid;NLD;rat;NTS_3.3;Immune disorders;NTS_3.1;Genetically modified and induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;sensitivity;PPL_3.1;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;method of induction;APX_2D;reduction of discomfort;duration of the study;APX_2D;biomarker identification;diagnostic tool;APX_2A
20174167_01;20174167;Reuma en vermoeidheid;Translational or applied research;human;Gedragstesten voor meten van fysieke en mentale vermoeidheid;NLD;rat;NTS_3.3;Immune disorders;NTS_3.1;Genetically modified and induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;sensitivity;PPL_3.1;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;use of one or both sexes;APX_2D;reduction of discomfort;duration of the study;APX_2D;biomarker identification;diagnostic tool;APX_2A
20174167_01;20174167;Reuma en vermoeidheid;Translational or applied research;human;Gedragstesten voor meten van fysieke en mentale vermoeidheid;NLD;rat;NTS_3.3;Immune disorders;NTS_3.1;Genetically modified and induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;sensitivity;PPL_3.1;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;method of induction;APX_2D;methods used in procedures;expertise;APX_2D;biomarker identification;diagnostic tool;APX_2A
20174167_01;20174167;Reuma en vermoeidheid;Translational or applied research;human;Gedragstesten voor meten van fysieke en mentale vermoeidheid;NLD;rat;NTS_3.3;Immune disorders;NTS_3.1;Genetically modified and induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;sensitivity;PPL_3.1;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;use of one or both sexes;APX_2D;methods used in procedures;expertise;APX_2D;biomarker identification;diagnostic tool;APX_2A
20174167_01;20174167;Reuma en vermoeidheid;Translational or applied research;human;Gedragstesten voor meten van fysieke en mentale vermoeidheid;NLD;rat;NTS_3.3;Immune disorders;NTS_3.1;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;sensitivity;PPL_3.1;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;method of induction;APX_2D;reduction of discomfort;duration of the study;APX_2D;biomarker identification;diagnostic tool;APX_2A
20174167_01;20174167;Reuma en vermoeidheid;Translational or applied research;human;Gedragstesten voor meten van fysieke en mentale vermoeidheid;NLD;rat;NTS_3.3;Immune disorders;NTS_3.1;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;sensitivity;PPL_3.1;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;use of one or both sexes;APX_2D;reduction of discomfort;duration of the study;APX_2D;biomarker identification;diagnostic tool;APX_2A
20174167_01;20174167;Reuma en vermoeidheid;Translational or applied research;human;Gedragstesten voor meten van fysieke en mentale vermoeidheid;NLD;rat;NTS_3.3;Immune disorders;NTS_3.1;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;sensitivity;PPL_3.1;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;method of induction;APX_2D;methods used in procedures;expertise;APX_2D;biomarker identification;diagnostic tool;APX_2A
20174167_01;20174167;Reuma en vermoeidheid;Translational or applied research;human;Gedragstesten voor meten van fysieke en mentale vermoeidheid;NLD;rat;NTS_3.3;Immune disorders;NTS_3.1;Genetically modified and induced;APX_2A;PPL_3.2;Main Text;availability of the animal model;sensitivity;PPL_3.1;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;experimental design;use of one or both sexes;APX_2D;methods used in procedures;expertise;APX_2D;biomarker identification;diagnostic tool;APX_2A
20174169_01;20174169;Uitvoerbaarheid en veiligheid van nieuwe technieken om afwijkend slijmvlies in het maagdarmkanaal te behandelen;Translational or applied research;human;Endoscopische behandeling van (pre)maligne aandoeningen van de tractus digestivus;NLD;pig;NTS_3.3;Cancer;NTS_1.3;Naive or healthy;APX_2A;NTS_4;Non-Technical Summary;similar disease pathology or symptoms;similar anatomy or organ system;NTS_4.3;technical feasibility;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174169_01;20174169;Uitvoerbaarheid en veiligheid van nieuwe technieken om afwijkend slijmvlies in het maagdarmkanaal te behandelen;Translational or applied research;human;Endoscopische behandeling van (pre)maligne aandoeningen van de tractus digestivus;NLD;pig;NTS_3.3;Cancer;NTS_1.3;Naive or healthy;APX_2A;NTS_4;Non-Technical Summary;similar disease pathology or symptoms;similar anatomy or organ system;NTS_4.3;technical feasibility;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174169_01;20174169;Uitvoerbaarheid en veiligheid van nieuwe technieken om afwijkend slijmvlies in het maagdarmkanaal te behandelen;Translational or applied research;human;Endoscopische behandeling van (pre)maligne aandoeningen van de tractus digestivus;NLD;pig;NTS_3.3;Cancer;NTS_1.3;Naive or healthy;APX_2A;NTS_4;Non-Technical Summary;similar disease pathology or symptoms;similar anatomy or organ system;NTS_4.3;technical feasibility;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174169_01;20174169;Uitvoerbaarheid en veiligheid van nieuwe technieken om afwijkend slijmvlies in het maagdarmkanaal te behandelen;Translational or applied research;human;Endoscopische behandeling van (pre)maligne aandoeningen van de tractus digestivus;NLD;pig;NTS_3.3;Cancer;NTS_1.3;Naive or healthy;APX_2A;NTS_4;Non-Technical Summary;similar disease pathology or symptoms;similar anatomy or organ system;NTS_4.3;technical feasibility;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174169_01;20174169;Uitvoerbaarheid en veiligheid van nieuwe technieken om afwijkend slijmvlies in het maagdarmkanaal te behandelen;Translational or applied research;human;Endoscopische behandeling van (pre)maligne aandoeningen van de tractus digestivus;NLD;pig;NTS_3.3;Cancer;NTS_1.3;Naive or healthy;APX_2A;NTS_4;Non-Technical Summary;similar disease pathology or symptoms;similar anatomy or organ system;NTS_4.3;technical feasibility;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;expertise;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174169_01;20174169;Uitvoerbaarheid en veiligheid van nieuwe technieken om afwijkend slijmvlies in het maagdarmkanaal te behandelen;Translational or applied research;human;Endoscopische behandeling van (pre)maligne aandoeningen van de tractus digestivus;NLD;pig;NTS_3.3;Cancer;NTS_1.3;Naive or healthy;APX_2A;NTS_4;Non-Technical Summary;similar disease pathology or symptoms;similar anatomy or organ system;NTS_4.3;technical feasibility;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;expertise;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174169_01;20174169;Uitvoerbaarheid en veiligheid van nieuwe technieken om afwijkend slijmvlies in het maagdarmkanaal te behandelen;Translational or applied research;human;Endoscopische behandeling van (pre)maligne aandoeningen van de tractus digestivus;NLD;pig;NTS_3.3;Cancer;NTS_1.3;Naive or healthy;APX_2A;NTS_4;Non-Technical Summary;similar disease pathology or symptoms;similar anatomy or organ system;NTS_4.3;technical feasibility;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;expertise;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174169_01;20174169;Uitvoerbaarheid en veiligheid van nieuwe technieken om afwijkend slijmvlies in het maagdarmkanaal te behandelen;Translational or applied research;human;Endoscopische behandeling van (pre)maligne aandoeningen van de tractus digestivus;NLD;pig;NTS_3.3;Cancer;NTS_1.3;Naive or healthy;APX_2A;NTS_4;Non-Technical Summary;similar disease pathology or symptoms;similar anatomy or organ system;NTS_4.3;technical feasibility;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;expertise;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174169_01;20174169;Uitvoerbaarheid en veiligheid van nieuwe technieken om afwijkend slijmvlies in het maagdarmkanaal te behandelen;Translational or applied research;human;Endoscopische behandeling van (pre)maligne aandoeningen van de tractus digestivus;NLD;pig;NTS_3.3;Cancer;NTS_1.3;Naive or healthy;APX_2A;NTS_4;Non-Technical Summary;similar disease pathology or symptoms;similar anatomy or organ system;NTS_4.3;technical feasibility;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174169_01;20174169;Uitvoerbaarheid en veiligheid van nieuwe technieken om afwijkend slijmvlies in het maagdarmkanaal te behandelen;Translational or applied research;human;Endoscopische behandeling van (pre)maligne aandoeningen van de tractus digestivus;NLD;pig;NTS_3.3;Cancer;NTS_1.3;Naive or healthy;APX_2A;NTS_4;Non-Technical Summary;similar disease pathology or symptoms;similar anatomy or organ system;NTS_4.3;technical feasibility;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174169_01;20174169;Uitvoerbaarheid en veiligheid van nieuwe technieken om afwijkend slijmvlies in het maagdarmkanaal te behandelen;Translational or applied research;human;Endoscopische behandeling van (pre)maligne aandoeningen van de tractus digestivus;NLD;pig;NTS_3.3;Cancer;NTS_1.3;Naive or healthy;APX_2A;NTS_4;Non-Technical Summary;similar disease pathology or symptoms;similar anatomy or organ system;NTS_4.3;technical feasibility;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174169_01;20174169;Uitvoerbaarheid en veiligheid van nieuwe technieken om afwijkend slijmvlies in het maagdarmkanaal te behandelen;Translational or applied research;human;Endoscopische behandeling van (pre)maligne aandoeningen van de tractus digestivus;NLD;pig;NTS_3.3;Cancer;NTS_1.3;Naive or healthy;APX_2A;NTS_4;Non-Technical Summary;similar disease pathology or symptoms;similar anatomy or organ system;NTS_4.3;technical feasibility;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174169_01;20174169;Uitvoerbaarheid en veiligheid van nieuwe technieken om afwijkend slijmvlies in het maagdarmkanaal te behandelen;Translational or applied research;human;Endoscopische behandeling van (pre)maligne aandoeningen van de tractus digestivus;NLD;pig;NTS_3.3;Cancer;NTS_1.3;Naive or healthy;APX_2A;NTS_4;Non-Technical Summary;similar disease pathology or symptoms;similar anatomy or organ system;NTS_4.3;technical feasibility;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;accomodation and care;cage enrichment;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174169_01;20174169;Uitvoerbaarheid en veiligheid van nieuwe technieken om afwijkend slijmvlies in het maagdarmkanaal te behandelen;Translational or applied research;human;Endoscopische behandeling van (pre)maligne aandoeningen van de tractus digestivus;NLD;pig;NTS_3.3;Cancer;NTS_1.3;Naive or healthy;APX_2A;NTS_4;Non-Technical Summary;similar disease pathology or symptoms;similar anatomy or organ system;NTS_4.3;technical feasibility;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;accomodation and care;cage enrichment;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174169_01;20174169;Uitvoerbaarheid en veiligheid van nieuwe technieken om afwijkend slijmvlies in het maagdarmkanaal te behandelen;Translational or applied research;human;Endoscopische behandeling van (pre)maligne aandoeningen van de tractus digestivus;NLD;pig;NTS_3.3;Cancer;NTS_1.3;Naive or healthy;APX_2A;NTS_4;Non-Technical Summary;similar disease pathology or symptoms;similar anatomy or organ system;NTS_4.3;technical feasibility;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;accomodation and care;cage enrichment;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174169_01;20174169;Uitvoerbaarheid en veiligheid van nieuwe technieken om afwijkend slijmvlies in het maagdarmkanaal te behandelen;Translational or applied research;human;Endoscopische behandeling van (pre)maligne aandoeningen van de tractus digestivus;NLD;pig;NTS_3.3;Cancer;NTS_1.3;Naive or healthy;APX_2A;NTS_4;Non-Technical Summary;similar disease pathology or symptoms;similar anatomy or organ system;NTS_4.3;technical feasibility;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;optimal combination of readouts;APX_2D;accomodation and care;cage enrichment;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174169_01;20174169;Uitvoerbaarheid en veiligheid van nieuwe technieken om afwijkend slijmvlies in het maagdarmkanaal te behandelen;Translational or applied research;human;Endoscopische behandeling van (pre)maligne aandoeningen van de tractus digestivus;NLD;pig;NTS_3.3;Cancer;NTS_1.3;Naive or healthy;APX_2A;NTS_4;Non-Technical Summary;similar disease pathology or symptoms;availability of research tools;NTS_4.3;technical feasibility;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174169_01;20174169;Uitvoerbaarheid en veiligheid van nieuwe technieken om afwijkend slijmvlies in het maagdarmkanaal te behandelen;Translational or applied research;human;Endoscopische behandeling van (pre)maligne aandoeningen van de tractus digestivus;NLD;pig;NTS_3.3;Cancer;NTS_1.3;Naive or healthy;APX_2A;NTS_4;Non-Technical Summary;similar disease pathology or symptoms;availability of research tools;NTS_4.3;technical feasibility;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174169_01;20174169;Uitvoerbaarheid en veiligheid van nieuwe technieken om afwijkend slijmvlies in het maagdarmkanaal te behandelen;Translational or applied research;human;Endoscopische behandeling van (pre)maligne aandoeningen van de tractus digestivus;NLD;pig;NTS_3.3;Cancer;NTS_1.3;Naive or healthy;APX_2A;NTS_4;Non-Technical Summary;similar disease pathology or symptoms;availability of research tools;NTS_4.3;technical feasibility;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174169_01;20174169;Uitvoerbaarheid en veiligheid van nieuwe technieken om afwijkend slijmvlies in het maagdarmkanaal te behandelen;Translational or applied research;human;Endoscopische behandeling van (pre)maligne aandoeningen van de tractus digestivus;NLD;pig;NTS_3.3;Cancer;NTS_1.3;Naive or healthy;APX_2A;NTS_4;Non-Technical Summary;similar disease pathology or symptoms;availability of research tools;NTS_4.3;technical feasibility;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174169_01;20174169;Uitvoerbaarheid en veiligheid van nieuwe technieken om afwijkend slijmvlies in het maagdarmkanaal te behandelen;Translational or applied research;human;Endoscopische behandeling van (pre)maligne aandoeningen van de tractus digestivus;NLD;pig;NTS_3.3;Cancer;NTS_1.3;Naive or healthy;APX_2A;NTS_4;Non-Technical Summary;similar disease pathology or symptoms;availability of research tools;NTS_4.3;technical feasibility;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;expertise;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174169_01;20174169;Uitvoerbaarheid en veiligheid van nieuwe technieken om afwijkend slijmvlies in het maagdarmkanaal te behandelen;Translational or applied research;human;Endoscopische behandeling van (pre)maligne aandoeningen van de tractus digestivus;NLD;pig;NTS_3.3;Cancer;NTS_1.3;Naive or healthy;APX_2A;NTS_4;Non-Technical Summary;similar disease pathology or symptoms;availability of research tools;NTS_4.3;technical feasibility;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;expertise;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174169_01;20174169;Uitvoerbaarheid en veiligheid van nieuwe technieken om afwijkend slijmvlies in het maagdarmkanaal te behandelen;Translational or applied research;human;Endoscopische behandeling van (pre)maligne aandoeningen van de tractus digestivus;NLD;pig;NTS_3.3;Cancer;NTS_1.3;Naive or healthy;APX_2A;NTS_4;Non-Technical Summary;similar disease pathology or symptoms;availability of research tools;NTS_4.3;technical feasibility;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;expertise;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174169_01;20174169;Uitvoerbaarheid en veiligheid van nieuwe technieken om afwijkend slijmvlies in het maagdarmkanaal te behandelen;Translational or applied research;human;Endoscopische behandeling van (pre)maligne aandoeningen van de tractus digestivus;NLD;pig;NTS_3.3;Cancer;NTS_1.3;Naive or healthy;APX_2A;NTS_4;Non-Technical Summary;similar disease pathology or symptoms;availability of research tools;NTS_4.3;technical feasibility;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;expertise;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174169_01;20174169;Uitvoerbaarheid en veiligheid van nieuwe technieken om afwijkend slijmvlies in het maagdarmkanaal te behandelen;Translational or applied research;human;Endoscopische behandeling van (pre)maligne aandoeningen van de tractus digestivus;NLD;pig;NTS_3.3;Cancer;NTS_1.3;Naive or healthy;APX_2A;NTS_4;Non-Technical Summary;similar disease pathology or symptoms;availability of research tools;NTS_4.3;technical feasibility;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174169_01;20174169;Uitvoerbaarheid en veiligheid van nieuwe technieken om afwijkend slijmvlies in het maagdarmkanaal te behandelen;Translational or applied research;human;Endoscopische behandeling van (pre)maligne aandoeningen van de tractus digestivus;NLD;pig;NTS_3.3;Cancer;NTS_1.3;Naive or healthy;APX_2A;NTS_4;Non-Technical Summary;similar disease pathology or symptoms;availability of research tools;NTS_4.3;technical feasibility;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174169_01;20174169;Uitvoerbaarheid en veiligheid van nieuwe technieken om afwijkend slijmvlies in het maagdarmkanaal te behandelen;Translational or applied research;human;Endoscopische behandeling van (pre)maligne aandoeningen van de tractus digestivus;NLD;pig;NTS_3.3;Cancer;NTS_1.3;Naive or healthy;APX_2A;NTS_4;Non-Technical Summary;similar disease pathology or symptoms;availability of research tools;NTS_4.3;technical feasibility;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174169_01;20174169;Uitvoerbaarheid en veiligheid van nieuwe technieken om afwijkend slijmvlies in het maagdarmkanaal te behandelen;Translational or applied research;human;Endoscopische behandeling van (pre)maligne aandoeningen van de tractus digestivus;NLD;pig;NTS_3.3;Cancer;NTS_1.3;Naive or healthy;APX_2A;NTS_4;Non-Technical Summary;similar disease pathology or symptoms;availability of research tools;NTS_4.3;technical feasibility;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174169_01;20174169;Uitvoerbaarheid en veiligheid van nieuwe technieken om afwijkend slijmvlies in het maagdarmkanaal te behandelen;Translational or applied research;human;Endoscopische behandeling van (pre)maligne aandoeningen van de tractus digestivus;NLD;pig;NTS_3.3;Cancer;NTS_1.3;Naive or healthy;APX_2A;NTS_4;Non-Technical Summary;similar disease pathology or symptoms;availability of research tools;NTS_4.3;technical feasibility;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;accomodation and care;cage enrichment;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174169_01;20174169;Uitvoerbaarheid en veiligheid van nieuwe technieken om afwijkend slijmvlies in het maagdarmkanaal te behandelen;Translational or applied research;human;Endoscopische behandeling van (pre)maligne aandoeningen van de tractus digestivus;NLD;pig;NTS_3.3;Cancer;NTS_1.3;Naive or healthy;APX_2A;NTS_4;Non-Technical Summary;similar disease pathology or symptoms;availability of research tools;NTS_4.3;technical feasibility;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;accomodation and care;cage enrichment;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174169_01;20174169;Uitvoerbaarheid en veiligheid van nieuwe technieken om afwijkend slijmvlies in het maagdarmkanaal te behandelen;Translational or applied research;human;Endoscopische behandeling van (pre)maligne aandoeningen van de tractus digestivus;NLD;pig;NTS_3.3;Cancer;NTS_1.3;Naive or healthy;APX_2A;NTS_4;Non-Technical Summary;similar disease pathology or symptoms;availability of research tools;NTS_4.3;technical feasibility;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;accomodation and care;cage enrichment;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174169_01;20174169;Uitvoerbaarheid en veiligheid van nieuwe technieken om afwijkend slijmvlies in het maagdarmkanaal te behandelen;Translational or applied research;human;Endoscopische behandeling van (pre)maligne aandoeningen van de tractus digestivus;NLD;pig;NTS_3.3;Cancer;NTS_1.3;Naive or healthy;APX_2A;NTS_4;Non-Technical Summary;similar disease pathology or symptoms;availability of research tools;NTS_4.3;technical feasibility;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;optimal combination of readouts;APX_2D;accomodation and care;cage enrichment;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174169_01;20174169;Uitvoerbaarheid en veiligheid van nieuwe technieken om afwijkend slijmvlies in het maagdarmkanaal te behandelen;Translational or applied research;human;Endoscopische behandeling van (pre)maligne aandoeningen van de tractus digestivus;NLD;pig;NTS_3.3;Cancer;NTS_1.3;Naive or healthy;APX_2A;NTS_4;Non-Technical Summary;availability of expertise;similar anatomy or organ system;NTS_4.3;technical feasibility;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174169_01;20174169;Uitvoerbaarheid en veiligheid van nieuwe technieken om afwijkend slijmvlies in het maagdarmkanaal te behandelen;Translational or applied research;human;Endoscopische behandeling van (pre)maligne aandoeningen van de tractus digestivus;NLD;pig;NTS_3.3;Cancer;NTS_1.3;Naive or healthy;APX_2A;NTS_4;Non-Technical Summary;availability of expertise;similar anatomy or organ system;NTS_4.3;technical feasibility;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174169_01;20174169;Uitvoerbaarheid en veiligheid van nieuwe technieken om afwijkend slijmvlies in het maagdarmkanaal te behandelen;Translational or applied research;human;Endoscopische behandeling van (pre)maligne aandoeningen van de tractus digestivus;NLD;pig;NTS_3.3;Cancer;NTS_1.3;Naive or healthy;APX_2A;NTS_4;Non-Technical Summary;availability of expertise;similar anatomy or organ system;NTS_4.3;technical feasibility;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174169_01;20174169;Uitvoerbaarheid en veiligheid van nieuwe technieken om afwijkend slijmvlies in het maagdarmkanaal te behandelen;Translational or applied research;human;Endoscopische behandeling van (pre)maligne aandoeningen van de tractus digestivus;NLD;pig;NTS_3.3;Cancer;NTS_1.3;Naive or healthy;APX_2A;NTS_4;Non-Technical Summary;availability of expertise;similar anatomy or organ system;NTS_4.3;technical feasibility;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174169_01;20174169;Uitvoerbaarheid en veiligheid van nieuwe technieken om afwijkend slijmvlies in het maagdarmkanaal te behandelen;Translational or applied research;human;Endoscopische behandeling van (pre)maligne aandoeningen van de tractus digestivus;NLD;pig;NTS_3.3;Cancer;NTS_1.3;Naive or healthy;APX_2A;NTS_4;Non-Technical Summary;availability of expertise;similar anatomy or organ system;NTS_4.3;technical feasibility;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;expertise;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174169_01;20174169;Uitvoerbaarheid en veiligheid van nieuwe technieken om afwijkend slijmvlies in het maagdarmkanaal te behandelen;Translational or applied research;human;Endoscopische behandeling van (pre)maligne aandoeningen van de tractus digestivus;NLD;pig;NTS_3.3;Cancer;NTS_1.3;Naive or healthy;APX_2A;NTS_4;Non-Technical Summary;availability of expertise;similar anatomy or organ system;NTS_4.3;technical feasibility;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;expertise;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174169_01;20174169;Uitvoerbaarheid en veiligheid van nieuwe technieken om afwijkend slijmvlies in het maagdarmkanaal te behandelen;Translational or applied research;human;Endoscopische behandeling van (pre)maligne aandoeningen van de tractus digestivus;NLD;pig;NTS_3.3;Cancer;NTS_1.3;Naive or healthy;APX_2A;NTS_4;Non-Technical Summary;availability of expertise;similar anatomy or organ system;NTS_4.3;technical feasibility;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;expertise;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174169_01;20174169;Uitvoerbaarheid en veiligheid van nieuwe technieken om afwijkend slijmvlies in het maagdarmkanaal te behandelen;Translational or applied research;human;Endoscopische behandeling van (pre)maligne aandoeningen van de tractus digestivus;NLD;pig;NTS_3.3;Cancer;NTS_1.3;Naive or healthy;APX_2A;NTS_4;Non-Technical Summary;availability of expertise;similar anatomy or organ system;NTS_4.3;technical feasibility;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;expertise;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174169_01;20174169;Uitvoerbaarheid en veiligheid van nieuwe technieken om afwijkend slijmvlies in het maagdarmkanaal te behandelen;Translational or applied research;human;Endoscopische behandeling van (pre)maligne aandoeningen van de tractus digestivus;NLD;pig;NTS_3.3;Cancer;NTS_1.3;Naive or healthy;APX_2A;NTS_4;Non-Technical Summary;availability of expertise;similar anatomy or organ system;NTS_4.3;technical feasibility;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174169_01;20174169;Uitvoerbaarheid en veiligheid van nieuwe technieken om afwijkend slijmvlies in het maagdarmkanaal te behandelen;Translational or applied research;human;Endoscopische behandeling van (pre)maligne aandoeningen van de tractus digestivus;NLD;pig;NTS_3.3;Cancer;NTS_1.3;Naive or healthy;APX_2A;NTS_4;Non-Technical Summary;availability of expertise;similar anatomy or organ system;NTS_4.3;technical feasibility;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174169_01;20174169;Uitvoerbaarheid en veiligheid van nieuwe technieken om afwijkend slijmvlies in het maagdarmkanaal te behandelen;Translational or applied research;human;Endoscopische behandeling van (pre)maligne aandoeningen van de tractus digestivus;NLD;pig;NTS_3.3;Cancer;NTS_1.3;Naive or healthy;APX_2A;NTS_4;Non-Technical Summary;availability of expertise;similar anatomy or organ system;NTS_4.3;technical feasibility;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174169_01;20174169;Uitvoerbaarheid en veiligheid van nieuwe technieken om afwijkend slijmvlies in het maagdarmkanaal te behandelen;Translational or applied research;human;Endoscopische behandeling van (pre)maligne aandoeningen van de tractus digestivus;NLD;pig;NTS_3.3;Cancer;NTS_1.3;Naive or healthy;APX_2A;NTS_4;Non-Technical Summary;availability of expertise;similar anatomy or organ system;NTS_4.3;technical feasibility;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174169_01;20174169;Uitvoerbaarheid en veiligheid van nieuwe technieken om afwijkend slijmvlies in het maagdarmkanaal te behandelen;Translational or applied research;human;Endoscopische behandeling van (pre)maligne aandoeningen van de tractus digestivus;NLD;pig;NTS_3.3;Cancer;NTS_1.3;Naive or healthy;APX_2A;NTS_4;Non-Technical Summary;availability of expertise;similar anatomy or organ system;NTS_4.3;technical feasibility;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;accomodation and care;cage enrichment;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174169_01;20174169;Uitvoerbaarheid en veiligheid van nieuwe technieken om afwijkend slijmvlies in het maagdarmkanaal te behandelen;Translational or applied research;human;Endoscopische behandeling van (pre)maligne aandoeningen van de tractus digestivus;NLD;pig;NTS_3.3;Cancer;NTS_1.3;Naive or healthy;APX_2A;NTS_4;Non-Technical Summary;availability of expertise;similar anatomy or organ system;NTS_4.3;technical feasibility;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;accomodation and care;cage enrichment;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174169_01;20174169;Uitvoerbaarheid en veiligheid van nieuwe technieken om afwijkend slijmvlies in het maagdarmkanaal te behandelen;Translational or applied research;human;Endoscopische behandeling van (pre)maligne aandoeningen van de tractus digestivus;NLD;pig;NTS_3.3;Cancer;NTS_1.3;Naive or healthy;APX_2A;NTS_4;Non-Technical Summary;availability of expertise;similar anatomy or organ system;NTS_4.3;technical feasibility;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;accomodation and care;cage enrichment;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174169_01;20174169;Uitvoerbaarheid en veiligheid van nieuwe technieken om afwijkend slijmvlies in het maagdarmkanaal te behandelen;Translational or applied research;human;Endoscopische behandeling van (pre)maligne aandoeningen van de tractus digestivus;NLD;pig;NTS_3.3;Cancer;NTS_1.3;Naive or healthy;APX_2A;NTS_4;Non-Technical Summary;availability of expertise;similar anatomy or organ system;NTS_4.3;technical feasibility;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;optimal combination of readouts;APX_2D;accomodation and care;cage enrichment;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174169_01;20174169;Uitvoerbaarheid en veiligheid van nieuwe technieken om afwijkend slijmvlies in het maagdarmkanaal te behandelen;Translational or applied research;human;Endoscopische behandeling van (pre)maligne aandoeningen van de tractus digestivus;NLD;pig;NTS_3.3;Cancer;NTS_1.3;Naive or healthy;APX_2A;NTS_4;Non-Technical Summary;availability of expertise;availability of research tools;NTS_4.3;technical feasibility;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174169_01;20174169;Uitvoerbaarheid en veiligheid van nieuwe technieken om afwijkend slijmvlies in het maagdarmkanaal te behandelen;Translational or applied research;human;Endoscopische behandeling van (pre)maligne aandoeningen van de tractus digestivus;NLD;pig;NTS_3.3;Cancer;NTS_1.3;Naive or healthy;APX_2A;NTS_4;Non-Technical Summary;availability of expertise;availability of research tools;NTS_4.3;technical feasibility;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174169_01;20174169;Uitvoerbaarheid en veiligheid van nieuwe technieken om afwijkend slijmvlies in het maagdarmkanaal te behandelen;Translational or applied research;human;Endoscopische behandeling van (pre)maligne aandoeningen van de tractus digestivus;NLD;pig;NTS_3.3;Cancer;NTS_1.3;Naive or healthy;APX_2A;NTS_4;Non-Technical Summary;availability of expertise;availability of research tools;NTS_4.3;technical feasibility;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174169_01;20174169;Uitvoerbaarheid en veiligheid van nieuwe technieken om afwijkend slijmvlies in het maagdarmkanaal te behandelen;Translational or applied research;human;Endoscopische behandeling van (pre)maligne aandoeningen van de tractus digestivus;NLD;pig;NTS_3.3;Cancer;NTS_1.3;Naive or healthy;APX_2A;NTS_4;Non-Technical Summary;availability of expertise;availability of research tools;NTS_4.3;technical feasibility;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174169_01;20174169;Uitvoerbaarheid en veiligheid van nieuwe technieken om afwijkend slijmvlies in het maagdarmkanaal te behandelen;Translational or applied research;human;Endoscopische behandeling van (pre)maligne aandoeningen van de tractus digestivus;NLD;pig;NTS_3.3;Cancer;NTS_1.3;Naive or healthy;APX_2A;NTS_4;Non-Technical Summary;availability of expertise;availability of research tools;NTS_4.3;technical feasibility;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;expertise;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174169_01;20174169;Uitvoerbaarheid en veiligheid van nieuwe technieken om afwijkend slijmvlies in het maagdarmkanaal te behandelen;Translational or applied research;human;Endoscopische behandeling van (pre)maligne aandoeningen van de tractus digestivus;NLD;pig;NTS_3.3;Cancer;NTS_1.3;Naive or healthy;APX_2A;NTS_4;Non-Technical Summary;availability of expertise;availability of research tools;NTS_4.3;technical feasibility;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;expertise;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174169_01;20174169;Uitvoerbaarheid en veiligheid van nieuwe technieken om afwijkend slijmvlies in het maagdarmkanaal te behandelen;Translational or applied research;human;Endoscopische behandeling van (pre)maligne aandoeningen van de tractus digestivus;NLD;pig;NTS_3.3;Cancer;NTS_1.3;Naive or healthy;APX_2A;NTS_4;Non-Technical Summary;availability of expertise;availability of research tools;NTS_4.3;technical feasibility;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;expertise;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174169_01;20174169;Uitvoerbaarheid en veiligheid van nieuwe technieken om afwijkend slijmvlies in het maagdarmkanaal te behandelen;Translational or applied research;human;Endoscopische behandeling van (pre)maligne aandoeningen van de tractus digestivus;NLD;pig;NTS_3.3;Cancer;NTS_1.3;Naive or healthy;APX_2A;NTS_4;Non-Technical Summary;availability of expertise;availability of research tools;NTS_4.3;technical feasibility;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;expertise;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174169_01;20174169;Uitvoerbaarheid en veiligheid van nieuwe technieken om afwijkend slijmvlies in het maagdarmkanaal te behandelen;Translational or applied research;human;Endoscopische behandeling van (pre)maligne aandoeningen van de tractus digestivus;NLD;pig;NTS_3.3;Cancer;NTS_1.3;Naive or healthy;APX_2A;NTS_4;Non-Technical Summary;availability of expertise;availability of research tools;NTS_4.3;technical feasibility;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174169_01;20174169;Uitvoerbaarheid en veiligheid van nieuwe technieken om afwijkend slijmvlies in het maagdarmkanaal te behandelen;Translational or applied research;human;Endoscopische behandeling van (pre)maligne aandoeningen van de tractus digestivus;NLD;pig;NTS_3.3;Cancer;NTS_1.3;Naive or healthy;APX_2A;NTS_4;Non-Technical Summary;availability of expertise;availability of research tools;NTS_4.3;technical feasibility;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174169_01;20174169;Uitvoerbaarheid en veiligheid van nieuwe technieken om afwijkend slijmvlies in het maagdarmkanaal te behandelen;Translational or applied research;human;Endoscopische behandeling van (pre)maligne aandoeningen van de tractus digestivus;NLD;pig;NTS_3.3;Cancer;NTS_1.3;Naive or healthy;APX_2A;NTS_4;Non-Technical Summary;availability of expertise;availability of research tools;NTS_4.3;technical feasibility;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174169_01;20174169;Uitvoerbaarheid en veiligheid van nieuwe technieken om afwijkend slijmvlies in het maagdarmkanaal te behandelen;Translational or applied research;human;Endoscopische behandeling van (pre)maligne aandoeningen van de tractus digestivus;NLD;pig;NTS_3.3;Cancer;NTS_1.3;Naive or healthy;APX_2A;NTS_4;Non-Technical Summary;availability of expertise;availability of research tools;NTS_4.3;technical feasibility;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174169_01;20174169;Uitvoerbaarheid en veiligheid van nieuwe technieken om afwijkend slijmvlies in het maagdarmkanaal te behandelen;Translational or applied research;human;Endoscopische behandeling van (pre)maligne aandoeningen van de tractus digestivus;NLD;pig;NTS_3.3;Cancer;NTS_1.3;Naive or healthy;APX_2A;NTS_4;Non-Technical Summary;availability of expertise;availability of research tools;NTS_4.3;technical feasibility;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;accomodation and care;cage enrichment;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174169_01;20174169;Uitvoerbaarheid en veiligheid van nieuwe technieken om afwijkend slijmvlies in het maagdarmkanaal te behandelen;Translational or applied research;human;Endoscopische behandeling van (pre)maligne aandoeningen van de tractus digestivus;NLD;pig;NTS_3.3;Cancer;NTS_1.3;Naive or healthy;APX_2A;NTS_4;Non-Technical Summary;availability of expertise;availability of research tools;NTS_4.3;technical feasibility;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;accomodation and care;cage enrichment;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174169_01;20174169;Uitvoerbaarheid en veiligheid van nieuwe technieken om afwijkend slijmvlies in het maagdarmkanaal te behandelen;Translational or applied research;human;Endoscopische behandeling van (pre)maligne aandoeningen van de tractus digestivus;NLD;pig;NTS_3.3;Cancer;NTS_1.3;Naive or healthy;APX_2A;NTS_4;Non-Technical Summary;availability of expertise;availability of research tools;NTS_4.3;technical feasibility;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;accomodation and care;cage enrichment;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174169_01;20174169;Uitvoerbaarheid en veiligheid van nieuwe technieken om afwijkend slijmvlies in het maagdarmkanaal te behandelen;Translational or applied research;human;Endoscopische behandeling van (pre)maligne aandoeningen van de tractus digestivus;NLD;pig;NTS_3.3;Cancer;NTS_1.3;Naive or healthy;APX_2A;NTS_4;Non-Technical Summary;availability of expertise;availability of research tools;NTS_4.3;technical feasibility;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;optimal combination of readouts;APX_2D;accomodation and care;cage enrichment;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174169_01;20174169;Uitvoerbaarheid en veiligheid van nieuwe technieken om afwijkend slijmvlies in het maagdarmkanaal te behandelen;Translational or applied research;human;Endoscopische behandeling van (pre)maligne aandoeningen van de tractus digestivus;NLD;pig;NTS_3.3;Cancer;NTS_3.1;Naive or healthy;APX_2A;NTS_4;Non-Technical Summary;similar disease pathology or symptoms;similar anatomy or organ system;NTS_4.3;technical feasibility;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174169_01;20174169;Uitvoerbaarheid en veiligheid van nieuwe technieken om afwijkend slijmvlies in het maagdarmkanaal te behandelen;Translational or applied research;human;Endoscopische behandeling van (pre)maligne aandoeningen van de tractus digestivus;NLD;pig;NTS_3.3;Cancer;NTS_3.1;Naive or healthy;APX_2A;NTS_4;Non-Technical Summary;similar disease pathology or symptoms;similar anatomy or organ system;NTS_4.3;technical feasibility;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174169_01;20174169;Uitvoerbaarheid en veiligheid van nieuwe technieken om afwijkend slijmvlies in het maagdarmkanaal te behandelen;Translational or applied research;human;Endoscopische behandeling van (pre)maligne aandoeningen van de tractus digestivus;NLD;pig;NTS_3.3;Cancer;NTS_3.1;Naive or healthy;APX_2A;NTS_4;Non-Technical Summary;similar disease pathology or symptoms;similar anatomy or organ system;NTS_4.3;technical feasibility;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174169_01;20174169;Uitvoerbaarheid en veiligheid van nieuwe technieken om afwijkend slijmvlies in het maagdarmkanaal te behandelen;Translational or applied research;human;Endoscopische behandeling van (pre)maligne aandoeningen van de tractus digestivus;NLD;pig;NTS_3.3;Cancer;NTS_3.1;Naive or healthy;APX_2A;NTS_4;Non-Technical Summary;similar disease pathology or symptoms;similar anatomy or organ system;NTS_4.3;technical feasibility;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174169_01;20174169;Uitvoerbaarheid en veiligheid van nieuwe technieken om afwijkend slijmvlies in het maagdarmkanaal te behandelen;Translational or applied research;human;Endoscopische behandeling van (pre)maligne aandoeningen van de tractus digestivus;NLD;pig;NTS_3.3;Cancer;NTS_3.1;Naive or healthy;APX_2A;NTS_4;Non-Technical Summary;similar disease pathology or symptoms;similar anatomy or organ system;NTS_4.3;technical feasibility;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;expertise;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174169_01;20174169;Uitvoerbaarheid en veiligheid van nieuwe technieken om afwijkend slijmvlies in het maagdarmkanaal te behandelen;Translational or applied research;human;Endoscopische behandeling van (pre)maligne aandoeningen van de tractus digestivus;NLD;pig;NTS_3.3;Cancer;NTS_3.1;Naive or healthy;APX_2A;NTS_4;Non-Technical Summary;similar disease pathology or symptoms;similar anatomy or organ system;NTS_4.3;technical feasibility;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;expertise;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174169_01;20174169;Uitvoerbaarheid en veiligheid van nieuwe technieken om afwijkend slijmvlies in het maagdarmkanaal te behandelen;Translational or applied research;human;Endoscopische behandeling van (pre)maligne aandoeningen van de tractus digestivus;NLD;pig;NTS_3.3;Cancer;NTS_3.1;Naive or healthy;APX_2A;NTS_4;Non-Technical Summary;similar disease pathology or symptoms;similar anatomy or organ system;NTS_4.3;technical feasibility;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;expertise;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174169_01;20174169;Uitvoerbaarheid en veiligheid van nieuwe technieken om afwijkend slijmvlies in het maagdarmkanaal te behandelen;Translational or applied research;human;Endoscopische behandeling van (pre)maligne aandoeningen van de tractus digestivus;NLD;pig;NTS_3.3;Cancer;NTS_3.1;Naive or healthy;APX_2A;NTS_4;Non-Technical Summary;similar disease pathology or symptoms;similar anatomy or organ system;NTS_4.3;technical feasibility;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;expertise;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174169_01;20174169;Uitvoerbaarheid en veiligheid van nieuwe technieken om afwijkend slijmvlies in het maagdarmkanaal te behandelen;Translational or applied research;human;Endoscopische behandeling van (pre)maligne aandoeningen van de tractus digestivus;NLD;pig;NTS_3.3;Cancer;NTS_3.1;Naive or healthy;APX_2A;NTS_4;Non-Technical Summary;similar disease pathology or symptoms;similar anatomy or organ system;NTS_4.3;technical feasibility;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174169_01;20174169;Uitvoerbaarheid en veiligheid van nieuwe technieken om afwijkend slijmvlies in het maagdarmkanaal te behandelen;Translational or applied research;human;Endoscopische behandeling van (pre)maligne aandoeningen van de tractus digestivus;NLD;pig;NTS_3.3;Cancer;NTS_3.1;Naive or healthy;APX_2A;NTS_4;Non-Technical Summary;similar disease pathology or symptoms;similar anatomy or organ system;NTS_4.3;technical feasibility;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174169_01;20174169;Uitvoerbaarheid en veiligheid van nieuwe technieken om afwijkend slijmvlies in het maagdarmkanaal te behandelen;Translational or applied research;human;Endoscopische behandeling van (pre)maligne aandoeningen van de tractus digestivus;NLD;pig;NTS_3.3;Cancer;NTS_3.1;Naive or healthy;APX_2A;NTS_4;Non-Technical Summary;similar disease pathology or symptoms;similar anatomy or organ system;NTS_4.3;technical feasibility;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174169_01;20174169;Uitvoerbaarheid en veiligheid van nieuwe technieken om afwijkend slijmvlies in het maagdarmkanaal te behandelen;Translational or applied research;human;Endoscopische behandeling van (pre)maligne aandoeningen van de tractus digestivus;NLD;pig;NTS_3.3;Cancer;NTS_3.1;Naive or healthy;APX_2A;NTS_4;Non-Technical Summary;similar disease pathology or symptoms;similar anatomy or organ system;NTS_4.3;technical feasibility;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174169_01;20174169;Uitvoerbaarheid en veiligheid van nieuwe technieken om afwijkend slijmvlies in het maagdarmkanaal te behandelen;Translational or applied research;human;Endoscopische behandeling van (pre)maligne aandoeningen van de tractus digestivus;NLD;pig;NTS_3.3;Cancer;NTS_3.1;Naive or healthy;APX_2A;NTS_4;Non-Technical Summary;similar disease pathology or symptoms;similar anatomy or organ system;NTS_4.3;technical feasibility;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;accomodation and care;cage enrichment;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174169_01;20174169;Uitvoerbaarheid en veiligheid van nieuwe technieken om afwijkend slijmvlies in het maagdarmkanaal te behandelen;Translational or applied research;human;Endoscopische behandeling van (pre)maligne aandoeningen van de tractus digestivus;NLD;pig;NTS_3.3;Cancer;NTS_3.1;Naive or healthy;APX_2A;NTS_4;Non-Technical Summary;similar disease pathology or symptoms;similar anatomy or organ system;NTS_4.3;technical feasibility;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;accomodation and care;cage enrichment;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174169_01;20174169;Uitvoerbaarheid en veiligheid van nieuwe technieken om afwijkend slijmvlies in het maagdarmkanaal te behandelen;Translational or applied research;human;Endoscopische behandeling van (pre)maligne aandoeningen van de tractus digestivus;NLD;pig;NTS_3.3;Cancer;NTS_3.1;Naive or healthy;APX_2A;NTS_4;Non-Technical Summary;similar disease pathology or symptoms;similar anatomy or organ system;NTS_4.3;technical feasibility;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;accomodation and care;cage enrichment;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174169_01;20174169;Uitvoerbaarheid en veiligheid van nieuwe technieken om afwijkend slijmvlies in het maagdarmkanaal te behandelen;Translational or applied research;human;Endoscopische behandeling van (pre)maligne aandoeningen van de tractus digestivus;NLD;pig;NTS_3.3;Cancer;NTS_3.1;Naive or healthy;APX_2A;NTS_4;Non-Technical Summary;similar disease pathology or symptoms;similar anatomy or organ system;NTS_4.3;technical feasibility;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;optimal combination of readouts;APX_2D;accomodation and care;cage enrichment;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174169_01;20174169;Uitvoerbaarheid en veiligheid van nieuwe technieken om afwijkend slijmvlies in het maagdarmkanaal te behandelen;Translational or applied research;human;Endoscopische behandeling van (pre)maligne aandoeningen van de tractus digestivus;NLD;pig;NTS_3.3;Cancer;NTS_3.1;Naive or healthy;APX_2A;NTS_4;Non-Technical Summary;similar disease pathology or symptoms;availability of research tools;NTS_4.3;technical feasibility;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174169_01;20174169;Uitvoerbaarheid en veiligheid van nieuwe technieken om afwijkend slijmvlies in het maagdarmkanaal te behandelen;Translational or applied research;human;Endoscopische behandeling van (pre)maligne aandoeningen van de tractus digestivus;NLD;pig;NTS_3.3;Cancer;NTS_3.1;Naive or healthy;APX_2A;NTS_4;Non-Technical Summary;similar disease pathology or symptoms;availability of research tools;NTS_4.3;technical feasibility;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174169_01;20174169;Uitvoerbaarheid en veiligheid van nieuwe technieken om afwijkend slijmvlies in het maagdarmkanaal te behandelen;Translational or applied research;human;Endoscopische behandeling van (pre)maligne aandoeningen van de tractus digestivus;NLD;pig;NTS_3.3;Cancer;NTS_3.1;Naive or healthy;APX_2A;NTS_4;Non-Technical Summary;similar disease pathology or symptoms;availability of research tools;NTS_4.3;technical feasibility;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174169_01;20174169;Uitvoerbaarheid en veiligheid van nieuwe technieken om afwijkend slijmvlies in het maagdarmkanaal te behandelen;Translational or applied research;human;Endoscopische behandeling van (pre)maligne aandoeningen van de tractus digestivus;NLD;pig;NTS_3.3;Cancer;NTS_3.1;Naive or healthy;APX_2A;NTS_4;Non-Technical Summary;similar disease pathology or symptoms;availability of research tools;NTS_4.3;technical feasibility;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174169_01;20174169;Uitvoerbaarheid en veiligheid van nieuwe technieken om afwijkend slijmvlies in het maagdarmkanaal te behandelen;Translational or applied research;human;Endoscopische behandeling van (pre)maligne aandoeningen van de tractus digestivus;NLD;pig;NTS_3.3;Cancer;NTS_3.1;Naive or healthy;APX_2A;NTS_4;Non-Technical Summary;similar disease pathology or symptoms;availability of research tools;NTS_4.3;technical feasibility;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;expertise;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174169_01;20174169;Uitvoerbaarheid en veiligheid van nieuwe technieken om afwijkend slijmvlies in het maagdarmkanaal te behandelen;Translational or applied research;human;Endoscopische behandeling van (pre)maligne aandoeningen van de tractus digestivus;NLD;pig;NTS_3.3;Cancer;NTS_3.1;Naive or healthy;APX_2A;NTS_4;Non-Technical Summary;similar disease pathology or symptoms;availability of research tools;NTS_4.3;technical feasibility;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;expertise;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174169_01;20174169;Uitvoerbaarheid en veiligheid van nieuwe technieken om afwijkend slijmvlies in het maagdarmkanaal te behandelen;Translational or applied research;human;Endoscopische behandeling van (pre)maligne aandoeningen van de tractus digestivus;NLD;pig;NTS_3.3;Cancer;NTS_3.1;Naive or healthy;APX_2A;NTS_4;Non-Technical Summary;similar disease pathology or symptoms;availability of research tools;NTS_4.3;technical feasibility;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;expertise;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174169_01;20174169;Uitvoerbaarheid en veiligheid van nieuwe technieken om afwijkend slijmvlies in het maagdarmkanaal te behandelen;Translational or applied research;human;Endoscopische behandeling van (pre)maligne aandoeningen van de tractus digestivus;NLD;pig;NTS_3.3;Cancer;NTS_3.1;Naive or healthy;APX_2A;NTS_4;Non-Technical Summary;similar disease pathology or symptoms;availability of research tools;NTS_4.3;technical feasibility;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;expertise;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174169_01;20174169;Uitvoerbaarheid en veiligheid van nieuwe technieken om afwijkend slijmvlies in het maagdarmkanaal te behandelen;Translational or applied research;human;Endoscopische behandeling van (pre)maligne aandoeningen van de tractus digestivus;NLD;pig;NTS_3.3;Cancer;NTS_3.1;Naive or healthy;APX_2A;NTS_4;Non-Technical Summary;similar disease pathology or symptoms;availability of research tools;NTS_4.3;technical feasibility;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174169_01;20174169;Uitvoerbaarheid en veiligheid van nieuwe technieken om afwijkend slijmvlies in het maagdarmkanaal te behandelen;Translational or applied research;human;Endoscopische behandeling van (pre)maligne aandoeningen van de tractus digestivus;NLD;pig;NTS_3.3;Cancer;NTS_3.1;Naive or healthy;APX_2A;NTS_4;Non-Technical Summary;similar disease pathology or symptoms;availability of research tools;NTS_4.3;technical feasibility;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174169_01;20174169;Uitvoerbaarheid en veiligheid van nieuwe technieken om afwijkend slijmvlies in het maagdarmkanaal te behandelen;Translational or applied research;human;Endoscopische behandeling van (pre)maligne aandoeningen van de tractus digestivus;NLD;pig;NTS_3.3;Cancer;NTS_3.1;Naive or healthy;APX_2A;NTS_4;Non-Technical Summary;similar disease pathology or symptoms;availability of research tools;NTS_4.3;technical feasibility;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174169_01;20174169;Uitvoerbaarheid en veiligheid van nieuwe technieken om afwijkend slijmvlies in het maagdarmkanaal te behandelen;Translational or applied research;human;Endoscopische behandeling van (pre)maligne aandoeningen van de tractus digestivus;NLD;pig;NTS_3.3;Cancer;NTS_3.1;Naive or healthy;APX_2A;NTS_4;Non-Technical Summary;similar disease pathology or symptoms;availability of research tools;NTS_4.3;technical feasibility;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174169_01;20174169;Uitvoerbaarheid en veiligheid van nieuwe technieken om afwijkend slijmvlies in het maagdarmkanaal te behandelen;Translational or applied research;human;Endoscopische behandeling van (pre)maligne aandoeningen van de tractus digestivus;NLD;pig;NTS_3.3;Cancer;NTS_3.1;Naive or healthy;APX_2A;NTS_4;Non-Technical Summary;similar disease pathology or symptoms;availability of research tools;NTS_4.3;technical feasibility;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;accomodation and care;cage enrichment;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174169_01;20174169;Uitvoerbaarheid en veiligheid van nieuwe technieken om afwijkend slijmvlies in het maagdarmkanaal te behandelen;Translational or applied research;human;Endoscopische behandeling van (pre)maligne aandoeningen van de tractus digestivus;NLD;pig;NTS_3.3;Cancer;NTS_3.1;Naive or healthy;APX_2A;NTS_4;Non-Technical Summary;similar disease pathology or symptoms;availability of research tools;NTS_4.3;technical feasibility;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;accomodation and care;cage enrichment;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174169_01;20174169;Uitvoerbaarheid en veiligheid van nieuwe technieken om afwijkend slijmvlies in het maagdarmkanaal te behandelen;Translational or applied research;human;Endoscopische behandeling van (pre)maligne aandoeningen van de tractus digestivus;NLD;pig;NTS_3.3;Cancer;NTS_3.1;Naive or healthy;APX_2A;NTS_4;Non-Technical Summary;similar disease pathology or symptoms;availability of research tools;NTS_4.3;technical feasibility;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;accomodation and care;cage enrichment;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174169_01;20174169;Uitvoerbaarheid en veiligheid van nieuwe technieken om afwijkend slijmvlies in het maagdarmkanaal te behandelen;Translational or applied research;human;Endoscopische behandeling van (pre)maligne aandoeningen van de tractus digestivus;NLD;pig;NTS_3.3;Cancer;NTS_3.1;Naive or healthy;APX_2A;NTS_4;Non-Technical Summary;similar disease pathology or symptoms;availability of research tools;NTS_4.3;technical feasibility;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;optimal combination of readouts;APX_2D;accomodation and care;cage enrichment;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174169_01;20174169;Uitvoerbaarheid en veiligheid van nieuwe technieken om afwijkend slijmvlies in het maagdarmkanaal te behandelen;Translational or applied research;human;Endoscopische behandeling van (pre)maligne aandoeningen van de tractus digestivus;NLD;pig;NTS_3.3;Cancer;NTS_3.1;Naive or healthy;APX_2A;NTS_4;Non-Technical Summary;availability of expertise;similar anatomy or organ system;NTS_4.3;technical feasibility;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174169_01;20174169;Uitvoerbaarheid en veiligheid van nieuwe technieken om afwijkend slijmvlies in het maagdarmkanaal te behandelen;Translational or applied research;human;Endoscopische behandeling van (pre)maligne aandoeningen van de tractus digestivus;NLD;pig;NTS_3.3;Cancer;NTS_3.1;Naive or healthy;APX_2A;NTS_4;Non-Technical Summary;availability of expertise;similar anatomy or organ system;NTS_4.3;technical feasibility;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174169_01;20174169;Uitvoerbaarheid en veiligheid van nieuwe technieken om afwijkend slijmvlies in het maagdarmkanaal te behandelen;Translational or applied research;human;Endoscopische behandeling van (pre)maligne aandoeningen van de tractus digestivus;NLD;pig;NTS_3.3;Cancer;NTS_3.1;Naive or healthy;APX_2A;NTS_4;Non-Technical Summary;availability of expertise;similar anatomy or organ system;NTS_4.3;technical feasibility;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174169_01;20174169;Uitvoerbaarheid en veiligheid van nieuwe technieken om afwijkend slijmvlies in het maagdarmkanaal te behandelen;Translational or applied research;human;Endoscopische behandeling van (pre)maligne aandoeningen van de tractus digestivus;NLD;pig;NTS_3.3;Cancer;NTS_3.1;Naive or healthy;APX_2A;NTS_4;Non-Technical Summary;availability of expertise;similar anatomy or organ system;NTS_4.3;technical feasibility;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174169_01;20174169;Uitvoerbaarheid en veiligheid van nieuwe technieken om afwijkend slijmvlies in het maagdarmkanaal te behandelen;Translational or applied research;human;Endoscopische behandeling van (pre)maligne aandoeningen van de tractus digestivus;NLD;pig;NTS_3.3;Cancer;NTS_3.1;Naive or healthy;APX_2A;NTS_4;Non-Technical Summary;availability of expertise;similar anatomy or organ system;NTS_4.3;technical feasibility;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;expertise;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174169_01;20174169;Uitvoerbaarheid en veiligheid van nieuwe technieken om afwijkend slijmvlies in het maagdarmkanaal te behandelen;Translational or applied research;human;Endoscopische behandeling van (pre)maligne aandoeningen van de tractus digestivus;NLD;pig;NTS_3.3;Cancer;NTS_3.1;Naive or healthy;APX_2A;NTS_4;Non-Technical Summary;availability of expertise;similar anatomy or organ system;NTS_4.3;technical feasibility;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;expertise;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174169_01;20174169;Uitvoerbaarheid en veiligheid van nieuwe technieken om afwijkend slijmvlies in het maagdarmkanaal te behandelen;Translational or applied research;human;Endoscopische behandeling van (pre)maligne aandoeningen van de tractus digestivus;NLD;pig;NTS_3.3;Cancer;NTS_3.1;Naive or healthy;APX_2A;NTS_4;Non-Technical Summary;availability of expertise;similar anatomy or organ system;NTS_4.3;technical feasibility;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;expertise;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174169_01;20174169;Uitvoerbaarheid en veiligheid van nieuwe technieken om afwijkend slijmvlies in het maagdarmkanaal te behandelen;Translational or applied research;human;Endoscopische behandeling van (pre)maligne aandoeningen van de tractus digestivus;NLD;pig;NTS_3.3;Cancer;NTS_3.1;Naive or healthy;APX_2A;NTS_4;Non-Technical Summary;availability of expertise;similar anatomy or organ system;NTS_4.3;technical feasibility;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;expertise;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174169_01;20174169;Uitvoerbaarheid en veiligheid van nieuwe technieken om afwijkend slijmvlies in het maagdarmkanaal te behandelen;Translational or applied research;human;Endoscopische behandeling van (pre)maligne aandoeningen van de tractus digestivus;NLD;pig;NTS_3.3;Cancer;NTS_3.1;Naive or healthy;APX_2A;NTS_4;Non-Technical Summary;availability of expertise;similar anatomy or organ system;NTS_4.3;technical feasibility;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174169_01;20174169;Uitvoerbaarheid en veiligheid van nieuwe technieken om afwijkend slijmvlies in het maagdarmkanaal te behandelen;Translational or applied research;human;Endoscopische behandeling van (pre)maligne aandoeningen van de tractus digestivus;NLD;pig;NTS_3.3;Cancer;NTS_3.1;Naive or healthy;APX_2A;NTS_4;Non-Technical Summary;availability of expertise;similar anatomy or organ system;NTS_4.3;technical feasibility;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174169_01;20174169;Uitvoerbaarheid en veiligheid van nieuwe technieken om afwijkend slijmvlies in het maagdarmkanaal te behandelen;Translational or applied research;human;Endoscopische behandeling van (pre)maligne aandoeningen van de tractus digestivus;NLD;pig;NTS_3.3;Cancer;NTS_3.1;Naive or healthy;APX_2A;NTS_4;Non-Technical Summary;availability of expertise;similar anatomy or organ system;NTS_4.3;technical feasibility;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174169_01;20174169;Uitvoerbaarheid en veiligheid van nieuwe technieken om afwijkend slijmvlies in het maagdarmkanaal te behandelen;Translational or applied research;human;Endoscopische behandeling van (pre)maligne aandoeningen van de tractus digestivus;NLD;pig;NTS_3.3;Cancer;NTS_3.1;Naive or healthy;APX_2A;NTS_4;Non-Technical Summary;availability of expertise;similar anatomy or organ system;NTS_4.3;technical feasibility;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174169_01;20174169;Uitvoerbaarheid en veiligheid van nieuwe technieken om afwijkend slijmvlies in het maagdarmkanaal te behandelen;Translational or applied research;human;Endoscopische behandeling van (pre)maligne aandoeningen van de tractus digestivus;NLD;pig;NTS_3.3;Cancer;NTS_3.1;Naive or healthy;APX_2A;NTS_4;Non-Technical Summary;availability of expertise;similar anatomy or organ system;NTS_4.3;technical feasibility;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;accomodation and care;cage enrichment;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174169_01;20174169;Uitvoerbaarheid en veiligheid van nieuwe technieken om afwijkend slijmvlies in het maagdarmkanaal te behandelen;Translational or applied research;human;Endoscopische behandeling van (pre)maligne aandoeningen van de tractus digestivus;NLD;pig;NTS_3.3;Cancer;NTS_3.1;Naive or healthy;APX_2A;NTS_4;Non-Technical Summary;availability of expertise;similar anatomy or organ system;NTS_4.3;technical feasibility;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;accomodation and care;cage enrichment;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174169_01;20174169;Uitvoerbaarheid en veiligheid van nieuwe technieken om afwijkend slijmvlies in het maagdarmkanaal te behandelen;Translational or applied research;human;Endoscopische behandeling van (pre)maligne aandoeningen van de tractus digestivus;NLD;pig;NTS_3.3;Cancer;NTS_3.1;Naive or healthy;APX_2A;NTS_4;Non-Technical Summary;availability of expertise;similar anatomy or organ system;NTS_4.3;technical feasibility;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;accomodation and care;cage enrichment;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174169_01;20174169;Uitvoerbaarheid en veiligheid van nieuwe technieken om afwijkend slijmvlies in het maagdarmkanaal te behandelen;Translational or applied research;human;Endoscopische behandeling van (pre)maligne aandoeningen van de tractus digestivus;NLD;pig;NTS_3.3;Cancer;NTS_3.1;Naive or healthy;APX_2A;NTS_4;Non-Technical Summary;availability of expertise;similar anatomy or organ system;NTS_4.3;technical feasibility;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;optimal combination of readouts;APX_2D;accomodation and care;cage enrichment;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174169_01;20174169;Uitvoerbaarheid en veiligheid van nieuwe technieken om afwijkend slijmvlies in het maagdarmkanaal te behandelen;Translational or applied research;human;Endoscopische behandeling van (pre)maligne aandoeningen van de tractus digestivus;NLD;pig;NTS_3.3;Cancer;NTS_3.1;Naive or healthy;APX_2A;NTS_4;Non-Technical Summary;availability of expertise;availability of research tools;NTS_4.3;technical feasibility;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174169_01;20174169;Uitvoerbaarheid en veiligheid van nieuwe technieken om afwijkend slijmvlies in het maagdarmkanaal te behandelen;Translational or applied research;human;Endoscopische behandeling van (pre)maligne aandoeningen van de tractus digestivus;NLD;pig;NTS_3.3;Cancer;NTS_3.1;Naive or healthy;APX_2A;NTS_4;Non-Technical Summary;availability of expertise;availability of research tools;NTS_4.3;technical feasibility;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174169_01;20174169;Uitvoerbaarheid en veiligheid van nieuwe technieken om afwijkend slijmvlies in het maagdarmkanaal te behandelen;Translational or applied research;human;Endoscopische behandeling van (pre)maligne aandoeningen van de tractus digestivus;NLD;pig;NTS_3.3;Cancer;NTS_3.1;Naive or healthy;APX_2A;NTS_4;Non-Technical Summary;availability of expertise;availability of research tools;NTS_4.3;technical feasibility;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174169_01;20174169;Uitvoerbaarheid en veiligheid van nieuwe technieken om afwijkend slijmvlies in het maagdarmkanaal te behandelen;Translational or applied research;human;Endoscopische behandeling van (pre)maligne aandoeningen van de tractus digestivus;NLD;pig;NTS_3.3;Cancer;NTS_3.1;Naive or healthy;APX_2A;NTS_4;Non-Technical Summary;availability of expertise;availability of research tools;NTS_4.3;technical feasibility;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174169_01;20174169;Uitvoerbaarheid en veiligheid van nieuwe technieken om afwijkend slijmvlies in het maagdarmkanaal te behandelen;Translational or applied research;human;Endoscopische behandeling van (pre)maligne aandoeningen van de tractus digestivus;NLD;pig;NTS_3.3;Cancer;NTS_3.1;Naive or healthy;APX_2A;NTS_4;Non-Technical Summary;availability of expertise;availability of research tools;NTS_4.3;technical feasibility;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;expertise;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174169_01;20174169;Uitvoerbaarheid en veiligheid van nieuwe technieken om afwijkend slijmvlies in het maagdarmkanaal te behandelen;Translational or applied research;human;Endoscopische behandeling van (pre)maligne aandoeningen van de tractus digestivus;NLD;pig;NTS_3.3;Cancer;NTS_3.1;Naive or healthy;APX_2A;NTS_4;Non-Technical Summary;availability of expertise;availability of research tools;NTS_4.3;technical feasibility;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;expertise;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174169_01;20174169;Uitvoerbaarheid en veiligheid van nieuwe technieken om afwijkend slijmvlies in het maagdarmkanaal te behandelen;Translational or applied research;human;Endoscopische behandeling van (pre)maligne aandoeningen van de tractus digestivus;NLD;pig;NTS_3.3;Cancer;NTS_3.1;Naive or healthy;APX_2A;NTS_4;Non-Technical Summary;availability of expertise;availability of research tools;NTS_4.3;technical feasibility;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;expertise;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174169_01;20174169;Uitvoerbaarheid en veiligheid van nieuwe technieken om afwijkend slijmvlies in het maagdarmkanaal te behandelen;Translational or applied research;human;Endoscopische behandeling van (pre)maligne aandoeningen van de tractus digestivus;NLD;pig;NTS_3.3;Cancer;NTS_3.1;Naive or healthy;APX_2A;NTS_4;Non-Technical Summary;availability of expertise;availability of research tools;NTS_4.3;technical feasibility;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;expertise;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174169_01;20174169;Uitvoerbaarheid en veiligheid van nieuwe technieken om afwijkend slijmvlies in het maagdarmkanaal te behandelen;Translational or applied research;human;Endoscopische behandeling van (pre)maligne aandoeningen van de tractus digestivus;NLD;pig;NTS_3.3;Cancer;NTS_3.1;Naive or healthy;APX_2A;NTS_4;Non-Technical Summary;availability of expertise;availability of research tools;NTS_4.3;technical feasibility;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174169_01;20174169;Uitvoerbaarheid en veiligheid van nieuwe technieken om afwijkend slijmvlies in het maagdarmkanaal te behandelen;Translational or applied research;human;Endoscopische behandeling van (pre)maligne aandoeningen van de tractus digestivus;NLD;pig;NTS_3.3;Cancer;NTS_3.1;Naive or healthy;APX_2A;NTS_4;Non-Technical Summary;availability of expertise;availability of research tools;NTS_4.3;technical feasibility;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174169_01;20174169;Uitvoerbaarheid en veiligheid van nieuwe technieken om afwijkend slijmvlies in het maagdarmkanaal te behandelen;Translational or applied research;human;Endoscopische behandeling van (pre)maligne aandoeningen van de tractus digestivus;NLD;pig;NTS_3.3;Cancer;NTS_3.1;Naive or healthy;APX_2A;NTS_4;Non-Technical Summary;availability of expertise;availability of research tools;NTS_4.3;technical feasibility;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174169_01;20174169;Uitvoerbaarheid en veiligheid van nieuwe technieken om afwijkend slijmvlies in het maagdarmkanaal te behandelen;Translational or applied research;human;Endoscopische behandeling van (pre)maligne aandoeningen van de tractus digestivus;NLD;pig;NTS_3.3;Cancer;NTS_3.1;Naive or healthy;APX_2A;NTS_4;Non-Technical Summary;availability of expertise;availability of research tools;NTS_4.3;technical feasibility;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174169_01;20174169;Uitvoerbaarheid en veiligheid van nieuwe technieken om afwijkend slijmvlies in het maagdarmkanaal te behandelen;Translational or applied research;human;Endoscopische behandeling van (pre)maligne aandoeningen van de tractus digestivus;NLD;pig;NTS_3.3;Cancer;NTS_3.1;Naive or healthy;APX_2A;NTS_4;Non-Technical Summary;availability of expertise;availability of research tools;NTS_4.3;technical feasibility;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;accomodation and care;cage enrichment;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174169_01;20174169;Uitvoerbaarheid en veiligheid van nieuwe technieken om afwijkend slijmvlies in het maagdarmkanaal te behandelen;Translational or applied research;human;Endoscopische behandeling van (pre)maligne aandoeningen van de tractus digestivus;NLD;pig;NTS_3.3;Cancer;NTS_3.1;Naive or healthy;APX_2A;NTS_4;Non-Technical Summary;availability of expertise;availability of research tools;NTS_4.3;technical feasibility;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;accomodation and care;cage enrichment;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174169_01;20174169;Uitvoerbaarheid en veiligheid van nieuwe technieken om afwijkend slijmvlies in het maagdarmkanaal te behandelen;Translational or applied research;human;Endoscopische behandeling van (pre)maligne aandoeningen van de tractus digestivus;NLD;pig;NTS_3.3;Cancer;NTS_3.1;Naive or healthy;APX_2A;NTS_4;Non-Technical Summary;availability of expertise;availability of research tools;NTS_4.3;technical feasibility;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;accomodation and care;cage enrichment;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174169_01;20174169;Uitvoerbaarheid en veiligheid van nieuwe technieken om afwijkend slijmvlies in het maagdarmkanaal te behandelen;Translational or applied research;human;Endoscopische behandeling van (pre)maligne aandoeningen van de tractus digestivus;NLD;pig;NTS_3.3;Cancer;NTS_3.1;Naive or healthy;APX_2A;NTS_4;Non-Technical Summary;availability of expertise;availability of research tools;NTS_4.3;technical feasibility;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;optimal combination of readouts;APX_2D;accomodation and care;cage enrichment;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174169_02;20174169;Uitvoerbaarheid en veiligheid van nieuwe technieken om afwijkend slijmvlies in het maagdarmkanaal te behandelen;Translational or applied research;human;Preventie van complicaties na endoscopische resectie en ablatie;NLD;pig;NTS_3.3;Cancer;NTS_1.3;Naive or healthy;APX_2A;NTS_4;Non-Technical Summary;similar disease pathology or symptoms;similar anatomy or organ system;NTS_4.3;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174169_02;20174169;Uitvoerbaarheid en veiligheid van nieuwe technieken om afwijkend slijmvlies in het maagdarmkanaal te behandelen;Translational or applied research;human;Preventie van complicaties na endoscopische resectie en ablatie;NLD;pig;NTS_3.3;Cancer;NTS_1.3;Naive or healthy;APX_2A;NTS_4;Non-Technical Summary;similar disease pathology or symptoms;similar anatomy or organ system;NTS_4.3;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174169_02;20174169;Uitvoerbaarheid en veiligheid van nieuwe technieken om afwijkend slijmvlies in het maagdarmkanaal te behandelen;Translational or applied research;human;Preventie van complicaties na endoscopische resectie en ablatie;NLD;pig;NTS_3.3;Cancer;NTS_1.3;Naive or healthy;APX_2A;NTS_4;Non-Technical Summary;similar disease pathology or symptoms;similar anatomy or organ system;NTS_4.3;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174169_02;20174169;Uitvoerbaarheid en veiligheid van nieuwe technieken om afwijkend slijmvlies in het maagdarmkanaal te behandelen;Translational or applied research;human;Preventie van complicaties na endoscopische resectie en ablatie;NLD;pig;NTS_3.3;Cancer;NTS_1.3;Naive or healthy;APX_2A;NTS_4;Non-Technical Summary;similar disease pathology or symptoms;similar anatomy or organ system;NTS_4.3;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174169_02;20174169;Uitvoerbaarheid en veiligheid van nieuwe technieken om afwijkend slijmvlies in het maagdarmkanaal te behandelen;Translational or applied research;human;Preventie van complicaties na endoscopische resectie en ablatie;NLD;pig;NTS_3.3;Cancer;NTS_1.3;Naive or healthy;APX_2A;NTS_4;Non-Technical Summary;similar disease pathology or symptoms;similar anatomy or organ system;NTS_4.3;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;expertise;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174169_02;20174169;Uitvoerbaarheid en veiligheid van nieuwe technieken om afwijkend slijmvlies in het maagdarmkanaal te behandelen;Translational or applied research;human;Preventie van complicaties na endoscopische resectie en ablatie;NLD;pig;NTS_3.3;Cancer;NTS_1.3;Naive or healthy;APX_2A;NTS_4;Non-Technical Summary;similar disease pathology or symptoms;similar anatomy or organ system;NTS_4.3;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;expertise;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174169_02;20174169;Uitvoerbaarheid en veiligheid van nieuwe technieken om afwijkend slijmvlies in het maagdarmkanaal te behandelen;Translational or applied research;human;Preventie van complicaties na endoscopische resectie en ablatie;NLD;pig;NTS_3.3;Cancer;NTS_1.3;Naive or healthy;APX_2A;NTS_4;Non-Technical Summary;similar disease pathology or symptoms;similar anatomy or organ system;NTS_4.3;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;expertise;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174169_02;20174169;Uitvoerbaarheid en veiligheid van nieuwe technieken om afwijkend slijmvlies in het maagdarmkanaal te behandelen;Translational or applied research;human;Preventie van complicaties na endoscopische resectie en ablatie;NLD;pig;NTS_3.3;Cancer;NTS_1.3;Naive or healthy;APX_2A;NTS_4;Non-Technical Summary;similar disease pathology or symptoms;similar anatomy or organ system;NTS_4.3;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;expertise;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174169_02;20174169;Uitvoerbaarheid en veiligheid van nieuwe technieken om afwijkend slijmvlies in het maagdarmkanaal te behandelen;Translational or applied research;human;Preventie van complicaties na endoscopische resectie en ablatie;NLD;pig;NTS_3.3;Cancer;NTS_1.3;Naive or healthy;APX_2A;NTS_4;Non-Technical Summary;similar disease pathology or symptoms;similar anatomy or organ system;NTS_4.3;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174169_02;20174169;Uitvoerbaarheid en veiligheid van nieuwe technieken om afwijkend slijmvlies in het maagdarmkanaal te behandelen;Translational or applied research;human;Preventie van complicaties na endoscopische resectie en ablatie;NLD;pig;NTS_3.3;Cancer;NTS_1.3;Naive or healthy;APX_2A;NTS_4;Non-Technical Summary;similar disease pathology or symptoms;similar anatomy or organ system;NTS_4.3;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174169_02;20174169;Uitvoerbaarheid en veiligheid van nieuwe technieken om afwijkend slijmvlies in het maagdarmkanaal te behandelen;Translational or applied research;human;Preventie van complicaties na endoscopische resectie en ablatie;NLD;pig;NTS_3.3;Cancer;NTS_1.3;Naive or healthy;APX_2A;NTS_4;Non-Technical Summary;similar disease pathology or symptoms;similar anatomy or organ system;NTS_4.3;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174169_02;20174169;Uitvoerbaarheid en veiligheid van nieuwe technieken om afwijkend slijmvlies in het maagdarmkanaal te behandelen;Translational or applied research;human;Preventie van complicaties na endoscopische resectie en ablatie;NLD;pig;NTS_3.3;Cancer;NTS_1.3;Naive or healthy;APX_2A;NTS_4;Non-Technical Summary;similar disease pathology or symptoms;similar anatomy or organ system;NTS_4.3;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174169_02;20174169;Uitvoerbaarheid en veiligheid van nieuwe technieken om afwijkend slijmvlies in het maagdarmkanaal te behandelen;Translational or applied research;human;Preventie van complicaties na endoscopische resectie en ablatie;NLD;pig;NTS_3.3;Cancer;NTS_1.3;Naive or healthy;APX_2A;NTS_4;Non-Technical Summary;similar disease pathology or symptoms;similar anatomy or organ system;NTS_4.3;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;accomodation and care;cage enrichment;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174169_02;20174169;Uitvoerbaarheid en veiligheid van nieuwe technieken om afwijkend slijmvlies in het maagdarmkanaal te behandelen;Translational or applied research;human;Preventie van complicaties na endoscopische resectie en ablatie;NLD;pig;NTS_3.3;Cancer;NTS_1.3;Naive or healthy;APX_2A;NTS_4;Non-Technical Summary;similar disease pathology or symptoms;similar anatomy or organ system;NTS_4.3;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;accomodation and care;cage enrichment;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174169_02;20174169;Uitvoerbaarheid en veiligheid van nieuwe technieken om afwijkend slijmvlies in het maagdarmkanaal te behandelen;Translational or applied research;human;Preventie van complicaties na endoscopische resectie en ablatie;NLD;pig;NTS_3.3;Cancer;NTS_1.3;Naive or healthy;APX_2A;NTS_4;Non-Technical Summary;similar disease pathology or symptoms;similar anatomy or organ system;NTS_4.3;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;accomodation and care;cage enrichment;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174169_02;20174169;Uitvoerbaarheid en veiligheid van nieuwe technieken om afwijkend slijmvlies in het maagdarmkanaal te behandelen;Translational or applied research;human;Preventie van complicaties na endoscopische resectie en ablatie;NLD;pig;NTS_3.3;Cancer;NTS_1.3;Naive or healthy;APX_2A;NTS_4;Non-Technical Summary;similar disease pathology or symptoms;similar anatomy or organ system;NTS_4.3;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;optimal combination of readouts;APX_2D;accomodation and care;cage enrichment;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174169_02;20174169;Uitvoerbaarheid en veiligheid van nieuwe technieken om afwijkend slijmvlies in het maagdarmkanaal te behandelen;Translational or applied research;human;Preventie van complicaties na endoscopische resectie en ablatie;NLD;pig;NTS_3.3;Cancer;NTS_1.3;Naive or healthy;APX_2A;NTS_4;Non-Technical Summary;similar disease pathology or symptoms;availability of research tools;NTS_4.3;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174169_02;20174169;Uitvoerbaarheid en veiligheid van nieuwe technieken om afwijkend slijmvlies in het maagdarmkanaal te behandelen;Translational or applied research;human;Preventie van complicaties na endoscopische resectie en ablatie;NLD;pig;NTS_3.3;Cancer;NTS_1.3;Naive or healthy;APX_2A;NTS_4;Non-Technical Summary;similar disease pathology or symptoms;availability of research tools;NTS_4.3;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174169_02;20174169;Uitvoerbaarheid en veiligheid van nieuwe technieken om afwijkend slijmvlies in het maagdarmkanaal te behandelen;Translational or applied research;human;Preventie van complicaties na endoscopische resectie en ablatie;NLD;pig;NTS_3.3;Cancer;NTS_1.3;Naive or healthy;APX_2A;NTS_4;Non-Technical Summary;similar disease pathology or symptoms;availability of research tools;NTS_4.3;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174169_02;20174169;Uitvoerbaarheid en veiligheid van nieuwe technieken om afwijkend slijmvlies in het maagdarmkanaal te behandelen;Translational or applied research;human;Preventie van complicaties na endoscopische resectie en ablatie;NLD;pig;NTS_3.3;Cancer;NTS_1.3;Naive or healthy;APX_2A;NTS_4;Non-Technical Summary;similar disease pathology or symptoms;availability of research tools;NTS_4.3;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174169_02;20174169;Uitvoerbaarheid en veiligheid van nieuwe technieken om afwijkend slijmvlies in het maagdarmkanaal te behandelen;Translational or applied research;human;Preventie van complicaties na endoscopische resectie en ablatie;NLD;pig;NTS_3.3;Cancer;NTS_1.3;Naive or healthy;APX_2A;NTS_4;Non-Technical Summary;similar disease pathology or symptoms;availability of research tools;NTS_4.3;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;expertise;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174169_02;20174169;Uitvoerbaarheid en veiligheid van nieuwe technieken om afwijkend slijmvlies in het maagdarmkanaal te behandelen;Translational or applied research;human;Preventie van complicaties na endoscopische resectie en ablatie;NLD;pig;NTS_3.3;Cancer;NTS_1.3;Naive or healthy;APX_2A;NTS_4;Non-Technical Summary;similar disease pathology or symptoms;availability of research tools;NTS_4.3;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;expertise;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174169_02;20174169;Uitvoerbaarheid en veiligheid van nieuwe technieken om afwijkend slijmvlies in het maagdarmkanaal te behandelen;Translational or applied research;human;Preventie van complicaties na endoscopische resectie en ablatie;NLD;pig;NTS_3.3;Cancer;NTS_1.3;Naive or healthy;APX_2A;NTS_4;Non-Technical Summary;similar disease pathology or symptoms;availability of research tools;NTS_4.3;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;expertise;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174169_02;20174169;Uitvoerbaarheid en veiligheid van nieuwe technieken om afwijkend slijmvlies in het maagdarmkanaal te behandelen;Translational or applied research;human;Preventie van complicaties na endoscopische resectie en ablatie;NLD;pig;NTS_3.3;Cancer;NTS_1.3;Naive or healthy;APX_2A;NTS_4;Non-Technical Summary;similar disease pathology or symptoms;availability of research tools;NTS_4.3;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;expertise;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174169_02;20174169;Uitvoerbaarheid en veiligheid van nieuwe technieken om afwijkend slijmvlies in het maagdarmkanaal te behandelen;Translational or applied research;human;Preventie van complicaties na endoscopische resectie en ablatie;NLD;pig;NTS_3.3;Cancer;NTS_1.3;Naive or healthy;APX_2A;NTS_4;Non-Technical Summary;similar disease pathology or symptoms;availability of research tools;NTS_4.3;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174169_02;20174169;Uitvoerbaarheid en veiligheid van nieuwe technieken om afwijkend slijmvlies in het maagdarmkanaal te behandelen;Translational or applied research;human;Preventie van complicaties na endoscopische resectie en ablatie;NLD;pig;NTS_3.3;Cancer;NTS_1.3;Naive or healthy;APX_2A;NTS_4;Non-Technical Summary;similar disease pathology or symptoms;availability of research tools;NTS_4.3;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174169_02;20174169;Uitvoerbaarheid en veiligheid van nieuwe technieken om afwijkend slijmvlies in het maagdarmkanaal te behandelen;Translational or applied research;human;Preventie van complicaties na endoscopische resectie en ablatie;NLD;pig;NTS_3.3;Cancer;NTS_1.3;Naive or healthy;APX_2A;NTS_4;Non-Technical Summary;similar disease pathology or symptoms;availability of research tools;NTS_4.3;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174169_02;20174169;Uitvoerbaarheid en veiligheid van nieuwe technieken om afwijkend slijmvlies in het maagdarmkanaal te behandelen;Translational or applied research;human;Preventie van complicaties na endoscopische resectie en ablatie;NLD;pig;NTS_3.3;Cancer;NTS_1.3;Naive or healthy;APX_2A;NTS_4;Non-Technical Summary;similar disease pathology or symptoms;availability of research tools;NTS_4.3;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174169_02;20174169;Uitvoerbaarheid en veiligheid van nieuwe technieken om afwijkend slijmvlies in het maagdarmkanaal te behandelen;Translational or applied research;human;Preventie van complicaties na endoscopische resectie en ablatie;NLD;pig;NTS_3.3;Cancer;NTS_1.3;Naive or healthy;APX_2A;NTS_4;Non-Technical Summary;similar disease pathology or symptoms;availability of research tools;NTS_4.3;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;accomodation and care;cage enrichment;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174169_02;20174169;Uitvoerbaarheid en veiligheid van nieuwe technieken om afwijkend slijmvlies in het maagdarmkanaal te behandelen;Translational or applied research;human;Preventie van complicaties na endoscopische resectie en ablatie;NLD;pig;NTS_3.3;Cancer;NTS_1.3;Naive or healthy;APX_2A;NTS_4;Non-Technical Summary;similar disease pathology or symptoms;availability of research tools;NTS_4.3;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;accomodation and care;cage enrichment;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174169_02;20174169;Uitvoerbaarheid en veiligheid van nieuwe technieken om afwijkend slijmvlies in het maagdarmkanaal te behandelen;Translational or applied research;human;Preventie van complicaties na endoscopische resectie en ablatie;NLD;pig;NTS_3.3;Cancer;NTS_1.3;Naive or healthy;APX_2A;NTS_4;Non-Technical Summary;similar disease pathology or symptoms;availability of research tools;NTS_4.3;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;accomodation and care;cage enrichment;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174169_02;20174169;Uitvoerbaarheid en veiligheid van nieuwe technieken om afwijkend slijmvlies in het maagdarmkanaal te behandelen;Translational or applied research;human;Preventie van complicaties na endoscopische resectie en ablatie;NLD;pig;NTS_3.3;Cancer;NTS_1.3;Naive or healthy;APX_2A;NTS_4;Non-Technical Summary;similar disease pathology or symptoms;availability of research tools;NTS_4.3;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;optimal combination of readouts;APX_2D;accomodation and care;cage enrichment;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174169_02;20174169;Uitvoerbaarheid en veiligheid van nieuwe technieken om afwijkend slijmvlies in het maagdarmkanaal te behandelen;Translational or applied research;human;Preventie van complicaties na endoscopische resectie en ablatie;NLD;pig;NTS_3.3;Cancer;NTS_1.3;Naive or healthy;APX_2A;NTS_4;Non-Technical Summary;availability of expertise;similar anatomy or organ system;NTS_4.3;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174169_02;20174169;Uitvoerbaarheid en veiligheid van nieuwe technieken om afwijkend slijmvlies in het maagdarmkanaal te behandelen;Translational or applied research;human;Preventie van complicaties na endoscopische resectie en ablatie;NLD;pig;NTS_3.3;Cancer;NTS_1.3;Naive or healthy;APX_2A;NTS_4;Non-Technical Summary;availability of expertise;similar anatomy or organ system;NTS_4.3;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174169_02;20174169;Uitvoerbaarheid en veiligheid van nieuwe technieken om afwijkend slijmvlies in het maagdarmkanaal te behandelen;Translational or applied research;human;Preventie van complicaties na endoscopische resectie en ablatie;NLD;pig;NTS_3.3;Cancer;NTS_1.3;Naive or healthy;APX_2A;NTS_4;Non-Technical Summary;availability of expertise;similar anatomy or organ system;NTS_4.3;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174169_02;20174169;Uitvoerbaarheid en veiligheid van nieuwe technieken om afwijkend slijmvlies in het maagdarmkanaal te behandelen;Translational or applied research;human;Preventie van complicaties na endoscopische resectie en ablatie;NLD;pig;NTS_3.3;Cancer;NTS_1.3;Naive or healthy;APX_2A;NTS_4;Non-Technical Summary;availability of expertise;similar anatomy or organ system;NTS_4.3;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174169_02;20174169;Uitvoerbaarheid en veiligheid van nieuwe technieken om afwijkend slijmvlies in het maagdarmkanaal te behandelen;Translational or applied research;human;Preventie van complicaties na endoscopische resectie en ablatie;NLD;pig;NTS_3.3;Cancer;NTS_1.3;Naive or healthy;APX_2A;NTS_4;Non-Technical Summary;availability of expertise;similar anatomy or organ system;NTS_4.3;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;expertise;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174169_02;20174169;Uitvoerbaarheid en veiligheid van nieuwe technieken om afwijkend slijmvlies in het maagdarmkanaal te behandelen;Translational or applied research;human;Preventie van complicaties na endoscopische resectie en ablatie;NLD;pig;NTS_3.3;Cancer;NTS_1.3;Naive or healthy;APX_2A;NTS_4;Non-Technical Summary;availability of expertise;similar anatomy or organ system;NTS_4.3;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;expertise;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174169_02;20174169;Uitvoerbaarheid en veiligheid van nieuwe technieken om afwijkend slijmvlies in het maagdarmkanaal te behandelen;Translational or applied research;human;Preventie van complicaties na endoscopische resectie en ablatie;NLD;pig;NTS_3.3;Cancer;NTS_1.3;Naive or healthy;APX_2A;NTS_4;Non-Technical Summary;availability of expertise;similar anatomy or organ system;NTS_4.3;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;expertise;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174169_02;20174169;Uitvoerbaarheid en veiligheid van nieuwe technieken om afwijkend slijmvlies in het maagdarmkanaal te behandelen;Translational or applied research;human;Preventie van complicaties na endoscopische resectie en ablatie;NLD;pig;NTS_3.3;Cancer;NTS_1.3;Naive or healthy;APX_2A;NTS_4;Non-Technical Summary;availability of expertise;similar anatomy or organ system;NTS_4.3;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;expertise;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174169_02;20174169;Uitvoerbaarheid en veiligheid van nieuwe technieken om afwijkend slijmvlies in het maagdarmkanaal te behandelen;Translational or applied research;human;Preventie van complicaties na endoscopische resectie en ablatie;NLD;pig;NTS_3.3;Cancer;NTS_1.3;Naive or healthy;APX_2A;NTS_4;Non-Technical Summary;availability of expertise;similar anatomy or organ system;NTS_4.3;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174169_02;20174169;Uitvoerbaarheid en veiligheid van nieuwe technieken om afwijkend slijmvlies in het maagdarmkanaal te behandelen;Translational or applied research;human;Preventie van complicaties na endoscopische resectie en ablatie;NLD;pig;NTS_3.3;Cancer;NTS_1.3;Naive or healthy;APX_2A;NTS_4;Non-Technical Summary;availability of expertise;similar anatomy or organ system;NTS_4.3;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174169_02;20174169;Uitvoerbaarheid en veiligheid van nieuwe technieken om afwijkend slijmvlies in het maagdarmkanaal te behandelen;Translational or applied research;human;Preventie van complicaties na endoscopische resectie en ablatie;NLD;pig;NTS_3.3;Cancer;NTS_1.3;Naive or healthy;APX_2A;NTS_4;Non-Technical Summary;availability of expertise;similar anatomy or organ system;NTS_4.3;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174169_02;20174169;Uitvoerbaarheid en veiligheid van nieuwe technieken om afwijkend slijmvlies in het maagdarmkanaal te behandelen;Translational or applied research;human;Preventie van complicaties na endoscopische resectie en ablatie;NLD;pig;NTS_3.3;Cancer;NTS_1.3;Naive or healthy;APX_2A;NTS_4;Non-Technical Summary;availability of expertise;similar anatomy or organ system;NTS_4.3;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174169_02;20174169;Uitvoerbaarheid en veiligheid van nieuwe technieken om afwijkend slijmvlies in het maagdarmkanaal te behandelen;Translational or applied research;human;Preventie van complicaties na endoscopische resectie en ablatie;NLD;pig;NTS_3.3;Cancer;NTS_1.3;Naive or healthy;APX_2A;NTS_4;Non-Technical Summary;availability of expertise;similar anatomy or organ system;NTS_4.3;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;accomodation and care;cage enrichment;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174169_02;20174169;Uitvoerbaarheid en veiligheid van nieuwe technieken om afwijkend slijmvlies in het maagdarmkanaal te behandelen;Translational or applied research;human;Preventie van complicaties na endoscopische resectie en ablatie;NLD;pig;NTS_3.3;Cancer;NTS_1.3;Naive or healthy;APX_2A;NTS_4;Non-Technical Summary;availability of expertise;similar anatomy or organ system;NTS_4.3;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;accomodation and care;cage enrichment;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174169_02;20174169;Uitvoerbaarheid en veiligheid van nieuwe technieken om afwijkend slijmvlies in het maagdarmkanaal te behandelen;Translational or applied research;human;Preventie van complicaties na endoscopische resectie en ablatie;NLD;pig;NTS_3.3;Cancer;NTS_1.3;Naive or healthy;APX_2A;NTS_4;Non-Technical Summary;availability of expertise;similar anatomy or organ system;NTS_4.3;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;accomodation and care;cage enrichment;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174169_02;20174169;Uitvoerbaarheid en veiligheid van nieuwe technieken om afwijkend slijmvlies in het maagdarmkanaal te behandelen;Translational or applied research;human;Preventie van complicaties na endoscopische resectie en ablatie;NLD;pig;NTS_3.3;Cancer;NTS_1.3;Naive or healthy;APX_2A;NTS_4;Non-Technical Summary;availability of expertise;similar anatomy or organ system;NTS_4.3;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;optimal combination of readouts;APX_2D;accomodation and care;cage enrichment;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174169_02;20174169;Uitvoerbaarheid en veiligheid van nieuwe technieken om afwijkend slijmvlies in het maagdarmkanaal te behandelen;Translational or applied research;human;Preventie van complicaties na endoscopische resectie en ablatie;NLD;pig;NTS_3.3;Cancer;NTS_1.3;Naive or healthy;APX_2A;NTS_4;Non-Technical Summary;availability of expertise;availability of research tools;NTS_4.3;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174169_02;20174169;Uitvoerbaarheid en veiligheid van nieuwe technieken om afwijkend slijmvlies in het maagdarmkanaal te behandelen;Translational or applied research;human;Preventie van complicaties na endoscopische resectie en ablatie;NLD;pig;NTS_3.3;Cancer;NTS_1.3;Naive or healthy;APX_2A;NTS_4;Non-Technical Summary;availability of expertise;availability of research tools;NTS_4.3;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174169_02;20174169;Uitvoerbaarheid en veiligheid van nieuwe technieken om afwijkend slijmvlies in het maagdarmkanaal te behandelen;Translational or applied research;human;Preventie van complicaties na endoscopische resectie en ablatie;NLD;pig;NTS_3.3;Cancer;NTS_1.3;Naive or healthy;APX_2A;NTS_4;Non-Technical Summary;availability of expertise;availability of research tools;NTS_4.3;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174169_02;20174169;Uitvoerbaarheid en veiligheid van nieuwe technieken om afwijkend slijmvlies in het maagdarmkanaal te behandelen;Translational or applied research;human;Preventie van complicaties na endoscopische resectie en ablatie;NLD;pig;NTS_3.3;Cancer;NTS_1.3;Naive or healthy;APX_2A;NTS_4;Non-Technical Summary;availability of expertise;availability of research tools;NTS_4.3;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174169_02;20174169;Uitvoerbaarheid en veiligheid van nieuwe technieken om afwijkend slijmvlies in het maagdarmkanaal te behandelen;Translational or applied research;human;Preventie van complicaties na endoscopische resectie en ablatie;NLD;pig;NTS_3.3;Cancer;NTS_1.3;Naive or healthy;APX_2A;NTS_4;Non-Technical Summary;availability of expertise;availability of research tools;NTS_4.3;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;expertise;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174169_02;20174169;Uitvoerbaarheid en veiligheid van nieuwe technieken om afwijkend slijmvlies in het maagdarmkanaal te behandelen;Translational or applied research;human;Preventie van complicaties na endoscopische resectie en ablatie;NLD;pig;NTS_3.3;Cancer;NTS_1.3;Naive or healthy;APX_2A;NTS_4;Non-Technical Summary;availability of expertise;availability of research tools;NTS_4.3;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;expertise;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174169_02;20174169;Uitvoerbaarheid en veiligheid van nieuwe technieken om afwijkend slijmvlies in het maagdarmkanaal te behandelen;Translational or applied research;human;Preventie van complicaties na endoscopische resectie en ablatie;NLD;pig;NTS_3.3;Cancer;NTS_1.3;Naive or healthy;APX_2A;NTS_4;Non-Technical Summary;availability of expertise;availability of research tools;NTS_4.3;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;expertise;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174169_02;20174169;Uitvoerbaarheid en veiligheid van nieuwe technieken om afwijkend slijmvlies in het maagdarmkanaal te behandelen;Translational or applied research;human;Preventie van complicaties na endoscopische resectie en ablatie;NLD;pig;NTS_3.3;Cancer;NTS_1.3;Naive or healthy;APX_2A;NTS_4;Non-Technical Summary;availability of expertise;availability of research tools;NTS_4.3;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;expertise;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174169_02;20174169;Uitvoerbaarheid en veiligheid van nieuwe technieken om afwijkend slijmvlies in het maagdarmkanaal te behandelen;Translational or applied research;human;Preventie van complicaties na endoscopische resectie en ablatie;NLD;pig;NTS_3.3;Cancer;NTS_1.3;Naive or healthy;APX_2A;NTS_4;Non-Technical Summary;availability of expertise;availability of research tools;NTS_4.3;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174169_02;20174169;Uitvoerbaarheid en veiligheid van nieuwe technieken om afwijkend slijmvlies in het maagdarmkanaal te behandelen;Translational or applied research;human;Preventie van complicaties na endoscopische resectie en ablatie;NLD;pig;NTS_3.3;Cancer;NTS_1.3;Naive or healthy;APX_2A;NTS_4;Non-Technical Summary;availability of expertise;availability of research tools;NTS_4.3;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174169_02;20174169;Uitvoerbaarheid en veiligheid van nieuwe technieken om afwijkend slijmvlies in het maagdarmkanaal te behandelen;Translational or applied research;human;Preventie van complicaties na endoscopische resectie en ablatie;NLD;pig;NTS_3.3;Cancer;NTS_1.3;Naive or healthy;APX_2A;NTS_4;Non-Technical Summary;availability of expertise;availability of research tools;NTS_4.3;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174169_02;20174169;Uitvoerbaarheid en veiligheid van nieuwe technieken om afwijkend slijmvlies in het maagdarmkanaal te behandelen;Translational or applied research;human;Preventie van complicaties na endoscopische resectie en ablatie;NLD;pig;NTS_3.3;Cancer;NTS_1.3;Naive or healthy;APX_2A;NTS_4;Non-Technical Summary;availability of expertise;availability of research tools;NTS_4.3;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174169_02;20174169;Uitvoerbaarheid en veiligheid van nieuwe technieken om afwijkend slijmvlies in het maagdarmkanaal te behandelen;Translational or applied research;human;Preventie van complicaties na endoscopische resectie en ablatie;NLD;pig;NTS_3.3;Cancer;NTS_1.3;Naive or healthy;APX_2A;NTS_4;Non-Technical Summary;availability of expertise;availability of research tools;NTS_4.3;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;accomodation and care;cage enrichment;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174169_02;20174169;Uitvoerbaarheid en veiligheid van nieuwe technieken om afwijkend slijmvlies in het maagdarmkanaal te behandelen;Translational or applied research;human;Preventie van complicaties na endoscopische resectie en ablatie;NLD;pig;NTS_3.3;Cancer;NTS_1.3;Naive or healthy;APX_2A;NTS_4;Non-Technical Summary;availability of expertise;availability of research tools;NTS_4.3;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;accomodation and care;cage enrichment;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174169_02;20174169;Uitvoerbaarheid en veiligheid van nieuwe technieken om afwijkend slijmvlies in het maagdarmkanaal te behandelen;Translational or applied research;human;Preventie van complicaties na endoscopische resectie en ablatie;NLD;pig;NTS_3.3;Cancer;NTS_1.3;Naive or healthy;APX_2A;NTS_4;Non-Technical Summary;availability of expertise;availability of research tools;NTS_4.3;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;accomodation and care;cage enrichment;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174169_02;20174169;Uitvoerbaarheid en veiligheid van nieuwe technieken om afwijkend slijmvlies in het maagdarmkanaal te behandelen;Translational or applied research;human;Preventie van complicaties na endoscopische resectie en ablatie;NLD;pig;NTS_3.3;Cancer;NTS_1.3;Naive or healthy;APX_2A;NTS_4;Non-Technical Summary;availability of expertise;availability of research tools;NTS_4.3;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;optimal combination of readouts;APX_2D;accomodation and care;cage enrichment;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174169_02;20174169;Uitvoerbaarheid en veiligheid van nieuwe technieken om afwijkend slijmvlies in het maagdarmkanaal te behandelen;Translational or applied research;human;Preventie van complicaties na endoscopische resectie en ablatie;NLD;pig;NTS_3.3;Cancer;NTS_3.1;Naive or healthy;APX_2A;NTS_4;Non-Technical Summary;similar disease pathology or symptoms;similar anatomy or organ system;NTS_4.3;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174169_02;20174169;Uitvoerbaarheid en veiligheid van nieuwe technieken om afwijkend slijmvlies in het maagdarmkanaal te behandelen;Translational or applied research;human;Preventie van complicaties na endoscopische resectie en ablatie;NLD;pig;NTS_3.3;Cancer;NTS_3.1;Naive or healthy;APX_2A;NTS_4;Non-Technical Summary;similar disease pathology or symptoms;similar anatomy or organ system;NTS_4.3;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174169_02;20174169;Uitvoerbaarheid en veiligheid van nieuwe technieken om afwijkend slijmvlies in het maagdarmkanaal te behandelen;Translational or applied research;human;Preventie van complicaties na endoscopische resectie en ablatie;NLD;pig;NTS_3.3;Cancer;NTS_3.1;Naive or healthy;APX_2A;NTS_4;Non-Technical Summary;similar disease pathology or symptoms;similar anatomy or organ system;NTS_4.3;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174169_02;20174169;Uitvoerbaarheid en veiligheid van nieuwe technieken om afwijkend slijmvlies in het maagdarmkanaal te behandelen;Translational or applied research;human;Preventie van complicaties na endoscopische resectie en ablatie;NLD;pig;NTS_3.3;Cancer;NTS_3.1;Naive or healthy;APX_2A;NTS_4;Non-Technical Summary;similar disease pathology or symptoms;similar anatomy or organ system;NTS_4.3;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174169_02;20174169;Uitvoerbaarheid en veiligheid van nieuwe technieken om afwijkend slijmvlies in het maagdarmkanaal te behandelen;Translational or applied research;human;Preventie van complicaties na endoscopische resectie en ablatie;NLD;pig;NTS_3.3;Cancer;NTS_3.1;Naive or healthy;APX_2A;NTS_4;Non-Technical Summary;similar disease pathology or symptoms;similar anatomy or organ system;NTS_4.3;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;expertise;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174169_02;20174169;Uitvoerbaarheid en veiligheid van nieuwe technieken om afwijkend slijmvlies in het maagdarmkanaal te behandelen;Translational or applied research;human;Preventie van complicaties na endoscopische resectie en ablatie;NLD;pig;NTS_3.3;Cancer;NTS_3.1;Naive or healthy;APX_2A;NTS_4;Non-Technical Summary;similar disease pathology or symptoms;similar anatomy or organ system;NTS_4.3;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;expertise;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174169_02;20174169;Uitvoerbaarheid en veiligheid van nieuwe technieken om afwijkend slijmvlies in het maagdarmkanaal te behandelen;Translational or applied research;human;Preventie van complicaties na endoscopische resectie en ablatie;NLD;pig;NTS_3.3;Cancer;NTS_3.1;Naive or healthy;APX_2A;NTS_4;Non-Technical Summary;similar disease pathology or symptoms;similar anatomy or organ system;NTS_4.3;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;expertise;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174169_02;20174169;Uitvoerbaarheid en veiligheid van nieuwe technieken om afwijkend slijmvlies in het maagdarmkanaal te behandelen;Translational or applied research;human;Preventie van complicaties na endoscopische resectie en ablatie;NLD;pig;NTS_3.3;Cancer;NTS_3.1;Naive or healthy;APX_2A;NTS_4;Non-Technical Summary;similar disease pathology or symptoms;similar anatomy or organ system;NTS_4.3;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;expertise;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174169_02;20174169;Uitvoerbaarheid en veiligheid van nieuwe technieken om afwijkend slijmvlies in het maagdarmkanaal te behandelen;Translational or applied research;human;Preventie van complicaties na endoscopische resectie en ablatie;NLD;pig;NTS_3.3;Cancer;NTS_3.1;Naive or healthy;APX_2A;NTS_4;Non-Technical Summary;similar disease pathology or symptoms;similar anatomy or organ system;NTS_4.3;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174169_02;20174169;Uitvoerbaarheid en veiligheid van nieuwe technieken om afwijkend slijmvlies in het maagdarmkanaal te behandelen;Translational or applied research;human;Preventie van complicaties na endoscopische resectie en ablatie;NLD;pig;NTS_3.3;Cancer;NTS_3.1;Naive or healthy;APX_2A;NTS_4;Non-Technical Summary;similar disease pathology or symptoms;similar anatomy or organ system;NTS_4.3;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174169_02;20174169;Uitvoerbaarheid en veiligheid van nieuwe technieken om afwijkend slijmvlies in het maagdarmkanaal te behandelen;Translational or applied research;human;Preventie van complicaties na endoscopische resectie en ablatie;NLD;pig;NTS_3.3;Cancer;NTS_3.1;Naive or healthy;APX_2A;NTS_4;Non-Technical Summary;similar disease pathology or symptoms;similar anatomy or organ system;NTS_4.3;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174169_02;20174169;Uitvoerbaarheid en veiligheid van nieuwe technieken om afwijkend slijmvlies in het maagdarmkanaal te behandelen;Translational or applied research;human;Preventie van complicaties na endoscopische resectie en ablatie;NLD;pig;NTS_3.3;Cancer;NTS_3.1;Naive or healthy;APX_2A;NTS_4;Non-Technical Summary;similar disease pathology or symptoms;similar anatomy or organ system;NTS_4.3;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174169_02;20174169;Uitvoerbaarheid en veiligheid van nieuwe technieken om afwijkend slijmvlies in het maagdarmkanaal te behandelen;Translational or applied research;human;Preventie van complicaties na endoscopische resectie en ablatie;NLD;pig;NTS_3.3;Cancer;NTS_3.1;Naive or healthy;APX_2A;NTS_4;Non-Technical Summary;similar disease pathology or symptoms;similar anatomy or organ system;NTS_4.3;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;accomodation and care;cage enrichment;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174169_02;20174169;Uitvoerbaarheid en veiligheid van nieuwe technieken om afwijkend slijmvlies in het maagdarmkanaal te behandelen;Translational or applied research;human;Preventie van complicaties na endoscopische resectie en ablatie;NLD;pig;NTS_3.3;Cancer;NTS_3.1;Naive or healthy;APX_2A;NTS_4;Non-Technical Summary;similar disease pathology or symptoms;similar anatomy or organ system;NTS_4.3;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;accomodation and care;cage enrichment;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174169_02;20174169;Uitvoerbaarheid en veiligheid van nieuwe technieken om afwijkend slijmvlies in het maagdarmkanaal te behandelen;Translational or applied research;human;Preventie van complicaties na endoscopische resectie en ablatie;NLD;pig;NTS_3.3;Cancer;NTS_3.1;Naive or healthy;APX_2A;NTS_4;Non-Technical Summary;similar disease pathology or symptoms;similar anatomy or organ system;NTS_4.3;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;accomodation and care;cage enrichment;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174169_02;20174169;Uitvoerbaarheid en veiligheid van nieuwe technieken om afwijkend slijmvlies in het maagdarmkanaal te behandelen;Translational or applied research;human;Preventie van complicaties na endoscopische resectie en ablatie;NLD;pig;NTS_3.3;Cancer;NTS_3.1;Naive or healthy;APX_2A;NTS_4;Non-Technical Summary;similar disease pathology or symptoms;similar anatomy or organ system;NTS_4.3;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;optimal combination of readouts;APX_2D;accomodation and care;cage enrichment;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174169_02;20174169;Uitvoerbaarheid en veiligheid van nieuwe technieken om afwijkend slijmvlies in het maagdarmkanaal te behandelen;Translational or applied research;human;Preventie van complicaties na endoscopische resectie en ablatie;NLD;pig;NTS_3.3;Cancer;NTS_3.1;Naive or healthy;APX_2A;NTS_4;Non-Technical Summary;similar disease pathology or symptoms;availability of research tools;NTS_4.3;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174169_02;20174169;Uitvoerbaarheid en veiligheid van nieuwe technieken om afwijkend slijmvlies in het maagdarmkanaal te behandelen;Translational or applied research;human;Preventie van complicaties na endoscopische resectie en ablatie;NLD;pig;NTS_3.3;Cancer;NTS_3.1;Naive or healthy;APX_2A;NTS_4;Non-Technical Summary;similar disease pathology or symptoms;availability of research tools;NTS_4.3;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174169_02;20174169;Uitvoerbaarheid en veiligheid van nieuwe technieken om afwijkend slijmvlies in het maagdarmkanaal te behandelen;Translational or applied research;human;Preventie van complicaties na endoscopische resectie en ablatie;NLD;pig;NTS_3.3;Cancer;NTS_3.1;Naive or healthy;APX_2A;NTS_4;Non-Technical Summary;similar disease pathology or symptoms;availability of research tools;NTS_4.3;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174169_02;20174169;Uitvoerbaarheid en veiligheid van nieuwe technieken om afwijkend slijmvlies in het maagdarmkanaal te behandelen;Translational or applied research;human;Preventie van complicaties na endoscopische resectie en ablatie;NLD;pig;NTS_3.3;Cancer;NTS_3.1;Naive or healthy;APX_2A;NTS_4;Non-Technical Summary;similar disease pathology or symptoms;availability of research tools;NTS_4.3;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174169_02;20174169;Uitvoerbaarheid en veiligheid van nieuwe technieken om afwijkend slijmvlies in het maagdarmkanaal te behandelen;Translational or applied research;human;Preventie van complicaties na endoscopische resectie en ablatie;NLD;pig;NTS_3.3;Cancer;NTS_3.1;Naive or healthy;APX_2A;NTS_4;Non-Technical Summary;similar disease pathology or symptoms;availability of research tools;NTS_4.3;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;expertise;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174169_02;20174169;Uitvoerbaarheid en veiligheid van nieuwe technieken om afwijkend slijmvlies in het maagdarmkanaal te behandelen;Translational or applied research;human;Preventie van complicaties na endoscopische resectie en ablatie;NLD;pig;NTS_3.3;Cancer;NTS_3.1;Naive or healthy;APX_2A;NTS_4;Non-Technical Summary;similar disease pathology or symptoms;availability of research tools;NTS_4.3;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;expertise;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174169_02;20174169;Uitvoerbaarheid en veiligheid van nieuwe technieken om afwijkend slijmvlies in het maagdarmkanaal te behandelen;Translational or applied research;human;Preventie van complicaties na endoscopische resectie en ablatie;NLD;pig;NTS_3.3;Cancer;NTS_3.1;Naive or healthy;APX_2A;NTS_4;Non-Technical Summary;similar disease pathology or symptoms;availability of research tools;NTS_4.3;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;expertise;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174169_02;20174169;Uitvoerbaarheid en veiligheid van nieuwe technieken om afwijkend slijmvlies in het maagdarmkanaal te behandelen;Translational or applied research;human;Preventie van complicaties na endoscopische resectie en ablatie;NLD;pig;NTS_3.3;Cancer;NTS_3.1;Naive or healthy;APX_2A;NTS_4;Non-Technical Summary;similar disease pathology or symptoms;availability of research tools;NTS_4.3;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;expertise;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174169_02;20174169;Uitvoerbaarheid en veiligheid van nieuwe technieken om afwijkend slijmvlies in het maagdarmkanaal te behandelen;Translational or applied research;human;Preventie van complicaties na endoscopische resectie en ablatie;NLD;pig;NTS_3.3;Cancer;NTS_3.1;Naive or healthy;APX_2A;NTS_4;Non-Technical Summary;similar disease pathology or symptoms;availability of research tools;NTS_4.3;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174169_02;20174169;Uitvoerbaarheid en veiligheid van nieuwe technieken om afwijkend slijmvlies in het maagdarmkanaal te behandelen;Translational or applied research;human;Preventie van complicaties na endoscopische resectie en ablatie;NLD;pig;NTS_3.3;Cancer;NTS_3.1;Naive or healthy;APX_2A;NTS_4;Non-Technical Summary;similar disease pathology or symptoms;availability of research tools;NTS_4.3;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174169_02;20174169;Uitvoerbaarheid en veiligheid van nieuwe technieken om afwijkend slijmvlies in het maagdarmkanaal te behandelen;Translational or applied research;human;Preventie van complicaties na endoscopische resectie en ablatie;NLD;pig;NTS_3.3;Cancer;NTS_3.1;Naive or healthy;APX_2A;NTS_4;Non-Technical Summary;similar disease pathology or symptoms;availability of research tools;NTS_4.3;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174169_02;20174169;Uitvoerbaarheid en veiligheid van nieuwe technieken om afwijkend slijmvlies in het maagdarmkanaal te behandelen;Translational or applied research;human;Preventie van complicaties na endoscopische resectie en ablatie;NLD;pig;NTS_3.3;Cancer;NTS_3.1;Naive or healthy;APX_2A;NTS_4;Non-Technical Summary;similar disease pathology or symptoms;availability of research tools;NTS_4.3;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174169_02;20174169;Uitvoerbaarheid en veiligheid van nieuwe technieken om afwijkend slijmvlies in het maagdarmkanaal te behandelen;Translational or applied research;human;Preventie van complicaties na endoscopische resectie en ablatie;NLD;pig;NTS_3.3;Cancer;NTS_3.1;Naive or healthy;APX_2A;NTS_4;Non-Technical Summary;similar disease pathology or symptoms;availability of research tools;NTS_4.3;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;accomodation and care;cage enrichment;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174169_02;20174169;Uitvoerbaarheid en veiligheid van nieuwe technieken om afwijkend slijmvlies in het maagdarmkanaal te behandelen;Translational or applied research;human;Preventie van complicaties na endoscopische resectie en ablatie;NLD;pig;NTS_3.3;Cancer;NTS_3.1;Naive or healthy;APX_2A;NTS_4;Non-Technical Summary;similar disease pathology or symptoms;availability of research tools;NTS_4.3;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;accomodation and care;cage enrichment;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174169_02;20174169;Uitvoerbaarheid en veiligheid van nieuwe technieken om afwijkend slijmvlies in het maagdarmkanaal te behandelen;Translational or applied research;human;Preventie van complicaties na endoscopische resectie en ablatie;NLD;pig;NTS_3.3;Cancer;NTS_3.1;Naive or healthy;APX_2A;NTS_4;Non-Technical Summary;similar disease pathology or symptoms;availability of research tools;NTS_4.3;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;accomodation and care;cage enrichment;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174169_02;20174169;Uitvoerbaarheid en veiligheid van nieuwe technieken om afwijkend slijmvlies in het maagdarmkanaal te behandelen;Translational or applied research;human;Preventie van complicaties na endoscopische resectie en ablatie;NLD;pig;NTS_3.3;Cancer;NTS_3.1;Naive or healthy;APX_2A;NTS_4;Non-Technical Summary;similar disease pathology or symptoms;availability of research tools;NTS_4.3;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;optimal combination of readouts;APX_2D;accomodation and care;cage enrichment;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174169_02;20174169;Uitvoerbaarheid en veiligheid van nieuwe technieken om afwijkend slijmvlies in het maagdarmkanaal te behandelen;Translational or applied research;human;Preventie van complicaties na endoscopische resectie en ablatie;NLD;pig;NTS_3.3;Cancer;NTS_3.1;Naive or healthy;APX_2A;NTS_4;Non-Technical Summary;availability of expertise;similar anatomy or organ system;NTS_4.3;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174169_02;20174169;Uitvoerbaarheid en veiligheid van nieuwe technieken om afwijkend slijmvlies in het maagdarmkanaal te behandelen;Translational or applied research;human;Preventie van complicaties na endoscopische resectie en ablatie;NLD;pig;NTS_3.3;Cancer;NTS_3.1;Naive or healthy;APX_2A;NTS_4;Non-Technical Summary;availability of expertise;similar anatomy or organ system;NTS_4.3;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174169_02;20174169;Uitvoerbaarheid en veiligheid van nieuwe technieken om afwijkend slijmvlies in het maagdarmkanaal te behandelen;Translational or applied research;human;Preventie van complicaties na endoscopische resectie en ablatie;NLD;pig;NTS_3.3;Cancer;NTS_3.1;Naive or healthy;APX_2A;NTS_4;Non-Technical Summary;availability of expertise;similar anatomy or organ system;NTS_4.3;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174169_02;20174169;Uitvoerbaarheid en veiligheid van nieuwe technieken om afwijkend slijmvlies in het maagdarmkanaal te behandelen;Translational or applied research;human;Preventie van complicaties na endoscopische resectie en ablatie;NLD;pig;NTS_3.3;Cancer;NTS_3.1;Naive or healthy;APX_2A;NTS_4;Non-Technical Summary;availability of expertise;similar anatomy or organ system;NTS_4.3;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174169_02;20174169;Uitvoerbaarheid en veiligheid van nieuwe technieken om afwijkend slijmvlies in het maagdarmkanaal te behandelen;Translational or applied research;human;Preventie van complicaties na endoscopische resectie en ablatie;NLD;pig;NTS_3.3;Cancer;NTS_3.1;Naive or healthy;APX_2A;NTS_4;Non-Technical Summary;availability of expertise;similar anatomy or organ system;NTS_4.3;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;expertise;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174169_02;20174169;Uitvoerbaarheid en veiligheid van nieuwe technieken om afwijkend slijmvlies in het maagdarmkanaal te behandelen;Translational or applied research;human;Preventie van complicaties na endoscopische resectie en ablatie;NLD;pig;NTS_3.3;Cancer;NTS_3.1;Naive or healthy;APX_2A;NTS_4;Non-Technical Summary;availability of expertise;similar anatomy or organ system;NTS_4.3;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;expertise;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174169_02;20174169;Uitvoerbaarheid en veiligheid van nieuwe technieken om afwijkend slijmvlies in het maagdarmkanaal te behandelen;Translational or applied research;human;Preventie van complicaties na endoscopische resectie en ablatie;NLD;pig;NTS_3.3;Cancer;NTS_3.1;Naive or healthy;APX_2A;NTS_4;Non-Technical Summary;availability of expertise;similar anatomy or organ system;NTS_4.3;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;expertise;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174169_02;20174169;Uitvoerbaarheid en veiligheid van nieuwe technieken om afwijkend slijmvlies in het maagdarmkanaal te behandelen;Translational or applied research;human;Preventie van complicaties na endoscopische resectie en ablatie;NLD;pig;NTS_3.3;Cancer;NTS_3.1;Naive or healthy;APX_2A;NTS_4;Non-Technical Summary;availability of expertise;similar anatomy or organ system;NTS_4.3;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;expertise;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174169_02;20174169;Uitvoerbaarheid en veiligheid van nieuwe technieken om afwijkend slijmvlies in het maagdarmkanaal te behandelen;Translational or applied research;human;Preventie van complicaties na endoscopische resectie en ablatie;NLD;pig;NTS_3.3;Cancer;NTS_3.1;Naive or healthy;APX_2A;NTS_4;Non-Technical Summary;availability of expertise;similar anatomy or organ system;NTS_4.3;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174169_02;20174169;Uitvoerbaarheid en veiligheid van nieuwe technieken om afwijkend slijmvlies in het maagdarmkanaal te behandelen;Translational or applied research;human;Preventie van complicaties na endoscopische resectie en ablatie;NLD;pig;NTS_3.3;Cancer;NTS_3.1;Naive or healthy;APX_2A;NTS_4;Non-Technical Summary;availability of expertise;similar anatomy or organ system;NTS_4.3;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174169_02;20174169;Uitvoerbaarheid en veiligheid van nieuwe technieken om afwijkend slijmvlies in het maagdarmkanaal te behandelen;Translational or applied research;human;Preventie van complicaties na endoscopische resectie en ablatie;NLD;pig;NTS_3.3;Cancer;NTS_3.1;Naive or healthy;APX_2A;NTS_4;Non-Technical Summary;availability of expertise;similar anatomy or organ system;NTS_4.3;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174169_02;20174169;Uitvoerbaarheid en veiligheid van nieuwe technieken om afwijkend slijmvlies in het maagdarmkanaal te behandelen;Translational or applied research;human;Preventie van complicaties na endoscopische resectie en ablatie;NLD;pig;NTS_3.3;Cancer;NTS_3.1;Naive or healthy;APX_2A;NTS_4;Non-Technical Summary;availability of expertise;similar anatomy or organ system;NTS_4.3;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174169_02;20174169;Uitvoerbaarheid en veiligheid van nieuwe technieken om afwijkend slijmvlies in het maagdarmkanaal te behandelen;Translational or applied research;human;Preventie van complicaties na endoscopische resectie en ablatie;NLD;pig;NTS_3.3;Cancer;NTS_3.1;Naive or healthy;APX_2A;NTS_4;Non-Technical Summary;availability of expertise;similar anatomy or organ system;NTS_4.3;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;accomodation and care;cage enrichment;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174169_02;20174169;Uitvoerbaarheid en veiligheid van nieuwe technieken om afwijkend slijmvlies in het maagdarmkanaal te behandelen;Translational or applied research;human;Preventie van complicaties na endoscopische resectie en ablatie;NLD;pig;NTS_3.3;Cancer;NTS_3.1;Naive or healthy;APX_2A;NTS_4;Non-Technical Summary;availability of expertise;similar anatomy or organ system;NTS_4.3;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;accomodation and care;cage enrichment;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174169_02;20174169;Uitvoerbaarheid en veiligheid van nieuwe technieken om afwijkend slijmvlies in het maagdarmkanaal te behandelen;Translational or applied research;human;Preventie van complicaties na endoscopische resectie en ablatie;NLD;pig;NTS_3.3;Cancer;NTS_3.1;Naive or healthy;APX_2A;NTS_4;Non-Technical Summary;availability of expertise;similar anatomy or organ system;NTS_4.3;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;accomodation and care;cage enrichment;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174169_02;20174169;Uitvoerbaarheid en veiligheid van nieuwe technieken om afwijkend slijmvlies in het maagdarmkanaal te behandelen;Translational or applied research;human;Preventie van complicaties na endoscopische resectie en ablatie;NLD;pig;NTS_3.3;Cancer;NTS_3.1;Naive or healthy;APX_2A;NTS_4;Non-Technical Summary;availability of expertise;similar anatomy or organ system;NTS_4.3;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;optimal combination of readouts;APX_2D;accomodation and care;cage enrichment;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174169_02;20174169;Uitvoerbaarheid en veiligheid van nieuwe technieken om afwijkend slijmvlies in het maagdarmkanaal te behandelen;Translational or applied research;human;Preventie van complicaties na endoscopische resectie en ablatie;NLD;pig;NTS_3.3;Cancer;NTS_3.1;Naive or healthy;APX_2A;NTS_4;Non-Technical Summary;availability of expertise;availability of research tools;NTS_4.3;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174169_02;20174169;Uitvoerbaarheid en veiligheid van nieuwe technieken om afwijkend slijmvlies in het maagdarmkanaal te behandelen;Translational or applied research;human;Preventie van complicaties na endoscopische resectie en ablatie;NLD;pig;NTS_3.3;Cancer;NTS_3.1;Naive or healthy;APX_2A;NTS_4;Non-Technical Summary;availability of expertise;availability of research tools;NTS_4.3;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174169_02;20174169;Uitvoerbaarheid en veiligheid van nieuwe technieken om afwijkend slijmvlies in het maagdarmkanaal te behandelen;Translational or applied research;human;Preventie van complicaties na endoscopische resectie en ablatie;NLD;pig;NTS_3.3;Cancer;NTS_3.1;Naive or healthy;APX_2A;NTS_4;Non-Technical Summary;availability of expertise;availability of research tools;NTS_4.3;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174169_02;20174169;Uitvoerbaarheid en veiligheid van nieuwe technieken om afwijkend slijmvlies in het maagdarmkanaal te behandelen;Translational or applied research;human;Preventie van complicaties na endoscopische resectie en ablatie;NLD;pig;NTS_3.3;Cancer;NTS_3.1;Naive or healthy;APX_2A;NTS_4;Non-Technical Summary;availability of expertise;availability of research tools;NTS_4.3;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;(pre and post) procedure care;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174169_02;20174169;Uitvoerbaarheid en veiligheid van nieuwe technieken om afwijkend slijmvlies in het maagdarmkanaal te behandelen;Translational or applied research;human;Preventie van complicaties na endoscopische resectie en ablatie;NLD;pig;NTS_3.3;Cancer;NTS_3.1;Naive or healthy;APX_2A;NTS_4;Non-Technical Summary;availability of expertise;availability of research tools;NTS_4.3;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;expertise;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174169_02;20174169;Uitvoerbaarheid en veiligheid van nieuwe technieken om afwijkend slijmvlies in het maagdarmkanaal te behandelen;Translational or applied research;human;Preventie van complicaties na endoscopische resectie en ablatie;NLD;pig;NTS_3.3;Cancer;NTS_3.1;Naive or healthy;APX_2A;NTS_4;Non-Technical Summary;availability of expertise;availability of research tools;NTS_4.3;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;expertise;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174169_02;20174169;Uitvoerbaarheid en veiligheid van nieuwe technieken om afwijkend slijmvlies in het maagdarmkanaal te behandelen;Translational or applied research;human;Preventie van complicaties na endoscopische resectie en ablatie;NLD;pig;NTS_3.3;Cancer;NTS_3.1;Naive or healthy;APX_2A;NTS_4;Non-Technical Summary;availability of expertise;availability of research tools;NTS_4.3;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;expertise;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174169_02;20174169;Uitvoerbaarheid en veiligheid van nieuwe technieken om afwijkend slijmvlies in het maagdarmkanaal te behandelen;Translational or applied research;human;Preventie van complicaties na endoscopische resectie en ablatie;NLD;pig;NTS_3.3;Cancer;NTS_3.1;Naive or healthy;APX_2A;NTS_4;Non-Technical Summary;availability of expertise;availability of research tools;NTS_4.3;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;optimal combination of readouts;APX_2D;reduction of discomfort;expertise;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174169_02;20174169;Uitvoerbaarheid en veiligheid van nieuwe technieken om afwijkend slijmvlies in het maagdarmkanaal te behandelen;Translational or applied research;human;Preventie van complicaties na endoscopische resectie en ablatie;NLD;pig;NTS_3.3;Cancer;NTS_3.1;Naive or healthy;APX_2A;NTS_4;Non-Technical Summary;availability of expertise;availability of research tools;NTS_4.3;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174169_02;20174169;Uitvoerbaarheid en veiligheid van nieuwe technieken om afwijkend slijmvlies in het maagdarmkanaal te behandelen;Translational or applied research;human;Preventie van complicaties na endoscopische resectie en ablatie;NLD;pig;NTS_3.3;Cancer;NTS_3.1;Naive or healthy;APX_2A;NTS_4;Non-Technical Summary;availability of expertise;availability of research tools;NTS_4.3;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174169_02;20174169;Uitvoerbaarheid en veiligheid van nieuwe technieken om afwijkend slijmvlies in het maagdarmkanaal te behandelen;Translational or applied research;human;Preventie van complicaties na endoscopische resectie en ablatie;NLD;pig;NTS_3.3;Cancer;NTS_3.1;Naive or healthy;APX_2A;NTS_4;Non-Technical Summary;availability of expertise;availability of research tools;NTS_4.3;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174169_02;20174169;Uitvoerbaarheid en veiligheid van nieuwe technieken om afwijkend slijmvlies in het maagdarmkanaal te behandelen;Translational or applied research;human;Preventie van complicaties na endoscopische resectie en ablatie;NLD;pig;NTS_3.3;Cancer;NTS_3.1;Naive or healthy;APX_2A;NTS_4;Non-Technical Summary;availability of expertise;availability of research tools;NTS_4.3;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174169_02;20174169;Uitvoerbaarheid en veiligheid van nieuwe technieken om afwijkend slijmvlies in het maagdarmkanaal te behandelen;Translational or applied research;human;Preventie van complicaties na endoscopische resectie en ablatie;NLD;pig;NTS_3.3;Cancer;NTS_3.1;Naive or healthy;APX_2A;NTS_4;Non-Technical Summary;availability of expertise;availability of research tools;NTS_4.3;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;accomodation and care;cage enrichment;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174169_02;20174169;Uitvoerbaarheid en veiligheid van nieuwe technieken om afwijkend slijmvlies in het maagdarmkanaal te behandelen;Translational or applied research;human;Preventie van complicaties na endoscopische resectie en ablatie;NLD;pig;NTS_3.3;Cancer;NTS_3.1;Naive or healthy;APX_2A;NTS_4;Non-Technical Summary;availability of expertise;availability of research tools;NTS_4.3;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;accomodation and care;cage enrichment;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174169_02;20174169;Uitvoerbaarheid en veiligheid van nieuwe technieken om afwijkend slijmvlies in het maagdarmkanaal te behandelen;Translational or applied research;human;Preventie van complicaties na endoscopische resectie en ablatie;NLD;pig;NTS_3.3;Cancer;NTS_3.1;Naive or healthy;APX_2A;NTS_4;Non-Technical Summary;availability of expertise;availability of research tools;NTS_4.3;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;accomodation and care;cage enrichment;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174169_02;20174169;Uitvoerbaarheid en veiligheid van nieuwe technieken om afwijkend slijmvlies in het maagdarmkanaal te behandelen;Translational or applied research;human;Preventie van complicaties na endoscopische resectie en ablatie;NLD;pig;NTS_3.3;Cancer;NTS_3.1;Naive or healthy;APX_2A;NTS_4;Non-Technical Summary;availability of expertise;availability of research tools;NTS_4.3;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;optimal combination of readouts;APX_2D;accomodation and care;cage enrichment;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174169_03;20174169;Uitvoerbaarheid en veiligheid van nieuwe technieken om afwijkend slijmvlies in het maagdarmkanaal te behandelen;Translational or applied research;human;Training endoscopisten;NLD;pig;NTS_3.3;Cancer;NTS_1.3;Naive or healthy;APX_2A;NTS_4;Non-Technical Summary;similar disease pathology or symptoms;similar anatomy or organ system;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;(pre and post) procedure care;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174169_03;20174169;Uitvoerbaarheid en veiligheid van nieuwe technieken om afwijkend slijmvlies in het maagdarmkanaal te behandelen;Translational or applied research;human;Training endoscopisten;NLD;pig;NTS_3.3;Cancer;NTS_1.3;Naive or healthy;APX_2A;NTS_4;Non-Technical Summary;similar disease pathology or symptoms;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;(pre and post) procedure care;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174169_03;20174169;Uitvoerbaarheid en veiligheid van nieuwe technieken om afwijkend slijmvlies in het maagdarmkanaal te behandelen;Translational or applied research;human;Training endoscopisten;NLD;pig;NTS_3.3;Cancer;NTS_1.3;Naive or healthy;APX_2A;NTS_4;Non-Technical Summary;similar disease pathology or symptoms;similar anatomy or organ system;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174169_03;20174169;Uitvoerbaarheid en veiligheid van nieuwe technieken om afwijkend slijmvlies in het maagdarmkanaal te behandelen;Translational or applied research;human;Training endoscopisten;NLD;pig;NTS_3.3;Cancer;NTS_1.3;Naive or healthy;APX_2A;NTS_4;Non-Technical Summary;similar disease pathology or symptoms;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174169_03;20174169;Uitvoerbaarheid en veiligheid van nieuwe technieken om afwijkend slijmvlies in het maagdarmkanaal te behandelen;Translational or applied research;human;Training endoscopisten;NLD;pig;NTS_3.3;Cancer;NTS_1.3;Naive or healthy;APX_2A;NTS_4;Non-Technical Summary;availability of expertise;similar anatomy or organ system;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;(pre and post) procedure care;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174169_03;20174169;Uitvoerbaarheid en veiligheid van nieuwe technieken om afwijkend slijmvlies in het maagdarmkanaal te behandelen;Translational or applied research;human;Training endoscopisten;NLD;pig;NTS_3.3;Cancer;NTS_1.3;Naive or healthy;APX_2A;NTS_4;Non-Technical Summary;availability of expertise;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;(pre and post) procedure care;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174169_03;20174169;Uitvoerbaarheid en veiligheid van nieuwe technieken om afwijkend slijmvlies in het maagdarmkanaal te behandelen;Translational or applied research;human;Training endoscopisten;NLD;pig;NTS_3.3;Cancer;NTS_1.3;Naive or healthy;APX_2A;NTS_4;Non-Technical Summary;availability of expertise;similar anatomy or organ system;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174169_03;20174169;Uitvoerbaarheid en veiligheid van nieuwe technieken om afwijkend slijmvlies in het maagdarmkanaal te behandelen;Translational or applied research;human;Training endoscopisten;NLD;pig;NTS_3.3;Cancer;NTS_1.3;Naive or healthy;APX_2A;NTS_4;Non-Technical Summary;availability of expertise;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174169_03;20174169;Uitvoerbaarheid en veiligheid van nieuwe technieken om afwijkend slijmvlies in het maagdarmkanaal te behandelen;Translational or applied research;human;Training endoscopisten;NLD;pig;NTS_3.3;Cancer;NTS_3.1;Naive or healthy;APX_2A;NTS_4;Non-Technical Summary;similar disease pathology or symptoms;similar anatomy or organ system;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;(pre and post) procedure care;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174169_03;20174169;Uitvoerbaarheid en veiligheid van nieuwe technieken om afwijkend slijmvlies in het maagdarmkanaal te behandelen;Translational or applied research;human;Training endoscopisten;NLD;pig;NTS_3.3;Cancer;NTS_3.1;Naive or healthy;APX_2A;NTS_4;Non-Technical Summary;similar disease pathology or symptoms;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;(pre and post) procedure care;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174169_03;20174169;Uitvoerbaarheid en veiligheid van nieuwe technieken om afwijkend slijmvlies in het maagdarmkanaal te behandelen;Translational or applied research;human;Training endoscopisten;NLD;pig;NTS_3.3;Cancer;NTS_3.1;Naive or healthy;APX_2A;NTS_4;Non-Technical Summary;similar disease pathology or symptoms;similar anatomy or organ system;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174169_03;20174169;Uitvoerbaarheid en veiligheid van nieuwe technieken om afwijkend slijmvlies in het maagdarmkanaal te behandelen;Translational or applied research;human;Training endoscopisten;NLD;pig;NTS_3.3;Cancer;NTS_3.1;Naive or healthy;APX_2A;NTS_4;Non-Technical Summary;similar disease pathology or symptoms;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174169_03;20174169;Uitvoerbaarheid en veiligheid van nieuwe technieken om afwijkend slijmvlies in het maagdarmkanaal te behandelen;Translational or applied research;human;Training endoscopisten;NLD;pig;NTS_3.3;Cancer;NTS_3.1;Naive or healthy;APX_2A;NTS_4;Non-Technical Summary;availability of expertise;similar anatomy or organ system;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;(pre and post) procedure care;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174169_03;20174169;Uitvoerbaarheid en veiligheid van nieuwe technieken om afwijkend slijmvlies in het maagdarmkanaal te behandelen;Translational or applied research;human;Training endoscopisten;NLD;pig;NTS_3.3;Cancer;NTS_3.1;Naive or healthy;APX_2A;NTS_4;Non-Technical Summary;availability of expertise;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;(pre and post) procedure care;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174169_03;20174169;Uitvoerbaarheid en veiligheid van nieuwe technieken om afwijkend slijmvlies in het maagdarmkanaal te behandelen;Translational or applied research;human;Training endoscopisten;NLD;pig;NTS_3.3;Cancer;NTS_3.1;Naive or healthy;APX_2A;NTS_4;Non-Technical Summary;availability of expertise;similar anatomy or organ system;APX_2B;intervention related;APX_2A;prior studies;in silico, in vitro or ex vivo pre-screening;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174169_03;20174169;Uitvoerbaarheid en veiligheid van nieuwe technieken om afwijkend slijmvlies in het maagdarmkanaal te behandelen;Translational or applied research;human;Training endoscopisten;NLD;pig;NTS_3.3;Cancer;NTS_3.1;Naive or healthy;APX_2A;NTS_4;Non-Technical Summary;availability of expertise;similar anatomy or organ system;APX_2B;intervention related;APX_2A;no alternative model;intact and functional (organ) system;APX_2D;experimental design;optimal combination of readouts;APX_2D;methods used in procedures;prior (pilot) studies;APX_2D;endoscopic;diagnostic tool;NTS_3.1
20174226_01;20174226;Een muismodel voor het bestuderen van de aanwezigheid van schadelijke plasmafactoren in het bloed van patienten met FSGS/MCD;Translational or applied research;human;Een muismodel voor het detecteren van circulerende permeabiliteits factoren in het plasma van patienten met FSGS/MCD.;NLD;mouse;NTS_3.3;Urogenital or reproductive disorders;NTS_1.3;Genetically modified and induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;sensitivity;PPL_3.1;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;expertise;expert collaborations;APX_2D;methods used in procedures;expertise;APX_2D;human plasma;biologics;APX_2A
20174226_01;20174226;Een muismodel voor het bestuderen van de aanwezigheid van schadelijke plasmafactoren in het bloed van patienten met FSGS/MCD;Translational or applied research;human;Een muismodel voor het detecteren van circulerende permeabiliteits factoren in het plasma van patienten met FSGS/MCD.;NLD;mouse;NTS_3.3;Urogenital or reproductive disorders;NTS_1.3;Genetically modified and induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;sensitivity;PPL_3.1;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;methods used in procedures;expertise;APX_2D;human plasma;biologics;APX_2A
20174226_01;20174226;Een muismodel voor het bestuderen van de aanwezigheid van schadelijke plasmafactoren in het bloed van patienten met FSGS/MCD;Translational or applied research;human;Een muismodel voor het detecteren van circulerende permeabiliteits factoren in het plasma van patienten met FSGS/MCD.;NLD;mouse;NTS_3.3;Urogenital or reproductive disorders;NTS_1.3;Genetically modified and induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;sensitivity;PPL_3.1;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;expertise;APX_2D;human plasma;biologics;APX_2A
20174226_01;20174226;Een muismodel voor het bestuderen van de aanwezigheid van schadelijke plasmafactoren in het bloed van patienten met FSGS/MCD;Translational or applied research;human;Een muismodel voor het detecteren van circulerende permeabiliteits factoren in het plasma van patienten met FSGS/MCD.;NLD;mouse;NTS_3.3;Urogenital or reproductive disorders;NTS_1.3;Genetically modified and induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;sensitivity;PPL_3.1;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;expertise;expert collaborations;APX_2D;reduction of discomfort;expertise;APX_2D;human plasma;biologics;APX_2A
20174226_01;20174226;Een muismodel voor het bestuderen van de aanwezigheid van schadelijke plasmafactoren in het bloed van patienten met FSGS/MCD;Translational or applied research;human;Een muismodel voor het detecteren van circulerende permeabiliteits factoren in het plasma van patienten met FSGS/MCD.;NLD;mouse;NTS_3.3;Urogenital or reproductive disorders;NTS_1.3;Genetically modified and induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;sensitivity;PPL_3.1;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;expertise;APX_2D;human plasma;biologics;APX_2A
20174226_01;20174226;Een muismodel voor het bestuderen van de aanwezigheid van schadelijke plasmafactoren in het bloed van patienten met FSGS/MCD;Translational or applied research;human;Een muismodel voor het detecteren van circulerende permeabiliteits factoren in het plasma van patienten met FSGS/MCD.;NLD;mouse;NTS_3.3;Urogenital or reproductive disorders;NTS_1.3;Genetically modified and induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;sensitivity;PPL_3.1;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;expertise;APX_2D;human plasma;biologics;APX_2A
20174226_01;20174226;Een muismodel voor het bestuderen van de aanwezigheid van schadelijke plasmafactoren in het bloed van patienten met FSGS/MCD;Translational or applied research;human;Een muismodel voor het detecteren van circulerende permeabiliteits factoren in het plasma van patienten met FSGS/MCD.;NLD;mouse;NTS_3.3;Urogenital or reproductive disorders;NTS_1.3;Genetically modified and induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;sensitivity;PPL_3.1;disease pathology related;APX_2A;no alternative model;lowest possible species;APX_2D;expertise;expert collaborations;APX_2D;methods used in procedures;expertise;APX_2D;human plasma;biologics;APX_2A
20174226_01;20174226;Een muismodel voor het bestuderen van de aanwezigheid van schadelijke plasmafactoren in het bloed van patienten met FSGS/MCD;Translational or applied research;human;Een muismodel voor het detecteren van circulerende permeabiliteits factoren in het plasma van patienten met FSGS/MCD.;NLD;mouse;NTS_3.3;Urogenital or reproductive disorders;NTS_1.3;Genetically modified and induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;sensitivity;PPL_3.1;disease pathology related;APX_2A;no alternative model;lowest possible species;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;methods used in procedures;expertise;APX_2D;human plasma;biologics;APX_2A
20174226_01;20174226;Een muismodel voor het bestuderen van de aanwezigheid van schadelijke plasmafactoren in het bloed van patienten met FSGS/MCD;Translational or applied research;human;Een muismodel voor het detecteren van circulerende permeabiliteits factoren in het plasma van patienten met FSGS/MCD.;NLD;mouse;NTS_3.3;Urogenital or reproductive disorders;NTS_1.3;Genetically modified and induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;sensitivity;PPL_3.1;disease pathology related;APX_2A;no alternative model;lowest possible species;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;expertise;APX_2D;human plasma;biologics;APX_2A
20174226_01;20174226;Een muismodel voor het bestuderen van de aanwezigheid van schadelijke plasmafactoren in het bloed van patienten met FSGS/MCD;Translational or applied research;human;Een muismodel voor het detecteren van circulerende permeabiliteits factoren in het plasma van patienten met FSGS/MCD.;NLD;mouse;NTS_3.3;Urogenital or reproductive disorders;NTS_1.3;Genetically modified and induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;sensitivity;PPL_3.1;disease pathology related;APX_2A;no alternative model;lowest possible species;APX_2D;expertise;expert collaborations;APX_2D;reduction of discomfort;expertise;APX_2D;human plasma;biologics;APX_2A
20174226_01;20174226;Een muismodel voor het bestuderen van de aanwezigheid van schadelijke plasmafactoren in het bloed van patienten met FSGS/MCD;Translational or applied research;human;Een muismodel voor het detecteren van circulerende permeabiliteits factoren in het plasma van patienten met FSGS/MCD.;NLD;mouse;NTS_3.3;Urogenital or reproductive disorders;NTS_1.3;Genetically modified and induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;sensitivity;PPL_3.1;disease pathology related;APX_2A;no alternative model;lowest possible species;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;expertise;APX_2D;human plasma;biologics;APX_2A
20174226_01;20174226;Een muismodel voor het bestuderen van de aanwezigheid van schadelijke plasmafactoren in het bloed van patienten met FSGS/MCD;Translational or applied research;human;Een muismodel voor het detecteren van circulerende permeabiliteits factoren in het plasma van patienten met FSGS/MCD.;NLD;mouse;NTS_3.3;Urogenital or reproductive disorders;NTS_1.3;Genetically modified and induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;sensitivity;PPL_3.1;disease pathology related;APX_2A;no alternative model;lowest possible species;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;expertise;APX_2D;human plasma;biologics;APX_2A
20174226_01;20174226;Een muismodel voor het bestuderen van de aanwezigheid van schadelijke plasmafactoren in het bloed van patienten met FSGS/MCD;Translational or applied research;human;Een muismodel voor het detecteren van circulerende permeabiliteits factoren in het plasma van patienten met FSGS/MCD.;NLD;mouse;NTS_3.3;Urogenital or reproductive disorders;NTS_1.3;Genetically modified and induced;APX_2A;PPL_3.1;Main Text;prefered to other model;sensitivity;PPL_3.1;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;expertise;expert collaborations;APX_2D;methods used in procedures;expertise;APX_2D;human plasma;biologics;APX_2A
20174226_01;20174226;Een muismodel voor het bestuderen van de aanwezigheid van schadelijke plasmafactoren in het bloed van patienten met FSGS/MCD;Translational or applied research;human;Een muismodel voor het detecteren van circulerende permeabiliteits factoren in het plasma van patienten met FSGS/MCD.;NLD;mouse;NTS_3.3;Urogenital or reproductive disorders;NTS_1.3;Genetically modified and induced;APX_2A;PPL_3.1;Main Text;prefered to other model;sensitivity;PPL_3.1;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;methods used in procedures;expertise;APX_2D;human plasma;biologics;APX_2A
20174226_01;20174226;Een muismodel voor het bestuderen van de aanwezigheid van schadelijke plasmafactoren in het bloed van patienten met FSGS/MCD;Translational or applied research;human;Een muismodel voor het detecteren van circulerende permeabiliteits factoren in het plasma van patienten met FSGS/MCD.;NLD;mouse;NTS_3.3;Urogenital or reproductive disorders;NTS_1.3;Genetically modified and induced;APX_2A;PPL_3.1;Main Text;prefered to other model;sensitivity;PPL_3.1;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;expertise;APX_2D;human plasma;biologics;APX_2A
20174226_01;20174226;Een muismodel voor het bestuderen van de aanwezigheid van schadelijke plasmafactoren in het bloed van patienten met FSGS/MCD;Translational or applied research;human;Een muismodel voor het detecteren van circulerende permeabiliteits factoren in het plasma van patienten met FSGS/MCD.;NLD;mouse;NTS_3.3;Urogenital or reproductive disorders;NTS_1.3;Genetically modified and induced;APX_2A;PPL_3.1;Main Text;prefered to other model;sensitivity;PPL_3.1;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;expertise;expert collaborations;APX_2D;reduction of discomfort;expertise;APX_2D;human plasma;biologics;APX_2A
20174226_01;20174226;Een muismodel voor het bestuderen van de aanwezigheid van schadelijke plasmafactoren in het bloed van patienten met FSGS/MCD;Translational or applied research;human;Een muismodel voor het detecteren van circulerende permeabiliteits factoren in het plasma van patienten met FSGS/MCD.;NLD;mouse;NTS_3.3;Urogenital or reproductive disorders;NTS_1.3;Genetically modified and induced;APX_2A;PPL_3.1;Main Text;prefered to other model;sensitivity;PPL_3.1;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;expertise;APX_2D;human plasma;biologics;APX_2A
20174226_01;20174226;Een muismodel voor het bestuderen van de aanwezigheid van schadelijke plasmafactoren in het bloed van patienten met FSGS/MCD;Translational or applied research;human;Een muismodel voor het detecteren van circulerende permeabiliteits factoren in het plasma van patienten met FSGS/MCD.;NLD;mouse;NTS_3.3;Urogenital or reproductive disorders;NTS_1.3;Genetically modified and induced;APX_2A;PPL_3.1;Main Text;prefered to other model;sensitivity;PPL_3.1;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;expertise;APX_2D;human plasma;biologics;APX_2A
20174226_01;20174226;Een muismodel voor het bestuderen van de aanwezigheid van schadelijke plasmafactoren in het bloed van patienten met FSGS/MCD;Translational or applied research;human;Een muismodel voor het detecteren van circulerende permeabiliteits factoren in het plasma van patienten met FSGS/MCD.;NLD;mouse;NTS_3.3;Urogenital or reproductive disorders;NTS_1.3;Genetically modified and induced;APX_2A;PPL_3.1;Main Text;prefered to other model;sensitivity;PPL_3.1;disease pathology related;APX_2A;no alternative model;lowest possible species;APX_2D;expertise;expert collaborations;APX_2D;methods used in procedures;expertise;APX_2D;human plasma;biologics;APX_2A
20174226_01;20174226;Een muismodel voor het bestuderen van de aanwezigheid van schadelijke plasmafactoren in het bloed van patienten met FSGS/MCD;Translational or applied research;human;Een muismodel voor het detecteren van circulerende permeabiliteits factoren in het plasma van patienten met FSGS/MCD.;NLD;mouse;NTS_3.3;Urogenital or reproductive disorders;NTS_1.3;Genetically modified and induced;APX_2A;PPL_3.1;Main Text;prefered to other model;sensitivity;PPL_3.1;disease pathology related;APX_2A;no alternative model;lowest possible species;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;methods used in procedures;expertise;APX_2D;human plasma;biologics;APX_2A
20174226_01;20174226;Een muismodel voor het bestuderen van de aanwezigheid van schadelijke plasmafactoren in het bloed van patienten met FSGS/MCD;Translational or applied research;human;Een muismodel voor het detecteren van circulerende permeabiliteits factoren in het plasma van patienten met FSGS/MCD.;NLD;mouse;NTS_3.3;Urogenital or reproductive disorders;NTS_1.3;Genetically modified and induced;APX_2A;PPL_3.1;Main Text;prefered to other model;sensitivity;PPL_3.1;disease pathology related;APX_2A;no alternative model;lowest possible species;APX_2D;substantiated statistics;use of statistical methods;APX_2D;methods used in procedures;expertise;APX_2D;human plasma;biologics;APX_2A
20174226_01;20174226;Een muismodel voor het bestuderen van de aanwezigheid van schadelijke plasmafactoren in het bloed van patienten met FSGS/MCD;Translational or applied research;human;Een muismodel voor het detecteren van circulerende permeabiliteits factoren in het plasma van patienten met FSGS/MCD.;NLD;mouse;NTS_3.3;Urogenital or reproductive disorders;NTS_1.3;Genetically modified and induced;APX_2A;PPL_3.1;Main Text;prefered to other model;sensitivity;PPL_3.1;disease pathology related;APX_2A;no alternative model;lowest possible species;APX_2D;expertise;expert collaborations;APX_2D;reduction of discomfort;expertise;APX_2D;human plasma;biologics;APX_2A
20174226_01;20174226;Een muismodel voor het bestuderen van de aanwezigheid van schadelijke plasmafactoren in het bloed van patienten met FSGS/MCD;Translational or applied research;human;Een muismodel voor het detecteren van circulerende permeabiliteits factoren in het plasma van patienten met FSGS/MCD.;NLD;mouse;NTS_3.3;Urogenital or reproductive disorders;NTS_1.3;Genetically modified and induced;APX_2A;PPL_3.1;Main Text;prefered to other model;sensitivity;PPL_3.1;disease pathology related;APX_2A;no alternative model;lowest possible species;APX_2D;prior studies;in vivo (pilot) studies;APX_2D;reduction of discomfort;expertise;APX_2D;human plasma;biologics;APX_2A
20174226_01;20174226;Een muismodel voor het bestuderen van de aanwezigheid van schadelijke plasmafactoren in het bloed van patienten met FSGS/MCD;Translational or applied research;human;Een muismodel voor het detecteren van circulerende permeabiliteits factoren in het plasma van patienten met FSGS/MCD.;NLD;mouse;NTS_3.3;Urogenital or reproductive disorders;NTS_1.3;Genetically modified and induced;APX_2A;PPL_3.1;Main Text;prefered to other model;sensitivity;PPL_3.1;disease pathology related;APX_2A;no alternative model;lowest possible species;APX_2D;substantiated statistics;use of statistical methods;APX_2D;reduction of discomfort;expertise;APX_2D;human plasma;biologics;APX_2A
20174226_01;20174226;Een muismodel voor het bestuderen van de aanwezigheid van schadelijke plasmafactoren in het bloed van patienten met FSGS/MCD;Translational or applied research;human;Een muismodel voor het detecteren van circulerende permeabiliteits factoren in het plasma van patienten met FSGS/MCD.;NLD;mouse;NTS_3.3;Urogenital or reproductive disorders;NTS_3.1;Genetically modified and induced;APX_2A;PPL_3.1;Main Text;availability of the animal model;sensitivity;PPL_3.1;disease pathology related;APX_2A;no alternative model;complex interaction between environmental factors, cells and tissues;APX_2D;expertise;expert collaborations;APX_2D;methods used in procedures;expertise;APX_2D;human plasma;biologics;APX_2A
20174226_01;20174226;Een muismodel voor het bestuderen van de aanwezigheid van schadelijke plasmafactoren in het bloed van patienten met FSGS/MCD;Translational or applied research;human;Een muismodel voor het detecteren van circulerende permeabil